{
  "pmcid": "PMC12673801",
  "source": "PMC",
  "download_date": "2025-12-09T16:37:23.144778",
  "metadata": {
    "journal_title": "Cancer Cell International",
    "journal_nlm_ta": "Cancer Cell Int",
    "journal_iso_abbrev": "Cancer Cell Int",
    "journal": "Cancer Cell International",
    "pmcid": "PMC12673801",
    "pmid": "41339875",
    "doi": "10.1186/s12935-025-04063-8",
    "title": "AI-based neoadjuvant immunotherapy response prediction across pan-cancer: a comprehensive review",
    "year": "2025",
    "month": "12",
    "day": "3",
    "pub_date": {
      "year": "2025",
      "month": "12",
      "day": "3"
    },
    "authors": [
      "Deng Yishu",
      "Li Tailin",
      "Wang Yunze",
      "Chen Silin",
      "Tang Feilong",
      "Zhu Taoyu",
      "Ran Jiayi",
      "Yang Bo",
      "Zhang Xiaohan",
      "Xu Ruijie",
      "Ray Manas K.",
      "Zhang Yimin",
      "Chen Shuifang",
      "Liu Jian"
    ],
    "abstract": "Neoadjuvant immunotherapy (NIT) has emerged as a transformative treatment strategy across various cancer types. However, due to the significant heterogeneity of tumors, patients exhibit highly variable responses to NIT, making the accurate preoperative identification of those who would benefit a pressing clinical challenge. In recent years, artificial intelligence (AI), particularly machine learning (ML) and deep learning (DL), has opened new pathways for predicting treatment response. AI-driven approaches have the ability to extract latent features from high-dimensional, multimodal oncological data, facilitating the construction of efficient predictive models that can optimize individualized treatment strategies. In this review, we systematically summarize existing AI-driven computational approaches for NIT response prediction, categorizing them into indirect and direct predictive paradigms. The indirect paradigm predicts clinically validated surrogate biomarkers to infer therapeutic response to NIT. In contrast, the direct paradigm leverages AI to analyze high-throughput data and establish data-driven biomarkers that directly predict clinical endpoints of NIT. Additionally, we categorize existing AI predictive models based on data modalities, spanning radiomics, pathomics, genomics, and multi-omics approaches, each providing distinct insights into tumor characteristics and treatment response. Despite notable progress, current predictive models still face significant challenges, which we broadly classify into biomarker-based and AI-based limitations. We further discuss potential strategies to address these challenges. This review systematically summarizes recent AI-based predictive models for NIT response across cancer types. By offering a structured analysis of current methodologies and challenges, we aim to guide future research and accelerate the integration of AI into precision immunotherapy.",
    "keywords": [
      "Neoadjuvant immunotherapy",
      "Artificial intelligence",
      "Multi-omics",
      "Biomarkers",
      "Response prediction"
    ]
  },
  "xml": "<?xml version=\"1.0\"  ?><!DOCTYPE pmc-articleset PUBLIC \"-//NLM//DTD ARTICLE SET 2.0//EN\" \"https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd\"><pmc-articleset><article xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:ali=\"http://www.niso.org/schemas/ali/1.0/\" article-type=\"review-article\" xml:lang=\"en\" dtd-version=\"1.4\"><processing-meta base-tagset=\"archiving\" mathml-version=\"3.0\" table-model=\"xhtml\" tagset-family=\"jats\"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type=\"nlm-ta\">Cancer Cell Int</journal-id><journal-id journal-id-type=\"iso-abbrev\">Cancer Cell Int</journal-id><journal-id journal-id-type=\"pmc-domain-id\">96</journal-id><journal-id journal-id-type=\"pmc-domain\">cancell</journal-id><journal-title-group><journal-title>Cancer Cell International</journal-title></journal-title-group><issn pub-type=\"epub\">1475-2867</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type=\"pmcid\">PMC12673801</article-id><article-id pub-id-type=\"pmcid-ver\">PMC12673801.1</article-id><article-id pub-id-type=\"pmcaid\">12673801</article-id><article-id pub-id-type=\"pmcaiid\">12673801</article-id><article-id pub-id-type=\"pmid\">41339875</article-id><article-id pub-id-type=\"doi\">10.1186/s12935-025-04063-8</article-id><article-id pub-id-type=\"publisher-id\">4063</article-id><article-version article-version-type=\"pmc-version\">1</article-version><article-categories><subj-group subj-group-type=\"heading\"><subject>Review</subject></subj-group></article-categories><title-group><article-title>AI-based neoadjuvant immunotherapy response prediction across pan-cancer: a comprehensive review</article-title></title-group><contrib-group><contrib contrib-type=\"author\" equal-contrib=\"yes\"><name name-style=\"western\"><surname>Deng</surname><given-names initials=\"Y\">Yishu</given-names></name><xref ref-type=\"aff\" rid=\"Aff1\">1</xref><xref ref-type=\"aff\" rid=\"Aff2\">2</xref><xref ref-type=\"aff\" rid=\"Aff3\">3</xref><xref ref-type=\"aff\" rid=\"Aff4\">4</xref></contrib><contrib contrib-type=\"author\" equal-contrib=\"yes\"><name name-style=\"western\"><surname>Li</surname><given-names initials=\"T\">Tailin</given-names></name><xref ref-type=\"aff\" rid=\"Aff1\">1</xref><xref ref-type=\"aff\" rid=\"Aff2\">2</xref><xref ref-type=\"aff\" rid=\"Aff3\">3</xref><xref ref-type=\"aff\" rid=\"Aff4\">4</xref></contrib><contrib contrib-type=\"author\" equal-contrib=\"yes\"><name name-style=\"western\"><surname>Wang</surname><given-names initials=\"Y\">Yunze</given-names></name><xref ref-type=\"aff\" rid=\"Aff1\">1</xref><xref ref-type=\"aff\" rid=\"Aff2\">2</xref><xref ref-type=\"aff\" rid=\"Aff3\">3</xref><xref ref-type=\"aff\" rid=\"Aff4\">4</xref></contrib><contrib contrib-type=\"author\" equal-contrib=\"yes\"><name name-style=\"western\"><surname>Chen</surname><given-names initials=\"S\">Silin</given-names></name><xref ref-type=\"aff\" rid=\"Aff1\">1</xref><xref ref-type=\"aff\" rid=\"Aff2\">2</xref><xref ref-type=\"aff\" rid=\"Aff3\">3</xref><xref ref-type=\"aff\" rid=\"Aff4\">4</xref></contrib><contrib contrib-type=\"author\"><name name-style=\"western\"><surname>Tang</surname><given-names initials=\"F\">Feilong</given-names></name><xref ref-type=\"aff\" rid=\"Aff5\">5</xref><xref ref-type=\"aff\" rid=\"Aff6\">6</xref></contrib><contrib contrib-type=\"author\"><name name-style=\"western\"><surname>Zhu</surname><given-names initials=\"T\">Taoyu</given-names></name><xref ref-type=\"aff\" rid=\"Aff1\">1</xref><xref ref-type=\"aff\" rid=\"Aff2\">2</xref><xref ref-type=\"aff\" rid=\"Aff3\">3</xref><xref ref-type=\"aff\" rid=\"Aff4\">4</xref></contrib><contrib contrib-type=\"author\"><name name-style=\"western\"><surname>Ran</surname><given-names initials=\"J\">Jiayi</given-names></name><xref ref-type=\"aff\" rid=\"Aff1\">1</xref><xref ref-type=\"aff\" rid=\"Aff2\">2</xref><xref ref-type=\"aff\" rid=\"Aff3\">3</xref><xref ref-type=\"aff\" rid=\"Aff4\">4</xref></contrib><contrib contrib-type=\"author\"><name name-style=\"western\"><surname>Yang</surname><given-names initials=\"B\">Bo</given-names></name><xref ref-type=\"aff\" rid=\"Aff1\">1</xref><xref ref-type=\"aff\" rid=\"Aff2\">2</xref><xref ref-type=\"aff\" rid=\"Aff3\">3</xref><xref ref-type=\"aff\" rid=\"Aff4\">4</xref></contrib><contrib contrib-type=\"author\"><name name-style=\"western\"><surname>Zhang</surname><given-names initials=\"X\">Xiaohan</given-names></name><xref ref-type=\"aff\" rid=\"Aff1\">1</xref><xref ref-type=\"aff\" rid=\"Aff2\">2</xref><xref ref-type=\"aff\" rid=\"Aff3\">3</xref><xref ref-type=\"aff\" rid=\"Aff4\">4</xref></contrib><contrib contrib-type=\"author\"><name name-style=\"western\"><surname>Xu</surname><given-names initials=\"R\">Ruijie</given-names></name><xref ref-type=\"aff\" rid=\"Aff1\">1</xref><xref ref-type=\"aff\" rid=\"Aff2\">2</xref><xref ref-type=\"aff\" rid=\"Aff3\">3</xref><xref ref-type=\"aff\" rid=\"Aff4\">4</xref></contrib><contrib contrib-type=\"author\"><name name-style=\"western\"><surname>Ray</surname><given-names initials=\"MK\">Manas K.</given-names></name><xref ref-type=\"aff\" rid=\"Aff7\">7</xref></contrib><contrib contrib-type=\"author\" corresp=\"yes\"><name name-style=\"western\"><surname>Zhang</surname><given-names initials=\"Y\">Yimin</given-names></name><address><email>1307020@zju.edu.cn</email></address><xref ref-type=\"aff\" rid=\"Aff8\">8</xref><xref ref-type=\"aff\" rid=\"Aff9\">9</xref></contrib><contrib contrib-type=\"author\" corresp=\"yes\"><name name-style=\"western\"><surname>Chen</surname><given-names initials=\"S\">Shuifang</given-names></name><address><email>chen-sf@zju.edu.cn</email></address><xref ref-type=\"aff\" rid=\"Aff10\">10</xref><xref ref-type=\"aff\" rid=\"Aff11\">11</xref></contrib><contrib contrib-type=\"author\" corresp=\"yes\"><name name-style=\"western\"><surname>Liu</surname><given-names initials=\"J\">Jian</given-names></name><address><email>JianL@intl.zju.edu.cn</email></address><xref ref-type=\"aff\" rid=\"Aff1\">1</xref><xref ref-type=\"aff\" rid=\"Aff2\">2</xref><xref ref-type=\"aff\" rid=\"Aff3\">3</xref><xref ref-type=\"aff\" rid=\"Aff4\">4</xref></contrib><aff id=\"Aff1\"><label>1</label><institution-wrap><institution-id institution-id-type=\"ROR\">https://ror.org/00a2xv884</institution-id><institution-id institution-id-type=\"GRID\">grid.13402.34</institution-id><institution-id institution-id-type=\"ISNI\">0000 0004 1759 700X</institution-id><institution>Department of Respiratory and Critical Care Medicine, the Second Affiliated Hospital, and Centre for Infection Immunity and Cancer (IIC) of Zhejiang University-University of Edinburgh Institute (ZJU-UoE Institute), </institution><institution>Zhejiang University School of Medicine, Zhejiang University, </institution></institution-wrap>Hangzhou, Zhejiang China </aff><aff id=\"Aff2\"><label>2</label><institution-wrap><institution-id institution-id-type=\"ROR\">https://ror.org/01nrxwf90</institution-id><institution-id institution-id-type=\"GRID\">grid.4305.2</institution-id><institution-id institution-id-type=\"ISNI\">0000 0004 1936 7988</institution-id><institution>Biomedical Sciences, </institution><institution>Edinburgh Medical School, College of Medicine and Veterinary Medicine, University of Edinburgh, </institution></institution-wrap>Edinburgh, UK </aff><aff id=\"Aff3\"><label>3</label>Zhejiang Key Laboratory of Medical Imaging Artificial Intelligence, 310058 Hangzhou, China </aff><aff id=\"Aff4\"><label>4</label>Biomedical and Health Translational Research Center of Zhejiang Province, Haining, China </aff><aff id=\"Aff5\"><label>5</label><institution-wrap><institution-id institution-id-type=\"ROR\">https://ror.org/02bfwt286</institution-id><institution-id institution-id-type=\"GRID\">grid.1002.3</institution-id><institution-id institution-id-type=\"ISNI\">0000 0004 1936 7857</institution-id><institution>Monash University, </institution></institution-wrap>Melbourne, Australia </aff><aff id=\"Aff6\"><label>6</label><institution-wrap><institution-id institution-id-type=\"ROR\">https://ror.org/03snqfa66</institution-id><institution-id institution-id-type=\"GRID\">grid.444464.2</institution-id><institution-id institution-id-type=\"ISNI\">0000 0001 0650 0848</institution-id><institution>Mohamed bin Zayed University of AI, </institution></institution-wrap>Abu Dhabi, UAE </aff><aff id=\"Aff7\"><label>7</label><institution-wrap><institution-id institution-id-type=\"ROR\">https://ror.org/00j4k1h63</institution-id><institution-id institution-id-type=\"GRID\">grid.280664.e</institution-id><institution-id institution-id-type=\"ISNI\">0000 0001 2110 5790</institution-id><institution>Gene Editing and Mouse Model Core Facility, NIEHS, </institution></institution-wrap>Research Triangle Park, USA </aff><aff id=\"Aff8\"><label>8</label><institution-wrap><institution-id institution-id-type=\"ROR\">https://ror.org/00325dg83</institution-id><institution>State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, </institution></institution-wrap>Hangzhou, Zhejiang China </aff><aff id=\"Aff9\"><label>9</label><institution-wrap><institution-id institution-id-type=\"ROR\">https://ror.org/00j2a7k55</institution-id><institution-id institution-id-type=\"GRID\">grid.411870.b</institution-id><institution-id institution-id-type=\"ISNI\">0000 0001 0063 8301</institution-id><institution>Department of Infectious Diseases, </institution><institution>Affiliated Haining Hospital of Jiaxing University, Haining People&#8217;s Hospital, </institution></institution-wrap>Jiaxing, Zhejiang China </aff><aff id=\"Aff10\"><label>10</label><institution-wrap><institution-id institution-id-type=\"ROR\">https://ror.org/05m1p5x56</institution-id><institution-id institution-id-type=\"GRID\">grid.452661.2</institution-id><institution-id institution-id-type=\"ISNI\">0000 0004 1803 6319</institution-id><institution>First Affiliated Hospital of Zhejiang University, </institution></institution-wrap>Hangzhou, Zhejiang China </aff><aff id=\"Aff11\"><label>11</label><institution-wrap><institution-id institution-id-type=\"ROR\">https://ror.org/02ez0zm48</institution-id><institution-id institution-id-type=\"GRID\">grid.459988.1</institution-id><institution>Department of Respiratory Diseases, </institution><institution>Haining People&#8217;s Hospital, </institution></institution-wrap>Haining, Zhejiang China </aff></contrib-group><pub-date pub-type=\"epub\"><day>3</day><month>12</month><year>2025</year></pub-date><pub-date pub-type=\"collection\"><year>2025</year></pub-date><volume>25</volume><issue-id pub-id-type=\"pmc-issue-id\">478344</issue-id><elocation-id>430</elocation-id><history><date date-type=\"received\"><day>15</day><month>4</month><year>2025</year></date><date date-type=\"accepted\"><day>23</day><month>10</month><year>2025</year></date></history><pub-history><event event-type=\"pmc-release\"><date><day>03</day><month>12</month><year>2025</year></date></event><event event-type=\"pmc-live\"><date><day>04</day><month>12</month><year>2025</year></date></event><event event-type=\"pmc-last-change\"><date iso-8601-date=\"2025-12-05 14:25:12.820\"><day>05</day><month>12</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use=\"textmining\" content-type=\"ccbyncndlicense\">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" xlink:href=\"https://creativecommons.org/licenses/by-nc-nd/4.0/\">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink=\"http://www.w3.org/1999/xlink\" content-type=\"pmc-pdf\" xlink:href=\"12935_2025_Article_4063.pdf\"/><abstract id=\"Abs1\"><p id=\"Par1\">Neoadjuvant immunotherapy (NIT) has emerged as a transformative treatment strategy across various cancer types. However, due to the significant heterogeneity of tumors, patients exhibit highly variable responses to NIT, making the accurate preoperative identification of those who would benefit a pressing clinical challenge. In recent years, artificial intelligence (AI), particularly machine learning (ML) and deep learning (DL), has opened new pathways for predicting treatment response. AI-driven approaches have the ability to extract latent features from high-dimensional, multimodal oncological data, facilitating the construction of efficient predictive models that can optimize individualized treatment strategies. In this review, we systematically summarize existing AI-driven computational approaches for NIT response prediction, categorizing them into indirect and direct predictive paradigms. The indirect paradigm predicts clinically validated surrogate biomarkers to infer therapeutic response to NIT. In contrast, the direct paradigm leverages AI to analyze high-throughput data and establish data-driven biomarkers that directly predict clinical endpoints of NIT. Additionally, we categorize existing AI predictive models based on data modalities, spanning radiomics, pathomics, genomics, and multi-omics approaches, each providing distinct insights into tumor characteristics and treatment response. Despite notable progress, current predictive models still face significant challenges, which we broadly classify into biomarker-based and AI-based limitations. We further discuss potential strategies to address these challenges. This review systematically summarizes recent AI-based predictive models for NIT response across cancer types. By offering a structured analysis of current methodologies and challenges, we aim to guide future research and accelerate the integration of AI into precision immunotherapy.</p></abstract><kwd-group xml:lang=\"en\"><title>Keywords</title><kwd>Neoadjuvant immunotherapy</kwd><kwd>Artificial intelligence</kwd><kwd>Multi-omics</kwd><kwd>Biomarkers</kwd><kwd>Response prediction</kwd></kwd-group><funding-group><award-group><funding-source><institution>The Intramural Research Program</institution></funding-source><award-id>ES102425</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution>The Natural Science Foundation (NSF) of China</institution></funding-source><award-id>82172899</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution>The Natural Science Foundation of Zhejiang Province</institution></funding-source><award-id>LR22H160002</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution>Noncommunicable Chronic Diseases-National Science and Technology Major Project</institution></funding-source><award-id>2023ZD0502900/ 2023ZD0502902</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution>Dr. Li Dak Sum Yip Yio Chin Development Fund for Regenerative Medicine, Zhejiang University, the Open Fund of Zhejiang Provincial Key Laboratory of Pulmonology</institution></funding-source><award-id>KF202302</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution>the Haining People&#8217;s Hospital Tertiary-A Public Hospital Establishment Project Municipal Finance Support Fund</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution>the Joint University-Local Cooperation Fund between ZJU-UoE Institute and Haining People&#8217;s Hospital</institution></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id=\"Sec1\"><title>Introduction</title><p id=\"Par150\">Immunotherapy, particularly immune checkpoint inhibitors (ICIs), has emerged as a significant breakthrough in cancer treatment. By targeting programmed cell death protein 1 (PD-1), its ligand PD-L1, and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), ICIs can relieve the immune suppression exerted by tumor cells, restoring the effector functions of T cells and thereby effectively promoting the clearance of tumor cells [<xref ref-type=\"bibr\" rid=\"CR1\">1</xref>]. However, the application of immunotherapy in resectable cancers remains an area of active exploration. Neoadjuvant immunotherapy (NIT) is an innovative treatment strategy that primarily involves the use of ICIs before surgery to eliminate potential micrometastases or microtumor foci, thus reducing tumor burden and lowering the risk of postoperative recurrence [<xref ref-type=\"bibr\" rid=\"CR2\">2</xref>]. Preliminary clinical data have shown favorable pathological response rates for NIT across various tumor types. Despite these promising results, current clinical research still faces the challenge of accurately predicting which patients will benefit from NIT [<xref ref-type=\"bibr\" rid=\"CR3\">3</xref>]. Therefore, the precise identification of patients who are most likely to benefit from NIT remains a significant challenge in clinical practice, necessitating the development of accurate predictive models to identify potential responders and optimize treatment strategies before therapy begins.</p><p id=\"Par151\">The tumor characteristics of cancer patients can be characterized by a variety of data modalities, each contributing valuable insights into different aspects of tumor biology and the immune status [<xref ref-type=\"bibr\" rid=\"CR4\">4</xref>]. These include radiological images, digitized histopathological slides, genomic sequencing, proteomic profiles, epigenomic modifications, and microbiome features [<xref ref-type=\"bibr\" rid=\"CR5\">5</xref>]. Radiological imaging provides critical details on tumor size, shape, and location, while histopathological slides offer information about tumor-infiltrating immune cells and microenvironment characteristics. Genomic sequencing, through techniques such as whole-genome sequencing and targeted gene panels, identifies specific genetic mutations and alterations that drive tumor progression and immune evasion. Transcriptomics examines gene expression at the RNA level by analyzing the complete set of transcripts, including mRNA and non-coding RNA, to reveal cellular functions and regulatory mechanisms. Proteomic profiling, which analyzes protein expression in the tumor and its microenvironment, reveals biomarkers associated with tumor metastasis and immune suppression. Microbiome data explore the role of microbial communities in modulating immune responses. Epigenomic modifications, including DNA methylation, histone modifications, and chromatin accessibility, provide insights into gene regulation within both the tumor and immune microenvironment, influencing tumor behavior and immune escape mechanisms [<xref ref-type=\"bibr\" rid=\"CR5\">5</xref>, <xref ref-type=\"bibr\" rid=\"CR6\">6</xref>]. The integration of these data allows for a more comprehensive understanding of tumors.</p><p id=\"Par152\">However, these diverse data sources are inherently complex, often exhibiting high dimensionality, non-linearity, and heterogeneity, making it difficult to accurately model them using traditional human observation and statistical analysis [<xref ref-type=\"bibr\" rid=\"CR7\">7</xref>]. This complexity underscores the limitations of conventional methods, which struggle to account for intricate relationships between tumor biology, immune function, and treatment outcomes. In contrast, artificial intelligence (AI) technologies, particularly machine learning (ML) and deep learning (DL), offer a promising solution by efficiently processing and analyzing these large, heterogeneous datasets [<xref ref-type=\"bibr\" rid=\"CR8\">8</xref>]. These techniques can uncover hidden, non-linear patterns between multi-dimensional patient data and their treatment outcomes, resulting in more accurate and generalized predictions of NIT efficacy and helping to tailor personalized treatment strategies.</p><p id=\"Par153\">In this review, we provide the comprehensive and structured review of existing AI-based predictive models for assessing NIT efficacy. Specifically, we introduce a new taxonomy that classifies current approaches into two principal paradigms. The indirect paradigm infers therapeutic response by predicting clinically validated surrogate biomarkers such as PD-L1 expression, tumor mutational burden (TMB), microsatellite instability (MSI), and the tumor microenvironment (TME) features. In contrast, the direct paradigm leverages AI-driven algorithms to model clinical treatment endpoints directly, including major pathological response (MPR), pathological complete response (pCR), and progression-free survival (PFS). Furthermore, we subgroup these predictive models according to the data modality&#8212;distinguishing between single-omics and multi-omics frameworks&#8212;to emphasize the strengths of AI in capturing complex biological signals through feature extraction and data integration. Despite significant advances, AI-based computational approaches for NIT prediction remain limited by several challenges and we outline key future directions to address these limitations. Overcoming these barriers will be critical for enhancing the clinical translation of AI models and advancing precision oncology in the NIT landscape.</p></sec><sec id=\"Sec2\"><title>Comparison with existing reviews</title><p id=\"Par154\">Several reviews have been published on the application of AI in predicting immunotherapy outcomes. However, our review distinguishes itself in several key aspects. Firstly, while many existing reviews broadly examine AI in immunotherapy, our work specifically focuses on NIT. This narrower scope highlights a clinically significant and rapidly evolving treatment setting, where accurate prediction is particularly critical for guiding patient selection and optimizing perioperative strategies, thereby distinguishing our review from prior surveys that address immunotherapy in general [<xref ref-type=\"bibr\" rid=\"CR9\">9</xref>&#8211;<xref ref-type=\"bibr\" rid=\"CR13\">13</xref>]. Secondly, unlike reviews that concentrate on specific cancer types, our study adopts a pan-cancer perspective, providing a more comprehensive overview of AI-driven prediction methods across multiple malignancies. This broader scope allows us to identify cross-cancer patterns and insights that would remain hidden in single-entity surveys [<xref ref-type=\"bibr\" rid=\"CR14\">14</xref>&#8211;<xref ref-type=\"bibr\" rid=\"CR18\">18</xref>]. Thirdly, while earlier reviews often confine themselves to a single biomarker class or a specific data modality, our framework embraces both direct prediction of clinical outcomes and indirect prediction via validated biomarkers, without being restricted to one omics layer or biomarker type [<xref ref-type=\"bibr\" rid=\"CR19\">19</xref>&#8211;<xref ref-type=\"bibr\" rid=\"CR26\">26</xref>]. Finally, our review is organized in a structured manner with comparative tables that clearly summarize study attributes such as data modality, cohort size, validation strategy, and performance metrics, thereby facilitating transparent cross-study comparison and synthesis. Together, these perspectives underscore the novelty of our review and provide readers with a structured, integrative, and clinically relevant overview of AI-based prediction in NIT.<fig id=\"Fig1\" position=\"float\" orientation=\"portrait\"><label>Fig. 1</label><caption><p>Historical evolution of artificial intelligence and representative algorithm architectures. (<bold>A</bold>) Timeline illustrating the major developmental phases of AI, from symbolic logic and expert systems (1950s), through machine learning (1980s) and deep learning (2000s), to the current foundation model (2020s). (<bold>B</bold>) Schematic representations of classical ML algorithms, including LR, KNN, SVM, RF, and GBDT. (<bold>C</bold>) Architectures of widely used DL models, specifically MLP, CNN, RNN, Transformer, and GNN</p></caption><graphic xmlns:xlink=\"http://www.w3.org/1999/xlink\" id=\"MO1\" position=\"float\" orientation=\"portrait\" xlink:href=\"12935_2025_4063_Fig1_HTML.jpg\"/></fig></p></sec><sec id=\"Sec3\"><title>AI foundations in cancer research</title><p id=\"Par155\">AI, a branch of computer science (CS), is dedicated to replicating human intelligence to enable machines to learn and reason autonomously [<xref ref-type=\"bibr\" rid=\"CR27\">27</xref>]. Its evolution can be categorized into four distinct stages (Fig. <xref rid=\"Fig1\" ref-type=\"fig\">1</xref>A). From the 1950&#8201;s to the 1980&#8201;s, research was dominated by symbolic reasoning and expert systems, though progress was limited by insufficient computational resources and data. Between the 1980&#8201;s and the 2000&#8201;s, the adoption of statistical learning marked a shift towards data-driven methods, leading to notable advances in ML [<xref ref-type=\"bibr\" rid=\"CR28\">28</xref>]. Since the 2000&#8201;s, the emergence of DL has significantly improved AI capabilities, particularly in CV and complex decision-making. Entering the 2020&#8201;s, AI has transitioned into the foundation model era, exemplified by large-scale pre-trained systems such as generative pre-trained transformer (GPT), contrastive language-Image pre-training (CLIP), and segment anything model (SAM) [<xref ref-type=\"bibr\" rid=\"CR29\">29</xref>]. Trained on massive datasets using self-supervised learning, these models exhibit strong generalizability and adaptability across tasks [<xref ref-type=\"bibr\" rid=\"CR28\">28</xref>]. These advancements have laid a robust foundation for the integration of AI into complex real-world domains [<xref ref-type=\"bibr\" rid=\"CR30\">30</xref>]. These advancements have laid a solid foundation for integrating AI into complex real-world domains. Among these, AI has been applied to biomedical predictive analytics problems. For example, machine learning models have been used to analyze time-series data from wearable devices, such as heart rate monitors, electrocardiograms, and fitness trackers. These models can predict cardiovascular events, like heart attacks, by detecting abnormalities in heart rhythms and other physiological signals [<xref ref-type=\"bibr\" rid=\"CR31\">31</xref>]. Additionally, graph neural networks are being utilized to predict how molecules interact with biological targets [<xref ref-type=\"bibr\" rid=\"CR32\">32</xref>]. These models analyze extensive chemical and biological datasets to identify promising compounds for drug development or repurposing.</p><p id=\"Par156\">Machine learning (ML), a subfield of artificial intelligence (AI), involves constructing mathematical models that enable computers to identify patterns from data and make predictions or decisions without explicit programming [<xref ref-type=\"bibr\" rid=\"CR33\">33</xref>]. Among commonly used ML algorithms, logistic regression (LR) is a classic statistical model for binary classification, widely applied in tasks such as disease risk prediction, treatment response evaluation, and survival analysis [<xref ref-type=\"bibr\" rid=\"CR34\">34</xref>]. K-Nearest Neighbors (KNN), a non-parametric algorithm based on sample similarity (e.g., Euclidean distance), is valued for its simplicity and interpretability [<xref ref-type=\"bibr\" rid=\"CR35\">35</xref>]. Support Vector Machines (SVMs) construct optimal hyperplanes to separate classes, demonstrating robust performance in high-dimensional biomedical data [<xref ref-type=\"bibr\" rid=\"CR36\">36</xref>]. Random Forests (RFs), as ensemble methods combining multiple decision trees, improve model robustness and generalization. They are frequently employed in clinical outcome prediction and disease risk assessment, especially in settings with heterogeneous, multidimensional clinical data [<xref ref-type=\"bibr\" rid=\"CR37\">37</xref>]. Gradient Boosted Decision Trees (GBDTs) iteratively correct prediction errors to build strong learners, showing effectiveness in genomic feature selection and personalized treatment modeling, particularly when dealing with small but high-quality datasets [<xref ref-type=\"bibr\" rid=\"CR38\">38</xref>].</p><p id=\"Par157\">While conventional ML approaches provide interpretable models with lower computational costs, they heavily depend on handcrafted feature engineering, which may lead to the loss of critical information [<xref ref-type=\"bibr\" rid=\"CR39\">39</xref>]. However, DL, another branch of AI, overcomes the limitations of traditional ML methods by leveraging multi-layered neural networks to automatically extract hierarchical features from data [<xref ref-type=\"bibr\" rid=\"CR39\">39</xref>]. DL models typically contain multiple hidden layers that abstract data features from low to high levels. Its primary advantage lies in its powerful feature learning capability, particularly in processing large-scale, complex, unstructured data (<italic toggle=\"yes\">e.g.</italic>, image and speech data), where it exhibits exceptional performance (Fig. <xref rid=\"Fig1\" ref-type=\"fig\">1</xref>C). Specifically, multi-layer perceptrons (MLPs), as fundamental feedforward networks, capture non-linear relationships and serve as the basis for more advanced architectures [<xref ref-type=\"bibr\" rid=\"CR40\">40</xref>]. Convolutional Neural Networks (CNNs) are among the most commonly used DL models, particularly for medical image analysis. In NIT, CNNs are widely applied for automated tumor image analysis, such as tumor detection, segmentation, classification, and evaluation of immune microenvironments. CNNs can progressively capture both local and global features of tumor images, enabling precise classification or regression analyses that inform clinical decision-making [<xref ref-type=\"bibr\" rid=\"CR41\">41</xref>]. Besides, recurrent neural networks (RNNs) are particularly suited for handling sequential data. In genomics, RNNs have been applied to tasks such as predicting gene expression from promoter sequences by incorporating context information across nucleotide positions [<xref ref-type=\"bibr\" rid=\"CR41\">41</xref>]. Unlike CNNs, which rely on convolutional operations to extract local features, vision transformers (ViTs) employ self-attention mechanisms that enable global feature modeling across the entire image. This architecture not only facilitates efficient parallel computation but also enhances the model&#8217;s ability to capture long-range dependencies. Consequently, ViTs have demonstrated strong performance in complex visual tasks such as tumor subtyping, segmentation, and multi-modal image fusion [<xref ref-type=\"bibr\" rid=\"CR42\">42</xref>]. Also, graph neural networks (GNNs) are gaining traction in medical AI, particularly in modeling relational data, such as protein interactions, molecular structures, and patient networks [<xref ref-type=\"bibr\" rid=\"CR42\">42</xref>].</p></sec><sec id=\"Sec4\"><title>Indirect biomarker-based prediction methods</title><sec id=\"Sec5\"><title>PD-L1</title><p id=\"Par158\">As a key immune-regulatory molecule, elevated PD-L1 expression is thought to enhance the tumor&#8217;s sensitivity to immune checkpoint blockade, which could improve the likelihood of therapeutic benefit [<xref ref-type=\"bibr\" rid=\"CR43\">43</xref>]. Extensive clinical trials have consistently demonstrated that tumors with high PD-L1 expression (<inline-formula id=\"IEq1\"><tex-math id=\"d33e1263\">\\documentclass[12pt]{minimal}\n\t\t\t\t\\usepackage{amsmath}\n\t\t\t\t\\usepackage{wasysym} \n\t\t\t\t\\usepackage{amsfonts} \n\t\t\t\t\\usepackage{amssymb} \n\t\t\t\t\\usepackage{amsbsy}\n\t\t\t\t\\usepackage{mathrsfs}\n\t\t\t\t\\usepackage{upgreek}\n\t\t\t\t\\setlength{\\oddsidemargin}{-69pt}\n\t\t\t\t\\begin{document}$$\\ge$$\\end{document}</tex-math></inline-formula> 1%) tend to achieve higher rates of MPR or pCR following NIT or neoadjuvant chemoimmunotherapy (NCIT), suggesting an indirect association between PD-L1 levels and treatment response [<xref ref-type=\"bibr\" rid=\"CR44\">44</xref>&#8211;<xref ref-type=\"bibr\" rid=\"CR49\">49</xref>]. Therefore, PD-L1 expression is considered a viable indirect biomarker for predicting potential benefits from NIT, contributing to improved preoperative treatment stratification and patient selection. By automating the quantification of PD-L1 expression with exceptional precision, AI models mitigate the inherent variability of manual assessment and provide a means to capture the dynamic spatiotemporal heterogeneity of tumors [<xref ref-type=\"bibr\" rid=\"CR20\">20</xref>]. This technological advance could significantly enhance the accuracy of patient selection and ultimately enable more refined, evidence-based decision-making in the clinical application of NIT. A systematic literature search was conducted, followed by independent screening and quality assessment by two researchers, leading to the inclusion of 19 studies that met the predefined criteria and focused on PD-L1 as a biomarker. Among these, 18 studies employed a single-omics approach, with radiomics-driven analyses comprising 10 studies (55.6%), pathomics-based investigations accounting for six studies (33.3%), and genomics-focused research representing two studies (11.1%) (Tab. <xref rid=\"Tab1\" ref-type=\"table\">1</xref>, Fig. <xref rid=\"Fig2\" ref-type=\"fig\">2</xref>). Herein, a model built with data from a single type of omics (e.g., radiomics, pathomics, genomics, etc.) is referred to as a single-omics model. In contrast, a model built using data from two or more omics layers is classified as a multi-omics model.</p><sec id=\"Sec6\"><title>Single omics-based methods</title><p id=\"Par159\"><bold><italic toggle=\"yes\">Radiomics</italic></bold> Using an unbiased search approach, we included 10 AI-based radiomics studies focused on lung, bladder, gastric, and breast cancers, with seven studies centered on lung cancer [<xref ref-type=\"bibr\" rid=\"CR50\">50</xref>&#8211;<xref ref-type=\"bibr\" rid=\"CR59\">59</xref>]. Five retrospective studies in lung cancers have demonstrated that CT-based models are effective in predicting PD-L1 expression, with AUC values exceeding 0.75. Following this progression, another NSCLC study introduced a hybrid radiomics model that integrated delta-radiomics and DL features with mathematical models and replaced eight original model features with non-linear fitting parameters, which indicates its high prediction accuracy (cross-validation AUC of 0.91) [<xref ref-type=\"bibr\" rid=\"CR51\">51</xref>]. While the majority of previous studies have been concentrated on primary lung cancer, a particular investigation by Mei&#223;ner et al. [<xref ref-type=\"bibr\" rid=\"CR59\">59</xref>] provides a novel non-invasive assessment method for predicting PD-L1 expression in brain metastases from NSCLC. They proposed a radiomics-based model on intracranial PD-L1 expression, which, using stratified cross-validation, achieved an AUC of 0.84 in external validation, demonstrating its ability to accurately predict intracranial PD-L1 expression in NSCLC patients with brain metastases. Furthermore, AI-driven radiomics has also shown broad potential in other cancers. Notably, one study in advanced BC found that subgroup analysis revealed the radiomics model&#8217;s independence from IHC-based PD-L1 status, tumor metastatic load, and molecular subtypes, emphasizing its significant value in the automated quantification of PD-L1 expression [<xref ref-type=\"bibr\" rid=\"CR53\">53</xref>]. These studies highlight the emerging potential of radiomics in predicting PD-L1 expression, particularly in lung cancer, and underscore ongoing efforts to refine model algorithms.</p><p id=\"Par160\"><bold><italic toggle=\"yes\">Pathomics</italic></bold> We conducted an unbiased selection of five studies, focusing on NSCLC, esophageal squamous cell carcinoma (ESCC), BC, and glioblastoma (GBM) [<xref ref-type=\"bibr\" rid=\"CR60\">60</xref>&#8211;<xref ref-type=\"bibr\" rid=\"CR65\">65</xref>]. Nearly all of the AI models employed CNN and RNN as core methodologies. Among these, the largest study involved 3,376 BC patients and utilized automated analysis of H&amp;E-stained tissue slide images to predict PD-L1 expression levels, achieving AUC values ranging from 0.91 to 0.93 [<xref ref-type=\"bibr\" rid=\"CR62\">62</xref>]. Moreover, two retrospective studies on NSCLC focused on the automated analysis of PD-L1 IHC images labeled with 22C3 and SP263 antibodies. These studies applied a CNN-based PD-L1 tumor proportion score (TPS) model, demonstrating high consistency with pathologist-calculated TPS results (<inline-formula id=\"IEq2\"><tex-math id=\"d33e1317\">\\documentclass[12pt]{minimal}\n\t\t\t\t\\usepackage{amsmath}\n\t\t\t\t\\usepackage{wasysym} \n\t\t\t\t\\usepackage{amsfonts} \n\t\t\t\t\\usepackage{amssymb} \n\t\t\t\t\\usepackage{amsbsy}\n\t\t\t\t\\usepackage{mathrsfs}\n\t\t\t\t\\usepackage{upgreek}\n\t\t\t\t\\setlength{\\oddsidemargin}{-69pt}\n\t\t\t\t\\begin{document}$$\\text {R}&gt; 0.950$$\\end{document}</tex-math></inline-formula>), further validating the reliability of this model for automated PD-L1 expression assessment [<xref ref-type=\"bibr\" rid=\"CR60\">60</xref>, <xref ref-type=\"bibr\" rid=\"CR61\">61</xref>]. Besides NSCLC, another study on GBM developed an ML model based on Raman histopathology. Leveraging a machine learning classifier (MLC), the model successfully visualized PD-L1 expression in glioma cells, CD8<sup>+</sup> T cells, macrophages, and normal cells, achieving an average accuracy of 0.990. This method not only accurately delineated tumor-normal tissue boundaries but also completed the entire process&#8212;from signal collection to image visualization&#8212;in just 30 minutes, showcasing its remarkable potential for rapid and efficient analysis [<xref ref-type=\"bibr\" rid=\"CR64\">64</xref>]. Overall, AI-based models show strong potential in automated PD-L1 assessment across various cancers, utilizing diverse pathological inputs to enhance accuracy.</p><p id=\"Par161\"><bold><italic toggle=\"yes\">Others</italic></bold> AI methods have been successfully applied to genomics for predicting PD-L1 expression in cancer. Two multicenter, retrospective studies have demonstrated the potential of AI in predicting durable clinical benefit and survival outcomes in NSCLC patients, achieving exceptional predictive accuracy (<inline-formula id=\"IEq3\"><tex-math id=\"d33e1337\">\\documentclass[12pt]{minimal}\n\t\t\t\t\\usepackage{amsmath}\n\t\t\t\t\\usepackage{wasysym} \n\t\t\t\t\\usepackage{amsfonts} \n\t\t\t\t\\usepackage{amssymb} \n\t\t\t\t\\usepackage{amsbsy}\n\t\t\t\t\\usepackage{mathrsfs}\n\t\t\t\t\\usepackage{upgreek}\n\t\t\t\t\\setlength{\\oddsidemargin}{-69pt}\n\t\t\t\t\\begin{document}$$\\text {AUC}&gt; 0.80$$\\end{document}</tex-math></inline-formula>) [<xref ref-type=\"bibr\" rid=\"CR66\">66</xref>, <xref ref-type=\"bibr\" rid=\"CR67\">67</xref>]. These studies underscore the effectiveness of AI techniques in forecasting PD-L1 expression to predict patient outcomes.</p></sec><sec id=\"Sec7\"><title>Multi-omics-based methods</title><p id=\"Par162\">In AI-based studies on PD-L1 biomarkers, the integration of multiple input data types has proven to be a powerful approach, leveraging the distinct advantages of various omics to enhance prediction accuracy. In a study on gastric cancer (GC), PD-L1 was used as a supplementary biomarker for evaluating immune responses, combined with radiomics and pathomics to assess the efficacy of anti-HER2 therapy in conjunction with immunotherapy [<xref ref-type=\"bibr\" rid=\"CR68\">68</xref>]. Specifically, in another study involving 57 NSCLC patients, Byeon et al. (2022) [<xref ref-type=\"bibr\" rid=\"CR69\">69</xref>] developed a multi-omics ML model that incorporated sequencing data, IHC images, demographic information, and clinical data. By combining these diverse data types, the model was able to capture the intricate relationships between gene expression, tumor immune microenvironment features, and cancer-specific intrinsic gene signatures, thus providing a precise prediction of immune treatment efficacy (AUC = 0.957). These multi-omics studies centered around PD-L1 highlight the significant potential of AI-driven models in advancing precision medicine and improving therapeutic outcomes.<fig id=\"Fig2\" position=\"float\" orientation=\"portrait\"><label>Fig. 2</label><caption><p>AI-based single- and multi-omics computational frameworks for pan-cancer NIT response prediction through surrogate biomarker (outer) and direct modeling (inner)</p></caption><graphic xmlns:xlink=\"http://www.w3.org/1999/xlink\" id=\"MO2\" position=\"float\" orientation=\"portrait\" xlink:href=\"12935_2025_4063_Fig2_HTML.jpg\"/></fig></p></sec></sec><sec id=\"Sec8\"><title>TMB</title><p id=\"Par163\">TMB reflects the overall quantity of somatic mutations within a tumor genome and has emerged as a potential biomarker for prognostic assessment and immunotherapy response prediction [<xref ref-type=\"bibr\" rid=\"CR70\">70</xref>]. TMB is closely associated with tumor immunogenicity, as higher mutational loads increase the likelihood of neoantigen generation, thereby enhancing tumor visibility to the host immune system [<xref ref-type=\"bibr\" rid=\"CR71\">71</xref>]. Clinical evidence across multiple studies indicates that tumors with high TMB (TMB-H) are more likely to exhibit substantial pathological regression and tumor shrinkage following NIT, with a strong correlation between TMB-H status and favorable immune responses [<xref ref-type=\"bibr\" rid=\"CR72\">72</xref>&#8211;<xref ref-type=\"bibr\" rid=\"CR74\">74</xref>]. Consequently, TMB-H is increasingly recognized as a viable biomarker to benefit from NIT. A systematic literature search was conducted, followed by independent screening and quality assessment by two researchers, resulting in the inclusion of 15 studies that met the predefined criteria and focused on TMB as a biomarker. Of these, 14 studies adopted a single-omics approach, with radiomics-driven analyses comprising five studies (35.7%), pathomics-based investigations accounting for seven studies (50%), genomics-focused research representing one studies (7.14%), and transcriptomics-focused research representing one studies (6.7%) (Tab. <xref rid=\"Tab1\" ref-type=\"table\">1</xref>, Fig. <xref rid=\"Fig2\" ref-type=\"fig\">2</xref>).</p><sec id=\"Sec9\"><title>Single omics-based methods</title><p id=\"Par164\"><bold><italic toggle=\"yes\">Radiomics</italic></bold> Through an unbiased search approach, we identified five studies validating the capability of AI-based radiomics models in assessing TMB, spanning endometrial cancer, lung adenocarcinoma, NSCLC, and low-grade glioma (LGG) cohorts [<xref ref-type=\"bibr\" rid=\"CR75\">75</xref>&#8211;<xref ref-type=\"bibr\" rid=\"CR79\">79</xref>]. Among these studies, He et al. (2020) [<xref ref-type=\"bibr\" rid=\"CR77\">77</xref>] developed a CNN model based on CT imaging to create a DL-based radiomics biomarker, which can accurately differentiate patients with high or low pre-treatment TMB status (AUC 0.8). They observed that the DL radiomics biomarkers also potentially predict the treatment responses to ICIs in NSCLC patients (AUC = 0.81), which also supports TMB as an efficacy biomarker of immunotherapy. In endometrial cancer, Veeraraghavan et al. (2020) [<xref ref-type=\"bibr\" rid=\"CR75\">75</xref>] utilized radiomic features from contrast-enhanced CT images to capture tumor morphology and explore the differences in features across various tumor regions and subpopulations. Based on these features, they successfully developed an ML model robustly assessing TMB status (AUC = 0.87) and further observed that peritumoral features are closely correlated with TMB status. Additionally, another study leverages ML algorithms for MRI radiomics model development and achieved TMB evaluation in lower-grade glioma cohorts [<xref ref-type=\"bibr\" rid=\"CR78\">78</xref>]. Overall, radiomics demonstrates significant potential as a valuable adjunct for TMB classification, providing sufficient information to guide clinical decision-making in immunotherapy, despite the inherent tumor heterogeneity.</p><p id=\"Par165\"><bold><italic toggle=\"yes\">Pathomics</italic></bold> We conducted an unbiased selection of six AI-based pathology studies, covering various cancer types, including colorectal cancer (CRC), renal cell carcinoma (RCC), glioma, bladder cancer (BLCA), and GC [<xref ref-type=\"bibr\" rid=\"CR80\">80</xref>&#8211;<xref ref-type=\"bibr\" rid=\"CR85\">85</xref>], [?]. All of these studies utilized data sourced from the TCGA database, with the images processed using H&amp;E staining for subsequent analysis. Also, nearly all studies have opted for CNN-based deep learning models, specifically utilizing architectures such as ResNet18, ResNet50, VGG19, and InceptionNet for image analysis. Notably, in a glioma study, a graph convolutional neural network-based (GCNN) framework was employed to identify pathological features on WSIs of H&amp;E stained tumor biopsies. The DL model can both classify patients into high and low TMB groups and stratify glioma patients based on their overall survival (OS), demonstrating a strong association between TMB-related histopathological features from H&amp;E staining and overall survival [<xref ref-type=\"bibr\" rid=\"CR82\">82</xref>]. Furthermore, a multicenter study on BLCA demonstrated that DL-driven spatial analysis of WSI can reliably predict TMB-H and TIL level, another therapeutic biomarker for NIT as elaborated in the following sections. The study also observed that TMB-H patients with lower spatial heterogeneity of TMB and enriched TILs show improved OS [<xref ref-type=\"bibr\" rid=\"CR84\">84</xref>]. Overall, AI-based pathology research effectively correlates stratified TMB-related features with clinical outcomes, marking a significant advancement in predicting therapeutic efficacy across cancers.</p><p id=\"Par166\"><bold><italic toggle=\"yes\">Others</italic></bold> We also reviewed three additional genomics-based studies, two of which focused on pan-cancer analysis rather than a single cancer type [<xref ref-type=\"bibr\" rid=\"CR86\">86</xref>&#8211;<xref ref-type=\"bibr\" rid=\"CR88\">88</xref>]. One pan-cancer study highlighted that the relationship between TMB and OS is not always monotonic, revealing more complex dynamics in certain cancer types. Using a dual-threshold approach combined with a Na&#239;ve Bayes (NB)-based machine learning model, this study leveraged large-scale pan-cancer data to capture nuanced interactions between TMB and cancer stem cell characteristics, deepening our understanding of TMB as a biomarker [<xref ref-type=\"bibr\" rid=\"CR88\">88</xref>].</p></sec><sec id=\"Sec10\"><title>Multi-omics-based methods</title><p id=\"Par167\">A growing number of studies are now exploring the predictive potential of TMB through multi-omics data combined with AI. In a study by Wang et al. (2022) [<xref ref-type=\"bibr\" rid=\"CR89\">89</xref>], a multi-omics model was developed to predict TMB status in lung adenocarcinoma (LUAD) patients by integrating gene expression, miRNA profiles, CpG methylation, and pathological tissue images. This approach enables more precise TMB prediction by capturing nuanced epigenetic changes in the tumor microenvironment, promoting prognostic accuracy. Also, the features selected from these mutational and epigenetic profiles could inspire the rationale and design of simplified clinical assays, such as qRT-PCR, enhancing patient stratification and treatment selection. However, further research is required to refine multi-omics integration methods and validate their applicability in larger, multi-center cohorts.</p></sec></sec><sec id=\"Sec11\"><title>MSI/dMMR</title><p id=\"Par168\">When the mismatch repair (MMR) system becomes dysfunctional, the accumulation of mismatches leads to genomic instability, including an increase in indels within microsatellite regions [<xref ref-type=\"bibr\" rid=\"CR90\">90</xref>]. This results in tumors typically exhibiting a higher mutational burden and tumor antigen presentation, associated with better efficacy in immunotherapy. A substantial number of clinical trials have demonstrated that, compared to microsatellite stability (MSS)/proficient MMR tumors, MSI/deficient MMR (dMMR) tumors generally exhibit a higher pathological response rate to NIT or NCIT across multiple cancer types [<xref ref-type=\"bibr\" rid=\"CR91\">91</xref>&#8211;<xref ref-type=\"bibr\" rid=\"CR97\">97</xref>]. Therefore, MSI/dMMR is considered a viable biomarker for predicting the benefit of NIT. Following a systematic search based on predefined criteria, and subsequent independent screening and quality assessment by two reviewers, we ultimately included 37 studies that employed AI to evaluate MSI/dMMR status in cancer patients. Of these, nine (24.3%) were radiomics-based, 23 (62.2%) were pathology-based, three (8.1%) were genomics-based, and two (5.4%) utilized multi-omics approaches (Tab. <xref rid=\"Tab1\" ref-type=\"table\">1</xref>, Fig. <xref rid=\"Fig2\" ref-type=\"fig\">2</xref>).</p><sec id=\"Sec12\"><title>Single omics-based methods</title><p id=\"Par169\"><bold><italic toggle=\"yes\">Radiomics</italic></bold> Recent studies have validated the potential of imaging-based AI models for the non-invasive prediction of MSI and dMMR. Through an unbiased literature review, we identified nine relevant studies, the majority of which were retrospective analyses conducted on large cohorts of over 100 patients [<xref ref-type=\"bibr\" rid=\"CR98\">98</xref>&#8211;<xref ref-type=\"bibr\" rid=\"CR106\">106</xref>]. The primary imaging modalities used in these studies included MRI (n=5) and CT or PET/CT (n=4). ML algorithms, including SVM, LR, and KNN, were employed in five studies, while DL was applied in four. CRC remains the most commonly studied cancer, accounting for more than half of the studies (n=5). Other cancer types investigated include EMC [<xref ref-type=\"bibr\" rid=\"CR98\">98</xref>, <xref ref-type=\"bibr\" rid=\"CR100\">100</xref>, <xref ref-type=\"bibr\" rid=\"CR101\">101</xref>] and GC [<xref ref-type=\"bibr\" rid=\"CR106\">106</xref>]. Nearly all studies reported satisfactory performance, with an area AUC value greater than 0.8. Notably, Wang et al. [<xref ref-type=\"bibr\" rid=\"CR101\">101</xref>] developed a composite model that integrates features extracted from diffusion-weighted imaging (DWI) MRI via CNN with traditional radiomics, clinical parameters, and apparent diffusion coefficient (ADC) values. The model demonstrated excellent predictive performance in an endometrial cancer cohort, highlighting the significant advantages and clinical potential of multi-level, multimodal feature fusion in the non-invasive prediction of MSI.</p><p id=\"Par170\"><bold><italic toggle=\"yes\">Pathomics</italic></bold> AI models are applied to predict tumor MSI or dMMR status from pathological slides, thereby aiding in individualized NIT regimens. By undergoing a comprehensive literature retrieval, we identified 18 studies focused on AI-based MSI prediction using pathomics features, of which 70% were conducted within CRC cohorts (n=13), while the remaining studies involved endometrial cancer (EMC), prostate cancer, epithelial ovarian cancer (EOC) and GC [<xref ref-type=\"bibr\" rid=\"CR107\">107</xref>&#8211;<xref ref-type=\"bibr\" rid=\"CR124\">124</xref>]. Regardless of cancer type, nearly all studies were retrospective analyses conducted on large cohorts of over 100 patients. In CRC research, 12 studies have demonstrated the robustness of DL models utilizing H&amp;E WSIs for MSI prediction, consistently achieving AUC values greater than 0.85. Among these studies, one study notably proposed an innovative multi-center collaboration approach. Specifically, the study from Saldanha et al.[<xref ref-type=\"bibr\" rid=\"CR114\">114</xref>] is the first to successfully apply a swarm learning (SL) framework to a large-scale, multicenter cancer histopathology image dataset comprising over 5,000 patients. Without requiring data sharing and while fully preserving data privacy, the study enabled cross-institutional collaborative training of AI models to predict MSI in CRC. This approach overcomes the reliance on centralized data aggregation typical of conventional AI training and addresses critical barriers related to ethics, legal constraints, and data sovereignty in clinical research. The SL-trained models outperformed most locally trained counterparts. They achieved performance comparable to models trained on pooled datasets, demonstrating strong data efficiency and promising potential for real-world clinical application. Meanwhile, several studies have successfully developed models for predicting MSI in CRC using other types of pathology data. For example, two studies demonstrated that DL models based on infrared imaging and Raman spectroscopy features of tumor biopsies were able to distinguish between MSI and MSS in CRC cohorts [<xref ref-type=\"bibr\" rid=\"CR109\">109</xref>, <xref ref-type=\"bibr\" rid=\"CR116\">116</xref>]. In other cancer types, all five studies reported DL models can automatically extract features from H&amp;E WSIs and differentiate patients with MSS or MSI with robust performance, indicating that DL models based on H&amp;E WSI are both more commonly studied across various cancer types.</p><p id=\"Par171\">Besides MSI, we identified four studies that applied DL models based on tumor tissue sections to directly predict the MMR status in CRC [<xref ref-type=\"bibr\" rid=\"CR125\">125</xref>, <xref ref-type=\"bibr\" rid=\"CR126\">126</xref>] and EMC [<xref ref-type=\"bibr\" rid=\"CR127\">127</xref>, <xref ref-type=\"bibr\" rid=\"CR128\">128</xref>]. While these studies are also primarily constructed upon H&amp;E WSIs (n = 3), Nowak et al. [<xref ref-type=\"bibr\" rid=\"CR125\">125</xref>] developed a DL&#8211;based model that predicts dMMR status in CRC using IHC images of MMR proteins, enabling single-cell&#8211;level assessment of protein expression. In two independent clinical trial cohorts, the model demonstrated excellent predictive performance (AUC = 0.86), achieving over 75% specificity at 98% sensitivity, with a positive predictive value of <inline-formula id=\"IEq4\"><tex-math id=\"d33e1528\">\\documentclass[12pt]{minimal}\n\t\t\t\t\\usepackage{amsmath}\n\t\t\t\t\\usepackage{wasysym} \n\t\t\t\t\\usepackage{amsfonts} \n\t\t\t\t\\usepackage{amssymb} \n\t\t\t\t\\usepackage{amsbsy}\n\t\t\t\t\\usepackage{mathrsfs}\n\t\t\t\t\\usepackage{upgreek}\n\t\t\t\t\\setlength{\\oddsidemargin}{-69pt}\n\t\t\t\t\\begin{document}$$\\ge 98\\%$$\\end{document}</tex-math></inline-formula> for the most common somatic dMMR subtype. Further validation in the SCOT trial confirmed the prognostic significance of dMMR status in patients treated with oxaliplatin. In summary, H&amp;E WSIs are the most extensively studied input for ML and DL models in predicting MSI/dMMR. AI models have demonstrated robust performance in predicting MSI/dMMR status across multiple cancer types, reducing the burden of pathological workload. While the majority of models are trained and validated in CRC cohorts, AI has shown efficacy in MSI/dMMR predictions across various cancers such as EMC, prostate cancer (PC), and EOC.</p><p id=\"Par172\"><bold><italic toggle=\"yes\">Others</italic></bold> Compared to traditional PCR-based methods, next-generation sequencing (NGS)-based computational approaches have emerged as promising alternatives for detecting MSI. These methods are less labor-intensive and allow for the simultaneous analysis of multiple samples and loci. However, a major limitation of conventional NGS-based MSI detection is the requirement for matched normal tissue, which serves as a reference to examine aligned reads&#8212;an approach that is computationally intensive and often impractical in clinical settings. To address this, ML algorithms have been developed to predict MSI directly from tumor samples, eliminating the need for normal-tumor pairings. For instance, Swaerts et al. [<xref ref-type=\"bibr\" rid=\"CR129\">129</xref>] introduced DeltaMSI, an ML tool that infers MSI status based on raw indel distributions across microsatellite loci. Similarly, Chen et al. [<xref ref-type=\"bibr\" rid=\"CR130\">130</xref>] proposed MSINGB, a model based on next-generation boosting (NGBoost) that utilizes tumor mutation annotation data. Both tools demonstrated excellent predictive performance, achieving AUCs of 0.95 and 0.999, respectively. In addition to ML-based methods, DL approaches have also been explored. One study proposes a novel and explainable GNN framework, which, for the first time, integrates RNA expression and DNA methylation data to predict MSI status. The model enables high-performance MSI detection using tumor-only samples, eliminating the need for matched normal tissue. It also identifies key MSI-associated biomarkers with potential relevance to immunotherapy, providing both predictive accuracy and biological interpretability [<xref ref-type=\"bibr\" rid=\"CR131\">131</xref>].</p></sec><sec id=\"Sec13\"><title>Multi-omics-based methods</title><p id=\"Par173\">Two studies have developed multi-omics AI models for MSI prediction by integrating data from different omics sources [<xref ref-type=\"bibr\" rid=\"CR132\">132</xref>, <xref ref-type=\"bibr\" rid=\"CR133\">133</xref>]. Shi et al. [<xref ref-type=\"bibr\" rid=\"CR132\">132</xref>] developed a multi-omics integrative model that combines Raman spectroscopy data from formalin-fixed paraffin-embedded (FFPE) tumor slides with preoperative CT imaging to accurately classify MSI status in gastric cancer. The model incorporates a newly proposed Euclidean Distance Raman Spectroscopy algorithm, which effectively mitigates signal variability caused by tumor heterogeneity. Among various machine learning approaches, the EDRS-based model achieved the highest classification accuracy (94.6%). Compared to the Raman-only model (AUC = 0.871), the multi-modal model demonstrated superior performance in distinguishing MSI from MSS tumors (AUC = 0.914), offering a novel and promising strategy for precise NIT prediction. Another study proposed a multimodal DL model for predicting MSI in CRC [<xref ref-type=\"bibr\" rid=\"CR133\">133</xref>]. It demonstrated robustness in MSI classification with H&amp;E WSIs alone (AUC=0.809) but can be further enhanced by integrating DNA methylation data (AUC=0.952). Interestingly, combining WSIs with multiple molecular data types (mRNA, miRNA, lncRNA, DNA methylation, and CNV) resulted in lower performance. The study attributed this to the noise from irrelevant features or overlapping information across omics data, which diluted the model&#8217;s focus. Overall, while combining multiple omics holds the potential to improve model efficacy, the addition of heterogeneous data can introduce noise and thus requires careful selection.</p></sec></sec><sec id=\"Sec14\"><title>TME</title><p id=\"Par174\">Characteristics of the TME, particularly infiltrating immune cells such as TILs and CD8<sup>+</sup> T cells, have been widely studied as predictors of immunotherapy benefit and shown to correlate with NIT response rates in clinical trials [<xref ref-type=\"bibr\" rid=\"CR134\">134</xref>&#8211;<xref ref-type=\"bibr\" rid=\"CR139\">139</xref>]. Also, tumor-stromal ratio (TSR), tertiary lymphoid structure (TLS), molecular markers including CTLA-4, and vascular endothelial growth factor (VEGF), have been reported to reflect ICI therapeutic outcomes [<xref ref-type=\"bibr\" rid=\"CR140\">140</xref>], with growing evidence suggesting their potential as predictive parameters of NIT outcomes [<xref ref-type=\"bibr\" rid=\"CR141\">141</xref>&#8211;<xref ref-type=\"bibr\" rid=\"CR144\">144</xref>]. The integration of AI holds promise for directly predicting TME components from imaging features, thereby potentially guiding the use of NIT. Following a systematic search based on predefined criteria, followed by independent screening and quality assessment by two reviewers, we ultimately included 34 studies that utilized AI to evaluate components of the TME related to the benefits of NIT in cancer patients. Among these, 18 studies (52.9%) were radiomics-driven, while 16 studies (47.1%) were pathomics-driven (Tab. <xref rid=\"Tab1\" ref-type=\"table\">1</xref>, Fig. <xref rid=\"Fig2\" ref-type=\"fig\">2</xref>).</p><sec id=\"Sec15\"><title>Single omics-based methods</title><p id=\"Par175\"><bold><italic toggle=\"yes\">Radiomics</italic></bold> Through an unbiased literature search, we identified 18 studies involving AI models based on radiomics for evaluating TME profiles that are correlated to NIT efficacy. All of these studies were retrospective, with a large proportion of the data originating from single-center cohorts (n=10). Approximately half of the studies focused on BC (n=8), while the remaining studies covered oral tongue squamous cell carcinoma (OTSCC), GC, glioma, clear cell RCC (ccRCC), lung cancer, pancreatic ductal adenocarcinoma (PDAC) and hepatocellular carcinoma (HCC) [<xref ref-type=\"bibr\" rid=\"CR145\">145</xref>&#8211;<xref ref-type=\"bibr\" rid=\"CR162\">162</xref>]. The primary objective of these radiomics models was to predict immune cell infiltration within the TME, particularly TILs (n=7). Most researches focus on the imaging data from BC patients (n=6)[<xref ref-type=\"bibr\" rid=\"CR145\">145</xref>&#8211;<xref ref-type=\"bibr\" rid=\"CR150\">150</xref>]. Additionally, six studies utilized radiomics to evaluate other immune or stromal cell populations within the TME, all employing ML techniques[<xref ref-type=\"bibr\" rid=\"CR151\">151</xref>, <xref ref-type=\"bibr\" rid=\"CR152\">152</xref>, <xref ref-type=\"bibr\" rid=\"CR154\">154</xref>, <xref ref-type=\"bibr\" rid=\"CR155\">155</xref>, <xref ref-type=\"bibr\" rid=\"CR157\">157</xref>, <xref ref-type=\"bibr\" rid=\"CR158\">158</xref>]. Four of these studies used MRI radiomics, while the other two employed CT radiomics. These studies were based on various cancer cohorts and predicted different TME cell populations, highlighting the broad applicability of AI models based on MRI and CT radiomics in predicting TME cellular composition. Interestingly, even within the same study, models built with the same sample group and algorithm showed significant differences in performance when predicting various infiltrating cell populations. For example, in a study of an NSCLC cohort, the ML model based on radiomics predicted <inline-formula id=\"IEq5\"><tex-math id=\"d33e1626\">\\documentclass[12pt]{minimal}\n\t\t\t\t\\usepackage{amsmath}\n\t\t\t\t\\usepackage{wasysym} \n\t\t\t\t\\usepackage{amsfonts} \n\t\t\t\t\\usepackage{amssymb} \n\t\t\t\t\\usepackage{amsbsy}\n\t\t\t\t\\usepackage{mathrsfs}\n\t\t\t\t\\usepackage{upgreek}\n\t\t\t\t\\setlength{\\oddsidemargin}{-69pt}\n\t\t\t\t\\begin{document}$${CD3}^+$$\\end{document}</tex-math></inline-formula> and <inline-formula id=\"IEq6\"><tex-math id=\"d33e1631\">\\documentclass[12pt]{minimal}\n\t\t\t\t\\usepackage{amsmath}\n\t\t\t\t\\usepackage{wasysym} \n\t\t\t\t\\usepackage{amsfonts} \n\t\t\t\t\\usepackage{amssymb} \n\t\t\t\t\\usepackage{amsbsy}\n\t\t\t\t\\usepackage{mathrsfs}\n\t\t\t\t\\usepackage{upgreek}\n\t\t\t\t\\setlength{\\oddsidemargin}{-69pt}\n\t\t\t\t\\begin{document}$${CD8}^+$$\\end{document}</tex-math></inline-formula> infiltrating cells with AUCs of 0.943 and 0.837, respectively, which may reflect the distinct distribution patterns of these cells within the TME [<xref ref-type=\"bibr\" rid=\"CR158\">158</xref>]. As important TME features associated with immunotherapy efficacy, the TSR and TLS can also be assessed through AI models based on radiomics [<xref ref-type=\"bibr\" rid=\"CR160\">160</xref>&#8211;<xref ref-type=\"bibr\" rid=\"CR162\">162</xref>]. For instance, a recent multicenter study in an HCC cohort validated the feasibility of non-invasive TLS quantification using an MRI-based radiomic model with transfer learning, achieving high predictive accuracy and demonstrating clinical relevance in survival stratification and treatment response evaluation [<xref ref-type=\"bibr\" rid=\"CR162\">162</xref>]. In addition to cellular composition, radiomics has also been employed to predict the expression levels of certain molecular biomarkers within the TME. For example, He et al. [<xref ref-type=\"bibr\" rid=\"CR156\">156</xref>] and Wu et al. [<xref ref-type=\"bibr\" rid=\"CR159\">159</xref>] developed machine learning models based on CT radiomics to predict the expression levels of CTLA-4, VEGF, and EGFR in ccRCC and peripheral lung cancer, respectively. In conclusion, radiomics models, when combined with ML or DL techniques, effectively predict TME features associated with NIT efficacy, including cellular populations and molecular biomarkers.</p><p id=\"Par176\"><bold><italic toggle=\"yes\">Pathomics</italic></bold> In the field of TME analysis, traditional methods for evaluating TILs have long relied on pathologists manually interpreting H&amp;E-stained slides. This visually-based approach is not only time-consuming and labor-intensive but is also prone to inter-observer variability, limiting the reproducibility of results and significantly hindering its widespread application in clinical practice. AI technology, particularly its breakthroughs in automating TME component quantification, offers a novel solution for TIL assessment. Through a literature review, we identified 11 relevant studies that validated the feasibility of AI algorithms in TIL evaluation [<xref ref-type=\"bibr\" rid=\"CR163\">163</xref>&#8211;<xref ref-type=\"bibr\" rid=\"CR173\">173</xref>]. All studies retrospectively collected H&amp;E-stained slide data, with the majority of the data coming from multi-center cohorts (n=8). Among them, seven studies established DL models, while four employed ML models, all demonstrating excellent TIL assessment capabilities across various cancer cohorts. Notably, a model developed by Abousamra et al. [<xref ref-type=\"bibr\" rid=\"CR168\">168</xref>] was trained on a large dataset of 7,983 pathological slides, enabling reliable evaluation of TILs across 23 different cancer types. Similarly, another study proposed a generalizable model for tumor-infiltrating lymphocytes classification across multiple cancer types by introducing a CNN simplification approach&#8212;Network Auto-Reduction&#8212;that substantially reduces computational cost (up to <inline-formula id=\"IEq7\"><tex-math id=\"d33e1667\">\\documentclass[12pt]{minimal}\n\t\t\t\t\\usepackage{amsmath}\n\t\t\t\t\\usepackage{wasysym} \n\t\t\t\t\\usepackage{amsfonts} \n\t\t\t\t\\usepackage{amssymb} \n\t\t\t\t\\usepackage{amsbsy}\n\t\t\t\t\\usepackage{mathrsfs}\n\t\t\t\t\\usepackage{upgreek}\n\t\t\t\t\\setlength{\\oddsidemargin}{-69pt}\n\t\t\t\t\\begin{document}$$4\\times$$\\end{document}</tex-math></inline-formula> fewer FLOPs) without sacrificing classification accuracy, thereby enabling efficient large-scale digital pathology analysis [<xref ref-type=\"bibr\" rid=\"CR164\">164</xref>]. In addition to TILs, more pathomics-based AI models have been developed to predict other features of TME components. For example, Yang et al. [<xref ref-type=\"bibr\" rid=\"CR174\">174</xref>] developed an ML model that predicts the expression of CTLA-4 in the TME from H&amp;E WSIs in ccRCC patients. The CTLA-4 signature generated by the model was also effective in predicting the prognosis of ccRCC patients. Furthermore, four studies proposed DL models that were capable of assessing TSR and TLS from H&amp;E slides [<xref ref-type=\"bibr\" rid=\"CR175\">175</xref>&#8211;<xref ref-type=\"bibr\" rid=\"CR178\">178</xref>]. To illustrate, Lian et al. [<xref ref-type=\"bibr\" rid=\"CR176\">176</xref>] and Firmbach et al. [<xref ref-type=\"bibr\" rid=\"CR175\">175</xref>] developed DL models for accurate TSR evaluation in CRC and BC cohorts. The rest two DL models were also built with H&amp;E WSIs for TLS quantification but were valid across multiple cancer types [<xref ref-type=\"bibr\" rid=\"CR177\">177</xref>, <xref ref-type=\"bibr\" rid=\"CR178\">178</xref>]. Overall, AI models based on pathology have the potential for reproducible and automated assessment of TME components. Currently, the primary focus is on TILs, and these models are expected to guide clinical practice for NIT.</p></sec><sec id=\"Sec16\"><title>Multi-omics-based methods</title><p id=\"Par177\">Compared to established immunotherapy biomarkers such as PD-L1 and MSI, relatively few studies have focused on predicting TME parameters associated with response to NIT, particularly through the integration of multi-omics data. Although certain TME indicators have recently gained recognition in clinical trials and translational research as potential predictors of immunotherapy efficacy, the development of AI models targeting these markers remains limited. In particular, multi-omics-based models capable of capturing the complex interplay within the TME are still scarce. For instance, Failmezger et al. developed a multi-omics computational framework that integrates spatial pathology and transcriptomic data to characterize tumor immune infiltration in colorectal cancer [<xref ref-type=\"bibr\" rid=\"CR179\">179</xref>]. Specifically, the study applied a fused LASSO logistic regression model to classify spatial tumor infiltration phenotypes based on point pattern analysis of immune cell distributions from IHC-stained tissue sections, capturing intra-tumor heterogeneity in immune infiltration. These spatial phenotypes were then linked to genomic features by employing a support vector machine to derive predictive gene signatures from patient-matched transcriptomic data. The resulting model enabled accurate inference of spatial immune infiltration status from gene expression profiles alone and was successfully validated in an independent cohort. Furthermore, the study revealed significant associations between spatial infiltration patterns and common colorectal cancer mutations, highlighting the biological relevance of spatial immune heterogeneity in the tumor microenvironment. In the future, as more TME indicators are adopted in clinical practice, we anticipate that additional AI prediction models will be developed to offer a more comprehensive predictive approach for NIT.</p></sec></sec><sec id=\"Sec17\"><title>Other biomarkers</title><p id=\"Par178\">In recent years, biomarkers for predicting immunotherapy efficacy, particularly in NIT applications, have garnered significant attention. Alongside traditional biomarkers, emerging markers such as genes, cytokines, non-coding RNAs, and DNA methylation are being explored. AI-driven methods play a crucial role in identifying and developing these biomarkers, advancing precision medicine. Through a systematic review, we identified three studies that investigate immune-related lncRNAs as biomarkers across various cancer types, including CRC, LGG, and LUAD (Tab. <xref rid=\"Tab1\" ref-type=\"table\">1</xref>) [<xref ref-type=\"bibr\" rid=\"CR180\">180</xref>&#8211;<xref ref-type=\"bibr\" rid=\"CR182\">182</xref>]. They underscore the exceptional stability and accuracy of immune-related lncRNAs, which are intricately associated with crucial aspects of tumors, including their stage, grade, and prognosis, positioning them as potentially powerful biomarkers in oncology. Specifically in LGG patients, a random survival forest (RSF)-based ML model revealed that lncRNAs related to tumor-infiltrating immune cells were significantly associated with immune characteristics such as MSI, TMB, CD8, and interferon-<inline-formula id=\"IEq8\"><tex-math id=\"d33e1717\">\\documentclass[12pt]{minimal}\n\t\t\t\t\\usepackage{amsmath}\n\t\t\t\t\\usepackage{wasysym} \n\t\t\t\t\\usepackage{amsfonts} \n\t\t\t\t\\usepackage{amssymb} \n\t\t\t\t\\usepackage{amsbsy}\n\t\t\t\t\\usepackage{mathrsfs}\n\t\t\t\t\\usepackage{upgreek}\n\t\t\t\t\\setlength{\\oddsidemargin}{-69pt}\n\t\t\t\t\\begin{document}$$\\gamma$$\\end{document}</tex-math></inline-formula>, which were validated in internal datasets [<xref ref-type=\"bibr\" rid=\"CR180\">180</xref>]. Also, a study on LUAD demonstrated that lncRNAs effectively stratify patients and forecast OS, outperforming 95 established GBM biomarkers in prediction accuracy [<xref ref-type=\"bibr\" rid=\"CR182\">182</xref>].</p><p id=\"Par179\">Moreover, gene expression levels have emerged as promising biomarkers for predicting the efficacy [<xref ref-type=\"bibr\" rid=\"CR183\">183</xref>&#8211;<xref ref-type=\"bibr\" rid=\"CR185\">185</xref>]. Particularly, in a study on a small CRC cohort, <italic toggle=\"yes\">SREBF2</italic> was demonstrated to be closely associated with multiple immune infiltrating cells and immunotherapy-related genes. However, the underlying mechanisms of <italic toggle=\"yes\">SREBF2</italic> and its clinical therapeutic effectiveness require validation through large-scale clinical trials and biological experiments [<xref ref-type=\"bibr\" rid=\"CR183\">183</xref>]. These findings highlight the growing potential of emerging biomarkers&#8212;particularly those related to immune characteristics and tumor biology&#8212;revealing new insights into immunotherapy efficacy and driving the enhancement of treatment outcomes in NIT strategies.<table-wrap id=\"Tab1\" position=\"float\" orientation=\"portrait\"><label>Table 1</label><caption><p>Summary of studies on indirect biomarker-based prediction</p></caption><table frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\" colspan=\"1\" rowspan=\"1\">Ref.</th><th align=\"left\" colspan=\"1\" rowspan=\"1\">Author (Year)</th><th align=\"left\" colspan=\"1\" rowspan=\"1\">Biomarker</th><th align=\"left\" colspan=\"1\" rowspan=\"1\">Omics</th><th align=\"left\" colspan=\"1\" rowspan=\"1\">Cancer type</th><th align=\"left\" colspan=\"1\" rowspan=\"1\">Data source</th><th align=\"left\" colspan=\"1\" rowspan=\"1\">Analysis type</th><th align=\"left\" colspan=\"1\" rowspan=\"1\">Total patients</th><th align=\"left\" colspan=\"1\" rowspan=\"1\">Training set</th><th align=\"left\" colspan=\"1\" rowspan=\"1\">Validation set</th><th align=\"left\" colspan=\"1\" rowspan=\"1\">Testing set</th><th align=\"left\" colspan=\"1\" rowspan=\"1\">AI model</th><th align=\"left\" colspan=\"1\" rowspan=\"1\">Prediction performance</th></tr></thead><tbody><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR50\">50</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Wang et al. (2022)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">PD-L1</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Radiomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">NSCLC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">4404</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">3629</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">873</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">818</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">DL: NLP/LASSO</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.80</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR51\">51</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Jin et al. (2023)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">PD-L1</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Radiomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">LC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Prospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">104</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">97</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">46</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">DL: CNN</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.91 (cross-validation)&#8722;0.85 (external validation)</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR52\">52</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Saad et al. (2023)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">PD-L1</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Radiomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">NSCLC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">976</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">60%</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">10%</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">30%</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">DL</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">C-index: 0.70 (clinical model)&#8722;0.75 (composite model)</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR53\">53</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Zhao et al. (2023)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">PD-L1</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Radiomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">BC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">240</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">171</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">69</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">ML</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.99 (training)&#8722;0.96 (validation)</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR54\">54</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Wang et al. (2023)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">PD-L1</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Radiomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">GC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">249</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">168</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">39</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">42</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">DL: MLP/CNN</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.81</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR55\">55</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Mu et al. (2021)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">PD-L1</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Radiomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">LC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">284</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">116</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">117</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">DL: SResCNN</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.89, Sensitivity: 84.7%, Specificity: 80.4%</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR56\">56</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Tian et al. (2021)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">PD-L1</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Radiomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">NSCLC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">939</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">750</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">93</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">96</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">DL: CNN/KNN</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.78 (training)&#8722;0.71 (validation)-and 0.76 (testing)</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR57\">57</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Cao et al. (2024)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">PD-L1</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Radiomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">BC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">183</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">70%</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">30%</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">ML: SVM/RF</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.92 (training)&#8722;0.75 (validation)</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR58\">58</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Ronrick et al. (2024)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">PD-L1</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Radiomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">LC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">189</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">132</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">57</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">DL: CNN</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.83</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR59\">59</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Mei&#223;ner et al. (2023)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">PD-L1</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Radiomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">NSCLC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">53</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">36</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">17</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">ML: RF/SVM/CNN</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.83 &#177; 0.18 (training)&#8722;0.84 (testing)</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR60\">60</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Cheng et al. (2023)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">PD-L1</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Pathomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">NSCLC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Singlecenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">1288</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">627</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">577</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">84</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">DL: CNN</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Accuracy: 96.4%, Specificity: 96.8%</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR61\">61</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Wu et al. (2022)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">PD-L1</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Pathomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">NSCLC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">239</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">173</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">78</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">DL: CNN</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Accuracy: 93.3%, Specificity: 96.4%</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR62\">62</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Shamai et al. (2022)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">PD-L1</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Pathomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">BC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">3376</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">2516</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">860</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">DL: CNN</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.91&#8211;0.93.91.93</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR63\">63</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Li et al. (2024)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">PD-L1</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Pathomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">ESCC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Singlecenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">324 WSIs</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">227 WSIs</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">97 WSIs</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">DL: ViR-RNN</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.92, C-index: 0.81</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR64\">64</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Zhou et al. (2024)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">PD-L1</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Pathomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">GBM</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Singlecenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Prospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">80%</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">20%</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">ML: MLC-based Raman histopathology/SVM/RF/GBT</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Accuracy: 99%, Concordance: 84.3 %</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR65\">65</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Jin et al. (2024)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">PD-L1</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Pathomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Pan-cancer</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">6715</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">60%</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">15%</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">25%</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">DL: MITLS</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.83</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR66\">66</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Peng et al. (2022)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">PD-L1</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Genomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">NSCLC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">915</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">611</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">304</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">DL: CNN</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.97</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR67\">67</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Wiesweg et al. (2020)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">PD-L1</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Genomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">NSCLC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">67</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">55</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">22</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">16</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">ML: SVM/RF</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">HR: 0.46</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR68\">68</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Chen et al. (2024)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">PD-L1</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multi-omics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">GC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">429</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">271</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">39</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">DL: Transformer/MnasNet</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.82 (anti-HER2)&#8722;0.91 (combined with PD-L1)</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR69\">69</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Byeon et al. (2022)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">PD-L1</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multi-omics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">NSCLC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Singlecenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">57</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">ML: RF/SVM/CNN</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.96</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR75\">75</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Veeraraghavan et al. (2020)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">TMB/dMMR</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Radiomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">EC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Singlecenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">150</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">105</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">45</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">ML: RF</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.87 (TMB)&#8722;0.78 (dMMR)</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR76\">76</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Wang et al. (2019)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">TMB</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Radiomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">LUAD</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Singlecenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">51</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">41</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">20</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">ML: SVM</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.67</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR77\">77</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">He et al. (2020)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">TMB</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Radiomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">NSCLC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">327</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">236</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">26</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">65</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">DL: 3D-densenet/CNN</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.85 (training)&#8722;0.81 (testing)</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR78\">78</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Lam et al. (2022)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">TMB</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Radiomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">LGG</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">75</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">63</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">42</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">ML: Light Gradient Boosting Machine</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Accuracy: 79.4%</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR79\">79</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Hoshino et al. (2022)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">TMB</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Radiomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">CRC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Singlecenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">24</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">70%</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">30%</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">ML: RF</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.92, Accuracy: 87.5%, Sensitivity: 87.5%, Specificity: 85.7%</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR80\">80</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Shimada et al. (2021)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">TMB</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Pathomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">CRC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">201</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">77</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">DL: ResNet/InceptionNet/CNN</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.93</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR81\">81</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Zheng et al. (2024)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">TMB</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Pathomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">RCC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">513</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">350</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">163</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">DL: self-supervised attention-based instance learning</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.83 &#177; 0.02</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR82\">82</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Sun et al. (2023)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">TMB</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Pathomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Gliomas</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">856</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">619</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">237</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">DL: GCNN</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">HR: 4.81 (training)&#8722;4.00 (validation)</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR83\">83</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Huang et al. (2022)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">TMB</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Pathomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">CRC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">509</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">DL: ResNet/CNN/MLP</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.82, Accuracy: 87.2%, Precision: 74.8%</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR84\">84</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Xu et al. (2022)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">TMB</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Pathomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">BC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">386</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">DL: CNN/SVM/RF</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">HR: 3.30</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR85\">85</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Li et al. (2024)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">TMB</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Pathomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">GC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">450</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">362</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">88</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">DL: ResNet</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.75 (training)&#8722;0.97 (testing)</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\"> [?]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Liu et al. (2024)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">TMB</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Pathomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">ccCRC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">264</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">198</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">66</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">ML: LR</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.65 (training)&#8722;0.67 (validation)</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR86\">86</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Sanjaya et al. (2023)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">TMB</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Genomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Pan-Cancer</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">2,587</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">DL: DNN/MuAt/RF</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Accuracy: 97%</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR87\">87</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Nassar et al. (2021)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">TMB</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Genomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">BC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">58</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">90%</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">10%</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">ML: RF/SVM/KNN</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Positive expression [OR =0.35, 95% CI: 0.04&#8211;2.98.04.98]</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR88\">88</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Zhang et al. (2022)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">TMB</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Transcriptomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Pan-Cancer</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">722</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">620</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">154</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">149</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">ML: RF/SVM/NB</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.71 (validation and testing)</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR89\">89</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Wang et al. (2022)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">TMB</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multi-omics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">LC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">517</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">70%</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">30%</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">ML: RF/SVM</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.91 (training)&#8722;0.86 (validation)</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR98\">98</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Jia et al. (2024)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">MSI</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Radiomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">EMC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">225</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">158</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">67</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">132</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">ML: SVM/LR/KNN/NB/RF</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.86&#8211;0.90.86.90 (SVM), 0.62&#8211;0.68.62.68 (KNN), 0.81&#8211;0.82.81.82 (RF)</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR99\">99</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Xing et al. (2024)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">MSI</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Radiomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">RC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Singlecenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">308</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">ML: KNN</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.85</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR100\">100</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Li et al. (2023)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">MSI</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Radiomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">EMC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">82</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">60</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">22</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">ML: LR</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.83 (radiomics)&#8722;0.89 (radiomics+clinical data)</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR101\">101</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Wang et al. (2024)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">MSI</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Radiomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">EMC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Singlecenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">116</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">81</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">35</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">DL: CNN</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.87 (DL)&#8722;0.99 (combined)</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR102\">102</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Zhang et al. (2023)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">MSI</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Radiomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">RC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Singlecenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">383</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">268</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">115</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">ML: LR</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.83 (training)&#8722;0.74 (testing)</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR103\">103</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Kim et al. (2023)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">MSI</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Radiomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">CRC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Singlecenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">233</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">139</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">94</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">ML: LR</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.87 (training)&#8722;0.82 (testing)</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR104\">104</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Bodalal. et al. (2024)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">MSI</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Radiomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">CRC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">243</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">191</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">52</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">ML</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.69 (radiomics)&#8722;0.78 (combined with clinical data)</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR105\">105</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Cao et al. (2023)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">MSI</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Radiomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">CRC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">1812</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">1124</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">482</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">206</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">DL: Resnet/GPR</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.99 (training)&#8722;0.92 (testing)</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR106\">106</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Jiang et al. (2023)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">MSI</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Radiomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">GC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Singlecenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">223</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">167</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">56</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">DL: MLP</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.88 (training)&#8722;0.80 (testing)</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR107\">107</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Niehues et al. (2023)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">MSI</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Pathomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">CRC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">4638</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">2190</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">2448</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">DL: SSL-attMIL</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.94</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR108\">108</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Wagner et al. (2023)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">MSI</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Pathomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">CRC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">13689</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">8181</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">889</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">DL: Transformer</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.97, Sensitivity: 99%</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR109\">109</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Gerwert et al. (2023)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">MSI</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Pathomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">CC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">629</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">273</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">218</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">138</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">DL: CNN</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.90</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR110\">110</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Saillard et al. (2023)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">MSI</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Pathomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">CRC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">1034</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">434</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">600</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">DL: MLP</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.88</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR111\">111</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Zamanitajeddin et al. (2024)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">MSI</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Pathomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">CRC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">NA</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">549 slides</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">502 slides</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">47 slides</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">DL: MIL/Social Network Analysis</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.99</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR112\">112</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Chang et al. (2023)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">MSI</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Pathomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">CRC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">1884WSIs</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">1107WSIs</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">157WSIs</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">620WSIs</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">DL: Resnet</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.95</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR113\">113</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Echle et al. (2022)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">MSI</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Pathomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">CRC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">8343</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">7538</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">805</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">DL: Resnet</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.74&#8211;0.96.74.96</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR114\">114</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Saldanha et al. (2022)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">MSI</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Pathomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">CRC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">6820</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">3741</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">2579</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">ML: Swarm Learning</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.80&#8211;0.82.80.82</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR115\">115</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Lou et al. (2022)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">MSI</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Pathomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">CRC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">144</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">87</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">37</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">20</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">DL: PPsNet</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.94, Accuracy: 87.28%</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR116\">116</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Blake et al. (2023)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">MSI</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Pathomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">CRC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">NA</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">1490 spectra</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">DL/ML: CNN/SVM/PCA-LDA</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.65&#8211;0.75.65.75</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR117\">117</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Schirris et al. (2022)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">MSI</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Pathomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">CRC/BC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">360</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">260</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">100</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">DL: CNN/MIL</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.87</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR118\">118</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Tsai et al. (2023)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">MSI</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Pathomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">CRC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">NA</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">1888</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">60%</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">20%</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">20%</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">DL: CNN/Transformer</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.76&#8211;0.88.76.88</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR119\">119</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Fujii et al. (2022)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">MSI</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Pathomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">CRC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">NA</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">1657</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">986</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">248</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">423</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">DL: Resnet</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.86&#8211;0.92.86.92</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR120\">120</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Wang et al. (2024)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">MSI</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Pathomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">EMC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">529</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">353</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">176</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">DL</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Accuracy: 84%&#8722;94%, Precision: 81%&#8722;93%</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR121\">121</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Hu et al. (2024)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">MSI</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Pathomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">PC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Singlecenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">5538</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">4015</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">173</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">1350</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">DL: attMIL</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.78 (validation)&#8722;0.72 (testing)</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR122\">122</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Wang et al. (2023)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">MSI</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Pathomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">EOC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">1160</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">472</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">248</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">440</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">DL: MIL/RNN</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Accuracy: 77%, Sensitivity: 84%, Specificity: 67%</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR123\">123</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Su et al. (2022)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">MSI</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Pathomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">GC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Singlecenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">467WSIs</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">348WSIs</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">88WSIs</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">31WSIs</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">DL: Resnet</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Accuracy: 83.9%&#8722;86.4%</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR124\">124</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Lee et al. (2023)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">MSI</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Pathomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">GC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">714</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">331</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">102</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">383</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">DL: CNN</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.89&#8211;0.90.89.90</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR125\">125</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Nowak et al. (2024)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">dMMR</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Pathomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">CRC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">NA</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">3547</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">2352</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">1195</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">DL</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.98</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR126\">126</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Jiang et al. (2022)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">dMMR</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Pathomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">CRC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">1215WSIs</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">441WSIs</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">774WSIs</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">DL: Densenet/MIL</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.77&#8211;0.88.77.88</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR127\">127</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Whangbo et al. (2024)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">dMMR</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Pathomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">EMC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Singlecenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">1168WSIs</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">934WSIs</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">234WSIs</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">DL: GAN/CNN</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.77&#8211;0.82.77.82</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR128\">128</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Umemoto et al. (2024)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">dMMR</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Pathomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">EMC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Singlecenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">114</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">70%</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">15%</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">15%</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">DL: Resnet</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.91</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR129\">129</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Swaerts et al. (2023)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">MSI</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Genomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Pan-cancer</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Singlecenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">1188</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">1072</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">116</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">ML: LR/SVM</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.95</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR130\">130</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Chen et al. (2023)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">MSI</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Genomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Pan-cancer</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">2285</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">1432</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">853</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">ML: NGBoost</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.99</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR131\">131</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Cao et al. (2023)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">MSI</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Genomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Pan-cancer</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">7446</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">639</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">6807</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">DL: GNN/Catboost</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.91&#8211;0.99.91.99</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR132\">132</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Shi et al. (2025)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">MSI</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multiomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">GC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Singlecenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">NA</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">37</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">ML: KNN/RF/ELM</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.91</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR133\">133</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Qiu et al. (2022)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">MSI</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multiomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">CRC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">NA</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">353</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">282</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">71</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">DL: Resnet</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.81 (pathomics)&#8722;0.95 (combined)</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR145\">145</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Wu et al. (2023)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">TIL</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Radiomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">BC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">494</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">60%</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">20%</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">20%</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">DL</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.89</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR146\">146</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Jia et al. (2023)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">TIL</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Radiomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">BC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">494</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">298</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">98</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">98</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">DL: CNN</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.87</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR147\">147</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Zhang et al. (2024)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">TIL</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Radiomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">BC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Singlecenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">185</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">111</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">74</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">ML: LASSO/LR</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.80 (radiomics)&#8722;0.84 (combined with ultrasound features)</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR148\">148</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Hu et al. (2024)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">TIL</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Radiomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">BC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Singlecenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">145</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">70%</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">30%</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">ML: LASSO</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.84 (radiomics)&#8722;0.85 (combined with clinical data)</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR149\">149</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Lu et al. (2024)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">TIL</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Radiomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">BC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Singlecenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">378</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">80%</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">20%</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">ML: LASSO/LR</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.87(radiomics)&#8722;0.89 (combined with clinical data)</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR150\">150</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Su et al. (2022)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">TIL</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Radiomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">BC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Singlecenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">139</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">98</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">41</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">ML: Elastic Net Regression/LR</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.87 (training)&#8722;0.79 (testing)</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR151\">151</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Jeon et al. (2022)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">CD8 TILs</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Radiomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">BC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Singlecenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">182</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">137</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">45</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">ML: LASSO</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.97&#8211;0.99.97.99</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR152\">152</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Qian et al. (2024)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Immune Cell Infiltration</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Radiomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">BC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">73</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">70%</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">30%</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">ML: LASSO/LR</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.82 (peri-tumor)&#8722;0.84 (combined)</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR153\">153</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Ren et al. (2024)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">TIL</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Radiomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">OTSCC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Singlecenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">68</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">90%</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">10%</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">ML: LR/SVM/RF</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.85 (LR), 0.82 (SVM), 0.81 (RF)</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR154\">154</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Huang et al. (2024)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">CD3, CD4, and CD8 TILs</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Radiomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">GC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Singlecenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">103</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">90%</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">10%</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">ML: RF/LR</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.81&#8211;0.87.81.87 (CD3, LR), 0.90&#8211;0.91.90.91 (CD4, RF), 0.90&#8211;0.97.90.97 (CD8, RF)</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR155\">155</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Li et al. (2022)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Tumour-infiltrating macrophages</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Radiomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Glioma</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Ambispective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">652</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">167</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">485</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">ML: RF/DL</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">NA</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR156\">156</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">He et al. (2023)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">CTLA-4</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Radiomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">ccRCC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">NA</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">102</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">90%</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">10%</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">ML: SVM</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.72 (validation)&#8722;0.77 (testing)</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR157\">157</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Li et al. (2025)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">CD8, CD163 and SMA cells in TME</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Radiomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">ccRCC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">100</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">69</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">18</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">17</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">ML: LASSO/LR</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.87 (CD8), 0.90 (CD163), 0.86 (SMA)</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR158\">158</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Chen et al. (2023)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">CD3 and CD8 T Cells</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Radiomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">NSCLC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Singlecenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">105</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">70%</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">30%</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">ML: LASSO</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.94 (CD3), 0.84 (CD8)</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR159\">159</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Wu et al. (2022)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">VEGF and EGFR</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Radiomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">LC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Singlecenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">73</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">ML: LR</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.87 (VEGF), 0.95 (EGFR)</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR160\">160</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Meng et al. (2022)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">TSR</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Radiomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">PDAC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Singlecenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">148</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">110</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">38</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">ML: LASSO/XGBoost</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.82 (training)&#8722;0.78 (testing)</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR161\">161</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Liao et al. (2024)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">TSR</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Radiomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">PDAC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">207</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">70%</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">30%</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">DL: CNN/Transformer/self-attention</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.90&#8211;0.98.90.98</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR162\">162</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Long et al. (2025)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">TLS</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Radiomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">HCC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">660</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">307</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">76</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">277</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">ML</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.90 (training)&#8722;0.85 (validation)&#8722;0.85 (testing)</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR163\">163</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Liu et al. (2024)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">TIL</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Pathomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">BC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">NA</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">125</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">80%</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">20%</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">DL: U-Net</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.93</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR164\">164</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Meirelles et al. (2022)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">TIL</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Pathomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Pan-cancer</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">NA</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">NA</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">61WSI</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">56WSIs</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">5WSIs</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">DL: Resnet</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">NA</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR165\">165</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Yosofvand et al. (2023)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">TIL</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Pathomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">BC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Singlecenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">63WSIs</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">80%</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">20%</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">DL: U-Net/R-CNN</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Accuracy: 98.1%</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR166\">166</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Verdicchio et al. (2023)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">TIL</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Pathomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">BC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">NA</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">151WSIs</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">70%</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">30%</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">ML: LASSO/RF/DT</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.86 (training)&#8722;0.86 (testing)</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR167\">167</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Shevtsov et al. (2022)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">TIL</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Pathomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">NSCLC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">87</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">DL: HoVer-Net</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Precision&gt;90%</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR168\">168</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Abousamara et al. (2022)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">TIL</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Pathomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Pan-cancer</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">353411 patches</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">351272 patches</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">2139 patches</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">DL: CNN</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Accuracy: 89%</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR169\">169</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Machuca-Aguado et al. (2023)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">TIL</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Pathomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">EOC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Singlecenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">76</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">ML</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">NA</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR170\">170</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Xu et al. (2022)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">TIL</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Pathomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">CRC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">43440 tiles</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">80%</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">10%</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">10%</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">DL: Resnet</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Accuracy: 80.1%</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR171\">171</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Zheng et al. (2022)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">TIL</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Pathomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">BC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">380</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">133</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">247</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">ML</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">NA</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR172\">172</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Fassler et al. (2022)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">TIL</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Pathomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">BC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">NA</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">2015</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">2015</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">911</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">ML</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">NA</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR173\">173</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Pan et al. (2022)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">TIL</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Pathomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">LUAD</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">793</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">276</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">517</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">DL</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">NA</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR174\">174</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Yang et al. (2024)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">CTLA-4</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Pathomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">ccRCC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">NA</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">NA</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">354</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">70%</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">30%</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">ML: mRMR/REF/GBM</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.74</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR175\">175</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Firmbach et al. (2023)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">TSR</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Pathomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">CRC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Singlecenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">33WSIs</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">23WSIs</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">4WSIs</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">6WSIs</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">DL: BPN/U-Net</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Accuracy: 86.5% (BPN), 86.7% (U-Net)</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR176\">176</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Xinsen et al. (2023)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">TSR</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Pathomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">BC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">NA</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">80WSIs</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">56WSIs</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">24WSIs</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">DL: U-Net/Transformer</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Dice-coef: 0.88, IOU-metric: 0.80</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR177\">177</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Rijthoven et al. (2024)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">TLS</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Pathomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Pan-cancer</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">1024WSIs</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">188WSIs</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">69WSIs</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">767WSIs</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">DL: HoVer-Net</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">NA</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR178\">178</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Chen et al. (2024)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">TLS</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Pathomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Pan-cancer</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">65</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">70%</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">10%</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">20%</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">DL: Encoder-decoder</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.98 (training)&#8722;0.99 (validation)&#8722;0.97 (testing)</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR179\">179</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Failmezger et al. (2021)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">TIL</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multi-omics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">CRC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">80</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">80%</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">20%</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">ML: LR/SVM</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Accuracy: 85%</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR180\">180</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Liu et al. (2022)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">lncRNA</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Transcriptomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">CRC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">2277</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">791</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">232</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">ML: RF/SVF/LASSO/Cox</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.75</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR181\">181</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Zhang et al. (2022)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">lncRNA</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Transcriptomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">LGG</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">932</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">518</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">169</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">168</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">ML: RSF</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">NA</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR182\">182</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Pan et al. (2024)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">lncRNA</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Transcriptomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">LUAD</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">916</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">27</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">ML: LASSO/RSF</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.75 (1 year)&#8722;0.72 (2/3 years)</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR183\">183</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Peng et al. (2024)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Lipid metabolism-associated genes</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Genomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">RC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">NA (datasets)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">ML: SVM-RFE/RF</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.68</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR184\">184</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Wei et al. (2023)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Cytokines</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Proteomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">NSCLC</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">222</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">123</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">99</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">ML: RSF</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">C-index: 0.76 (training)&#8722;0.76 (validation)</td></tr><tr><td align=\"left\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR185\">185</xref>]</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Li et al. (2022)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">NRF2</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Genomics</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Pan-cancer</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">NA (datasets)</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">ML; RSF/LASSO/Cox</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.77</td></tr></tbody></table><table-wrap-foot><p>AUC, Area Under the Curve; C-Index, Concordance index; CI, Confidence Interval; HR, Hazard Ratio; OR, Odds Ratio; NA, Not Available</p></table-wrap-foot></table-wrap></p></sec></sec><sec id=\"Sec18\"><title>Direct biomarker-based prediction methods</title><sec id=\"Sec19\"><title>Single omics-based methods</title><p id=\"Par180\">In recent studies, multiple categories of omics data have been used to build models that directly predict the benefits of NIT or NCIT. The integration of AI further facilitates feature identification and response prediction. Through an unbiased search, we identified 40 studies that applied AI to develop single-omics models for predicting the outcomes of NIT or NCIT. More than half of these studies (n=21) relied on patient radiomics data, while the remaining models were constructed using clinical assays, hematology, transcriptomics, pathology, proteomics, and microbiomics data. Most models predicted outcomes such as MPR (n=14) or pCR (n=15) following neoadjuvant treatment, with others predicting indicators like PFS. Radiomics-based models were predominantly established in lung cancer populations (n=14), likely reflecting the widespread application of imaging screening in lung cancer management (Tab. <xref rid=\"Tab2\" ref-type=\"table\">2</xref>). This suggests that, irrespective of the type of omics input, integrated predictive efforts have primarily focused on lung cancer. This finding aligns with the high incidence of lung cancer and the increasing adoption of NIT in this patient population. Additionally, we observed that radiomics data were mostly derived from multicenter studies, whereas single-center data were more common in models using other omics. This difference highlights the adoption and relative prevalence of multicenter collaborations when utilizing imaging data. (Fig. <xref rid=\"Fig2\" ref-type=\"fig\">2</xref>).</p><p id=\"Par181\"><bold><italic toggle=\"yes\">Radiomics</italic></bold> We report 21 studies focused on imaging and histology-based approaches for NIT efficacy prediction, with 14 studies specifically targeting lung cancer, and others addressing various cancers, including ESCC, triple-negative breast cancer (TNBC), and head and neck squamous cell carcinoma (HNSCC) [<xref ref-type=\"bibr\" rid=\"CR186\">186</xref>&#8211;<xref ref-type=\"bibr\" rid=\"CR206\">206</xref>]. Among these studies, CT imaging serves as a widely used input, particularly in the prediction of lung cancer treatments. For instance, Han et al. [<xref ref-type=\"bibr\" rid=\"CR191\">191</xref>] notably developed a predictive model based on conventional CT imaging in NSCLC cohorts, incorporating innovative delta-radiomics methods to capture dynamic changes in imaging features during treatment. Unlike traditional static image analysis, delta-radiomics quantifies the variation in CT image characteristics before and after treatment, offering a more comprehensive reflection of tumor biology and its response to therapy. Specifically, significant tumor regression in certain areas post-treatment, especially when compared to pre-treatment images, is often considered a marker of favorable prognosis. These dynamic features further enhanced the accuracy of MPR prediction (<inline-formula id=\"IEq9\"><tex-math id=\"d33e5445\">\\documentclass[12pt]{minimal}\n\t\t\t\t\\usepackage{amsmath}\n\t\t\t\t\\usepackage{wasysym} \n\t\t\t\t\\usepackage{amsfonts} \n\t\t\t\t\\usepackage{amssymb} \n\t\t\t\t\\usepackage{amsbsy}\n\t\t\t\t\\usepackage{mathrsfs}\n\t\t\t\t\\usepackage{upgreek}\n\t\t\t\t\\setlength{\\oddsidemargin}{-69pt}\n\t\t\t\t\\begin{document}$$\\text {AUC}&gt; 0.8$$\\end{document}</tex-math></inline-formula>), demonstrating the high accuracy and predictive power of delta-radiomics in evaluating MPR [<xref ref-type=\"bibr\" rid=\"CR191\">191</xref>]. Similarly, radiomics features derived from [18F]-FDG PET/CT imaging were employed to predict pathological responses in patients with resectable stage III NSCLC, achieving an AUC of 0.925 [<xref ref-type=\"bibr\" rid=\"CR189\">189</xref>]. This further indicates that the combination of PET/CT imaging&#8217;s quantitative assessment of tumor metabolic activity with radiomics methods provides a more comprehensive and highly accurate prediction. Incorporating AI methodologies prompt biological insights, as a study predicting the pCR to NIT in NSCLC revealed that higher DL scores were associated with substantially enriched cell proliferation and metabolic pathways, as well as increased infiltration of activated immune cells, including B cells, natural killer cells, and T helper 17 (Th17) cells [<xref ref-type=\"bibr\" rid=\"CR187\">187</xref>]. These biological findings underscore the critical role of tumor and TME dynamics in therapeutic responses, highlighting the potential of integrating imaging and biological data to more precisely forecast the efficacy of NIT. While current research primarily focuses on lung cancer, there is a growing exploration of the potential of AI-driven radiomics modeling in other cancer types as well. For instance, Kong et al. [<xref ref-type=\"bibr\" rid=\"CR202\">202</xref>] introduced a novel CT-based habitat radiomics approach for predicting treatment response to NCIT in ESCC. This method clusters conventional radiomic features into distinct habitats and models each cluster independently. Results further indicated that the habitat-based model outperforms traditional radiomics analysis models, highlighting its superior predictive capability and providing a more nuanced understanding of tumor biology [<xref ref-type=\"bibr\" rid=\"CR202\">202</xref>]. This emphasizes the immense potential of radiomics-based AI models and single omics data in predicting NIT therapeutic outcomes in pan-cancer treatment.</p><p id=\"Par182\"><bold><italic toggle=\"yes\">Pathomics</italic></bold> Five Studies have validated the feasibility of AI models based on the pathological profiles of patient tissue biopsies to directly predict the efficacy of NIT across different cancer types, like NSCLC, ESCC, and GC [<xref ref-type=\"bibr\" rid=\"CR207\">207</xref>&#8211;<xref ref-type=\"bibr\" rid=\"CR211\">211</xref>]. For example, Han et al. [<xref ref-type=\"bibr\" rid=\"CR208\">208</xref>] developed a DL model predicting MPR of NIT in NSCLC cohorts from pathomics features on H&amp;E-stained tumor sections. The study compared various DL algorithms in model construction and utilized gradient-weighted class activation mapping (Grad-CAM) for model explanation. Similarly, another study reported a Transformer framework that automatically identifies pathological features on WSIs of H&amp;E-stained tumor sections and predicts residual tumor percentage in ESCC patients taking NIT [<xref ref-type=\"bibr\" rid=\"CR207\">207</xref>]. Besides H&amp;E WSIs, one study reported an ML model based on multiple immunofluorescence (mIF) profiles of immune cell surface markers (<italic toggle=\"yes\">e.g.</italic>, CD8) and immune checkpoints (<italic toggle=\"yes\">e.g.</italic>, PD-L1) to predict the MPR of NIT in ESCC cohorts [<xref ref-type=\"bibr\" rid=\"CR209\">209</xref>]. With an ambispective design, the model was trained in a retrospective cohort but validated in a prospective cohort with reliable performance (AUC = 0.832). In addition, leveraging LASSO for feature selection, the model construction indicates that PD-L1 and CD3 levels are associated with NIT benefits, consistent with the predictive value of PD-L1 expression in NIT, as discussed previously.</p><p id=\"Par183\"><bold><italic toggle=\"yes\">Transcriptomics</italic></bold> In patients receiving NIT, gene expression differences between responders and non-responders have been identified, particularly among genes related to the TME [<xref ref-type=\"bibr\" rid=\"CR212\">212</xref>]. ML algorithms are employed to select the differentially expressed genes (DEGs) most closely associated with treatment efficacy and to develop predictive models. For example, two studies constructed ML models using DEGs derived from pre-treatment RNA-seq data, reliably predicting pCR and MPR following NIT in HER2-negative BC and Gastric and Gastroesophageal Junction Cancer (GGJC) (AUC = 0.841 and 1, respectively) [<xref ref-type=\"bibr\" rid=\"CR213\">213</xref>, <xref ref-type=\"bibr\" rid=\"CR214\">214</xref>]. However, the latter study had a very small sample size. Both studies also revealed that an inflammatory TME is correlated with improved treatment outcomes. Furthermore, one study built a model based solely on glycosylation-related gene features identified from RNA-seq data, which was able to screen for potential beneficiaries of neoadjuvant therapy in HCC [<xref ref-type=\"bibr\" rid=\"CR215\">215</xref>]. This model-building process also highlighted the potential role of glycosylation in modulating the TME and NIT response, warranting further investigation.</p><p id=\"Par184\"><bold><italic toggle=\"yes\">Microbiomics</italic></bold> AI algorithms have been applied to identify gut microbiome features associated with treatment efficacy in patients undergoing NIT or NCIT, leading to the development of predictive models for selecting likely responders [<xref ref-type=\"bibr\" rid=\"CR216\">216</xref>]. In this study, researchers analyzed the 16S rRNA sequences of patients with ESCC receiving NCIT and observed significant differences in the gut microbiome between responders and non-responders. They used the Extreme Gradient Boosting (XGBoost) algorithm to determine the microbial features most relevant to treatment outcomes and then applied the LightGBM algorithm to construct a predictive model that reliably identified responders (AUC = 0.868). This study not only validated the potential of microbial biomarkers in predicting NIT outcomes but also revealed that enrichment of short-chain fatty acid-producing bacteria is associated with favorable responses, whereas a higher abundance of potential pathogenic microbes (<italic toggle=\"yes\">e.g.</italic>, Veillonella) is enriched in non-responders.</p><p id=\"Par185\"><bold><italic toggle=\"yes\">Proteomics</italic></bold> Proteomic characteristics of certain TME markers, such as expression levels and spatial distribution, have been found to correlate with patient responses to NIT or NCIT, making them valuable inputs for AI-based predictive models. For instance, one study utilized mass cytometry to assess the spatial distribution of various protein markers within the TME, including those associated with epithelial cells, endothelial cells, stromal cells, immune cells, cytokines, and immune checkpoints [<xref ref-type=\"bibr\" rid=\"CR217\">217</xref>]. Feature selection was conducted using an SVM algorithm, followed by model construction with an RF algorithm, resulting in excellent predictive performance for NCIT response (AUC = 0.97). Moreover, the feature selection process provided important biological insights, identifying that CD8<sup>+</sup> T cells and B cells within TLS, as well as inflammatory macrophages in fibrotic regions, were associated with favorable treatment responses.</p><p id=\"Par186\"><bold><italic toggle=\"yes\">Others</italic></bold> We identified nine studies developed ML models that predict NIT or NCIT outcomes leveraging rapid clinical test or blood-based parameters [<xref ref-type=\"bibr\" rid=\"CR218\">218</xref>&#8211;<xref ref-type=\"bibr\" rid=\"CR226\">226</xref>]. Among studies leveraging hematological profiles for model construction, six focused on predicting MPR, pCR, and PFS in NSCLC patients treated with NIT, whereas the rest two studies aimed at predicting NCIT pCR in ESCC cohorts. In these studies, features screened for prediction were either individual hematological parameters or inflammation scores calculated by integrating these parameters, sometimes combined with clinical pathological data such as cancer stage and smoking status. Despite the different hematological features selected, including immune cell ratios (<italic toggle=\"yes\">e.g.</italic>, neutrophil-to-lymphocyte ratio (NLR) and monocyte-to-lymphocyte ratio (MLR)), specific immune cell types (<italic toggle=\"yes\">e.g.</italic>, CD3<sup>+</sup>CD56<sup>+</sup> natural killer T cells), and other indicators such as neutrophil percentage (NEUT%) and PD-L1 expression levels, most of these models demonstrated reliable predictive efficacy in large cohorts of over 100 patients. Besides laboratory hematology analysis, one study validates the feasibility of establishing a prediction model based on a rapid breathing test. Huang et al. [<xref ref-type=\"bibr\" rid=\"CR219\">219</xref>] proposed an innovative ML model that identified high-pressure photon ionization time-of-flight mass spectrometry (HPPI-TOFMS) features in patient respiratory samples, capable of distinguishing responders from non-responders to NCIT in ESCC cohorts (AUC = 0.86). Collectively, these studies confirm that ML models can predict responses to NIT using clinical test data, providing a fast, cost-effective, and less invasive approach.</p></sec><sec id=\"Sec20\"><title>Multi-omics-based methods</title><p id=\"Par187\">Multi-omics AI models that integrate omics features from different dimensions have the potential to provide a more accurate method for predicting responses to NIT or NCIT. We report five relevant studies [<xref ref-type=\"bibr\" rid=\"CR227\">227</xref>&#8211;<xref ref-type=\"bibr\" rid=\"CR231\">231</xref>]. Among these studies, Xu et al. [<xref ref-type=\"bibr\" rid=\"CR228\">228</xref>] developed a composite model that combines DL-based CT radiomics scores, the mutation counts in ctDNA, and clinical data. It had robust prediction for MPR in a prospective cohort of NSCLC patients undergoing NCIT (AUC = 0.82) and outperformed single-omics DL models in the same cohort (AUC = 0.703). Another study leverages SVM to construct three single-omics models and a multi-omics model predicting NCIT pCR in esophageal cancer cohorts. The single-omics models were developed individually based on CT images (AUC = 0.70), WSIs of H&amp;E-stained tumor biopsies (AUC = 0.77), and clinical data (AUC = 0.63). In contrast, the multi-omics models integrating all three inputs achieved superior performance in predicting performance (AUC = 0.89) [<xref ref-type=\"bibr\" rid=\"CR229\">229</xref>]. Similarly, Nie et al. [<xref ref-type=\"bibr\" rid=\"CR230\">230</xref>] combined CT radiomics and pathomics inputs in a model predicting NCIT therapeutic responses in extensive-stage small cell lung cancer (ES-SCLC). A combined model based on radiomics and hematological parameters has also been developed, as another study by Yang et al. [<xref ref-type=\"bibr\" rid=\"CR227\">227</xref>] proposed an ML model that leverages CT images and laboratory blood tests to predict NCIT pCR in ESCC patients. Consistent with the aforementioned multi-omics approaches, the integrated model in the ES-SCLC and ESCC studies outperformed single omics methodologies in the same cohorts [<xref ref-type=\"bibr\" rid=\"CR227\">227</xref>, <xref ref-type=\"bibr\" rid=\"CR230\">230</xref>]. Besides combining omics input, one study notably developed an open-source longitudinal MLP model for predicting the outcomes of BC neoadjuvant therapy [<xref ref-type=\"bibr\" rid=\"CR231\">231</xref>]. The model combined longitudinal MRI imaging and clinical parameters, achieving superior performance in predicting pCR (AUC = 0.852). Consistent with the above studies, the model integrating the two categories of input (AUC = 0.934) outperformed the radiomics (AUC = 0.874) and hematology models (AUC = 0.772). Collectively, AI algorithms showed feasibility in combining various inputs for enhancing the prediction of NIT clinical endpoints. However, current research remains focused on limited cancer types and omics categories, highlighting the need for broader validation across diverse tumor types and integration of additional omics layers (Tab. <xref rid=\"Tab2\" ref-type=\"table\">2</xref>, Fig. <xref rid=\"Fig2\" ref-type=\"fig\">2</xref>).<table-wrap id=\"Tab2\" position=\"float\" orientation=\"portrait\"><label>Table 2</label><caption><p>Summary of studies on direct biomarker-based prediction</p></caption><table frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\" colspan=\"1\" rowspan=\"1\">Ref.</th><th align=\"left\" colspan=\"1\" rowspan=\"1\">Author (Year)</th><th align=\"left\" colspan=\"1\" rowspan=\"1\">Omics</th><th align=\"left\" colspan=\"1\" rowspan=\"1\">Cancer type</th><th align=\"left\" colspan=\"1\" rowspan=\"1\">Data source</th><th align=\"left\" colspan=\"1\" rowspan=\"1\">Predictive marker</th><th align=\"left\" colspan=\"1\" rowspan=\"1\">Analysis type</th><th align=\"left\" colspan=\"1\" rowspan=\"1\">Total patients</th><th align=\"left\" colspan=\"1\" rowspan=\"1\">Training set</th><th align=\"left\" colspan=\"1\" rowspan=\"1\">Validation set</th><th align=\"left\" colspan=\"1\" rowspan=\"1\">Testing set</th><th align=\"left\" colspan=\"1\" rowspan=\"1\">AI model</th><th align=\"left\" colspan=\"1\" rowspan=\"1\">Prediction performance</th></tr></thead><tbody><tr><td align=\"center\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR186\">186</xref>]</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Ye et al. (2024)</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Radiomics</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">NSCLC</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">pCR</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">178</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">108</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">70</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">ML/DL</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.78, Accuracy: 81.5%</td></tr><tr><td align=\"center\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR187\">187</xref>]</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Qu et al. (2024)</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Radiomics</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">LC</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">pCR</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">248</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">104</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">69</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">75</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">DL: CNN</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.78 (training)&#8722;0.74 (validation)</td></tr><tr><td align=\"center\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR188\">188</xref>]</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Huang et al. (2024)</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Radiomics</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">NSCLC</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">MPR</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">148</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">105</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">43</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">ML/DL: SVM/CNN</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.81 (training)&#8722;0.77 (testing)</td></tr><tr><td align=\"center\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR189\">189</xref>]</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Liu et al. (2024)</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Radiomics</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">NSCLC</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">pCR</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">106</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">74</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">32</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">ML: SVM/RF</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.93 (training)&#8722;0.86 (testing)</td></tr><tr><td align=\"center\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR190\">190</xref>]</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Ye et al. (2024)</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Radiomics</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">NSCLC</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">pCR</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">113</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">80%</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">20%</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">DL: CNN</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.86</td></tr><tr><td align=\"center\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR191\">191</xref>]</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Han et al. (2024)</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Radiomics</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">NSCLC</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">MPR</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">204</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">164</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">21</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">21</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">DL: CNN</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.77 (training)&#8722;0.73 (validation)&#8722;0.83 (testing)</td></tr><tr><td align=\"center\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR192\">192</xref>]</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Cui et al. (2022)</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Radiomics</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">NSCLC</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Singlecenter</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">pCR</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Pilot study</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">50</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">30</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">19</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">ML/DL</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.85; Accuracy: 83%; Sensitivity: 80%, Specificity: 85%</td></tr><tr><td align=\"center\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR193\">193</xref>]</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Yang et al. (2023)</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Radiomics</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">NSCLC</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">pCR</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">110</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">77</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">33</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">ML: LASSO</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.85; Accuracy: 81%; Specificity: 81%; Sensitivity: 83%</td></tr><tr><td align=\"center\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR194\">194</xref>]</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">She et al. (2022)</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Radiomics</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">NSCLC</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">MPR</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">274</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">142</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">61</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">71</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">DL: CNN</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.73 (training)&#8722;0.72 (testing)</td></tr><tr><td align=\"center\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR196\">196</xref>]</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Wang et al. (2024)</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Radiomics</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">NSCLC</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">MPR</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">211</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">148</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">63</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">ML: LASSO</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.70 (training)&#8722;0.60 (testing)</td></tr><tr><td align=\"center\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR197\">197</xref>]</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Li et al. (2024)</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Radiomics</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">NSCLC</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Singlecenter</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">PFS</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">60</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">ML: SVM</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Accuracy: 92.3%, Specificity: 96.6%</td></tr><tr><td align=\"center\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR198\">198</xref>]</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Han et al. (2024)</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Radiomics</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">NSCLC</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">MPR</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">186</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">105</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">45</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">36</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">DL</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.99</td></tr><tr><td align=\"center\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR199\">199</xref>]</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Zhao et al. (2024)</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Radiomics</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">SCLC</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">PFS</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">379</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">253</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">51</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">75</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">ML: LASSO</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.73 (training)&#8722;0.66 (validation)&#8722;0.73 (testing)</td></tr><tr><td align=\"center\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR200\">200</xref>]</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Wang et al. (2024)</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Radiomics</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">ESCC</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">MPR</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">82</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">57</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">25</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">ML: SVM/RF/LASSO</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.93 (training)&#8722;0.85 (testing)</td></tr><tr><td align=\"center\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR201\">201</xref>]</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Shi et al. (2024)</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Radiomics</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">ESCC</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">pCR</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">105</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">75%</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">25%</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">ML</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.89 (training)&#8722;0.80 (testing)</td></tr><tr><td align=\"center\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR202\">202</xref>]</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Kong et al. (2024)</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Radiomics</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">ESCC</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">pCR</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">112</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">85</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">27</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">ML: LASSO/LR</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.90</td></tr><tr><td align=\"center\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR203\">203</xref>]</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Zhang et al. (2025)</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Radiomics</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">ESCC</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">pCR</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">741</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">469</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">118</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">120</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">DL: 3D-ResNet/ViT</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.91 (traning)&#8722;0.83 (validation)</td></tr><tr><td align=\"center\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR204\">204</xref>]</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Ramtohulet al. (2024)</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Radiomics</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">TNBC</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">pCR</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Prospective</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">112</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">83</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">ML: LASSO</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.86</td></tr><tr><td align=\"center\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR205\">205</xref>]</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Seban et al. (2023)</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Radiomics</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">TNBC</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">pCR</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">191</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">70%</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">30%</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">ML: SVM/RF</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">OR: 3.7 [95% CI 1.3&#8211;12.4]</td></tr><tr><td align=\"center\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR206\">206</xref>]</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Lin et al. (2024)</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Radiomics</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">HNSCC</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">pCR</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">172</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">84</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">37</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">51</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">ML: LASSO</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.90 (training)&#8722;0.85 (testing)</td></tr><tr><td align=\"center\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR207\">207</xref>]</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Wang et al. (2024)</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Pathomics</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">ESCC</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Singlecenter</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Residual Tumor Percentages</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">451</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">225WSIs</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">30WSIs</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">196WSIs</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">DL: Transformer</td><td align=\"left\" colspan=\"1\" rowspan=\"1\"><inline-formula id=\"IEq10\"><tex-math id=\"d33e6312\">\\documentclass[12pt]{minimal}\n\t\t\t\t\\usepackage{amsmath}\n\t\t\t\t\\usepackage{wasysym} \n\t\t\t\t\\usepackage{amsfonts} \n\t\t\t\t\\usepackage{amssymb} \n\t\t\t\t\\usepackage{amsbsy}\n\t\t\t\t\\usepackage{mathrsfs}\n\t\t\t\t\\usepackage{upgreek}\n\t\t\t\t\\setlength{\\oddsidemargin}{-69pt}\n\t\t\t\t\\begin{document}$$\\text {R}^2$$\\end{document}</tex-math></inline-formula>: 0.84</td></tr><tr><td align=\"center\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR208\">208</xref>]</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Han et al. (2024)</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Pathomics</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">NSCLC</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">MPR</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">186</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">105</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">45</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">36</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">DL: DenseNet/XGBoost</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.99 (training)&#8722;0.81 (validation)&#8722;0.82 (testing)</td></tr><tr><td align=\"center\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR209\">209</xref>]</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Yehan et al. (2024)</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Pathomics</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">ESCC</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Singlecenter</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">MPR</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Ambispective</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">78</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">30</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">48</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">ML: LASSO/LR</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.93 (training)&#8722;0.83 (testing)</td></tr><tr><td align=\"center\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR210\">210</xref>]</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Terada et al. (2023)</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Pathomics</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">NSCLC</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">MPR</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">125</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">55</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">70</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">DL: CNN</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Accuracy: 0.86 (cross-validation)</td></tr><tr><td align=\"center\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR211\">211</xref>]</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Han et al. (2024)</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Pathomics</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">GC</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">PFS</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">584</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">130</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">44</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">99</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">ML: RF/KNN</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.98 (training)&#8722;0.92 (validation)</td></tr><tr><td align=\"center\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR213\">213</xref>]</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Lu et al. (2024)</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Transcriptomics</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">BC</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">pCR</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">195</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">69</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">71</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">55</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">ML:Boruta/SVM-RFE/XGBoost</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.93 (training)&#8722;0.86 (validation)&#8722;0.84 (testing)</td></tr><tr><td align=\"center\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR214\">214</xref>]</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Ji et al. (2024)</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Transcriptomics</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">GGJC</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Singlecenter</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">MPR</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">NA</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">30</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">ML: LASSO</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 1</td></tr><tr><td align=\"center\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR215\">215</xref>]</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Tang et al. (2022)</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Transcriptomics</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">HC</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Responders/Non-responders</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">NA</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">1332</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">364</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">379</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">ML: LASSO/SVM</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">Accuracy: 72.4%</td></tr><tr><td align=\"center\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR218\">218</xref>]</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Zhang et al. (2024)</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Clinical Test and Hematology</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">NSCLC</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Singlecenter</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">PFS</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">175</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">50%</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">50%</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">ML: LASSO</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.74 (1 year)&#8722;0.81 (2 years)&#8722;0.79 (3 years)</td></tr><tr><td align=\"center\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR219\">219</xref>]</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Huang et al. (2024)</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Clinical Test</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">ESCC</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Singlecenter</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Responders/Non-responders</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Ambispective</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">133</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">70%</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">30%</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">ML</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.86 (training)&#8722;0.85 (testing)</td></tr><tr><td align=\"center\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR220\">220</xref>]</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Wang et al. (2024)</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Clinical Test and Hematology</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">LUSC</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Singlecenter</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">MPR</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">91</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">ML: LR</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.91</td></tr><tr><td align=\"center\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR221\">221</xref>]</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Hu et al. (2024)</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Hematology</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">NSCLC</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Singlecenter</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">MPR</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Ambispective</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">206</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">166</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">40</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">ML: LASSO/LR</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.77 (training)&#8722;0.75 (validation)&#8722;0.84 (testing)</td></tr><tr><td align=\"center\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR222\">222</xref>]</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Feng et al. (2022)</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Hematology</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">ESCC</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Singlecenter</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">pCR</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">285</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">200</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">85</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">ML: LASSO/LR</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">C-index: 0.76 (training) &#8722;0.81 (testing)</td></tr><tr><td align=\"center\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR223\">223</xref>]</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Han et al. (2023)</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Hematology</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">ESCC</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Singlecenter</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">pCR</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">97</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">70%</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">30%</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">ML: LASSO/LR</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.72 (training)&#8722;0.82 (testing)</td></tr><tr><td align=\"center\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR224\">224</xref>]</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Zhai et al. (2024)</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Hematology</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">NSCLC</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">MPR</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">173</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">147</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">26</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">ML: LASSO</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.80 (training) &#8722;0.82 (testing)</td></tr><tr><td align=\"center\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR225\">225</xref>]</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Zhai et al. (2023)</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Hematology</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">NSCLC</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Singlecenter</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">pCR</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">128</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">ML: LASSO</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.74</td></tr><tr><td align=\"center\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR226\">226</xref>]</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Peng et al. (2021)</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Hematology</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">NSCLC</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Singlecenter</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">MPR</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Prospective</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">211</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">127</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">84</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">ML: LASSO/SVM</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.95 (training)&#8722;0.94 (testing)</td></tr><tr><td align=\"center\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR216\">216</xref>]</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Liu et al. (2024)</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Microbiomics</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">ESCC</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Singlecenter</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Responders/Non-responders</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">68</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">80%</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">20%</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">ML: XGBoost</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.87 (training)&#8722;0.77 (validation)&#8722;0.76 (testing)</td></tr><tr><td align=\"center\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR217\">217</xref>]</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Wu et al. (2024)</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Proteomics</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">ESCC</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Singlecenter</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Drug Response</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">NA</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">55</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">70%</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">30%</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">ML: RF/GLM</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.97</td></tr><tr><td align=\"center\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR227\">227</xref>]</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Yang et al. (2024)</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Multi-omics</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">ESCC</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Singlecenter</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">pCR</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">164</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">80%</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">20%</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">ML: LASSO</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.77 (hematology)&#8722;0.87 (radiomics)&#8722;0.93 (combined)</td></tr><tr><td align=\"center\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR228\">228</xref>]</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Xu et al. (2025)</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Multi-omics</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">NSCLC</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Singlecenter</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">MPR</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Prospective</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">45</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">DL</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.70 (DL)&#8722;0.82 (combined)</td></tr><tr><td align=\"center\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR229\">229</xref>]</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Qi et al. (2025)</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Multi-omics</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">ESCC</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Singlecenter</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">pCR</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">223</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">75%</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">25%</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">ML: SVM</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.99 (training)&#8722;0.89 (testing)</td></tr><tr><td align=\"center\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR230\">230</xref>]</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Nie et al. (2025)</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Multi-omics</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">SCLC</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">PFS/OS</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">309</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">ML: RF</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.76 (training)&#8722;0.90 (validation)</td></tr><tr><td align=\"center\" colspan=\"1\" rowspan=\"1\">[<xref ref-type=\"bibr\" rid=\"CR231\">231</xref>]</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Gao et al. (2024)</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Multi-omics</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">BC</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Multicenter</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">pCR</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">Retrospective</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">3352</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">80%</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">-</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">20%</td><td align=\"center\" colspan=\"1\" rowspan=\"1\">DL: MLP</td><td align=\"left\" colspan=\"1\" rowspan=\"1\">AUC: 0.85</td></tr></tbody></table></table-wrap></p></sec></sec><sec id=\"Sec21\"><title>Discussion</title><sec id=\"Sec22\"><title>Research quenstions and main findings</title><p id=\"Par188\"><bold><italic toggle=\"yes\">Q1: How has AI currently been applied to predicting pan-cancer NIT therapeutic outcomes?</italic></bold> We systematically reviewed AI-based models developed to predict therapeutic outcomes of NIT across cancer types, and categorized them into indirect and direct prediction paradigms. The indirect approach leverages AI to infer the status of established biomarkers, such as PD-L1, TMB, MSI, and TME features, based on omics data, thereby enabling stratification of patient response. In contrast, the direct paradigm involves constructing computational biomarkers or AI-derived scores directly from patient data to predict clinical endpoints such as pCR, MPR, and PFS, or to distinguish responders from non-responders. Current research in this field reveals several trends. First, AI-based predictions of conventional immunotherapy biomarkers have reached accuracies comparable to expert-level assessments; however, models targeting emerging TME features linked to NIT therapeutic outcomes, such as TLS, remain underrepresented. Second, direct prediction models are primarily concentrated in cancers with higher prevalence and NIT practice, particularly lung cancer, and tend to focus on short-term endpoints. Third, most models remain in the preclinical stage, with limited prospective and multi-center validation, posing a major barrier to clinical translation.</p><p id=\"Par189\"><bold><italic toggle=\"yes\">Q2: What are the data categories and sources in AI prediction model development?</italic></bold> Across studies, regardless of the prediction objective, the most commonly used input modalities are routine clinical imaging and H&amp;E-stained histopathology slides. This likely reflects their low acquisition cost, widespread availability, and standardized presence in clinical workflows. In addition to these conventional inputs, a number of studies have begun to explore novel data sources, such as Raman spectroscopy features from tumor sections, gut microbiome profiles, and spatial proteomics of the TME, to improve the prediction of both biomarker status and clinical outcomes. In terms of data sources, public repositories such as TCGA are frequently used for developing indirect prediction models, offering foundational multi-omics data for biomarker inference. In contrast, direct prediction models often rely on patient-level data obtained from clinical trials or institutional cohorts. Due to ethical and privacy constraints, such data are typically confidential and not publicly shared, which may explain the predominance of single-center studies in this domain. Furthermore, the vast majority of studies, irrespective of predictive targets or data modalities, employ retrospective study designs. In the research of leveraging AI for predicting treatment response, a retrospective study examines existing data collected in the past, often from patient records or databases, to investigate study outcomes. In contrast, a prospective study involves collecting new data moving forward, where participants are followed over time, and data is gathered as particular events occur or treatments are administered. This trend reflects the exploratory nature of NIT research, where prospective trials remain logistically challenging due to the requirements of patient recruitment, long-term follow-up, regulatory approval, and substantial funding. Retrospective designs, by contrast, allow efficient use of existing real-world datasets to rapidly test hypotheses and identify potential predictive features, thereby laying the groundwork for future high-quality prospective validation.</p><p id=\"Par190\"><bold><italic toggle=\"yes\">Q3: How do AI-based models differ from conventional biomarker assessment and therapeutic prediction models?</italic></bold> Traditional biomarker assessment methods are often costly, labor-intensive, and heavily reliant on clinical expertise. These processes are not only time-consuming but also subject to inter-observer variability and human bias. For example, manual delineation of TILs on histopathological slides frequently suffers from inconsistent accuracy and reproducibility [<xref ref-type=\"bibr\" rid=\"CR167\">167</xref>]. In contrast, the integration of AI technologies has introduced significant advantages in this domain. AI enables rapid and automated evaluation of biomarker status, particularly in tasks involving image interpretation and histopathological analysis. Beyond efficiency and scalability, AI-based approaches offer the potential to more comprehensively predict patient response to NIT. By identifying informative features from high-dimensional data, these models may facilitate the discovery of novel biomarkers and enhance our understanding of the underlying biological mechanisms of NIT efficacy. In addition, AI holds promise for reducing labor and time costs associated with conventional biomarker evaluation pipelines [<xref ref-type=\"bibr\" rid=\"CR232\">232</xref>, <xref ref-type=\"bibr\" rid=\"CR233\">233</xref>]. AI models and conventional therapeutic prediction models differ significantly in terms of necessary validation schemes due to their complexity, data requirements, and interpretability. AI models rely on large, high-dimensional datasets, including multiple omics layers, and often function as &#8220;black boxes&#8221;. This necessitates not only internal validation (e.g., cross-validation) for model evaluation and optimization, but also external validation on independent datasets to ensure generalizability and reproducibility. By contrast, conventional prediction models typically rely on more direct data input with fewer variables and smaller datasets. These models typically focus on more easily interpretable features like clinical parameters and are more generalizable. Therefore, a single internal validation may suffice if the model is well-understood and used in consistent clinical contexts.</p><p id=\"Par191\"><bold><italic toggle=\"yes\">Q4: What are the characteristics and potential of multi-omics models?</italic></bold> Multi-omics models offer a distinct advantage in their ability to simultaneously integrate heterogeneous data across different modalities, dimensions, and time points. By leveraging the complementary nature of these data types, such models can provide a more holistic and nuanced characterization of patient status [<xref ref-type=\"bibr\" rid=\"CR7\">7</xref>, <xref ref-type=\"bibr\" rid=\"CR234\">234</xref>]. Our synthesis of current literature indicates that, within the same patient cohorts, multi-omics models usually outperform their single-omics counterparts in predictive accuracy, underscoring the value of multi-source data integration. Moreover, AI algorithms are particularly well-suited for multi-omics integration, as they can automatically identify complex and subtle associations across diverse feature dimensions [<xref ref-type=\"bibr\" rid=\"CR235\">235</xref>, <xref ref-type=\"bibr\" rid=\"CR236\">236</xref>]. This capability not only enhances predictive performance but also holds promise for uncovering previously unrecognized biological interactions, potentially shedding light on the mechanisms underlying response to NIT. However, Current models predominantly rely on readily accessible data types. Moreover, despite the potential of data integration approaches, studies employing multi-omics strategies remain relatively limited, reflecting a practical emphasis on feasibility over breadth. This may be attributed to limitations posed by both NIT clinical landscape and AI algorithmic issues, which will be further elaborated in the following sections.</p></sec><sec id=\"Sec23\"><title>Biomarker-related limitations and future directions</title><p id=\"Par192\"><bold><italic toggle=\"yes\">Indirect Biomarkers</italic></bold> Although NIT has demonstrated promising clinical outcomes, the identification and validation of reliable indirect biomarkers remain a significant challenge. Several biomarkers, including PD-L1 expression, TMB, and MSI, have been investigated for predicting NIT efficacy, but their clinical applicability is limited by various constraints. For example, PD-L1 expression, while integrated into clinical decision-making, exhibits inconsistent predictive value due to factors such as intra-tumoral heterogeneity, variability in IHC scoring, and differences in testing platforms [<xref ref-type=\"bibr\" rid=\"CR44\">44</xref>, <xref ref-type=\"bibr\" rid=\"CR49\">49</xref>, <xref ref-type=\"bibr\" rid=\"CR237\">237</xref>]. TMB, however, lacks universally accepted thresholds across different tumor types and does not always correlate with effective anti-tumor immune responses [<xref ref-type=\"bibr\" rid=\"CR238\">238</xref>, <xref ref-type=\"bibr\" rid=\"CR239\">239</xref>]. MSI is a robust predictor of immunotherapy response in CRC, whereas its relevance in other malignancies is limited due to its lower prevalence [<xref ref-type=\"bibr\" rid=\"CR240\">240</xref>]. TME characteristics such as TIL, TLS, and CTLA-4 expression, have been identified to reflect NIT response in clinical, yet fewer studies validated their robustness as therapeutic biomarkers or explored AI-driven automated assessment of these components. Furthermore, the absence of large, diverse patient cohorts for biomarker validation impedes the generalization and widespread clinical implementation of these biomarkers [<xref ref-type=\"bibr\" rid=\"CR241\">241</xref>]. To address these challenges, future research should focus on improving the reliability, standardization, and regulatory approval of indirect biomarkers. Additionally, integrating AI-driven approaches into biomarker discovery could accelerate the identification of novel predictive markers from complex multi-omics data and inspire biological insights.</p><p id=\"Par193\"><bold><italic toggle=\"yes\">Direct Biomarkers</italic></bold> Direct prediction models based on pre-treatment data mainly focus on short-term NIT outcomes such as pCR and MPR, which offer early efficacy signals but fail to capture long-term risks and benefits better reflected by PFS and OS, such as recurrence and metastasis [<xref ref-type=\"bibr\" rid=\"CR242\">242</xref>, <xref ref-type=\"bibr\" rid=\"CR243\">243</xref>]. Moreover, evidence suggests that the correlation between short-term indicators and long-term treatment outcomes can vary across individuals and cancer types [<xref ref-type=\"bibr\" rid=\"CR244\">244</xref>, <xref ref-type=\"bibr\" rid=\"CR245\">245</xref>]. However, research focusing on long-term treatment indicators remains relatively limited in the context of NIT. Our analysis indicates that the majority of direct prediction studies have been conducted on NSCLC and ESCC cohorts. As NIT continues to gain traction in other cancer types, such as BC, there is a clear need for the development of prediction models for these underrepresented cohorts. The expansion of NIT research will help validate indirect prediction models and contribute to more diversified datasets for model construction. To advance direct prediction models, it is essential to prioritize the collection of long-term follow-up data from diverse patient populations. Additionally, the development of integrated learning models that combine preoperative imaging, pathological assessments, and postoperative outcomes holds significant promise for more accurate predictions of long-term treatment responses [<xref ref-type=\"bibr\" rid=\"CR246\">246</xref>, <xref ref-type=\"bibr\" rid=\"CR247\">247</xref>].</p></sec><sec id=\"Sec24\"><title>AI-related limitations and future directions</title><p id=\"Par194\"><bold><italic toggle=\"yes\">Interpretability and Trustworthiness</italic></bold> AI models, particularly DL and ML, often function as black boxes, making it difficult to understand how they arrive at their decisions [<xref ref-type=\"bibr\" rid=\"CR248\">248</xref>, <xref ref-type=\"bibr\" rid=\"CR249\">249</xref>]. Traditional models like decision trees, random forests, and logistic regression offer better interpretability, providing explicit decision rules or feature importance scores [<xref ref-type=\"bibr\" rid=\"CR250\">250</xref>]. In contrast, DL models such as CNNs and Transformer-based architectures extract highly abstract representations, which are challenging to explain [<xref ref-type=\"bibr\" rid=\"CR251\">251</xref>]. This lack of interpretability raises trust issues, particularly in healthcare, where clinicians must understand why a model makes a specific prediction before using it in decision-making. Regulatory bodies like the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) also require transparent explanations of how AI models function in medical applications [<xref ref-type=\"bibr\" rid=\"CR252\">252</xref>]. To address these challenges, Explainable AI (XAI) methods such as Shapley Additive Explanations (SHAP), Local Interpretable Model-agnostic Explanations (LIME), and saliency maps provide post-hoc explanations [<xref ref-type=\"bibr\" rid=\"CR39\">39</xref>, <xref ref-type=\"bibr\" rid=\"CR253\">253</xref>, <xref ref-type=\"bibr\" rid=\"CR254\">254</xref>]. Hybrid models, which combine deep learning with interpretable techniques (e.g., CNNs with decision trees), could further help build trust and transparency among healthcare professionals and regulators [<xref ref-type=\"bibr\" rid=\"CR255\">255</xref>].</p><p id=\"Par195\"><bold><italic toggle=\"yes\">Generalization and Scalability</italic></bold> AI models in healthcare often face challenges related to generalization and scalability due to variability in data sources, patient demographics, and imaging techniques. A model trained on one dataset may not perform well when applied to another institution or demographic, due to differences in imaging protocols, scanner types, or clinical documentation styles [<xref ref-type=\"bibr\" rid=\"CR256\">256</xref>]. Furthermore, many AI models, particularly DL models, require large amounts of labeled data for training, which can be hard to obtain for rare diseases or underrepresented populations [<xref ref-type=\"bibr\" rid=\"CR257\">257</xref>]. Techniques such as domain adaptation, transfer learning, self-supervised learning, and federated learning are emerging to improve generalization by reducing the dependency on large, labeled datasets and enabling models to learn robust features across diverse settings [<xref ref-type=\"bibr\" rid=\"CR258\">258</xref>&#8211;<xref ref-type=\"bibr\" rid=\"CR260\">260</xref>]. Scalability remains a challenge, especially in resource-limited environments where access to high-performance computing (HPC) infrastructure may be restricted [<xref ref-type=\"bibr\" rid=\"CR261\">261</xref>]. To address this, lightweight neural networks, knowledge distillation, and edge AI solutions could improve scalability by enabling AI deployment on local clinical devices with fewer computational resources [<xref ref-type=\"bibr\" rid=\"CR262\">262</xref>].</p><p id=\"Par196\"><bold><italic toggle=\"yes\">Multi-source Data Integration</italic></bold> AI has the potential to integrate multi-omics data to improve predictive accuracy and aid in biomarker discovery, whereas multi-omics models are underrepresented in research [<xref ref-type=\"bibr\" rid=\"CR263\">263</xref>]. Multi-omics models tend to outperform single-omics models, capturing the complex, multi-factorial nature of diseases [<xref ref-type=\"bibr\" rid=\"CR227\">227</xref>, <xref ref-type=\"bibr\" rid=\"CR264\">264</xref>]. In addition, integrating longitudinal data, such as treatment response measurements taken at multiple time points, could enhance predictions of patient outcomes over time [<xref ref-type=\"bibr\" rid=\"CR246\">246</xref>, <xref ref-type=\"bibr\" rid=\"CR247\">247</xref>]. However, difficulties remain in aligning and merging heterogeneous data types, particularly data temporally or spatially misaligned [<xref ref-type=\"bibr\" rid=\"CR265\">265</xref>]. Therefore, future research should focus on robust data fusion methods that can effectively combine multi-omics and longitudinal data, minimizing noise and misalignment. Advanced techniques such as spatiotemporal models can capture the temporal dynamics inherent in longitudinal data, offering more accurate representations of disease progression or treatment responses [<xref ref-type=\"bibr\" rid=\"CR266\">266</xref>]. Attention mechanisms like self-attention and cross-modal attention could also enhance model performance by allowing the model to focus on the most informative features from each data modality, leading to more reliable predictions [<xref ref-type=\"bibr\" rid=\"CR267\">267</xref>, <xref ref-type=\"bibr\" rid=\"CR268\">268</xref>].</p><p id=\"Par197\"><bold><italic toggle=\"yes\">Bias and Fairness</italic></bold> AI models trained on biased datasets can lead to unfair and inaccurate predictions, disproportionately affecting underrepresented patient populations [<xref ref-type=\"bibr\" rid=\"CR269\">269</xref>]. In the case of NIT prediction, many publicly available medical datasets primarily feature data from high-income countries, introducing ethnic, geographic, and socioeconomic biases [<xref ref-type=\"bibr\" rid=\"CR270\">270</xref>]. Moreover, biases in data collection, such as disparities in imaging quality between well-funded and resource-limited healthcare settings, can further exacerbate these issues [<xref ref-type=\"bibr\" rid=\"CR271\">271</xref>, <xref ref-type=\"bibr\" rid=\"CR272\">272</xref>]. To mitigate bias, it is crucial to ensure that training datasets are diverse and representative of different demographic groups. Additionally, AI models should be evaluated using fairness-aware metrics like equalized odds and disparate impact analysis to ensure that they perform equitably across different subpopulations. Methods like adversarial debiasing, reweighting strategies, and subgroup-aware training can help reduce bias during model development [<xref ref-type=\"bibr\" rid=\"CR273\">273</xref>]. Regulatory agencies may also mandate fairness audits as part of AI model validation to promote equitable healthcare outcomes in immunotherapy predictions [<xref ref-type=\"bibr\" rid=\"CR274\">274</xref>].</p><p id=\"Par198\"><bold><italic toggle=\"yes\">Security and Privacy</italic></bold> Medical AI relies on sensitive data, making security and privacy critical concerns, as are vulnerable to data breaches, adversarial attacks, and model inversion [<xref ref-type=\"bibr\" rid=\"CR275\">275</xref>, <xref ref-type=\"bibr\" rid=\"CR276\">276</xref>]. Adversarial perturbations, like malicious modifications to medical images, can manipulate AI predictions, thereby harming model performance and compromising patient safety. Similarly, model extraction attacks can allow unauthorized entities to replicate proprietary AI models, posing risks of intellectual property theft and misuse [<xref ref-type=\"bibr\" rid=\"CR277\">277</xref>]. Therefore, researchers may adopt adversarial defense mechanisms such as adversarial training and robust model architectures [<xref ref-type=\"bibr\" rid=\"CR278\">278</xref>]. Privacy-preserving techniques like differential privacy and homomorphic encryption offer promising solutions to ensure patient data remains protected while enabling collaborative model development across institutions [<xref ref-type=\"bibr\" rid=\"CR279\">279</xref>, <xref ref-type=\"bibr\" rid=\"CR280\">280</xref>]. Furthermore, adherence to regulatory frameworks such as the General Data Protection Regulation (GDPR) and Health Insurance Portability and Accountability Act (HIPAA) is essential to safeguard patient data in AI development [<xref ref-type=\"bibr\" rid=\"CR281\">281</xref>]. Future research should focus on enhancing privacy-preserving algorithms and secure multi-party computation to enable safe, large-scale AI training without compromising patient confidentiality.</p></sec></sec><sec id=\"Sec25\"><title>Conclusion</title><p id=\"Par199\">In summary, the application of AI in predicting the efficacy of NIT represents a transformative advancement in precision immunotherapy. By leveraging diverse oncological data, AI-driven models have demonstrated the potential to accurately screen for NIT potential beneficiaries. In this review, we systematically categorized existing AI-based approaches into indirect prediction paradigms, which infer treatment response through clinically established biomarkers, and direct prediction paradigms, which utilize AI to define data-driven biomarkers that are directly linked to clinical endpoints. Despite these advancements, two main challenges remain spanning from the biomarker robustness to AI algorithmic issues that jointly hinder AI application in NIT efficacy prediction. Addressing these issues is essential for advancing medical AI in precision oncology.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>3D-DenseNet</term><def><p id=\"Par2\">Three-dimensional dense convolutional neural network</p></def></def-item><def-item><term>ACC</term><def><p id=\"Par3\">Accuracy</p></def></def-item><def-item><term>ADC</term><def><p id=\"Par4\">Apparent diffusion coefficient</p></def></def-item><def-item><term>AI</term><def><p id=\"Par5\">Artificial intelligence</p></def></def-item><def-item><term>ATAC-seq</term><def><p id=\"Par6\">Assay for transposase-accessible chromatin sequencing</p></def></def-item><def-item><term>attMIL</term><def><p id=\"Par7\">Attention-based multiple instance learning</p></def></def-item><def-item><term>AUC</term><def><p id=\"Par8\">Area under the curve</p></def></def-item><def-item><term>BC</term><def><p id=\"Par9\">Breast cancer</p></def></def-item><def-item><term>BLCA</term><def><p id=\"Par10\">Bladder cancer</p></def></def-item><def-item><term>CATBOOST</term><def><p id=\"Par11\">Categorical boosting</p></def></def-item><def-item><term>CD163</term><def><p id=\"Par12\">Cluster of differentiation 163</p></def></def-item><def-item><term>CD3</term><def><p id=\"Par13\">Cluster of differentiation 3</p></def></def-item><def-item><term>CD4</term><def><p id=\"Par14\">Cluster of differentiation 4</p></def></def-item><def-item><term>CD8</term><def><p id=\"Par15\">Cluster of differentiation 8</p></def></def-item><def-item><term>ChIP-seq</term><def><p id=\"Par16\">Chromatin immunoprecipitation sequencing</p></def></def-item><def-item><term>CLIP</term><def><p id=\"Par17\">Contrastive language-image pre-training</p></def></def-item><def-item><term>C-Index</term><def><p id=\"Par18\">Concordance index</p></def></def-item><def-item><term>CNVs</term><def><p id=\"Par19\">Copy number variations</p></def></def-item><def-item><term>CNN</term><def><p id=\"Par20\">Convolutional neural network</p></def></def-item><def-item><term>CONCH</term><def><p id=\"Par21\">Contrastive learning-based network for histopathology</p></def></def-item><def-item><term>CONSORT-AI</term><def><p id=\"Par22\">Consolidated standards of reporting trials &#8211; artificial intelligence</p></def></def-item><def-item><term>CRC</term><def><p id=\"Par23\">Colorectal cancer</p></def></def-item><def-item><term>CS</term><def><p id=\"Par24\">Computer science</p></def></def-item><def-item><term>CT</term><def><p id=\"Par25\">Computed tomography</p></def></def-item><def-item><term>CTLA-4</term><def><p id=\"Par26\">Cytotoxic T-lymphocyte-associated protein 4</p></def></def-item><def-item><term>ctDNA</term><def><p id=\"Par27\">Circulating tumor DNA</p></def></def-item><def-item><term>CV</term><def><p id=\"Par28\">Computer vision</p></def></def-item><def-item><term>dMMR</term><def><p id=\"Par29\">Deficient mismatch repair</p></def></def-item><def-item><term>DL</term><def><p id=\"Par30\">Deep learning</p></def></def-item><def-item><term>DNA</term><def><p id=\"Par31\">Deoxyribonucleic acid</p></def></def-item><def-item><term>DNN</term><def><p id=\"Par32\">Deep neural network</p></def></def-item><def-item><term>DWI</term><def><p id=\"Par33\">Diffusion-weighted imaging</p></def></def-item><def-item><term>EHRs</term><def><p id=\"Par34\">Electronic health records</p></def></def-item><def-item><term>EGFR</term><def><p id=\"Par35\">Epidermal growth factor receptor</p></def></def-item><def-item><term>EOC</term><def><p id=\"Par36\">Epithelial ovarian cancer</p></def></def-item><def-item><term>EMC</term><def><p id=\"Par37\">Endometrial cancer</p></def></def-item><def-item><term>EMA</term><def><p id=\"Par38\">European medicines agency</p></def></def-item><def-item><term>ENCODE</term><def><p id=\"Par39\">Encyclopedia of DNA elements</p></def></def-item><def-item><term>ESCC</term><def><p id=\"Par40\">Esophageal squamous cell carcinoma</p></def></def-item><def-item><term>ES-SCLC</term><def><p id=\"Par41\">Extensive-stage small cell lung cancer</p></def></def-item><def-item><term>FDA</term><def><p id=\"Par42\">Food and drug administration</p></def></def-item><def-item><term>FFPP</term><def><p id=\"Par43\">Formalin-fixed paraffin-embedded</p></def></def-item><def-item><term>F1-score</term><def><p id=\"Par44\">F1 score</p></def></def-item><def-item><term>FN</term><def><p id=\"Par45\">False negative</p></def></def-item><def-item><term>FP</term><def><p id=\"Par46\">False positive</p></def></def-item><def-item><term>FPR</term><def><p id=\"Par47\">False positive rate</p></def></def-item><def-item><term>GBDT</term><def><p id=\"Par48\">Gradient boosted decision trees</p></def></def-item><def-item><term>GBM</term><def><p id=\"Par49\">Glioblastoma</p></def></def-item><def-item><term>GC</term><def><p id=\"Par50\">Gastric cancer</p></def></def-item><def-item><term>GC-MS</term><def><p id=\"Par51\">Gas chromatography&#8211;mass spectrometry</p></def></def-item><def-item><term>GEO</term><def><p id=\"Par52\">Gene expression omnibus</p></def></def-item><def-item><term>GGJC</term><def><p id=\"Par53\">Gastric and gastroesophageal junction cancer</p></def></def-item><def-item><term>GLM</term><def><p id=\"Par54\">Generalized linear model</p></def></def-item><def-item><term>GNN</term><def><p id=\"Par55\">Graph neural network</p></def></def-item><def-item><term>gnomAD</term><def><p id=\"Par56\">Genome aggregation database</p></def></def-item><def-item><term>GPR</term><def><p id=\"Par57\">Gaussian process regression</p></def></def-item><def-item><term>GPT</term><def><p id=\"Par58\">Generative pre-trained transformer</p></def></def-item><def-item><term>HC</term><def><p id=\"Par59\">Hepatocellular carcinoma</p></def></def-item><def-item><term>HIPAA</term><def><p id=\"Par60\">Health insurance portability and accountability act</p></def></def-item><def-item><term>HMDB</term><def><p id=\"Par61\">Human metabolome database</p></def></def-item><def-item><term>HNSCC</term><def><p id=\"Par62\">Head and neck Squamous cell carcinoma</p></def></def-item><def-item><term>HR</term><def><p id=\"Par63\">Hazard ratio</p></def></def-item><def-item><term>ICGC</term><def><p id=\"Par64\">International cancer genome consortium</p></def></def-item><def-item><term>ICI</term><def><p id=\"Par65\">Immune checkpoint inhibitor</p></def></def-item><def-item><term>IHC</term><def><p id=\"Par66\">Immunohistochemistry</p></def></def-item><def-item><term>IOU</term><def><p id=\"Par67\">Intersection over union</p></def></def-item><def-item><term>KNN</term><def><p id=\"Par68\">K-nearest neighbors</p></def></def-item><def-item><term>LASSO</term><def><p id=\"Par69\">Least absolute shrinkage and selection operator</p></def></def-item><def-item><term>LC</term><def><p id=\"Par70\">Lung cancer</p></def></def-item><def-item><term>LC-MS</term><def><p id=\"Par71\">Liquid chromatography&#8211;mass spectrometry</p></def></def-item><def-item><term>LDA</term><def><p id=\"Par72\">Linear discriminant analysis</p></def></def-item><def-item><term>LGG</term><def><p id=\"Par73\">Low-grade glioma</p></def></def-item><def-item><term>LIME</term><def><p id=\"Par74\">Local interpretable model-agnostic explanations</p></def></def-item><def-item><term>lncRNA</term><def><p id=\"Par75\">Long non-coding RNA</p></def></def-item><def-item><term>LR</term><def><p id=\"Par76\">Logistic regression</p></def></def-item><def-item><term>LUAD</term><def><p id=\"Par77\">Lung adenocarcinoma</p></def></def-item><def-item><term>LUSC</term><def><p id=\"Par78\">Lung squamous cell carcinoma</p></def></def-item><def-item><term>MIL</term><def><p id=\"Par79\">Multiple instance learning</p></def></def-item><def-item><term>ML</term><def><p id=\"Par80\">Machine learning</p></def></def-item><def-item><term>MLC</term><def><p id=\"Par81\">Machine learning classifier</p></def></def-item><def-item><term>MLP</term><def><p id=\"Par82\">Multi-layer perceptron</p></def></def-item><def-item><term>MITLS</term><def><p id=\"Par83\">Multi-instance transformer learning system</p></def></def-item><def-item><term>MLR</term><def><p id=\"Par84\">Monocyte-to-lymphocyte ratio</p></def></def-item><def-item><term>MMR</term><def><p id=\"Par85\">Mismatch repair</p></def></def-item><def-item><term>mRNA</term><def><p id=\"Par86\">Messenger RNA</p></def></def-item><def-item><term>MRI</term><def><p id=\"Par87\">Magnetic resonance imaging</p></def></def-item><def-item><term>MS</term><def><p id=\"Par88\">Mass spectrometry</p></def></def-item><def-item><term>MSI</term><def><p id=\"Par89\">Microsatellite instability</p></def></def-item><def-item><term>MSS</term><def><p id=\"Par90\">Microsatellite stability</p></def></def-item><def-item><term>MuAt</term><def><p id=\"Par91\">Mutation attention</p></def></def-item><def-item><term>NIT</term><def><p id=\"Par92\">Neoadjuvant immunotherapy</p></def></def-item><def-item><term>NB</term><def><p id=\"Par93\">Na&#239;ve bayes</p></def></def-item><def-item><term>NCIT</term><def><p id=\"Par94\">Neoadjuvant chemoimmunotherapy</p></def></def-item><def-item><term>NKT cells</term><def><p id=\"Par95\">Natural killer T cells</p></def></def-item><def-item><term>NLR</term><def><p id=\"Par96\">Neutrophil-to-lymphocyte ratio</p></def></def-item><def-item><term>NLP</term><def><p id=\"Par97\">Natural language processing</p></def></def-item><def-item><term>NMR</term><def><p id=\"Par98\">Nuclear magnetic resonance</p></def></def-item><def-item><term>NSCLC</term><def><p id=\"Par99\">Non-small cell lung cancer</p></def></def-item><def-item><term>OR</term><def><p id=\"Par100\">Odds ratio</p></def></def-item><def-item><term>OS</term><def><p id=\"Par101\">Overall survival</p></def></def-item><def-item><term>PACS</term><def><p id=\"Par102\">Picture archiving and communication system</p></def></def-item><def-item><term>Pan-Cancer</term><def><p id=\"Par103\">Pan-cancer</p></def></def-item><def-item><term>PCA</term><def><p id=\"Par104\">Principal component analysis</p></def></def-item><def-item><term>PCR</term><def><p id=\"Par105\">Polymerase chain reaction</p></def></def-item><def-item><term>pCR</term><def><p id=\"Par106\">Pathological complete response</p></def></def-item><def-item><term>PEOS</term><def><p id=\"Par107\">Population, exposure, outcomes, and study design</p></def></def-item><def-item><term>PD-1</term><def><p id=\"Par108\">Programmed cell death protein 1</p></def></def-item><def-item><term>PD-L1</term><def><p id=\"Par109\">Programmed cell death 1 ligand 1</p></def></def-item><def-item><term>PDAC</term><def><p id=\"Par110\">Pancreatic ductal adenocarcinoma</p></def></def-item><def-item><term>PET</term><def><p id=\"Par111\">Positron emission tomography</p></def></def-item><def-item><term>PET/CT</term><def><p id=\"Par112\">Positron emission tomography/Computed tomography</p></def></def-item><def-item><term>PFS</term><def><p id=\"Par113\">Progression-free survival</p></def></def-item><def-item><term>PPsNet</term><def><p id=\"Par114\">Patch-wise pretrained segmentation network</p></def></def-item><def-item><term>PTM</term><def><p id=\"Par115\">Post-translational modification</p></def></def-item><def-item><term>qRT-PCR</term><def><p id=\"Par116\">quantitative Reverse transcription polymerase chain reaction</p></def></def-item><def-item><term>RC</term><def><p id=\"Par117\">Rectal cancer</p></def></def-item><def-item><term>RF</term><def><p id=\"Par118\">Random forest</p></def></def-item><def-item><term>RNN</term><def><p id=\"Par119\">Recurrent neural network</p></def></def-item><def-item><term>RSF</term><def><p id=\"Par120\">Random survival forest</p></def></def-item><def-item><term>SAM</term><def><p id=\"Par121\">Segment anything model</p></def></def-item><def-item><term>SCLC</term><def><p id=\"Par122\">Small cell lung cancer</p></def></def-item><def-item><term>SMA</term><def><p id=\"Par123\">Smooth muscle actin</p></def></def-item><def-item><term>SNP</term><def><p id=\"Par124\">Single nucleotide polymorphism</p></def></def-item><def-item><term>SSL</term><def><p id=\"Par125\">Semi-supervised learning</p></def></def-item><def-item><term>SSL-attMIL</term><def><p id=\"Par126\">Self-supervised learning attention-based multiple instance learning</p></def></def-item><def-item><term>SREBF2</term><def><p id=\"Par127\">Sterol regulatory element binding transcription factor 2</p></def></def-item><def-item><term>SVM</term><def><p id=\"Par128\">Support vector machine</p></def></def-item><def-item><term>TCGA</term><def><p id=\"Par129\">The cancer genome atlas</p></def></def-item><def-item><term>TCIA</term><def><p id=\"Par130\">The cancer imaging archive</p></def></def-item><def-item><term>TILs</term><def><p id=\"Par131\">Tumor-infiltrating lymphocytes</p></def></def-item><def-item><term>TLS</term><def><p id=\"Par132\">Tertiary lymphoid structures</p></def></def-item><def-item><term>TMB</term><def><p id=\"Par133\">Tumor mutational burden</p></def></def-item><def-item><term>TN</term><def><p id=\"Par134\">True negative</p></def></def-item><def-item><term>TNBC</term><def><p id=\"Par135\">Triple-negative breast cancer</p></def></def-item><def-item><term>TP</term><def><p id=\"Par136\">True positive</p></def></def-item><def-item><term>TPR</term><def><p id=\"Par137\">True positive rate</p></def></def-item><def-item><term>TPS</term><def><p id=\"Par138\">Tumor proportion score</p></def></def-item><def-item><term>TSR</term><def><p id=\"Par139\">Tumor-stroma ratio</p></def></def-item><def-item><term>Th17</term><def><p id=\"Par140\">T helper 17</p></def></def-item><def-item><term>UK Biobank</term><def><p id=\"Par141\">United kingdom biobank</p></def></def-item><def-item><term>UL</term><def><p id=\"Par142\">Unsupervised learning</p></def></def-item><def-item><term>UNI</term><def><p id=\"Par143\">Unified network for representation learning</p></def></def-item><def-item><term>VEGF</term><def><p id=\"Par144\">Vascular endothelial growth factor</p></def></def-item><def-item><term>ViTs</term><def><p id=\"Par145\">Vision transformers</p></def></def-item><def-item><term>WES</term><def><p id=\"Par146\">Whole-exome sequencing</p></def></def-item><def-item><term>WGS</term><def><p id=\"Par147\">Whole-genome sequencing</p></def></def-item><def-item><term>WSIs</term><def><p id=\"Par148\">Whole slide images</p></def></def-item><def-item><term>XGBoost</term><def><p id=\"Par149\">Extreme gradient boosting</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Yishu Deng, Tailin Li, Yunze Wang and Silin Chen contributed equally to this work.</p></fn></fn-group><ack><title>Acknowledgements</title><p>This work was supported by grants to Dr. Jian Liu from the Natural Science Foundation (NSF) of China (General Grant: 82172899 and 82472637), the NSF of Zhejiang Province (Distinguished Young Scholars: LR22H160002), Noncommunicable Chronic Diseases-National Science and Technology Major Project (2023ZD0502900/2023ZD0502902 and 2023ZD0507500/2023ZD0507501), Dr. Li Dak Sum &amp; Yip Yio Chin Development Fund for Regenerative Medicine, Zhejiang University, the Open Fund of Zhejiang Provincial Key Laboratory of Pulmonology (Grant No. KF202302), and Zhejiang Provincial Key R&amp;D Program of China (Grant No. 2025C02091). We also acknowledge support from the Haining People&#8217;s Hospital Tertiary-A Public Hospital Establishment Project Municipal Finance Support Fund, and the Joint University-Local Cooperation Fund between ZJU-UoE Institute and Haining People&#8217;s Hospital. We are grateful to the support by the Intramural Research Program, ES102425 to Dr. Manas K. Ray. Principal Supervisor Jian Liu led the work.The Zhejiang University &#8211; University of Edinburgh Institute (ZJE) undergraduate authors, such as Yishu Deng, Tailin Li, Taoyu Zhu, Jiayi Ran, Bo Yang, and Xiaohan Zhang, gratefully acknowledged the profound impact of the ZJE HDRC3A (Human Disease: From Research to Clinic 3A) course, whose innovative pedagogical framework was instrumental in developing the critical perspective and interdisciplinary approach essential for this comprehensive review. The conceptualization and critical analysis presented in this review were directly shaped by the research-driven and AI-enhanced learning paradigm of the HDRC3A course. We also acknowledge the help of members in JL's lab. We thank the Biomed-X Laboratory of 2.EInstitute, School of Medicine, Zhejiang University, for continuous support.</p></ack><notes notes-type=\"author-contribution\"><title>Author contributions</title><p>YD, TL, YW, and SC contributed to the conceptualization of the study, literature collection, manuscript preparation, and figure generation. SC, YZ, and JL provided critical supports. JL oversaw the project and provided critical supervision. All authors contributed to the preparation, writing, and editing of the manuscript. All authors reviewed and approved the final version of the manuscript. No generative AI has been used in the writing of the manuscript.</p></notes><notes notes-type=\"data-availability\"><title>Data availability</title><p>No datasets were generated or analysed during the current study.</p></notes><notes><title>Declarations</title><notes id=\"FPar1\" notes-type=\"COI-statement\"><title>Competing interests</title><p id=\"Par200\">The authors declare no competing interests.</p></notes></notes><ref-list id=\"Bib1\"><title>References</title><ref id=\"CR1\"><label>1.</label><citation-alternatives><element-citation id=\"ec-CR1\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Salas-Benito</surname><given-names>D</given-names></name><name name-style=\"western\"><surname>P&#233;rez-Gracia</surname><given-names>JL</given-names></name><name name-style=\"western\"><surname>Ponz-Sarvis&#233;</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Rodriguez-Ruiz</surname><given-names>ME</given-names></name><name name-style=\"western\"><surname>Mart&#237;nez-Forero</surname><given-names>I</given-names></name><name name-style=\"western\"><surname>Casta&#241;&#243;n</surname><given-names>E</given-names></name><etal/></person-group><article-title>Paradigms on immunotherapy combinations with chemotherapy</article-title><source>Cancer Discov</source><year>2021</year><volume>11</volume><issue>6</issue><fpage>1353</fpage><lpage>67</lpage><pub-id pub-id-type=\"doi\">10.1158/2159-8290.CD-20-1312</pub-id><pub-id pub-id-type=\"pmid\">33712487</pub-id></element-citation><mixed-citation id=\"mc-CR1\" publication-type=\"journal\">Salas-Benito D, P&#233;rez-Gracia JL, Ponz-Sarvis&#233; M, Rodriguez-Ruiz ME, Mart&#237;nez-Forero I, Casta&#241;&#243;n E, et al. Paradigms on immunotherapy combinations with chemotherapy. Cancer Discov. 2021;11(6):1353&#8211;67.<pub-id pub-id-type=\"pmid\">33712487</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1158/2159-8290.CD-20-1312</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR2\"><label>2.</label><citation-alternatives><element-citation id=\"ec-CR2\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Jiang</surname><given-names>S</given-names></name><name name-style=\"western\"><surname>Liu</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Zheng</surname><given-names>H</given-names></name><name name-style=\"western\"><surname>Zhang</surname><given-names>L</given-names></name><name name-style=\"western\"><surname>Zhao</surname><given-names>H</given-names></name><name name-style=\"western\"><surname>Sang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Evolutionary patterns and research frontiers in neoadjuvant immunotherapy: a bibliometric analysis</article-title><source>Int J Surg</source><year>2023</year><volume>109</volume><issue>9</issue><fpage>2774</fpage><lpage>83</lpage><pub-id pub-id-type=\"doi\">10.1097/JS9.0000000000000492</pub-id><pub-id pub-id-type=\"pmid\">37216225</pub-id><pub-id pub-id-type=\"pmcid\">PMC10498839</pub-id></element-citation><mixed-citation id=\"mc-CR2\" publication-type=\"journal\">Jiang S, Liu Y, Zheng H, Zhang L, Zhao H, Sang X, et al. Evolutionary patterns and research frontiers in neoadjuvant immunotherapy: a bibliometric analysis. Int J Surg. 2023;109(9):2774&#8211;83.<pub-id pub-id-type=\"pmid\">37216225</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1097/JS9.0000000000000492</pub-id><pub-id pub-id-type=\"pmcid\">PMC10498839</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR3\"><label>3.</label><citation-alternatives><element-citation id=\"ec-CR3\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Alizadeh</surname><given-names>AA</given-names></name><name name-style=\"western\"><surname>Aranda</surname><given-names>V</given-names></name><name name-style=\"western\"><surname>Bardelli</surname><given-names>A</given-names></name><name name-style=\"western\"><surname>Blanpain</surname><given-names>C</given-names></name><name name-style=\"western\"><surname>Bock</surname><given-names>C</given-names></name><name name-style=\"western\"><surname>Borowski</surname><given-names>C</given-names></name><etal/></person-group><article-title>Toward understanding and exploiting tumor heterogeneity</article-title><source>Nat Med</source><year>2015</year><volume>21</volume><issue>8</issue><fpage>846</fpage><lpage>53</lpage><pub-id pub-id-type=\"doi\">10.1038/nm.3915</pub-id><pub-id pub-id-type=\"pmid\">26248267</pub-id><pub-id pub-id-type=\"pmcid\">PMC4785013</pub-id></element-citation><mixed-citation id=\"mc-CR3\" publication-type=\"journal\">Alizadeh AA, Aranda V, Bardelli A, Blanpain C, Bock C, Borowski C, et al. Toward understanding and exploiting tumor heterogeneity. Nat Med. 2015;21(8):846&#8211;53.<pub-id pub-id-type=\"pmid\">26248267</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1038/nm.3915</pub-id><pub-id pub-id-type=\"pmcid\">PMC4785013</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR4\"><label>4.</label><citation-alternatives><element-citation id=\"ec-CR4\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>O&#8217;Donnell</surname><given-names>JS</given-names></name><name name-style=\"western\"><surname>Hoefsmit</surname><given-names>EP</given-names></name><name name-style=\"western\"><surname>Smyth</surname><given-names>MJ</given-names></name><name name-style=\"western\"><surname>Blank</surname><given-names>CU</given-names></name><name name-style=\"western\"><surname>Teng</surname><given-names>MW</given-names></name></person-group><article-title>The promise of neoadjuvant immunotherapy and surgery for cancer treatment</article-title><source>Clin Cancer Res</source><year>2019</year><volume>25</volume><issue>19</issue><fpage>5743</fpage><lpage>51</lpage><pub-id pub-id-type=\"doi\">10.1158/1078-0432.CCR-18-2641</pub-id><pub-id pub-id-type=\"pmid\">31040150</pub-id></element-citation><mixed-citation id=\"mc-CR4\" publication-type=\"journal\">O&#8217;Donnell JS, Hoefsmit EP, Smyth MJ, Blank CU, Teng MW. The promise of neoadjuvant immunotherapy and surgery for cancer treatment. Clin Cancer Res. 2019;25(19):5743&#8211;51.<pub-id pub-id-type=\"pmid\">31040150</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1158/1078-0432.CCR-18-2641</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR5\"><label>5.</label><citation-alternatives><element-citation id=\"ec-CR5\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Menyh&#225;rt</surname><given-names>O</given-names></name><name name-style=\"western\"><surname>Gy&#337;rffy</surname><given-names>B</given-names></name></person-group><article-title>Multi-omics approaches in cancer research with applications in tumor subtyping, prognosis, and diagnosis</article-title><source>Comput Struct Biotechnol J</source><year>2021</year><volume>19</volume><fpage>949</fpage><lpage>60</lpage><pub-id pub-id-type=\"doi\">10.1016/j.csbj.2021.01.009</pub-id><pub-id pub-id-type=\"pmid\">33613862</pub-id><pub-id pub-id-type=\"pmcid\">PMC7868685</pub-id></element-citation><mixed-citation id=\"mc-CR5\" publication-type=\"journal\">Menyh&#225;rt O, Gy&#337;rffy B. Multi-omics approaches in cancer research with applications in tumor subtyping, prognosis, and diagnosis. Comput Struct Biotechnol J. 2021;19:949&#8211;60.<pub-id pub-id-type=\"pmid\">33613862</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/j.csbj.2021.01.009</pub-id><pub-id pub-id-type=\"pmcid\">PMC7868685</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR6\"><label>6.</label><mixed-citation publication-type=\"other\">He X, Liu X, Zuo F, Shi H, Jing J. Artificial intelligence-based multi-omics analysis fuels cancer precision medicine. In: Seminars in Cancer Biology. vol.&#160;88. Elsevier; 2023. p. 187&#8211;200.<pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/j.semcancer.2022.12.009</pub-id><pub-id pub-id-type=\"pmid\">36596352</pub-id></mixed-citation></ref><ref id=\"CR7\"><label>7.</label><citation-alternatives><element-citation id=\"ec-CR7\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Chakraborty</surname><given-names>S</given-names></name><name name-style=\"western\"><surname>Sharma</surname><given-names>G</given-names></name><name name-style=\"western\"><surname>Karmakar</surname><given-names>S</given-names></name><name name-style=\"western\"><surname>Banerjee</surname><given-names>S</given-names></name></person-group><article-title>Multi-OMICS approaches in cancer biology: new era in cancer therapy</article-title><source>Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease</source><year>2024</year><volume>1870</volume><issue>5</issue><fpage>167120</fpage><pub-id pub-id-type=\"doi\">10.1016/j.bbadis.2024.167120</pub-id><pub-id pub-id-type=\"pmid\">38484941</pub-id></element-citation><mixed-citation id=\"mc-CR7\" publication-type=\"journal\">Chakraborty S, Sharma G, Karmakar S, Banerjee S. Multi-OMICS approaches in cancer biology: new era in cancer therapy. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. 2024;1870(5):167120.<pub-id pub-id-type=\"pmid\">38484941</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/j.bbadis.2024.167120</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR8\"><label>8.</label><citation-alternatives><element-citation id=\"ec-CR8\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Bhinder</surname><given-names>B</given-names></name><name name-style=\"western\"><surname>Gilvary</surname><given-names>C</given-names></name><name name-style=\"western\"><surname>Madhukar</surname><given-names>NS</given-names></name><name name-style=\"western\"><surname>Elemento</surname><given-names>O</given-names></name></person-group><article-title>Artificial intelligence in cancer research and precision medicine</article-title><source>Cancer Discov</source><year>2021</year><volume>11</volume><issue>4</issue><fpage>900</fpage><lpage>15</lpage><pub-id pub-id-type=\"doi\">10.1158/2159-8290.CD-21-0090</pub-id><pub-id pub-id-type=\"pmid\">33811123</pub-id><pub-id pub-id-type=\"pmcid\">PMC8034385</pub-id></element-citation><mixed-citation id=\"mc-CR8\" publication-type=\"journal\">Bhinder B, Gilvary C, Madhukar NS, Elemento O. Artificial intelligence in cancer research and precision medicine. Cancer Discov. 2021;11(4):900&#8211;15.<pub-id pub-id-type=\"pmid\">33811123</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1158/2159-8290.CD-21-0090</pub-id><pub-id pub-id-type=\"pmcid\">PMC8034385</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR9\"><label>9.</label><citation-alternatives><element-citation id=\"ec-CR9\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Yang</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Zhao</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Liu</surname><given-names>X</given-names></name><name name-style=\"western\"><surname>Huang</surname><given-names>J</given-names></name><collab>Elsevier</collab></person-group><article-title>Artificial intelligence for prediction of response to cancer immunotherapy</article-title><source>Semin Cancer Biol</source><year>2022</year><volume>87</volume><fpage>137</fpage><lpage>147</lpage><pub-id pub-id-type=\"doi\">10.1016/j.semcancer.2022.11.008</pub-id><pub-id pub-id-type=\"pmid\">36372326</pub-id></element-citation><mixed-citation id=\"mc-CR9\" publication-type=\"journal\">Yang Y, Zhao Y, Liu X, Huang J, Elsevier. Artificial intelligence for prediction of response to cancer immunotherapy. Semin Cancer Biol. 2022;87:137&#8211;47.<pub-id pub-id-type=\"pmid\">36372326</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/j.semcancer.2022.11.008</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR10\"><label>10.</label><citation-alternatives><element-citation id=\"ec-CR10\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Xie</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Luo</surname><given-names>X</given-names></name><name name-style=\"western\"><surname>Deng</surname><given-names>X</given-names></name><name name-style=\"western\"><surname>Tang</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Tian</surname><given-names>W</given-names></name><name name-style=\"western\"><surname>Cheng</surname><given-names>H</given-names></name><etal/></person-group><article-title>Advances in artificial intelligence to predict cancer immunotherapy efficacy</article-title><source>Front Immunol</source><year>2023</year><volume>13</volume><fpage>1076883</fpage><pub-id pub-id-type=\"doi\">10.3389/fimmu.2022.1076883</pub-id><pub-id pub-id-type=\"pmid\">36685496</pub-id><pub-id pub-id-type=\"pmcid\">PMC9845588</pub-id></element-citation><mixed-citation id=\"mc-CR10\" publication-type=\"journal\">Xie J, Luo X, Deng X, Tang Y, Tian W, Cheng H, et al. Advances in artificial intelligence to predict cancer immunotherapy efficacy. Front Immunol. 2023;13:1076883.<pub-id pub-id-type=\"pmid\">36685496</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.3389/fimmu.2022.1076883</pub-id><pub-id pub-id-type=\"pmcid\">PMC9845588</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR11\"><label>11.</label><citation-alternatives><element-citation id=\"ec-CR11\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Ghaffari Laleh</surname><given-names>N</given-names></name><name name-style=\"western\"><surname>Ligero</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Perez-Lopez</surname><given-names>R</given-names></name><name name-style=\"western\"><surname>Kather</surname><given-names>JN</given-names></name></person-group><article-title>Facts and hopes on the use of artificial intelligence for predictive immunotherapy biomarkers in cancer</article-title><source>Clin Cancer Res</source><year>2023</year><volume>29</volume><issue>2</issue><fpage>316</fpage><lpage>23</lpage><pub-id pub-id-type=\"doi\">10.1158/1078-0432.CCR-22-0390</pub-id><pub-id pub-id-type=\"pmid\">36083132</pub-id></element-citation><mixed-citation id=\"mc-CR11\" publication-type=\"journal\">Ghaffari Laleh N, Ligero M, Perez-Lopez R, Kather JN. Facts and hopes on the use of artificial intelligence for predictive immunotherapy biomarkers in cancer. Clin Cancer Res. 2023;29(2):316&#8211;23.<pub-id pub-id-type=\"pmid\">36083132</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1158/1078-0432.CCR-22-0390</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR12\"><label>12.</label><citation-alternatives><element-citation id=\"ec-CR12\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Zhou</surname><given-names>X</given-names></name><name name-style=\"western\"><surname>Qu</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Tebon</surname><given-names>P</given-names></name><name name-style=\"western\"><surname>Jiang</surname><given-names>X</given-names></name><name name-style=\"western\"><surname>Wang</surname><given-names>C</given-names></name><name name-style=\"western\"><surname>Xue</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Screening cancer immunotherapy: when engineering approaches meet artificial intelligence</article-title><source>Adv Sci</source><year>2020</year><volume>7</volume><issue>19</issue><fpage>2001447</fpage><pub-id pub-id-type=\"doi\">10.1002/advs.202001447</pub-id><pub-id pub-id-type=\"pmcid\">PMC7539186</pub-id><pub-id pub-id-type=\"pmid\">33042756</pub-id></element-citation><mixed-citation id=\"mc-CR12\" publication-type=\"journal\">Zhou X, Qu M, Tebon P, Jiang X, Wang C, Xue Y, et al. Screening cancer immunotherapy: when engineering approaches meet artificial intelligence. Adv Sci. 2020;7(19):2001447.<pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1002/advs.202001447</pub-id><pub-id pub-id-type=\"pmcid\">PMC7539186</pub-id><pub-id pub-id-type=\"pmid\">33042756</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR13\"><label>13.</label><citation-alternatives><element-citation id=\"ec-CR13\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Pilard</surname><given-names>C</given-names></name><name name-style=\"western\"><surname>Ancion</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Delvenne</surname><given-names>P</given-names></name><name name-style=\"western\"><surname>Jerusalem</surname><given-names>G</given-names></name><name name-style=\"western\"><surname>Hubert</surname><given-names>P</given-names></name><name name-style=\"western\"><surname>Herfs</surname><given-names>M</given-names></name></person-group><article-title>Cancer immunotherapy: it&#8217;s time to better predict patients&#8217; response</article-title><source>Br J Cancer</source><year>2021</year><volume>125</volume><issue>7</issue><fpage>927</fpage><lpage>38</lpage><pub-id pub-id-type=\"doi\">10.1038/s41416-021-01413-x</pub-id><pub-id pub-id-type=\"pmid\">34112949</pub-id><pub-id pub-id-type=\"pmcid\">PMC8476530</pub-id></element-citation><mixed-citation id=\"mc-CR13\" publication-type=\"journal\">Pilard C, Ancion M, Delvenne P, Jerusalem G, Hubert P, Herfs M. Cancer immunotherapy: it&#8217;s time to better predict patients&#8217; response. Br J Cancer. 2021;125(7):927&#8211;38.<pub-id pub-id-type=\"pmid\">34112949</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1038/s41416-021-01413-x</pub-id><pub-id pub-id-type=\"pmcid\">PMC8476530</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR14\"><label>14.</label><mixed-citation publication-type=\"other\">Yin X, Liao H, Yun H, Lin N, Li S, Xiang Y, et&#160;al. Artificial intelligence-based prediction of clinical outcome in immunotherapy and targeted therapy of lung cancer. In: Seminars in cancer biology. vol.&#160;86. Elsevier; 2022. p. 146&#8211;159.<pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/j.semcancer.2022.08.002</pub-id><pub-id pub-id-type=\"pmid\">35963564</pub-id></mixed-citation></ref><ref id=\"CR15\"><label>15.</label><citation-alternatives><element-citation id=\"ec-CR15\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Gao</surname><given-names>Q</given-names></name><name name-style=\"western\"><surname>Yang</surname><given-names>L</given-names></name><name name-style=\"western\"><surname>Lu</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Jin</surname><given-names>R</given-names></name><name name-style=\"western\"><surname>Ye</surname><given-names>H</given-names></name><name name-style=\"western\"><surname>Ma</surname><given-names>T</given-names></name></person-group><article-title>The artificial intelligence and machine learning in lung cancer immunotherapy</article-title><source>J Hematol Oncol</source><year>2023</year><volume>16</volume><issue>1</issue><fpage>55</fpage><pub-id pub-id-type=\"doi\">10.1186/s13045-023-01456-y</pub-id><pub-id pub-id-type=\"pmid\">37226190</pub-id><pub-id pub-id-type=\"pmcid\">PMC10207827</pub-id></element-citation><mixed-citation id=\"mc-CR15\" publication-type=\"journal\">Gao Q, Yang L, Lu M, Jin R, Ye H, Ma T. The artificial intelligence and machine learning in lung cancer immunotherapy. J Hematol Oncol. 2023;16(1):55.<pub-id pub-id-type=\"pmid\">37226190</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1186/s13045-023-01456-y</pub-id><pub-id pub-id-type=\"pmcid\">PMC10207827</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR16\"><label>16.</label><mixed-citation publication-type=\"other\">Wang Z, Liu Y, Niu X. Application of artificial intelligence for improving early detection and prediction of therapeutic outcomes for gastric cancer in the era of precision oncology. In: Seminars in Cancer Biology. vol.&#160;93. Elsevier; 2023. p. 83&#8211;96.<pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/j.semcancer.2023.04.009</pub-id><pub-id pub-id-type=\"pmid\">37116818</pub-id></mixed-citation></ref><ref id=\"CR17\"><label>17.</label><mixed-citation publication-type=\"other\">Zhang W, Song LN, You YF, Qi FN, Cui XH, Yi MX, et&#160;al. Application of artificial intelligence in the prediction of immunotherapy efficacy in hepatocellular carcinoma: Current status and prospects. Artif Intel Gastroenterol. 2024;5(1).</mixed-citation></ref><ref id=\"CR18\"><label>18.</label><citation-alternatives><element-citation id=\"ec-CR18\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Li</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Dan</surname><given-names>K</given-names></name><name name-style=\"western\"><surname>Ai</surname><given-names>J</given-names></name></person-group><article-title>Machine learning in the prediction of immunotherapy response and prognosis of melanoma: a systematic review and meta-analysis</article-title><source>Front Immunol</source><year>2024</year><volume>15</volume><fpage>1281940</fpage><pub-id pub-id-type=\"doi\">10.3389/fimmu.2024.1281940</pub-id><pub-id pub-id-type=\"pmid\">38835779</pub-id><pub-id pub-id-type=\"pmcid\">PMC11148209</pub-id></element-citation><mixed-citation id=\"mc-CR18\" publication-type=\"journal\">Li J, Dan K, Ai J. Machine learning in the prediction of immunotherapy response and prognosis of melanoma: a systematic review and meta-analysis. Front Immunol. 2024;15:1281940.<pub-id pub-id-type=\"pmid\">38835779</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.3389/fimmu.2024.1281940</pub-id><pub-id pub-id-type=\"pmcid\">PMC11148209</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR19\"><label>19.</label><citation-alternatives><element-citation id=\"ec-CR19\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Mei</surname><given-names>T</given-names></name><name name-style=\"western\"><surname>Wang</surname><given-names>T</given-names></name><name name-style=\"western\"><surname>Zhou</surname><given-names>Q</given-names></name></person-group><article-title>Multi-omics and artificial intelligence predict clinical outcomes of immunotherapy in non-small cell lung cancer patients</article-title><source>Clin Exp Med</source><year>2024</year><volume>24</volume><issue>1</issue><fpage>60</fpage><pub-id pub-id-type=\"doi\">10.1007/s10238-024-01324-0</pub-id><pub-id pub-id-type=\"pmid\">38554212</pub-id><pub-id pub-id-type=\"pmcid\">PMC10981593</pub-id></element-citation><mixed-citation id=\"mc-CR19\" publication-type=\"journal\">Mei T, Wang T, Zhou Q. Multi-omics and artificial intelligence predict clinical outcomes of immunotherapy in non-small cell lung cancer patients. Clin Exp Med. 2024;24(1):60.<pub-id pub-id-type=\"pmid\">38554212</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1007/s10238-024-01324-0</pub-id><pub-id pub-id-type=\"pmcid\">PMC10981593</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR20\"><label>20.</label><citation-alternatives><element-citation id=\"ec-CR20\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Jin</surname><given-names>W</given-names></name><name name-style=\"western\"><surname>Luo</surname><given-names>Q</given-names></name></person-group><article-title>When artificial intelligence meets PD-1/PD-L1 inhibitors: population screening, response prediction and efficacy evaluation</article-title><source>Comput Biol Med</source><year>2022</year><volume>145</volume><fpage>105499</fpage><pub-id pub-id-type=\"doi\">10.1016/j.compbiomed.2022.105499</pub-id><pub-id pub-id-type=\"pmid\">35439641</pub-id></element-citation><mixed-citation id=\"mc-CR20\" publication-type=\"journal\">Jin W, Luo Q. When artificial intelligence meets PD-1/PD-L1 inhibitors: population screening, response prediction and efficacy evaluation. Comput Biol Med. 2022;145:105499.<pub-id pub-id-type=\"pmid\">35439641</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/j.compbiomed.2022.105499</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR21\"><label>21.</label><citation-alternatives><element-citation id=\"ec-CR21\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Hildebrand</surname><given-names>LA</given-names></name><name name-style=\"western\"><surname>Pierce</surname><given-names>CJ</given-names></name><name name-style=\"western\"><surname>Dennis</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Paracha</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Maoz</surname><given-names>A</given-names></name></person-group><article-title>Artificial intelligence for histology-based detection of microsatellite instability and prediction of response to immunotherapy in colorectal cancer</article-title><source>Cancers (Basel)</source><year>2021</year><volume>13</volume><issue>3</issue><fpage>391</fpage><pub-id pub-id-type=\"doi\">10.3390/cancers13030391</pub-id><pub-id pub-id-type=\"pmid\">33494280</pub-id><pub-id pub-id-type=\"pmcid\">PMC7864494</pub-id></element-citation><mixed-citation id=\"mc-CR21\" publication-type=\"journal\">Hildebrand LA, Pierce CJ, Dennis M, Paracha M, Maoz A. Artificial intelligence for histology-based detection of microsatellite instability and prediction of response to immunotherapy in colorectal cancer. Cancers (Basel). 2021;13(3):391.<pub-id pub-id-type=\"pmid\">33494280</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.3390/cancers13030391</pub-id><pub-id pub-id-type=\"pmcid\">PMC7864494</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR22\"><label>22.</label><citation-alternatives><element-citation id=\"ec-CR22\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Bera</surname><given-names>K</given-names></name><name name-style=\"western\"><surname>Braman</surname><given-names>N</given-names></name><name name-style=\"western\"><surname>Gupta</surname><given-names>A</given-names></name><name name-style=\"western\"><surname>Velcheti</surname><given-names>V</given-names></name><name name-style=\"western\"><surname>Madabhushi</surname><given-names>A</given-names></name></person-group><article-title>Predicting cancer outcomes with radiomics and artificial intelligence in radiology</article-title><source>Nat Rev Clin Oncol</source><year>2022</year><volume>19</volume><issue>2</issue><fpage>132</fpage><lpage>46</lpage><pub-id pub-id-type=\"doi\">10.1038/s41571-021-00560-7</pub-id><pub-id pub-id-type=\"pmid\">34663898</pub-id><pub-id pub-id-type=\"pmcid\">PMC9034765</pub-id></element-citation><mixed-citation id=\"mc-CR22\" publication-type=\"journal\">Bera K, Braman N, Gupta A, Velcheti V, Madabhushi A. Predicting cancer outcomes with radiomics and artificial intelligence in radiology. Nat Rev Clin Oncol. 2022;19(2):132&#8211;46.<pub-id pub-id-type=\"pmid\">34663898</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1038/s41571-021-00560-7</pub-id><pub-id pub-id-type=\"pmcid\">PMC9034765</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR23\"><label>23.</label><citation-alternatives><element-citation id=\"ec-CR23\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Dercle</surname><given-names>L</given-names></name><name name-style=\"western\"><surname>McGale</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Sun</surname><given-names>S</given-names></name><name name-style=\"western\"><surname>Marabelle</surname><given-names>A</given-names></name><name name-style=\"western\"><surname>Yeh</surname><given-names>R</given-names></name><name name-style=\"western\"><surname>Deutsch</surname><given-names>E</given-names></name><etal/></person-group><article-title>Artificial intelligence and radiomics: fundamentals, applications, and challenges in immunotherapy</article-title><source>J Immunother Cancer</source><year>2022</year><volume>10</volume><issue>9</issue><fpage>e005292</fpage><pub-id pub-id-type=\"doi\">10.1136/jitc-2022-005292</pub-id><pub-id pub-id-type=\"pmid\">36180071</pub-id><pub-id pub-id-type=\"pmcid\">PMC9528623</pub-id></element-citation><mixed-citation id=\"mc-CR23\" publication-type=\"journal\">Dercle L, McGale J, Sun S, Marabelle A, Yeh R, Deutsch E, et al. Artificial intelligence and radiomics: fundamentals, applications, and challenges in immunotherapy. J Immunother Cancer. 2022;10(9):e005292.<pub-id pub-id-type=\"pmid\">36180071</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1136/jitc-2022-005292</pub-id><pub-id pub-id-type=\"pmcid\">PMC9528623</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR24\"><label>24.</label><citation-alternatives><element-citation id=\"ec-CR24\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Kothari</surname><given-names>G</given-names></name></person-group><article-title>Role of radiomics in predicting immunotherapy response</article-title><source>J Med Imaging Radiat Oncol</source><year>2022</year><volume>66</volume><issue>4</issue><fpage>575</fpage><lpage>591</lpage><pub-id pub-id-type=\"doi\">10.1111/1754-9485.13426</pub-id><pub-id pub-id-type=\"pmid\">35581928</pub-id><pub-id pub-id-type=\"pmcid\">PMC9323544</pub-id></element-citation><mixed-citation id=\"mc-CR24\" publication-type=\"journal\">Kothari G. Role of radiomics in predicting immunotherapy response. J Med Imaging Radiat Oncol. 2022;66(4):575&#8211;91.<pub-id pub-id-type=\"pmid\">35581928</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1111/1754-9485.13426</pub-id><pub-id pub-id-type=\"pmcid\">PMC9323544</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR25\"><label>25.</label><citation-alternatives><element-citation id=\"ec-CR25\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Wu</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Liu</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Wu</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Ye</surname><given-names>Z</given-names></name></person-group><article-title>Imaging-based biomarkers for predicting and evaluating cancer immunotherapy response</article-title><source>Radiology: Imaging Cancer</source><year>2019</year><volume>1</volume><issue>2</issue><fpage>e190031</fpage><pub-id pub-id-type=\"pmid\">33778682</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1148/rycan.2019190031</pub-id><pub-id pub-id-type=\"pmcid\">PMC7983749</pub-id></element-citation><mixed-citation id=\"mc-CR25\" publication-type=\"journal\">Wu M, Zhang Y, Zhang Y, Liu Y, Wu M, Ye Z. Imaging-based biomarkers for predicting and evaluating cancer immunotherapy response. Radiology: Imaging Cancer. 2019;1(2):e190031.<pub-id pub-id-type=\"pmid\">33778682</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1148/rycan.2019190031</pub-id><pub-id pub-id-type=\"pmcid\">PMC7983749</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR26\"><label>26.</label><citation-alternatives><element-citation id=\"ec-CR26\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Fu</surname><given-names>X</given-names></name><name name-style=\"western\"><surname>Sahai</surname><given-names>E</given-names></name><name name-style=\"western\"><surname>Wilkins</surname><given-names>A</given-names></name></person-group><article-title>Application of digital pathology-based advanced analytics of tumour microenvironment organisation to predict prognosis and therapeutic response</article-title><source>J Pathol</source><year>2023</year><volume>260</volume><issue>5</issue><fpage>578</fpage><lpage>91</lpage><pub-id pub-id-type=\"doi\">10.1002/path.6153</pub-id><pub-id pub-id-type=\"pmid\">37551703</pub-id><pub-id pub-id-type=\"pmcid\">PMC10952145</pub-id></element-citation><mixed-citation id=\"mc-CR26\" publication-type=\"journal\">Fu X, Sahai E, Wilkins A. Application of digital pathology-based advanced analytics of tumour microenvironment organisation to predict prognosis and therapeutic response. J Pathol. 2023;260(5):578&#8211;91.<pub-id pub-id-type=\"pmid\">37551703</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1002/path.6153</pub-id><pub-id pub-id-type=\"pmcid\">PMC10952145</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR27\"><label>27.</label><citation-alternatives><element-citation id=\"ec-CR27\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Pareek</surname><given-names>A</given-names></name><name name-style=\"western\"><surname>Lungren</surname><given-names>MP</given-names></name><name name-style=\"western\"><surname>Halabi</surname><given-names>SS</given-names></name></person-group><article-title>The requirements for performing artificial-intelligence-related research and model development</article-title><source>Pediatr Radiol</source><year>2022</year><volume>52</volume><issue>11</issue><fpage>2094</fpage><lpage>100</lpage><pub-id pub-id-type=\"doi\">10.1007/s00247-022-05483-8</pub-id><pub-id pub-id-type=\"pmid\">35996023</pub-id></element-citation><mixed-citation id=\"mc-CR27\" publication-type=\"journal\">Pareek A, Lungren MP, Halabi SS. The requirements for performing artificial-intelligence-related research and model development. Pediatr Radiol. 2022;52(11):2094&#8211;100.<pub-id pub-id-type=\"pmid\">35996023</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1007/s00247-022-05483-8</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR28\"><label>28.</label><citation-alternatives><element-citation id=\"ec-CR28\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Wang</surname><given-names>H</given-names></name><name name-style=\"western\"><surname>Fu</surname><given-names>T</given-names></name><name name-style=\"western\"><surname>Du</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Gao</surname><given-names>W</given-names></name><name name-style=\"western\"><surname>Huang</surname><given-names>K</given-names></name><name name-style=\"western\"><surname>Liu</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Scientific discovery in the age of artificial intelligence</article-title><source>Nature</source><year>2023</year><volume>620</volume><issue>7972</issue><fpage>47</fpage><lpage>60</lpage><pub-id pub-id-type=\"doi\">10.1038/s41586-023-06221-2</pub-id><pub-id pub-id-type=\"pmid\">37532811</pub-id></element-citation><mixed-citation id=\"mc-CR28\" publication-type=\"journal\">Wang H, Fu T, Du Y, Gao W, Huang K, Liu Z, et al. Scientific discovery in the age of artificial intelligence. Nature. 2023;620(7972):47&#8211;60.<pub-id pub-id-type=\"pmid\">37532811</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1038/s41586-023-06221-2</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR29\"><label>29.</label><citation-alternatives><element-citation id=\"ec-CR29\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Awais</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Naseer</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Khan</surname><given-names>S</given-names></name><name name-style=\"western\"><surname>Anwer</surname><given-names>RM</given-names></name><name name-style=\"western\"><surname>Cholakkal</surname><given-names>H</given-names></name><name name-style=\"western\"><surname>Shah</surname><given-names>M</given-names></name><etal/></person-group><article-title>Foundation models defining a new era in vision: a survey and outlook</article-title><source>IEEE Trans Pattern Anal Mach Intell</source><year>2025</year><pub-id pub-id-type=\"doi\">10.1109/TPAMI.2024.3506283</pub-id><pub-id pub-id-type=\"pmid\">40030979</pub-id></element-citation><mixed-citation id=\"mc-CR29\" publication-type=\"journal\">Awais M, Naseer M, Khan S, Anwer RM, Cholakkal H, Shah M, et al. Foundation models defining a new era in vision: a survey and outlook. IEEE Trans Pattern Anal Mach Intell. 2025. 10.1109/TPAMI.2024.3506283.<pub-id pub-id-type=\"pmid\">40030979</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1109/TPAMI.2024.3506283</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR30\"><label>30.</label><citation-alternatives><element-citation id=\"ec-CR30\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Stanfill</surname><given-names>MH</given-names></name><name name-style=\"western\"><surname>Marc</surname><given-names>DT</given-names></name></person-group><article-title>Health information management: implications of artificial intelligence on healthcare data and information management</article-title><source>Yearb Med Inform</source><year>2019</year><volume>28</volume><issue>01</issue><fpage>056</fpage><lpage>64</lpage><pub-id pub-id-type=\"doi\">10.1055/s-0039-1677913</pub-id><pub-id pub-id-type=\"pmcid\">PMC6697524</pub-id><pub-id pub-id-type=\"pmid\">31419816</pub-id></element-citation><mixed-citation id=\"mc-CR30\" publication-type=\"journal\">Stanfill MH, Marc DT. Health information management: implications of artificial intelligence on healthcare data and information management. Yearb Med Inform. 2019;28(01):056&#8211;64.<pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1055/s-0039-1677913</pub-id><pub-id pub-id-type=\"pmcid\">PMC6697524</pub-id><pub-id pub-id-type=\"pmid\">31419816</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR31\"><label>31.</label><citation-alternatives><element-citation id=\"ec-CR31\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Kundrick</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Naniwadekar</surname><given-names>A</given-names></name><name name-style=\"western\"><surname>Singla</surname><given-names>V</given-names></name><name name-style=\"western\"><surname>Kancharla</surname><given-names>K</given-names></name><name name-style=\"western\"><surname>Bhonsale</surname><given-names>A</given-names></name><name name-style=\"western\"><surname>Voigt</surname><given-names>A</given-names></name><etal/></person-group><article-title>Machine learning applied to wearable fitness tracker data and the risk of hospitalizations and cardiovascular events</article-title><source>Am J Prev Cardiol</source><year>2025</year><pub-id pub-id-type=\"doi\">10.1016/j.ajpc.2025.101006</pub-id><pub-id pub-id-type=\"pmid\">40496758</pub-id><pub-id pub-id-type=\"pmcid\">PMC12149649</pub-id></element-citation><mixed-citation id=\"mc-CR31\" publication-type=\"journal\">Kundrick J, Naniwadekar A, Singla V, Kancharla K, Bhonsale A, Voigt A, et al. Machine learning applied to wearable fitness tracker data and the risk of hospitalizations and cardiovascular events. Am J Prev Cardiol. 2025. 10.1016/j.ajpc.2025.101006.<pub-id pub-id-type=\"pmid\">40496758</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/j.ajpc.2025.101006</pub-id><pub-id pub-id-type=\"pmcid\">PMC12149649</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR32\"><label>32.</label><citation-alternatives><element-citation id=\"ec-CR32\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Abbas</surname><given-names>K</given-names></name><name name-style=\"western\"><surname>Hao</surname><given-names>C</given-names></name><name name-style=\"western\"><surname>Yong</surname><given-names>X</given-names></name><name name-style=\"western\"><surname>Hasan</surname><given-names>MK</given-names></name><name name-style=\"western\"><surname>Islam</surname><given-names>S</given-names></name><name name-style=\"western\"><surname>Rahman</surname><given-names>AHA</given-names></name></person-group><article-title>Graph neural network-based drug-drug interaction prediction</article-title><source>Sci Rep</source><year>2025</year><volume>15</volume><issue>1</issue><fpage>30340</fpage><pub-id pub-id-type=\"doi\">10.1038/s41598-025-12936-1</pub-id><pub-id pub-id-type=\"pmid\">40830547</pub-id><pub-id pub-id-type=\"pmcid\">PMC12365209</pub-id></element-citation><mixed-citation id=\"mc-CR32\" publication-type=\"journal\">Abbas K, Hao C, Yong X, Hasan MK, Islam S, Rahman AHA. Graph neural network-based drug-drug interaction prediction. Sci Rep. 2025;15(1):30340.<pub-id pub-id-type=\"pmid\">40830547</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1038/s41598-025-12936-1</pub-id><pub-id pub-id-type=\"pmcid\">PMC12365209</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR33\"><label>33.</label><citation-alternatives><element-citation id=\"ec-CR33\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Greener</surname><given-names>JG</given-names></name><name name-style=\"western\"><surname>Kandathil</surname><given-names>SM</given-names></name><name name-style=\"western\"><surname>Moffat</surname><given-names>L</given-names></name><name name-style=\"western\"><surname>Jones</surname><given-names>DT</given-names></name></person-group><article-title>A guide to machine learning for biologists</article-title><source>Nat Rev Mol Cell Biol</source><year>2022</year><volume>23</volume><issue>1</issue><fpage>40</fpage><lpage>55</lpage><pub-id pub-id-type=\"doi\">10.1038/s41580-021-00407-0</pub-id><pub-id pub-id-type=\"pmid\">34518686</pub-id></element-citation><mixed-citation id=\"mc-CR33\" publication-type=\"journal\">Greener JG, Kandathil SM, Moffat L, Jones DT. A guide to machine learning for biologists. Nat Rev Mol Cell Biol. 2022;23(1):40&#8211;55.<pub-id pub-id-type=\"pmid\">34518686</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1038/s41580-021-00407-0</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR34\"><label>34.</label><citation-alternatives><element-citation id=\"ec-CR34\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Schober</surname><given-names>P</given-names></name><name name-style=\"western\"><surname>Vetter</surname><given-names>TR</given-names></name></person-group><article-title>Logistic regression in medical research</article-title><source>Anesthesia &amp; Analgesia</source><year>2021</year><volume>132</volume><issue>2</issue><fpage>365</fpage><lpage>366</lpage><pub-id pub-id-type=\"doi\">10.1213/ANE.0000000000005247</pub-id><pub-id pub-id-type=\"pmid\">33449558</pub-id><pub-id pub-id-type=\"pmcid\">PMC7785709</pub-id></element-citation><mixed-citation id=\"mc-CR34\" publication-type=\"journal\">Schober P, Vetter TR. Logistic regression in medical research. Anesthesia &amp; Analgesia. 2021;132(2):365&#8211;6.<pub-id pub-id-type=\"pmid\">33449558</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1213/ANE.0000000000005247</pub-id><pub-id pub-id-type=\"pmcid\">PMC7785709</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR35\"><label>35.</label><mixed-citation publication-type=\"other\">Nicola S, Chirila OS, Stoicu-Tivadar L. Recovery Gestures Classification Using KNN and LDA Models. In: Telehealth Ecosystems in Practice. IOS Press; 2023. p. 58&#8211;62.<pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.3233/SHTI230739</pub-id><pub-id pub-id-type=\"pmid\">37869806</pub-id></mixed-citation></ref><ref id=\"CR36\"><label>36.</label><citation-alternatives><element-citation id=\"ec-CR36\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Dong</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Yang</surname><given-names>L</given-names></name><name name-style=\"western\"><surname>Liu</surname><given-names>C</given-names></name><name name-style=\"western\"><surname>Cheng</surname><given-names>W</given-names></name><name name-style=\"western\"><surname>Wang</surname><given-names>W</given-names></name></person-group><article-title>Support vector machine embedding discriminative dictionary pair learning for pattern classification</article-title><source>Neural Netw</source><year>2022</year><volume>155</volume><fpage>498</fpage><lpage>511</lpage><pub-id pub-id-type=\"doi\">10.1016/j.neunet.2022.08.031</pub-id><pub-id pub-id-type=\"pmid\">36166977</pub-id></element-citation><mixed-citation id=\"mc-CR36\" publication-type=\"journal\">Dong J, Yang L, Liu C, Cheng W, Wang W. Support vector machine embedding discriminative dictionary pair learning for pattern classification. Neural Netw. 2022;155:498&#8211;511.<pub-id pub-id-type=\"pmid\">36166977</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/j.neunet.2022.08.031</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR37\"><label>37.</label><citation-alternatives><element-citation id=\"ec-CR37\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Hu</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Szymczak</surname><given-names>S</given-names></name></person-group><article-title>A review on longitudinal data analysis with random forest</article-title><source>Brief Bioinform</source><year>2023</year><volume>24</volume><issue>2</issue><fpage>bbad002</fpage><pub-id pub-id-type=\"doi\">10.1093/bib/bbad002</pub-id><pub-id pub-id-type=\"pmid\">36653905</pub-id><pub-id pub-id-type=\"pmcid\">PMC10025446</pub-id></element-citation><mixed-citation id=\"mc-CR37\" publication-type=\"journal\">Hu J, Szymczak S. A review on longitudinal data analysis with random forest. Brief Bioinform. 2023;24(2):bbad002.<pub-id pub-id-type=\"pmid\">36653905</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1093/bib/bbad002</pub-id><pub-id pub-id-type=\"pmcid\">PMC10025446</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR38\"><label>38.</label><citation-alternatives><element-citation id=\"ec-CR38\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Seto</surname><given-names>H</given-names></name><name name-style=\"western\"><surname>Oyama</surname><given-names>A</given-names></name><name name-style=\"western\"><surname>Kitora</surname><given-names>S</given-names></name><name name-style=\"western\"><surname>Toki</surname><given-names>H</given-names></name><name name-style=\"western\"><surname>Yamamoto</surname><given-names>R</given-names></name><name name-style=\"western\"><surname>Kotoku</surname><given-names>J</given-names></name><etal/></person-group><article-title>Gradient boosting decision tree becomes more reliable than logistic regression in predicting probability for diabetes with big data</article-title><source>Sci Rep</source><year>2022</year><volume>12</volume><issue>1</issue><fpage>15889</fpage><pub-id pub-id-type=\"doi\">10.1038/s41598-022-20149-z</pub-id><pub-id pub-id-type=\"pmid\">36220875</pub-id><pub-id pub-id-type=\"pmcid\">PMC9553945</pub-id></element-citation><mixed-citation id=\"mc-CR38\" publication-type=\"journal\">Seto H, Oyama A, Kitora S, Toki H, Yamamoto R, Kotoku J, et al. Gradient boosting decision tree becomes more reliable than logistic regression in predicting probability for diabetes with big data. Sci Rep. 2022;12(1):15889.<pub-id pub-id-type=\"pmid\">36220875</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1038/s41598-022-20149-z</pub-id><pub-id pub-id-type=\"pmcid\">PMC9553945</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR39\"><label>39.</label><citation-alternatives><element-citation id=\"ec-CR39\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Van der Velden</surname><given-names>BH</given-names></name><name name-style=\"western\"><surname>Kuijf</surname><given-names>HJ</given-names></name><name name-style=\"western\"><surname>Gilhuijs</surname><given-names>KG</given-names></name><name name-style=\"western\"><surname>Viergever</surname><given-names>MA</given-names></name></person-group><article-title>Explainable artificial intelligence (XAI) in deep learning-based medical image analysis</article-title><source>Med Image Anal</source><year>2022</year><volume>79</volume><fpage>102470</fpage><pub-id pub-id-type=\"doi\">10.1016/j.media.2022.102470</pub-id><pub-id pub-id-type=\"pmid\">35576821</pub-id></element-citation><mixed-citation id=\"mc-CR39\" publication-type=\"journal\">Van der Velden BH, Kuijf HJ, Gilhuijs KG, Viergever MA. Explainable artificial intelligence (XAI) in deep learning-based medical image analysis. Med Image Anal. 2022;79:102470.<pub-id pub-id-type=\"pmid\">35576821</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/j.media.2022.102470</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR40\"><label>40.</label><mixed-citation publication-type=\"other\">V&#238;rgolici O, Virgolici H. Predicting Prediabetes Using Simple a Multi-Layer Perceptron Neural Network Model. In: ICIMTH; 2023. p. 168&#8211;171.<pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.3233/SHTI230453</pub-id><pub-id pub-id-type=\"pmid\">37386987</pub-id></mixed-citation></ref><ref id=\"CR41\"><label>41.</label><citation-alternatives><element-citation id=\"ec-CR41\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>You</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Lu</surname><given-names>C</given-names></name><name name-style=\"western\"><surname>Wang</surname><given-names>W</given-names></name><name name-style=\"western\"><surname>Tang</surname><given-names>CK</given-names></name></person-group><article-title>Relative CNN-RNN: learning relative atmospheric visibility from images</article-title><source>IEEE Trans Image Process</source><year>2018</year><volume>28</volume><issue>1</issue><fpage>45</fpage><lpage>55</lpage><pub-id pub-id-type=\"doi\">10.1109/TIP.2018.2857219</pub-id><pub-id pub-id-type=\"pmid\">30028702</pub-id></element-citation><mixed-citation id=\"mc-CR41\" publication-type=\"journal\">You Y, Lu C, Wang W, Tang CK. Relative CNN-RNN: learning relative atmospheric visibility from images. IEEE Trans Image Process. 2018;28(1):45&#8211;55.<pub-id pub-id-type=\"pmid\">30028702</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1109/TIP.2018.2857219</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR42\"><label>42.</label><mixed-citation publication-type=\"other\">Jahan I, Chowdhury ME, Vranic S, Al&#160;Saady RM, Kabir S, Pranto ZH, et&#160;al. Deep learning and vision transformers-based framework for breast cancer and subtype identification. Neural Comput Appl. 2025;p. 1&#8211;20.</mixed-citation></ref><ref id=\"CR43\"><label>43.</label><citation-alternatives><element-citation id=\"ec-CR43\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Topalian</surname><given-names>SL</given-names></name><name name-style=\"western\"><surname>Taube</surname><given-names>JM</given-names></name><name name-style=\"western\"><surname>Pardoll</surname><given-names>DM</given-names></name></person-group><article-title>Neoadjuvant checkpoint blockade for cancer immunotherapy</article-title><source>Science</source><year>2020</year><volume>367</volume><issue>6477</issue><fpage>eaax0182</fpage><pub-id pub-id-type=\"doi\">10.1126/science.aax0182</pub-id><pub-id pub-id-type=\"pmid\">32001626</pub-id><pub-id pub-id-type=\"pmcid\">PMC7789854</pub-id></element-citation><mixed-citation id=\"mc-CR43\" publication-type=\"journal\">Topalian SL, Taube JM, Pardoll DM. Neoadjuvant checkpoint blockade for cancer immunotherapy. Science. 2020;367(6477):eaax0182.<pub-id pub-id-type=\"pmid\">32001626</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1126/science.aax0182</pub-id><pub-id pub-id-type=\"pmcid\">PMC7789854</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR44\"><label>44.</label><citation-alternatives><element-citation id=\"ec-CR44\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Deng</surname><given-names>H</given-names></name><name name-style=\"western\"><surname>Zhao</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Cai</surname><given-names>X</given-names></name><name name-style=\"western\"><surname>Chen</surname><given-names>H</given-names></name><name name-style=\"western\"><surname>Cheng</surname><given-names>B</given-names></name><name name-style=\"western\"><surname>Zhong</surname><given-names>R</given-names></name><etal/></person-group><article-title>PD-L1 expression and tumor mutation burden as pathological response biomarkers of neoadjuvant immunotherapy for early-stage non-small cell lung cancer: a systematic review and meta-analysis</article-title><source>Crit Rev Oncol Hematol</source><year>2022</year><volume>170</volume><fpage>103582</fpage><pub-id pub-id-type=\"doi\">10.1016/j.critrevonc.2022.103582</pub-id><pub-id pub-id-type=\"pmid\">35031441</pub-id></element-citation><mixed-citation id=\"mc-CR44\" publication-type=\"journal\">Deng H, Zhao Y, Cai X, Chen H, Cheng B, Zhong R, et al. PD-L1 expression and tumor mutation burden as pathological response biomarkers of neoadjuvant immunotherapy for early-stage non-small cell lung cancer: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2022;170:103582.<pub-id pub-id-type=\"pmid\">35031441</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/j.critrevonc.2022.103582</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR45\"><label>45.</label><citation-alternatives><element-citation id=\"ec-CR45\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Wu</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Xia</surname><given-names>X</given-names></name><name name-style=\"western\"><surname>Gong</surname><given-names>L</given-names></name><name name-style=\"western\"><surname>Huang</surname><given-names>S</given-names></name><name name-style=\"western\"><surname>Zheng</surname><given-names>H</given-names></name><name name-style=\"western\"><surname>Qiao</surname><given-names>G</given-names></name><etal/></person-group><article-title>Neoadjuvant chemoimmunotherapy for small cell carcinoma of the esophagus: clinical efficacy and biomarker exploration</article-title><source>Hum Vaccin Immunother</source><year>2024</year><volume>20</volume><issue>1</issue><fpage>2370085</fpage><pub-id pub-id-type=\"doi\">10.1080/21645515.2024.2370085</pub-id><pub-id pub-id-type=\"pmid\">38967227</pub-id><pub-id pub-id-type=\"pmcid\">PMC11229733</pub-id></element-citation><mixed-citation id=\"mc-CR45\" publication-type=\"journal\">Wu J, Xia X, Gong L, Huang S, Zheng H, Qiao G, et al. Neoadjuvant chemoimmunotherapy for small cell carcinoma of the esophagus: clinical efficacy and biomarker exploration. Hum Vaccin Immunother. 2024;20(1):2370085.<pub-id pub-id-type=\"pmid\">38967227</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1080/21645515.2024.2370085</pub-id><pub-id pub-id-type=\"pmcid\">PMC11229733</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR46\"><label>46.</label><citation-alternatives><element-citation id=\"ec-CR46\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Sharma</surname><given-names>P</given-names></name><name name-style=\"western\"><surname>Stecklein</surname><given-names>SR</given-names></name><name name-style=\"western\"><surname>Yoder</surname><given-names>R</given-names></name><name name-style=\"western\"><surname>Staley</surname><given-names>JM</given-names></name><name name-style=\"western\"><surname>Schwensen</surname><given-names>K</given-names></name><name name-style=\"western\"><surname>O&#8217;Dea</surname><given-names>A</given-names></name><etal/></person-group><article-title>Clinical and biomarker findings of neoadjuvant pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer: NeoPACT phase 2 clinical trial</article-title><source>JAMA Oncol</source><year>2024</year><volume>10</volume><issue>2</issue><fpage>227</fpage><lpage>35</lpage><pub-id pub-id-type=\"doi\">10.1001/jamaoncol.2023.5033</pub-id><pub-id pub-id-type=\"pmid\">37991778</pub-id><pub-id pub-id-type=\"pmcid\">PMC10666040</pub-id></element-citation><mixed-citation id=\"mc-CR46\" publication-type=\"journal\">Sharma P, Stecklein SR, Yoder R, Staley JM, Schwensen K, O&#8217;Dea A, et al. Clinical and biomarker findings of neoadjuvant pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer: NeoPACT phase 2 clinical trial. JAMA Oncol. 2024;10(2):227&#8211;35.<pub-id pub-id-type=\"pmid\">37991778</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1001/jamaoncol.2023.5033</pub-id><pub-id pub-id-type=\"pmcid\">PMC10666040</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR47\"><label>47.</label><citation-alternatives><element-citation id=\"ec-CR47\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Liu</surname><given-names>SY</given-names></name><name name-style=\"western\"><surname>Dong</surname><given-names>S</given-names></name><name name-style=\"western\"><surname>Yang</surname><given-names>XN</given-names></name><name name-style=\"western\"><surname>Liao</surname><given-names>RQ</given-names></name><name name-style=\"western\"><surname>Jiang</surname><given-names>BY</given-names></name><name name-style=\"western\"><surname>Wang</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Neoadjuvant nivolumab with or without platinum-doublet chemotherapy based on PD-L1 expression in resectable NSCLC (CTONG1804): a multicenter open-label phase II study</article-title><source>Signal Transduct Target Ther</source><year>2023</year><volume>8</volume><issue>1</issue><fpage>442</fpage><pub-id pub-id-type=\"doi\">10.1038/s41392-023-01700-4</pub-id><pub-id pub-id-type=\"pmid\">38057314</pub-id><pub-id pub-id-type=\"pmcid\">PMC10700550</pub-id></element-citation><mixed-citation id=\"mc-CR47\" publication-type=\"journal\">Liu SY, Dong S, Yang XN, Liao RQ, Jiang BY, Wang Q, et al. Neoadjuvant nivolumab with or without platinum-doublet chemotherapy based on PD-L1 expression in resectable NSCLC (CTONG1804): a multicenter open-label phase II study. Signal Transduct Target Ther. 2023;8(1):442.<pub-id pub-id-type=\"pmid\">38057314</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1038/s41392-023-01700-4</pub-id><pub-id pub-id-type=\"pmcid\">PMC10700550</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR48\"><label>48.</label><citation-alternatives><element-citation id=\"ec-CR48\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Mittendorf</surname><given-names>EA</given-names></name><name name-style=\"western\"><surname>Zhang</surname><given-names>H</given-names></name><name name-style=\"western\"><surname>Barrios</surname><given-names>CH</given-names></name><name name-style=\"western\"><surname>Saji</surname><given-names>S</given-names></name><name name-style=\"western\"><surname>Jung</surname><given-names>KH</given-names></name><name name-style=\"western\"><surname>Hegg</surname><given-names>R</given-names></name><etal/></person-group><article-title>Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial</article-title><source>Lancet</source><year>2020</year><volume>396</volume><issue>10257</issue><fpage>1090</fpage><lpage>100</lpage><pub-id pub-id-type=\"doi\">10.1016/S0140-6736(20)31953-X</pub-id><pub-id pub-id-type=\"pmid\">32966830</pub-id></element-citation><mixed-citation id=\"mc-CR48\" publication-type=\"journal\">Mittendorf EA, Zhang H, Barrios CH, Saji S, Jung KH, Hegg R, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet. 2020;396(10257):1090&#8211;100.<pub-id pub-id-type=\"pmid\">32966830</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/S0140-6736(20)31953-X</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR49\"><label>49.</label><citation-alternatives><element-citation id=\"ec-CR49\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Gao</surname><given-names>S</given-names></name><name name-style=\"western\"><surname>Li</surname><given-names>N</given-names></name><name name-style=\"western\"><surname>Gao</surname><given-names>S</given-names></name><name name-style=\"western\"><surname>Xue</surname><given-names>Q</given-names></name><name name-style=\"western\"><surname>Ying</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Wang</surname><given-names>S</given-names></name><etal/></person-group><article-title>Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC</article-title><source>J Thorac Oncol</source><year>2020</year><volume>15</volume><issue>5</issue><fpage>816</fpage><lpage>26</lpage><pub-id pub-id-type=\"doi\">10.1016/j.jtho.2020.01.017</pub-id><pub-id pub-id-type=\"pmid\">32036071</pub-id></element-citation><mixed-citation id=\"mc-CR49\" publication-type=\"journal\">Gao S, Li N, Gao S, Xue Q, Ying J, Wang S, et al. Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC. J Thorac Oncol. 2020;15(5):816&#8211;26.<pub-id pub-id-type=\"pmid\">32036071</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/j.jtho.2020.01.017</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR50\"><label>50.</label><citation-alternatives><element-citation id=\"ec-CR50\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Wang</surname><given-names>CD</given-names></name><name name-style=\"western\"><surname>Ma</surname><given-names>JC</given-names></name><name name-style=\"western\"><surname>Shao</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Zhang</surname><given-names>S</given-names></name><name name-style=\"western\"><surname>Liu</surname><given-names>Z</given-names></name><name name-style=\"western\"><surname>Yu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Predicting EGFR and PD-L1 Status in NSCLC Patients Using Multitask AI System Based on CT Images</article-title><source>Front Immunol</source><year>2022</year><volume>13</volume><fpage>813072</fpage><pub-id pub-id-type=\"doi\">10.3389/fimmu.2022.813072</pub-id><pub-id pub-id-type=\"pmid\">35250988</pub-id><pub-id pub-id-type=\"pmcid\">PMC8895233</pub-id></element-citation><mixed-citation id=\"mc-CR50\" publication-type=\"journal\">Wang CD, Ma JC, Shao J, Zhang S, Liu Z, Yu Y, et al. Predicting EGFR and PD-L1 Status in NSCLC Patients Using Multitask AI System Based on CT Images. Front Immunol. 2022;13:813072. 10.3389/fimmu.2022.813072.<pub-id pub-id-type=\"pmid\">35250988</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.3389/fimmu.2022.813072</pub-id><pub-id pub-id-type=\"pmcid\">PMC8895233</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR51\"><label>51.</label><citation-alternatives><element-citation id=\"ec-CR51\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Jin</surname><given-names>W</given-names></name><name name-style=\"western\"><surname>Tian</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Xuzhang</surname><given-names>W</given-names></name><name name-style=\"western\"><surname>Zhu</surname><given-names>H</given-names></name><name name-style=\"western\"><surname>Zou</surname><given-names>N</given-names></name><name name-style=\"western\"><surname>Shen</surname><given-names>L</given-names></name><etal/></person-group><article-title>Non-linear modifications enhance prediction of pathological response to pre-operative PD-1 blockade in lung cancer: a longitudinal hybrid radiological model</article-title><source>Pharmacol Res</source><year>2023</year><volume>198</volume><fpage>106992</fpage><pub-id pub-id-type=\"doi\">10.1016/j.phrs.2023.106992</pub-id><pub-id pub-id-type=\"pmid\">37977237</pub-id></element-citation><mixed-citation id=\"mc-CR51\" publication-type=\"journal\">Jin W, Tian Y, Xuzhang W, Zhu H, Zou N, Shen L, et al. Non-linear modifications enhance prediction of pathological response to pre-operative PD-1 blockade in lung cancer: a longitudinal hybrid radiological model. Pharmacol Res. 2023;198:106992.<pub-id pub-id-type=\"pmid\">37977237</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/j.phrs.2023.106992</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR52\"><label>52.</label><citation-alternatives><element-citation id=\"ec-CR52\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Saad</surname><given-names>MZB</given-names></name><name name-style=\"western\"><surname>Hong</surname><given-names>L</given-names></name><name name-style=\"western\"><surname>Aminu</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Vokes</surname><given-names>NI</given-names></name><name name-style=\"western\"><surname>Chen</surname><given-names>PJ</given-names></name><name name-style=\"western\"><surname>Saleh Jahromi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study</article-title><source>The Lancet Digital Health</source><year>2023</year><volume>5</volume><issue>7</issue><fpage>e404</fpage><lpage>e420</lpage><pub-id pub-id-type=\"doi\">10.1016/S2589-7500(23)00082-1</pub-id><pub-id pub-id-type=\"pmid\">37268451</pub-id><pub-id pub-id-type=\"pmcid\">PMC10330920</pub-id></element-citation><mixed-citation id=\"mc-CR52\" publication-type=\"journal\">Saad MZB, Hong L, Aminu M, Vokes NI, Chen PJ, Saleh Jahromi M, et al. Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study. The Lancet Digital Health. 2023;5(7):e404&#8211;20. 10.1016/S2589-7500(23)00082-1.<pub-id pub-id-type=\"pmid\">37268451</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/S2589-7500(23)00082-1</pub-id><pub-id pub-id-type=\"pmcid\">PMC10330920</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR53\"><label>53.</label><citation-alternatives><element-citation id=\"ec-CR53\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Zhao</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Sun</surname><given-names>Z</given-names></name><name name-style=\"western\"><surname>Yu</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Yuan</surname><given-names>Z</given-names></name><name name-style=\"western\"><surname>Lin</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Tan</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Radiomic and clinical data integration using machine learning predict the efficacy of anti-PD-1 antibodies-based combinational treatment in advanced breast cancer: a multicentered study</article-title><source>J Immunother Cancer</source><year>2023</year><volume>11</volume><issue>5</issue><fpage>e006514</fpage><pub-id pub-id-type=\"doi\">10.1136/jitc-2022-006514</pub-id><pub-id pub-id-type=\"pmid\">37217246</pub-id><pub-id pub-id-type=\"pmcid\">PMC10230987</pub-id></element-citation><mixed-citation id=\"mc-CR53\" publication-type=\"journal\">Zhao J, Sun Z, Yu Y, Yuan Z, Lin Y, Tan Y, et al. Radiomic and clinical data integration using machine learning predict the efficacy of anti-PD-1 antibodies-based combinational treatment in advanced breast cancer: a multicentered study. J Immunother Cancer. 2023;11(5):e006514.<pub-id pub-id-type=\"pmid\">37217246</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1136/jitc-2022-006514</pub-id><pub-id pub-id-type=\"pmcid\">PMC10230987</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR54\"><label>54.</label><citation-alternatives><element-citation id=\"ec-CR54\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Wang</surname><given-names>X</given-names></name><name name-style=\"western\"><surname>Jiang</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Chen</surname><given-names>H</given-names></name><name name-style=\"western\"><surname>Zhang</surname><given-names>T</given-names></name><name name-style=\"western\"><surname>Han</surname><given-names>Z</given-names></name><name name-style=\"western\"><surname>Chen</surname><given-names>C</given-names></name><etal/></person-group><article-title>Cancer immunotherapy response prediction from multi-modal clinical and image data using semi-supervised deep learning</article-title><source>Radiother Oncol</source><year>2023</year><volume>186</volume><fpage>109793</fpage><pub-id pub-id-type=\"doi\">10.1016/j.radonc.2023.109793</pub-id><pub-id pub-id-type=\"pmid\">37414254</pub-id></element-citation><mixed-citation id=\"mc-CR54\" publication-type=\"journal\">Wang X, Jiang Y, Chen H, Zhang T, Han Z, Chen C, et al. Cancer immunotherapy response prediction from multi-modal clinical and image data using semi-supervised deep learning. Radiother Oncol. 2023;186:109793.<pub-id pub-id-type=\"pmid\">37414254</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/j.radonc.2023.109793</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR55\"><label>55.</label><citation-alternatives><element-citation id=\"ec-CR55\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Mu</surname><given-names>W</given-names></name><name name-style=\"western\"><surname>Jiang</surname><given-names>L</given-names></name><name name-style=\"western\"><surname>Shi</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Tunali</surname><given-names>I</given-names></name><name name-style=\"western\"><surname>Gray</surname><given-names>JE</given-names></name><name name-style=\"western\"><surname>Katsoulakis</surname><given-names>E</given-names></name><etal/></person-group><article-title>Non-invasive measurement of PD-L1 status and prediction of immunotherapy response using deep learning of PET/CT images</article-title><source>J Immunother Cancer</source><year>2021</year><volume>9</volume><issue>6</issue><fpage>e002118</fpage><pub-id pub-id-type=\"doi\">10.1136/jitc-2020-002118</pub-id><pub-id pub-id-type=\"pmid\">34135101</pub-id><pub-id pub-id-type=\"pmcid\">PMC8211060</pub-id></element-citation><mixed-citation id=\"mc-CR55\" publication-type=\"journal\">Mu W, Jiang L, Shi Y, Tunali I, Gray JE, Katsoulakis E, et al. Non-invasive measurement of PD-L1 status and prediction of immunotherapy response using deep learning of PET/CT images. J Immunother Cancer. 2021;9(6):e002118.<pub-id pub-id-type=\"pmid\">34135101</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1136/jitc-2020-002118</pub-id><pub-id pub-id-type=\"pmcid\">PMC8211060</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR56\"><label>56.</label><citation-alternatives><element-citation id=\"ec-CR56\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Tian</surname><given-names>P</given-names></name><name name-style=\"western\"><surname>He</surname><given-names>B</given-names></name><name name-style=\"western\"><surname>Mu</surname><given-names>W</given-names></name><name name-style=\"western\"><surname>Liu</surname><given-names>K</given-names></name><name name-style=\"western\"><surname>Liu</surname><given-names>L</given-names></name><name name-style=\"western\"><surname>Zeng</surname><given-names>H</given-names></name><etal/></person-group><article-title>Assessing PD-L1 expression in non-small cell lung cancer and predicting responses to immune checkpoint inhibitors using deep learning on computed tomography images</article-title><source>Theranostics</source><year>2021</year><volume>11</volume><issue>5</issue><fpage>2098</fpage><pub-id pub-id-type=\"doi\">10.7150/thno.48027</pub-id><pub-id pub-id-type=\"pmid\">33500713</pub-id><pub-id pub-id-type=\"pmcid\">PMC7797686</pub-id></element-citation><mixed-citation id=\"mc-CR56\" publication-type=\"journal\">Tian P, He B, Mu W, Liu K, Liu L, Zeng H, et al. Assessing PD-L1 expression in non-small cell lung cancer and predicting responses to immune checkpoint inhibitors using deep learning on computed tomography images. Theranostics. 2021;11(5):2098.<pub-id pub-id-type=\"pmid\">33500713</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.7150/thno.48027</pub-id><pub-id pub-id-type=\"pmcid\">PMC7797686</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR57\"><label>57.</label><citation-alternatives><element-citation id=\"ec-CR57\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Cao</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Zhu</surname><given-names>H</given-names></name><name name-style=\"western\"><surname>Li</surname><given-names>Z</given-names></name><name name-style=\"western\"><surname>Liu</surname><given-names>C</given-names></name><name name-style=\"western\"><surname>Ye</surname><given-names>J</given-names></name></person-group><article-title>CT image-based radiomic analysis for detecting PD-L1 expression status in bladder cancer patients</article-title><source>Acad Radiol</source><year>2024</year><volume>31</volume><issue>9</issue><fpage>3678</fpage><lpage>87</lpage><pub-id pub-id-type=\"doi\">10.1016/j.acra.2024.02.047</pub-id><pub-id pub-id-type=\"pmid\">38556431</pub-id></element-citation><mixed-citation id=\"mc-CR57\" publication-type=\"journal\">Cao Y, Zhu H, Li Z, Liu C, Ye J. CT image-based radiomic analysis for detecting PD-L1 expression status in bladder cancer patients. Acad Radiol. 2024;31(9):3678&#8211;87.<pub-id pub-id-type=\"pmid\">38556431</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/j.acra.2024.02.047</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR58\"><label>58.</label><citation-alternatives><element-citation id=\"ec-CR58\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Da-Ano</surname><given-names>R</given-names></name><name name-style=\"western\"><surname>Andrade-Miranda</surname><given-names>G</given-names></name><name name-style=\"western\"><surname>Tankyevych</surname><given-names>O</given-names></name><name name-style=\"western\"><surname>Visvikis</surname><given-names>D</given-names></name><name name-style=\"western\"><surname>Conze</surname><given-names>PH</given-names></name><name name-style=\"western\"><surname>Rest</surname><given-names>CCL</given-names></name></person-group><article-title>Automated PD-L1 status prediction in lung cancer with multi-modal PET/CT fusion</article-title><source>Sci Rep</source><year>2024</year><volume>14</volume><issue>1</issue><fpage>16720</fpage><pub-id pub-id-type=\"doi\">10.1038/s41598-024-66487-y</pub-id><pub-id pub-id-type=\"pmid\">39030240</pub-id><pub-id pub-id-type=\"pmcid\">PMC11271510</pub-id></element-citation><mixed-citation id=\"mc-CR58\" publication-type=\"journal\">Da-Ano R, Andrade-Miranda G, Tankyevych O, Visvikis D, Conze PH, Rest CCL. Automated PD-L1 status prediction in lung cancer with multi-modal PET/CT fusion. Sci Rep. 2024;14(1):16720.<pub-id pub-id-type=\"pmid\">39030240</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1038/s41598-024-66487-y</pub-id><pub-id pub-id-type=\"pmcid\">PMC11271510</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR59\"><label>59.</label><citation-alternatives><element-citation id=\"ec-CR59\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Mei&#223;ner</surname><given-names>AK</given-names></name><name name-style=\"western\"><surname>Gutsche</surname><given-names>R</given-names></name><name name-style=\"western\"><surname>Galldiks</surname><given-names>N</given-names></name><name name-style=\"western\"><surname>Kocher</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>J&#252;nger</surname><given-names>ST</given-names></name><name name-style=\"western\"><surname>Eich</surname><given-names>ML</given-names></name><etal/></person-group><article-title>Radiomics for the non-invasive prediction of PD-L1 expression in patients with brain metastases secondary to non-small cell lung cancer</article-title><source>J Neurooncol</source><year>2023</year><volume>163</volume><issue>3</issue><fpage>597</fpage><lpage>605</lpage><pub-id pub-id-type=\"doi\">10.1007/s11060-023-04367-7</pub-id><pub-id pub-id-type=\"pmid\">37382806</pub-id><pub-id pub-id-type=\"pmcid\">PMC10393847</pub-id></element-citation><mixed-citation id=\"mc-CR59\" publication-type=\"journal\">Mei&#223;ner AK, Gutsche R, Galldiks N, Kocher M, J&#252;nger ST, Eich ML, et al. Radiomics for the non-invasive prediction of PD-L1 expression in patients with brain metastases secondary to non-small cell lung cancer. J Neurooncol. 2023;163(3):597&#8211;605.<pub-id pub-id-type=\"pmid\">37382806</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1007/s11060-023-04367-7</pub-id><pub-id pub-id-type=\"pmcid\">PMC10393847</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR60\"><label>60.</label><citation-alternatives><element-citation id=\"ec-CR60\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Cheng</surname><given-names>G</given-names></name><name name-style=\"western\"><surname>Zhang</surname><given-names>F</given-names></name><name name-style=\"western\"><surname>Xing</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Hu</surname><given-names>X</given-names></name><name name-style=\"western\"><surname>Zhang</surname><given-names>H</given-names></name><name name-style=\"western\"><surname>Chen</surname><given-names>S</given-names></name><etal/></person-group><article-title>Artificial intelligence-assisted score analysis for predicting the expression of the immunotherapy biomarker PD-L1 in lung cancer</article-title><source>Front Immunol</source><year>2022</year><volume>13</volume><fpage>893198</fpage><pub-id pub-id-type=\"doi\">10.3389/fimmu.2022.893198</pub-id><pub-id pub-id-type=\"pmid\">35844508</pub-id><pub-id pub-id-type=\"pmcid\">PMC9286729</pub-id></element-citation><mixed-citation id=\"mc-CR60\" publication-type=\"journal\">Cheng G, Zhang F, Xing Y, Hu X, Zhang H, Chen S, et al. Artificial intelligence-assisted score analysis for predicting the expression of the immunotherapy biomarker PD-L1 in lung cancer. Front Immunol. 2022;13:893198.<pub-id pub-id-type=\"pmid\">35844508</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.3389/fimmu.2022.893198</pub-id><pub-id pub-id-type=\"pmcid\">PMC9286729</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR61\"><label>61.</label><citation-alternatives><element-citation id=\"ec-CR61\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Wu</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Liu</surname><given-names>C</given-names></name><name name-style=\"western\"><surname>Liu</surname><given-names>X</given-names></name><name name-style=\"western\"><surname>Sun</surname><given-names>W</given-names></name><name name-style=\"western\"><surname>Li</surname><given-names>L</given-names></name><name name-style=\"western\"><surname>Gao</surname><given-names>N</given-names></name><etal/></person-group><article-title>Artificial intelligence-assisted system for precision diagnosis of PD-L1 expression in non-small cell lung cancer</article-title><source>Mod Pathol</source><year>2022</year><volume>35</volume><issue>3</issue><fpage>403</fpage><lpage>11</lpage><pub-id pub-id-type=\"doi\">10.1038/s41379-021-00904-9</pub-id><pub-id pub-id-type=\"pmid\">34518630</pub-id></element-citation><mixed-citation id=\"mc-CR61\" publication-type=\"journal\">Wu J, Liu C, Liu X, Sun W, Li L, Gao N, et al. Artificial intelligence-assisted system for precision diagnosis of PD-L1 expression in non-small cell lung cancer. Mod Pathol. 2022;35(3):403&#8211;11.<pub-id pub-id-type=\"pmid\">34518630</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1038/s41379-021-00904-9</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR62\"><label>62.</label><citation-alternatives><element-citation id=\"ec-CR62\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Shamai</surname><given-names>G</given-names></name><name name-style=\"western\"><surname>Livne</surname><given-names>A</given-names></name><name name-style=\"western\"><surname>Pol&#243;nia</surname><given-names>A</given-names></name><name name-style=\"western\"><surname>Sabo</surname><given-names>E</given-names></name><name name-style=\"western\"><surname>Cretu</surname><given-names>A</given-names></name><name name-style=\"western\"><surname>Bar-Sela</surname><given-names>G</given-names></name><etal/></person-group><article-title>Deep learning-based image analysis predicts PD-L1 status from H &amp;E-stained histopathology images in breast cancer</article-title><source>Nat Commun</source><year>2022</year><volume>13</volume><issue>1</issue><fpage>6753</fpage><pub-id pub-id-type=\"doi\">10.1038/s41467-022-34275-9</pub-id><pub-id pub-id-type=\"pmid\">36347854</pub-id><pub-id pub-id-type=\"pmcid\">PMC9643479</pub-id></element-citation><mixed-citation id=\"mc-CR62\" publication-type=\"journal\">Shamai G, Livne A, Pol&#243;nia A, Sabo E, Cretu A, Bar-Sela G, et al. Deep learning-based image analysis predicts PD-L1 status from H &amp;E-stained histopathology images in breast cancer. Nat Commun. 2022;13(1):6753.<pub-id pub-id-type=\"pmid\">36347854</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1038/s41467-022-34275-9</pub-id><pub-id pub-id-type=\"pmcid\">PMC9643479</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR63\"><label>63.</label><citation-alternatives><element-citation id=\"ec-CR63\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Li</surname><given-names>B</given-names></name><name name-style=\"western\"><surname>Qin</surname><given-names>W</given-names></name><name name-style=\"western\"><surname>Yang</surname><given-names>L</given-names></name><name name-style=\"western\"><surname>Li</surname><given-names>H</given-names></name><name name-style=\"western\"><surname>Jiang</surname><given-names>C</given-names></name><name name-style=\"western\"><surname>Yao</surname><given-names>Y</given-names></name><etal/></person-group><article-title>From pixels to patient care: deep learning-enabled pathomics signature offers precise outcome predictions for immunotherapy in esophageal squamous cell cancer</article-title><source>J Transl Med</source><year>2024</year><volume>22</volume><issue>1</issue><fpage>195</fpage><pub-id pub-id-type=\"doi\">10.1186/s12967-024-04997-z</pub-id><pub-id pub-id-type=\"pmid\">38388379</pub-id><pub-id pub-id-type=\"pmcid\">PMC10885627</pub-id></element-citation><mixed-citation id=\"mc-CR63\" publication-type=\"journal\">Li B, Qin W, Yang L, Li H, Jiang C, Yao Y, et al. From pixels to patient care: deep learning-enabled pathomics signature offers precise outcome predictions for immunotherapy in esophageal squamous cell cancer. J Transl Med. 2024;22(1):195.<pub-id pub-id-type=\"pmid\">38388379</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1186/s12967-024-04997-z</pub-id><pub-id pub-id-type=\"pmcid\">PMC10885627</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR64\"><label>64.</label><citation-alternatives><element-citation id=\"ec-CR64\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Zhou</surname><given-names>QQ</given-names></name><name name-style=\"western\"><surname>Guo</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Wang</surname><given-names>Z</given-names></name><name name-style=\"western\"><surname>Li</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Chen</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Xu</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Rapid visualization of PD-L1 expression level in glioblastoma immune microenvironment via machine learning cascade-based Raman histopathology</article-title><source>J Adv Res</source><year>2024</year><volume>65</volume><fpage>257</fpage><lpage>71</lpage><pub-id pub-id-type=\"doi\">10.1016/j.jare.2023.12.002</pub-id><pub-id pub-id-type=\"pmid\">38072311</pub-id><pub-id pub-id-type=\"pmcid\">PMC11519053</pub-id></element-citation><mixed-citation id=\"mc-CR64\" publication-type=\"journal\">Zhou QQ, Guo J, Wang Z, Li J, Chen M, Xu Q, et al. Rapid visualization of PD-L1 expression level in glioblastoma immune microenvironment via machine learning cascade-based Raman histopathology. J Adv Res. 2024;65:257&#8211;71.<pub-id pub-id-type=\"pmid\">38072311</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/j.jare.2023.12.002</pub-id><pub-id pub-id-type=\"pmcid\">PMC11519053</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR65\"><label>65.</label><citation-alternatives><element-citation id=\"ec-CR65\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Jin</surname><given-names>D</given-names></name><name name-style=\"western\"><surname>Liang</surname><given-names>S</given-names></name><name name-style=\"western\"><surname>Shmatko</surname><given-names>A</given-names></name><name name-style=\"western\"><surname>Arnold</surname><given-names>A</given-names></name><name name-style=\"western\"><surname>Horst</surname><given-names>D</given-names></name><name name-style=\"western\"><surname>Gr&#252;newald</surname><given-names>TG</given-names></name><etal/></person-group><article-title>Teacher-student collaborated multiple instance learning for pan-cancer PDL1 expression prediction from histopathology slides</article-title><source>Nat Commun</source><year>2024</year><volume>15</volume><issue>1</issue><fpage>3063</fpage><pub-id pub-id-type=\"doi\">10.1038/s41467-024-46764-0</pub-id><pub-id pub-id-type=\"pmid\">38594278</pub-id><pub-id pub-id-type=\"pmcid\">PMC11004138</pub-id></element-citation><mixed-citation id=\"mc-CR65\" publication-type=\"journal\">Jin D, Liang S, Shmatko A, Arnold A, Horst D, Gr&#252;newald TG, et al. Teacher-student collaborated multiple instance learning for pan-cancer PDL1 expression prediction from histopathology slides. Nat Commun. 2024;15(1):3063.<pub-id pub-id-type=\"pmid\">38594278</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1038/s41467-024-46764-0</pub-id><pub-id pub-id-type=\"pmcid\">PMC11004138</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR66\"><label>66.</label><citation-alternatives><element-citation id=\"ec-CR66\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Peng</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Zhang</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Zou</surname><given-names>D</given-names></name><name name-style=\"western\"><surname>Xiao</surname><given-names>L</given-names></name><name name-style=\"western\"><surname>Ma</surname><given-names>H</given-names></name><name name-style=\"western\"><surname>Zhang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Deep learning to estimate durable clinical benefit and prognosis from patients with non-small cell lung cancer treated with PD-1/PD-L1 blockade</article-title><source>Front Immunol</source><year>2022</year><volume>13</volume><fpage>960459</fpage><pub-id pub-id-type=\"doi\">10.3389/fimmu.2022.960459</pub-id><pub-id pub-id-type=\"pmid\">36420269</pub-id><pub-id pub-id-type=\"pmcid\">PMC9677530</pub-id></element-citation><mixed-citation id=\"mc-CR66\" publication-type=\"journal\">Peng J, Zhang J, Zou D, Xiao L, Ma H, Zhang X, et al. Deep learning to estimate durable clinical benefit and prognosis from patients with non-small cell lung cancer treated with PD-1/PD-L1 blockade. Front Immunol. 2022;13:960459.<pub-id pub-id-type=\"pmid\">36420269</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.3389/fimmu.2022.960459</pub-id><pub-id pub-id-type=\"pmcid\">PMC9677530</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR67\"><label>67.</label><citation-alternatives><element-citation id=\"ec-CR67\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Wiesweg</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Mairinger</surname><given-names>F</given-names></name><name name-style=\"western\"><surname>Reis</surname><given-names>H</given-names></name><name name-style=\"western\"><surname>Goetz</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Kollmeier</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Misch</surname><given-names>D</given-names></name><etal/></person-group><article-title>Machine learning reveals a PD-L1-independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression context</article-title><source>Eur J Cancer</source><year>2020</year><volume>140</volume><fpage>76</fpage><lpage>85</lpage><pub-id pub-id-type=\"doi\">10.1016/j.ejca.2020.09.015</pub-id><pub-id pub-id-type=\"pmid\">33059196</pub-id></element-citation><mixed-citation id=\"mc-CR67\" publication-type=\"journal\">Wiesweg M, Mairinger F, Reis H, Goetz M, Kollmeier J, Misch D, et al. Machine learning reveals a PD-L1-independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression context. Eur J Cancer. 2020;140:76&#8211;85.<pub-id pub-id-type=\"pmid\">33059196</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/j.ejca.2020.09.015</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR68\"><label>68.</label><citation-alternatives><element-citation id=\"ec-CR68\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Chen</surname><given-names>Z</given-names></name><name name-style=\"western\"><surname>Chen</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Sun</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Tang</surname><given-names>L</given-names></name><name name-style=\"western\"><surname>Zhang</surname><given-names>L</given-names></name><name name-style=\"western\"><surname>Hu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Predicting gastric cancer response to anti-HER2 therapy or anti-HER2 combined immunotherapy based on multi-modal data</article-title><source>Signal Transduct Target Ther</source><year>2024</year><volume>9</volume><issue>1</issue><fpage>222</fpage><pub-id pub-id-type=\"doi\">10.1038/s41392-024-01932-y</pub-id><pub-id pub-id-type=\"pmid\">39183247</pub-id><pub-id pub-id-type=\"pmcid\">PMC11345439</pub-id></element-citation><mixed-citation id=\"mc-CR68\" publication-type=\"journal\">Chen Z, Chen Y, Sun Y, Tang L, Zhang L, Hu Y, et al. Predicting gastric cancer response to anti-HER2 therapy or anti-HER2 combined immunotherapy based on multi-modal data. Signal Transduct Target Ther. 2024;9(1):222.<pub-id pub-id-type=\"pmid\">39183247</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1038/s41392-024-01932-y</pub-id><pub-id pub-id-type=\"pmcid\">PMC11345439</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR69\"><label>69.</label><citation-alternatives><element-citation id=\"ec-CR69\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Byeon</surname><given-names>HE</given-names></name><name name-style=\"western\"><surname>Haam</surname><given-names>S</given-names></name><name name-style=\"western\"><surname>Han</surname><given-names>JH</given-names></name><name name-style=\"western\"><surname>Lee</surname><given-names>HW</given-names></name><name name-style=\"western\"><surname>Koh</surname><given-names>YW</given-names></name></person-group><article-title>Intrinsic and extrinsic transcriptional profiles that affect the clinical response to PD-1 inhibitors in patients with non-small cell lung cancer</article-title><source>Cancers (Basel)</source><year>2022</year><volume>15</volume><issue>1</issue><fpage>197</fpage><pub-id pub-id-type=\"doi\">10.3390/cancers15010197</pub-id><pub-id pub-id-type=\"pmid\">36612193</pub-id><pub-id pub-id-type=\"pmcid\">PMC9818269</pub-id></element-citation><mixed-citation id=\"mc-CR69\" publication-type=\"journal\">Byeon HE, Haam S, Han JH, Lee HW, Koh YW. Intrinsic and extrinsic transcriptional profiles that affect the clinical response to PD-1 inhibitors in patients with non-small cell lung cancer. Cancers (Basel). 2022;15(1):197.<pub-id pub-id-type=\"pmid\">36612193</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.3390/cancers15010197</pub-id><pub-id pub-id-type=\"pmcid\">PMC9818269</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR70\"><label>70.</label><citation-alternatives><element-citation id=\"ec-CR70\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Jardim</surname><given-names>DL</given-names></name><name name-style=\"western\"><surname>Goodman</surname><given-names>A</given-names></name><name name-style=\"western\"><surname>de Melo</surname><given-names>GD</given-names></name><name name-style=\"western\"><surname>Kurzrock</surname><given-names>R</given-names></name></person-group><article-title>The challenges of tumor mutational burden as an immunotherapy biomarker</article-title><source>Cancer Cell</source><year>2021</year><volume>39</volume><issue>2</issue><fpage>154</fpage><lpage>173</lpage><pub-id pub-id-type=\"doi\">10.1016/j.ccell.2020.10.001</pub-id><pub-id pub-id-type=\"pmid\">33125859</pub-id><pub-id pub-id-type=\"pmcid\">PMC7878292</pub-id></element-citation><mixed-citation id=\"mc-CR70\" publication-type=\"journal\">Jardim DL, Goodman A, de Melo GD, Kurzrock R. The challenges of tumor mutational burden as an immunotherapy biomarker. Cancer Cell. 2021;39(2):154&#8211;73.<pub-id pub-id-type=\"pmid\">33125859</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/j.ccell.2020.10.001</pub-id><pub-id pub-id-type=\"pmcid\">PMC7878292</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR71\"><label>71.</label><citation-alternatives><element-citation id=\"ec-CR71\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Palmeri</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Mehnert</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Silk</surname><given-names>A</given-names></name><name name-style=\"western\"><surname>Jabbour</surname><given-names>S</given-names></name><name name-style=\"western\"><surname>Ganesan</surname><given-names>S</given-names></name><name name-style=\"western\"><surname>Popli</surname><given-names>P</given-names></name><etal/></person-group><article-title>Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers</article-title><source>ESMO Open</source><year>2022</year><volume>7</volume><issue>1</issue><fpage>100336</fpage><pub-id pub-id-type=\"doi\">10.1016/j.esmoop.2021.100336</pub-id><pub-id pub-id-type=\"pmid\">34953399</pub-id><pub-id pub-id-type=\"pmcid\">PMC8717431</pub-id></element-citation><mixed-citation id=\"mc-CR71\" publication-type=\"journal\">Palmeri M, Mehnert J, Silk A, Jabbour S, Ganesan S, Popli P, et al. Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers. ESMO Open. 2022;7(1):100336.<pub-id pub-id-type=\"pmid\">34953399</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/j.esmoop.2021.100336</pub-id><pub-id pub-id-type=\"pmcid\">PMC8717431</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR72\"><label>72.</label><citation-alternatives><element-citation id=\"ec-CR72\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Li</surname><given-names>S</given-names></name><name name-style=\"western\"><surname>Yu</surname><given-names>W</given-names></name><name name-style=\"western\"><surname>Xie</surname><given-names>F</given-names></name><name name-style=\"western\"><surname>Luo</surname><given-names>H</given-names></name><name name-style=\"western\"><surname>Liu</surname><given-names>Z</given-names></name><name name-style=\"western\"><surname>Lv</surname><given-names>W</given-names></name><etal/></person-group><article-title>Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer</article-title><source>Nat Commun</source><year>2023</year><volume>14</volume><issue>1</issue><fpage>8</fpage><pub-id pub-id-type=\"doi\">10.1038/s41467-022-35431-x</pub-id><pub-id pub-id-type=\"pmid\">36596787</pub-id><pub-id pub-id-type=\"pmcid\">PMC9810618</pub-id></element-citation><mixed-citation id=\"mc-CR72\" publication-type=\"journal\">Li S, Yu W, Xie F, Luo H, Liu Z, Lv W, et al. Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer. Nat Commun. 2023;14(1):8.<pub-id pub-id-type=\"pmid\">36596787</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1038/s41467-022-35431-x</pub-id><pub-id pub-id-type=\"pmcid\">PMC9810618</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR73\"><label>73.</label><citation-alternatives><element-citation id=\"ec-CR73\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Zhang</surname><given-names>G</given-names></name><name name-style=\"western\"><surname>Yuan</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Pan</surname><given-names>C</given-names></name><name name-style=\"western\"><surname>Xu</surname><given-names>Q</given-names></name><name name-style=\"western\"><surname>Cui</surname><given-names>X</given-names></name><name name-style=\"western\"><surname>Zhang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Multi-omics analysis uncovers tumor ecosystem dynamics during neoadjuvant toripalimab plus nab-paclitaxel and S-1 for esophageal squamous cell carcinoma: a single-center, open-label, single-arm phase 2 trial</article-title><source>EBioMedicine</source><year>2023</year><pub-id pub-id-type=\"doi\">10.1016/j.ebiom.2023.104515</pub-id><pub-id pub-id-type=\"pmid\">36921563</pub-id><pub-id pub-id-type=\"pmcid\">PMC10024111</pub-id></element-citation><mixed-citation id=\"mc-CR73\" publication-type=\"journal\">Zhang G, Yuan J, Pan C, Xu Q, Cui X, Zhang J, et al. Multi-omics analysis uncovers tumor ecosystem dynamics during neoadjuvant toripalimab plus nab-paclitaxel and S-1 for esophageal squamous cell carcinoma: a single-center, open-label, single-arm phase 2 trial. EBioMedicine. 2023. 10.1016/j.ebiom.2023.104515.<pub-id pub-id-type=\"pmid\">36921563</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/j.ebiom.2023.104515</pub-id><pub-id pub-id-type=\"pmcid\">PMC10024111</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR74\"><label>74.</label><citation-alternatives><element-citation id=\"ec-CR74\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Mino-Kenudson</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Schalper</surname><given-names>K</given-names></name><name name-style=\"western\"><surname>Cooper</surname><given-names>W</given-names></name><name name-style=\"western\"><surname>Dacic</surname><given-names>S</given-names></name><name name-style=\"western\"><surname>Hirsch</surname><given-names>FR</given-names></name><name name-style=\"western\"><surname>Jain</surname><given-names>D</given-names></name><etal/></person-group><article-title>Predictive biomarkers for immunotherapy in lung cancer: perspective from the International Association for the Study of Lung Cancer Pathology Committee</article-title><source>J Thorac Oncol</source><year>2022</year><volume>17</volume><issue>12</issue><fpage>1335</fpage><lpage>54</lpage><pub-id pub-id-type=\"doi\">10.1016/j.jtho.2022.09.109</pub-id><pub-id pub-id-type=\"pmid\">36184066</pub-id></element-citation><mixed-citation id=\"mc-CR74\" publication-type=\"journal\">Mino-Kenudson M, Schalper K, Cooper W, Dacic S, Hirsch FR, Jain D, et al. Predictive biomarkers for immunotherapy in lung cancer: perspective from the International Association for the Study of Lung Cancer Pathology Committee. J Thorac Oncol. 2022;17(12):1335&#8211;54.<pub-id pub-id-type=\"pmid\">36184066</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/j.jtho.2022.09.109</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR75\"><label>75.</label><citation-alternatives><element-citation id=\"ec-CR75\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Veeraraghavan</surname><given-names>H</given-names></name><name name-style=\"western\"><surname>Friedman</surname><given-names>CF</given-names></name><name name-style=\"western\"><surname>DeLair</surname><given-names>DF</given-names></name><name name-style=\"western\"><surname>Nin&#269;evi&#263;</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Himoto</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Bruni</surname><given-names>SG</given-names></name><etal/></person-group><article-title>Machine learning-based prediction of microsatellite instability and high tumor mutation burden from contrast-enhanced computed tomography in endometrial cancers</article-title><source>Sci Rep</source><year>2020</year><volume>10</volume><issue>1</issue><fpage>17769</fpage><pub-id pub-id-type=\"doi\">10.1038/s41598-020-72475-9</pub-id><pub-id pub-id-type=\"pmid\">33082371</pub-id><pub-id pub-id-type=\"pmcid\">PMC7575573</pub-id></element-citation><mixed-citation id=\"mc-CR75\" publication-type=\"journal\">Veeraraghavan H, Friedman CF, DeLair DF, Nin&#269;evi&#263; J, Himoto Y, Bruni SG, et al. Machine learning-based prediction of microsatellite instability and high tumor mutation burden from contrast-enhanced computed tomography in endometrial cancers. Sci Rep. 2020;10(1):17769.<pub-id pub-id-type=\"pmid\">33082371</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1038/s41598-020-72475-9</pub-id><pub-id pub-id-type=\"pmcid\">PMC7575573</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR76\"><label>76.</label><citation-alternatives><element-citation id=\"ec-CR76\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Wang</surname><given-names>X</given-names></name><name name-style=\"western\"><surname>Kong</surname><given-names>C</given-names></name><name name-style=\"western\"><surname>Xu</surname><given-names>W</given-names></name><name name-style=\"western\"><surname>Yang</surname><given-names>S</given-names></name><name name-style=\"western\"><surname>Shi</surname><given-names>D</given-names></name><name name-style=\"western\"><surname>Zhang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Decoding tumor mutation burden and driver mutations in early stage lung adenocarcinoma using CT-based radiomics signature</article-title><source>Thorac Cancer</source><year>2019</year><volume>10</volume><issue>10</issue><fpage>1904</fpage><lpage>12</lpage><pub-id pub-id-type=\"doi\">10.1111/1759-7714.13163</pub-id><pub-id pub-id-type=\"pmid\">31414580</pub-id><pub-id pub-id-type=\"pmcid\">PMC6775017</pub-id></element-citation><mixed-citation id=\"mc-CR76\" publication-type=\"journal\">Wang X, Kong C, Xu W, Yang S, Shi D, Zhang J, et al. Decoding tumor mutation burden and driver mutations in early stage lung adenocarcinoma using CT-based radiomics signature. Thorac Cancer. 2019;10(10):1904&#8211;12.<pub-id pub-id-type=\"pmid\">31414580</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1111/1759-7714.13163</pub-id><pub-id pub-id-type=\"pmcid\">PMC6775017</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR77\"><label>77.</label><citation-alternatives><element-citation id=\"ec-CR77\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>He</surname><given-names>B</given-names></name><name name-style=\"western\"><surname>Dong</surname><given-names>D</given-names></name><name name-style=\"western\"><surname>She</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Zhou</surname><given-names>C</given-names></name><name name-style=\"western\"><surname>Fang</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Zhu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker</article-title><source>J Immunother Cancer</source><year>2020</year><volume>8</volume><issue>2</issue><fpage>e000550</fpage><pub-id pub-id-type=\"doi\">10.1136/jitc-2020-000550</pub-id><pub-id pub-id-type=\"pmid\">32636239</pub-id><pub-id pub-id-type=\"pmcid\">PMC7342823</pub-id></element-citation><mixed-citation id=\"mc-CR77\" publication-type=\"journal\">He B, Dong D, She Y, Zhou C, Fang M, Zhu Y, et al. Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker. J Immunother Cancer. 2020;8(2):e000550.<pub-id pub-id-type=\"pmid\">32636239</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1136/jitc-2020-000550</pub-id><pub-id pub-id-type=\"pmcid\">PMC7342823</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR78\"><label>78.</label><citation-alternatives><element-citation id=\"ec-CR78\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Lam</surname><given-names>LHT</given-names></name><name name-style=\"western\"><surname>Chu</surname><given-names>NT</given-names></name><name name-style=\"western\"><surname>Tran</surname><given-names>TO</given-names></name><name name-style=\"western\"><surname>Do</surname><given-names>DT</given-names></name><name name-style=\"western\"><surname>Le</surname><given-names>NQK</given-names></name></person-group><article-title>A radiomics-based machine learning model for prediction of tumor mutational burden in lower-grade gliomas</article-title><source>Cancers (Basel)</source><year>2022</year><volume>14</volume><issue>14</issue><fpage>3492</fpage><pub-id pub-id-type=\"doi\">10.3390/cancers14143492</pub-id><pub-id pub-id-type=\"pmid\">35884551</pub-id><pub-id pub-id-type=\"pmcid\">PMC9324877</pub-id></element-citation><mixed-citation id=\"mc-CR78\" publication-type=\"journal\">Lam LHT, Chu NT, Tran TO, Do DT, Le NQK. A radiomics-based machine learning model for prediction of tumor mutational burden in lower-grade gliomas. Cancers (Basel). 2022;14(14):3492.<pub-id pub-id-type=\"pmid\">35884551</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.3390/cancers14143492</pub-id><pub-id pub-id-type=\"pmcid\">PMC9324877</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR79\"><label>79.</label><citation-alternatives><element-citation id=\"ec-CR79\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Hoshino</surname><given-names>I</given-names></name><name name-style=\"western\"><surname>Yokota</surname><given-names>H</given-names></name><name name-style=\"western\"><surname>Iwatate</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Mori</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Kuwayama</surname><given-names>N</given-names></name><name name-style=\"western\"><surname>Ishige</surname><given-names>F</given-names></name><etal/></person-group><article-title>Prediction of the differences in tumor mutation burden between primary and metastatic lesions by radiogenomics</article-title><source>Cancer Sci</source><year>2022</year><volume>113</volume><issue>1</issue><fpage>229</fpage><lpage>39</lpage><pub-id pub-id-type=\"doi\">10.1111/cas.15173</pub-id><pub-id pub-id-type=\"pmid\">34689378</pub-id><pub-id pub-id-type=\"pmcid\">PMC8748253</pub-id></element-citation><mixed-citation id=\"mc-CR79\" publication-type=\"journal\">Hoshino I, Yokota H, Iwatate Y, Mori Y, Kuwayama N, Ishige F, et al. Prediction of the differences in tumor mutation burden between primary and metastatic lesions by radiogenomics. Cancer Sci. 2022;113(1):229&#8211;39.<pub-id pub-id-type=\"pmid\">34689378</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1111/cas.15173</pub-id><pub-id pub-id-type=\"pmcid\">PMC8748253</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR80\"><label>80.</label><citation-alternatives><element-citation id=\"ec-CR80\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Shimada</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Okuda</surname><given-names>S</given-names></name><name name-style=\"western\"><surname>Watanabe</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Tajima</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Nagahashi</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Ichikawa</surname><given-names>H</given-names></name><etal/></person-group><article-title>Histopathological characteristics and artificial intelligence for predicting tumor mutational burden-high colorectal cancer</article-title><source>J Gastroenterol</source><year>2021</year><volume>56</volume><issue>6</issue><fpage>547</fpage><lpage>59</lpage><pub-id pub-id-type=\"doi\">10.1007/s00535-021-01789-w</pub-id><pub-id pub-id-type=\"pmid\">33909150</pub-id></element-citation><mixed-citation id=\"mc-CR80\" publication-type=\"journal\">Shimada Y, Okuda S, Watanabe Y, Tajima Y, Nagahashi M, Ichikawa H, et al. Histopathological characteristics and artificial intelligence for predicting tumor mutational burden-high colorectal cancer. J Gastroenterol. 2021;56(6):547&#8211;59.<pub-id pub-id-type=\"pmid\">33909150</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1007/s00535-021-01789-w</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR81\"><label>81.</label><citation-alternatives><element-citation id=\"ec-CR81\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Zheng</surname><given-names>Q</given-names></name><name name-style=\"western\"><surname>Wang</surname><given-names>X</given-names></name><name name-style=\"western\"><surname>Yang</surname><given-names>R</given-names></name><name name-style=\"western\"><surname>Fan</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Yuan</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Liu</surname><given-names>X</given-names></name><etal/></person-group><article-title>Predicting tumor mutation burden and VHL mutation from renal cancer pathology slides with self-supervised deep learning</article-title><source>Cancer Med</source><year>2024</year><volume>13</volume><issue>16</issue><fpage>e70112</fpage><pub-id pub-id-type=\"doi\">10.1002/cam4.70112</pub-id><pub-id pub-id-type=\"pmid\">39166457</pub-id><pub-id pub-id-type=\"pmcid\">PMC11336896</pub-id></element-citation><mixed-citation id=\"mc-CR81\" publication-type=\"journal\">Zheng Q, Wang X, Yang R, Fan J, Yuan J, Liu X, et al. Predicting tumor mutation burden and VHL mutation from renal cancer pathology slides with self-supervised deep learning. Cancer Med. 2024;13(16):e70112.<pub-id pub-id-type=\"pmid\">39166457</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1002/cam4.70112</pub-id><pub-id pub-id-type=\"pmcid\">PMC11336896</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR82\"><label>82.</label><citation-alternatives><element-citation id=\"ec-CR82\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Sun</surname><given-names>C</given-names></name><name name-style=\"western\"><surname>Luo</surname><given-names>T</given-names></name><name name-style=\"western\"><surname>Liu</surname><given-names>Z</given-names></name><name name-style=\"western\"><surname>Ge</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Shao</surname><given-names>L</given-names></name><name name-style=\"western\"><surname>Liu</surname><given-names>X</given-names></name><etal/></person-group><article-title>Tumor mutation burden-related histopathologic features for predicting overall survival in gliomas using graph deep learning</article-title><source>Am J Pathol</source><year>2023</year><volume>193</volume><issue>12</issue><fpage>2111</fpage><lpage>21</lpage><pub-id pub-id-type=\"doi\">10.1016/j.ajpath.2023.08.015</pub-id><pub-id pub-id-type=\"pmid\">37741452</pub-id></element-citation><mixed-citation id=\"mc-CR82\" publication-type=\"journal\">Sun C, Luo T, Liu Z, Ge J, Shao L, Liu X, et al. Tumor mutation burden-related histopathologic features for predicting overall survival in gliomas using graph deep learning. Am J Pathol. 2023;193(12):2111&#8211;21.<pub-id pub-id-type=\"pmid\">37741452</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/j.ajpath.2023.08.015</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR83\"><label>83.</label><citation-alternatives><element-citation id=\"ec-CR83\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Huang</surname><given-names>K</given-names></name><name name-style=\"western\"><surname>Lin</surname><given-names>B</given-names></name><name name-style=\"western\"><surname>Liu</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Liu</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Li</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Tian</surname><given-names>G</given-names></name><etal/></person-group><article-title>Predicting colorectal cancer tumor mutational burden from histopathological images and clinical information using multi-modal deep learning</article-title><source>Bioinformatics</source><year>2022</year><volume>38</volume><issue>22</issue><fpage>5108</fpage><lpage>15</lpage><pub-id pub-id-type=\"doi\">10.1093/bioinformatics/btac641</pub-id><pub-id pub-id-type=\"pmid\">36130268</pub-id></element-citation><mixed-citation id=\"mc-CR83\" publication-type=\"journal\">Huang K, Lin B, Liu J, Liu Y, Li J, Tian G, et al. Predicting colorectal cancer tumor mutational burden from histopathological images and clinical information using multi-modal deep learning. Bioinformatics. 2022;38(22):5108&#8211;15.<pub-id pub-id-type=\"pmid\">36130268</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1093/bioinformatics/btac641</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR84\"><label>84.</label><citation-alternatives><element-citation id=\"ec-CR84\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Xu</surname><given-names>H</given-names></name><name name-style=\"western\"><surname>Clemenceau</surname><given-names>JR</given-names></name><name name-style=\"western\"><surname>Park</surname><given-names>S</given-names></name><name name-style=\"western\"><surname>Choi</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Lee</surname><given-names>SH</given-names></name><name name-style=\"western\"><surname>Hwang</surname><given-names>TH</given-names></name></person-group><article-title>Spatial heterogeneity and organization of tumor mutation burden with immune infiltrates within tumors based on whole slide images correlated with patient survival in bladder cancer</article-title><source>J Pathol Inform</source><year>2022</year><volume>13</volume><fpage>100105</fpage><pub-id pub-id-type=\"doi\">10.1016/j.jpi.2022.100105</pub-id><pub-id pub-id-type=\"pmid\">36268064</pub-id><pub-id pub-id-type=\"pmcid\">PMC9577053</pub-id></element-citation><mixed-citation id=\"mc-CR84\" publication-type=\"journal\">Xu H, Clemenceau JR, Park S, Choi J, Lee SH, Hwang TH. Spatial heterogeneity and organization of tumor mutation burden with immune infiltrates within tumors based on whole slide images correlated with patient survival in bladder cancer. J Pathol Inform. 2022;13:100105.<pub-id pub-id-type=\"pmid\">36268064</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/j.jpi.2022.100105</pub-id><pub-id pub-id-type=\"pmcid\">PMC9577053</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR85\"><label>85.</label><citation-alternatives><element-citation id=\"ec-CR85\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Li</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Liu</surname><given-names>H</given-names></name><name name-style=\"western\"><surname>Liu</surname><given-names>W</given-names></name><name name-style=\"western\"><surname>Zong</surname><given-names>P</given-names></name><name name-style=\"western\"><surname>Huang</surname><given-names>K</given-names></name><name name-style=\"western\"><surname>Li</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Predicting gastric cancer tumor mutational burden from histopathological images using multimodal deep learning</article-title><source>Brief Funct Genomics</source><year>2024</year><volume>23</volume><issue>3</issue><fpage>228</fpage><lpage>38</lpage><pub-id pub-id-type=\"doi\">10.1093/bfgp/elad032</pub-id><pub-id pub-id-type=\"pmid\">37525540</pub-id></element-citation><mixed-citation id=\"mc-CR85\" publication-type=\"journal\">Li J, Liu H, Liu W, Zong P, Huang K, Li Z, et al. Predicting gastric cancer tumor mutational burden from histopathological images using multimodal deep learning. Brief Funct Genomics. 2024;23(3):228&#8211;38.<pub-id pub-id-type=\"pmid\">37525540</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1093/bfgp/elad032</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR86\"><label>86.</label><citation-alternatives><element-citation id=\"ec-CR86\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Sanjaya</surname><given-names>P</given-names></name><name name-style=\"western\"><surname>Maljanen</surname><given-names>K</given-names></name><name name-style=\"western\"><surname>Katainen</surname><given-names>R</given-names></name><name name-style=\"western\"><surname>Waszak</surname><given-names>SM</given-names></name><name name-style=\"western\"><surname>Aaltonen</surname><given-names>LA</given-names></name><name name-style=\"western\"><surname>Stegle</surname><given-names>O</given-names></name><etal/></person-group><article-title>Mutation-attention (MuAt): deep representation learning of somatic mutations for tumour typing and subtyping</article-title><source>Genome Med</source><year>2023</year><volume>15</volume><issue>1</issue><fpage>47</fpage><pub-id pub-id-type=\"doi\">10.1186/s13073-023-01204-4</pub-id><pub-id pub-id-type=\"pmid\">37420249</pub-id><pub-id pub-id-type=\"pmcid\">PMC10326961</pub-id></element-citation><mixed-citation id=\"mc-CR86\" publication-type=\"journal\">Sanjaya P, Maljanen K, Katainen R, Waszak SM, Aaltonen LA, Stegle O, et al. Mutation-attention (MuAt): deep representation learning of somatic mutations for tumour typing and subtyping. Genome Med. 2023;15(1):47.<pub-id pub-id-type=\"pmid\">37420249</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1186/s13073-023-01204-4</pub-id><pub-id pub-id-type=\"pmcid\">PMC10326961</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR87\"><label>87.</label><citation-alternatives><element-citation id=\"ec-CR87\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Nassar</surname><given-names>A</given-names></name><name name-style=\"western\"><surname>Lymona</surname><given-names>AM</given-names></name><name name-style=\"western\"><surname>Lotfy</surname><given-names>MM</given-names></name><name name-style=\"western\"><surname>Youssef</surname><given-names>ASED</given-names></name><name name-style=\"western\"><surname>Mohanad</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Manie</surname><given-names>TM</given-names></name><etal/></person-group><article-title>Tumor mutation burden prediction model in Egyptian breast cancer patients based on next generation sequencing</article-title><source>Asian Pac J Cancer Prev</source><year>2021</year><volume>22</volume><issue>7</issue><fpage>2053</fpage><pub-id pub-id-type=\"doi\">10.31557/APJCP.2021.22.7.2053</pub-id><pub-id pub-id-type=\"pmid\">34319027</pub-id><pub-id pub-id-type=\"pmcid\">PMC8607104</pub-id></element-citation><mixed-citation id=\"mc-CR87\" publication-type=\"journal\">Nassar A, Lymona AM, Lotfy MM, Youssef ASED, Mohanad M, Manie TM, et al. Tumor mutation burden prediction model in Egyptian breast cancer patients based on next generation sequencing. Asian Pac J Cancer Prev. 2021;22(7):2053.<pub-id pub-id-type=\"pmid\">34319027</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.31557/APJCP.2021.22.7.2053</pub-id><pub-id pub-id-type=\"pmcid\">PMC8607104</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR88\"><label>88.</label><citation-alternatives><element-citation id=\"ec-CR88\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Zhang</surname><given-names>Z</given-names></name><name name-style=\"western\"><surname>Wang</surname><given-names>ZX</given-names></name><name name-style=\"western\"><surname>Chen</surname><given-names>YX</given-names></name><name name-style=\"western\"><surname>Wu</surname><given-names>HX</given-names></name><name name-style=\"western\"><surname>Yin</surname><given-names>L</given-names></name><name name-style=\"western\"><surname>Zhao</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Integrated analysis of single-cell and bulk RNA sequencing data reveals a pan-cancer stemness signature predicting immunotherapy response</article-title><source>Genome Med</source><year>2022</year><volume>14</volume><issue>1</issue><fpage>45</fpage><pub-id pub-id-type=\"doi\">10.1186/s13073-022-01050-w</pub-id><pub-id pub-id-type=\"pmid\">35488273</pub-id><pub-id pub-id-type=\"pmcid\">PMC9052621</pub-id></element-citation><mixed-citation id=\"mc-CR88\" publication-type=\"journal\">Zhang Z, Wang ZX, Chen YX, Wu HX, Yin L, Zhao Q, et al. Integrated analysis of single-cell and bulk RNA sequencing data reveals a pan-cancer stemness signature predicting immunotherapy response. Genome Med. 2022;14(1):45.<pub-id pub-id-type=\"pmid\">35488273</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1186/s13073-022-01050-w</pub-id><pub-id pub-id-type=\"pmcid\">PMC9052621</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR89\"><label>89.</label><citation-alternatives><element-citation id=\"ec-CR89\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Wang</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Chen</surname><given-names>P</given-names></name><name name-style=\"western\"><surname>Su</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Zhong</surname><given-names>G</given-names></name><name name-style=\"western\"><surname>Zhang</surname><given-names>S</given-names></name><name name-style=\"western\"><surname>Gou</surname><given-names>D</given-names></name></person-group><article-title>Integrative modeling of multiomics data for predicting tumor mutation burden in patients with lung cancer</article-title><source>BioMed Res Int</source><year>2022</year><volume>2022</volume><issue>1</issue><fpage>2698190</fpage><pub-id pub-id-type=\"doi\">10.1155/2022/2698190</pub-id><pub-id pub-id-type=\"pmid\">35097114</pub-id><pub-id pub-id-type=\"pmcid\">PMC8794677</pub-id></element-citation><mixed-citation id=\"mc-CR89\" publication-type=\"journal\">Wang J, Chen P, Su M, Zhong G, Zhang S, Gou D. Integrative modeling of multiomics data for predicting tumor mutation burden in patients with lung cancer. BioMed Res Int. 2022;2022(1):2698190.<pub-id pub-id-type=\"pmid\">35097114</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1155/2022/2698190</pub-id><pub-id pub-id-type=\"pmcid\">PMC8794677</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR90\"><label>90.</label><citation-alternatives><element-citation id=\"ec-CR90\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Ozer</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Vegivinti</surname><given-names>CTR</given-names></name><name name-style=\"western\"><surname>Syed</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Ferrell</surname><given-names>ME</given-names></name><name name-style=\"western\"><surname>Gonzalez Gomez</surname><given-names>C</given-names></name><name name-style=\"western\"><surname>Cheng</surname><given-names>S</given-names></name><etal/></person-group><article-title>Neoadjuvant immunotherapy for patients with dMMR/MSI-high gastrointestinal cancers: a changing paradigm</article-title><source>Cancers (Basel)</source><year>2023</year><volume>15</volume><issue>15</issue><fpage>3833</fpage><pub-id pub-id-type=\"doi\">10.3390/cancers15153833</pub-id><pub-id pub-id-type=\"pmid\">37568648</pub-id><pub-id pub-id-type=\"pmcid\">PMC10417711</pub-id></element-citation><mixed-citation id=\"mc-CR90\" publication-type=\"journal\">Ozer M, Vegivinti CTR, Syed M, Ferrell ME, Gonzalez Gomez C, Cheng S, et al. Neoadjuvant immunotherapy for patients with dMMR/MSI-high gastrointestinal cancers: a changing paradigm. Cancers (Basel). 2023;15(15):3833.<pub-id pub-id-type=\"pmid\">37568648</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.3390/cancers15153833</pub-id><pub-id pub-id-type=\"pmcid\">PMC10417711</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR91\"><label>91.</label><citation-alternatives><element-citation id=\"ec-CR91\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Zhang</surname><given-names>X</given-names></name><name name-style=\"western\"><surname>Wu</surname><given-names>T</given-names></name><name name-style=\"western\"><surname>Cai</surname><given-names>X</given-names></name><name name-style=\"western\"><surname>Dong</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Xia</surname><given-names>C</given-names></name><name name-style=\"western\"><surname>Zhou</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Neoadjuvant immunotherapy for MSI-H/dMMR locally advanced colorectal cancer: new strategies and unveiled opportunities</article-title><source>Front Immunol</source><year>2022</year><volume>13</volume><fpage>795972</fpage><pub-id pub-id-type=\"doi\">10.3389/fimmu.2022.795972</pub-id><pub-id pub-id-type=\"pmid\">35371084</pub-id><pub-id pub-id-type=\"pmcid\">PMC8968082</pub-id></element-citation><mixed-citation id=\"mc-CR91\" publication-type=\"journal\">Zhang X, Wu T, Cai X, Dong J, Xia C, Zhou Y, et al. Neoadjuvant immunotherapy for MSI-H/dMMR locally advanced colorectal cancer: new strategies and unveiled opportunities. Front Immunol. 2022;13:795972.<pub-id pub-id-type=\"pmid\">35371084</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.3389/fimmu.2022.795972</pub-id><pub-id pub-id-type=\"pmcid\">PMC8968082</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR92\"><label>92.</label><citation-alternatives><element-citation id=\"ec-CR92\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Zhang</surname><given-names>Z</given-names></name><name name-style=\"western\"><surname>Cheng</surname><given-names>S</given-names></name><name name-style=\"western\"><surname>Gong</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Lu</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Zhou</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Zhang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Efficacy and safety of neoadjuvant immunotherapy in patients with microsatellite instability-high gastrointestinal malignancies: A case series</article-title><source>Eur J Surg Oncol</source><year>2020</year><volume>46</volume><issue>10</issue><fpage>e33</fpage><lpage>e39</lpage><pub-id pub-id-type=\"doi\">10.1016/j.ejso.2020.06.034</pub-id><pub-id pub-id-type=\"pmid\">32732092</pub-id></element-citation><mixed-citation id=\"mc-CR92\" publication-type=\"journal\">Zhang Z, Cheng S, Gong J, Lu M, Zhou J, Zhang X, et al. Efficacy and safety of neoadjuvant immunotherapy in patients with microsatellite instability-high gastrointestinal malignancies: A case series. Eur J Surg Oncol. 2020;46(10):e33&#8211;9.<pub-id pub-id-type=\"pmid\">32732092</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/j.ejso.2020.06.034</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR93\"><label>93.</label><citation-alternatives><element-citation id=\"ec-CR93\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Ludford</surname><given-names>K</given-names></name><name name-style=\"western\"><surname>Ho</surname><given-names>WJ</given-names></name><name name-style=\"western\"><surname>Thomas</surname><given-names>JV</given-names></name><name name-style=\"western\"><surname>Raghav</surname><given-names>KP</given-names></name><name name-style=\"western\"><surname>Murphy</surname><given-names>MB</given-names></name><name name-style=\"western\"><surname>Fleming</surname><given-names>ND</given-names></name><etal/></person-group><article-title>Neoadjuvant pembrolizumab in localized microsatellite instability high/deficient mismatch repair solid tumors</article-title><source>J Clin Oncol</source><year>2023</year><volume>41</volume><issue>12</issue><fpage>2181</fpage><lpage>90</lpage><pub-id pub-id-type=\"doi\">10.1200/JCO.22.01351</pub-id><pub-id pub-id-type=\"pmid\">36623241</pub-id><pub-id pub-id-type=\"pmcid\">PMC10489404</pub-id></element-citation><mixed-citation id=\"mc-CR93\" publication-type=\"journal\">Ludford K, Ho WJ, Thomas JV, Raghav KP, Murphy MB, Fleming ND, et al. Neoadjuvant pembrolizumab in localized microsatellite instability high/deficient mismatch repair solid tumors. J Clin Oncol. 2023;41(12):2181&#8211;90.<pub-id pub-id-type=\"pmid\">36623241</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1200/JCO.22.01351</pub-id><pub-id pub-id-type=\"pmcid\">PMC10489404</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR94\"><label>94.</label><citation-alternatives><element-citation id=\"ec-CR94\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Pei</surname><given-names>F</given-names></name><name name-style=\"western\"><surname>Wu</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Zhao</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>He</surname><given-names>W</given-names></name><name name-style=\"western\"><surname>Yao</surname><given-names>Q</given-names></name><name name-style=\"western\"><surname>Huang</surname><given-names>M</given-names></name><etal/></person-group><article-title>Single-agent neoadjuvant immunotherapy with a PD-1 antibody in locally advanced mismatch repair-deficient or microsatellite instability-high colorectal cancer</article-title><source>Clin Colorectal Cancer</source><year>2023</year><volume>22</volume><issue>1</issue><fpage>85</fpage><lpage>91</lpage><pub-id pub-id-type=\"pmid\">36528470</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/j.clcc.2022.11.004</pub-id></element-citation><mixed-citation id=\"mc-CR94\" publication-type=\"journal\">Pei F, Wu J, Zhao Y, He W, Yao Q, Huang M, et al. Single-agent neoadjuvant immunotherapy with a PD-1 antibody in locally advanced mismatch repair-deficient or microsatellite instability-high colorectal cancer. Clin Colorectal Cancer. 2023;22(1):85&#8211;91.<pub-id pub-id-type=\"pmid\">36528470</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/j.clcc.2022.11.004</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR95\"><label>95.</label><citation-alternatives><element-citation id=\"ec-CR95\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Liu</surname><given-names>L</given-names></name><name name-style=\"western\"><surname>Woo</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>D&#8217;Apuzzo</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Melstrom</surname><given-names>L</given-names></name><name name-style=\"western\"><surname>Raoof</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Liang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Immunotherapy-based neoadjuvant treatment of advanced microsatellite instability-high gastric cancer: a case series</article-title><source>J Natl Compr Canc Netw</source><year>2022</year><volume>20</volume><issue>8</issue><fpage>857</fpage><lpage>65</lpage><pub-id pub-id-type=\"doi\">10.6004/jnccn.2022.7023</pub-id><pub-id pub-id-type=\"pmid\">35948034</pub-id></element-citation><mixed-citation id=\"mc-CR95\" publication-type=\"journal\">Liu L, Woo Y, D&#8217;Apuzzo M, Melstrom L, Raoof M, Liang Y, et al. Immunotherapy-based neoadjuvant treatment of advanced microsatellite instability-high gastric cancer: a case series. J Natl Compr Canc Netw. 2022;20(8):857&#8211;65.<pub-id pub-id-type=\"pmid\">35948034</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.6004/jnccn.2022.7023</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR96\"><label>96.</label><citation-alternatives><element-citation id=\"ec-CR96\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Andr&#233;</surname><given-names>T</given-names></name><name name-style=\"western\"><surname>Tougeron</surname><given-names>D</given-names></name><name name-style=\"western\"><surname>Piessen</surname><given-names>G</given-names></name><name name-style=\"western\"><surname>de La Fouchardi&#232;re</surname><given-names>C</given-names></name><name name-style=\"western\"><surname>Louvet</surname><given-names>C</given-names></name><name name-style=\"western\"><surname>Adenis</surname><given-names>A</given-names></name><etal/></person-group><article-title>Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: the GERCOR NEONIPIGA phase II study</article-title><source>J Clin Oncol</source><year>2023</year><volume>41</volume><issue>2</issue><fpage>255</fpage><lpage>65</lpage><pub-id pub-id-type=\"doi\">10.1200/JCO.22.00686</pub-id><pub-id pub-id-type=\"pmid\">35969830</pub-id><pub-id pub-id-type=\"pmcid\">PMC9839243</pub-id></element-citation><mixed-citation id=\"mc-CR96\" publication-type=\"journal\">Andr&#233; T, Tougeron D, Piessen G, de La Fouchardi&#232;re C, Louvet C, Adenis A, et al. Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: the GERCOR NEONIPIGA phase II study. J Clin Oncol. 2023;41(2):255&#8211;65.<pub-id pub-id-type=\"pmid\">35969830</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1200/JCO.22.00686</pub-id><pub-id pub-id-type=\"pmcid\">PMC9839243</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR97\"><label>97.</label><citation-alternatives><element-citation id=\"ec-CR97\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Sahin</surname><given-names>IH</given-names></name><name name-style=\"western\"><surname>Zhang</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Saridogan</surname><given-names>T</given-names></name><name name-style=\"western\"><surname>Gorantla</surname><given-names>V</given-names></name><name name-style=\"western\"><surname>Rhree</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Malhotra</surname><given-names>M</given-names></name><etal/></person-group><article-title>Neoadjuvant immune checkpoint inhibitor therapy for patients with microsatellite instability-high colorectal cancer: shedding light on the future</article-title><source>JCO Oncol Pract</source><year>2023</year><volume>19</volume><issue>5</issue><fpage>251</fpage><lpage>9</lpage><pub-id pub-id-type=\"doi\">10.1200/OP.22.00762</pub-id><pub-id pub-id-type=\"pmid\">36862965</pub-id></element-citation><mixed-citation id=\"mc-CR97\" publication-type=\"journal\">Sahin IH, Zhang J, Saridogan T, Gorantla V, Rhree J, Malhotra M, et al. Neoadjuvant immune checkpoint inhibitor therapy for patients with microsatellite instability-high colorectal cancer: shedding light on the future. JCO Oncol Pract. 2023;19(5):251&#8211;9.<pub-id pub-id-type=\"pmid\">36862965</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1200/OP.22.00762</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR98\"><label>98.</label><citation-alternatives><element-citation id=\"ec-CR98\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Jia</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Hou</surname><given-names>L</given-names></name><name name-style=\"western\"><surname>Zhao</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Ren</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Li</surname><given-names>D</given-names></name><name name-style=\"western\"><surname>Li</surname><given-names>H</given-names></name><etal/></person-group><article-title>Radiomics analysis of multiparametric MRI for preoperative prediction of microsatellite instability status in endometrial cancer: a dual-center study</article-title><source>Front Oncol</source><year>2024</year><volume>14</volume><fpage>1333020</fpage><pub-id pub-id-type=\"doi\">10.3389/fonc.2024.1333020</pub-id><pub-id pub-id-type=\"pmid\">38347846</pub-id><pub-id pub-id-type=\"pmcid\">PMC10860747</pub-id></element-citation><mixed-citation id=\"mc-CR98\" publication-type=\"journal\">Jia Y, Hou L, Zhao J, Ren J, Li D, Li H, et al. Radiomics analysis of multiparametric MRI for preoperative prediction of microsatellite instability status in endometrial cancer: a dual-center study. Front Oncol. 2024;14:1333020.<pub-id pub-id-type=\"pmid\">38347846</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.3389/fonc.2024.1333020</pub-id><pub-id pub-id-type=\"pmcid\">PMC10860747</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR99\"><label>99.</label><citation-alternatives><element-citation id=\"ec-CR99\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Xing</surname><given-names>X</given-names></name><name name-style=\"western\"><surname>Li</surname><given-names>D</given-names></name><name name-style=\"western\"><surname>Peng</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Shu</surname><given-names>Z</given-names></name><name name-style=\"western\"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Song</surname><given-names>Q</given-names></name></person-group><article-title>A combinatorial MRI sequence-based radiomics model for preoperative prediction of microsatellite instability status in rectal cancer</article-title><source>Sci Rep</source><year>2024</year><volume>14</volume><issue>1</issue><fpage>11760</fpage><pub-id pub-id-type=\"doi\">10.1038/s41598-024-62584-0</pub-id><pub-id pub-id-type=\"pmid\">38783014</pub-id><pub-id pub-id-type=\"pmcid\">PMC11116457</pub-id></element-citation><mixed-citation id=\"mc-CR99\" publication-type=\"journal\">Xing X, Li D, Peng J, Shu Z, Zhang Y, Song Q. A combinatorial MRI sequence-based radiomics model for preoperative prediction of microsatellite instability status in rectal cancer. Sci Rep. 2024;14(1):11760.<pub-id pub-id-type=\"pmid\">38783014</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1038/s41598-024-62584-0</pub-id><pub-id pub-id-type=\"pmcid\">PMC11116457</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR100\"><label>100.</label><citation-alternatives><element-citation id=\"ec-CR100\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Li</surname><given-names>Q</given-names></name><name name-style=\"western\"><surname>Xia</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Li</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Tang</surname><given-names>W</given-names></name><name name-style=\"western\"><surname>Zhang</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Zhao</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Radiogenomics for predicting microsatellite instability status and PD-L1 expression with machine learning in endometrial cancers: a multicenter study</article-title><source>Heliyon</source><year>2023</year><pub-id pub-id-type=\"doi\">10.1016/j.heliyon.2023.e23166</pub-id><pub-id pub-id-type=\"pmid\">38149198</pub-id><pub-id pub-id-type=\"pmcid\">PMC10750045</pub-id></element-citation><mixed-citation id=\"mc-CR100\" publication-type=\"journal\">Li Q, Xia Y, Li M, Tang W, Zhang M, Zhao Z, et al. Radiogenomics for predicting microsatellite instability status and PD-L1 expression with machine learning in endometrial cancers: a multicenter study. Heliyon. 2023. 10.1016/j.heliyon.2023.e23166.<pub-id pub-id-type=\"pmid\">38149198</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/j.heliyon.2023.e23166</pub-id><pub-id pub-id-type=\"pmcid\">PMC10750045</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR101\"><label>101.</label><citation-alternatives><element-citation id=\"ec-CR101\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Wang</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Song</surname><given-names>P</given-names></name><name name-style=\"western\"><surname>Zhang</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Liu</surname><given-names>W</given-names></name><name name-style=\"western\"><surname>Zeng</surname><given-names>X</given-names></name><name name-style=\"western\"><surname>Chen</surname><given-names>N</given-names></name><etal/></person-group><article-title>A prediction model based on deep learning and radiomics features of DWI for the assessment of microsatellite instability in endometrial cancer</article-title><source>Cancer Med</source><year>2024</year><volume>13</volume><issue>16</issue><fpage>e70046</fpage><pub-id pub-id-type=\"doi\">10.1002/cam4.70046</pub-id><pub-id pub-id-type=\"pmid\">39171859</pub-id><pub-id pub-id-type=\"pmcid\">PMC11339853</pub-id></element-citation><mixed-citation id=\"mc-CR101\" publication-type=\"journal\">Wang J, Song P, Zhang M, Liu W, Zeng X, Chen N, et al. A prediction model based on deep learning and radiomics features of DWI for the assessment of microsatellite instability in endometrial cancer. Cancer Med. 2024;13(16):e70046.<pub-id pub-id-type=\"pmid\">39171859</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1002/cam4.70046</pub-id><pub-id pub-id-type=\"pmcid\">PMC11339853</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR102\"><label>102.</label><citation-alternatives><element-citation id=\"ec-CR102\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Liu</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Wu</surname><given-names>C</given-names></name><name name-style=\"western\"><surname>Peng</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Wei</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Cui</surname><given-names>S</given-names></name></person-group><article-title>Preoperative prediction of microsatellite instability in rectal cancer using five machine learning algorithms based on multiparametric MRI radiomics</article-title><source>Diagnostics</source><year>2023</year><volume>13</volume><issue>2</issue><fpage>269</fpage><pub-id pub-id-type=\"doi\">10.3390/diagnostics13020269</pub-id><pub-id pub-id-type=\"pmid\">36673079</pub-id><pub-id pub-id-type=\"pmcid\">PMC9858257</pub-id></element-citation><mixed-citation id=\"mc-CR102\" publication-type=\"journal\">Zhang Y, Liu J, Wu C, Peng J, Wei Y, Cui S. Preoperative prediction of microsatellite instability in rectal cancer using five machine learning algorithms based on multiparametric MRI radiomics. Diagnostics. 2023;13(2):269.<pub-id pub-id-type=\"pmid\">36673079</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.3390/diagnostics13020269</pub-id><pub-id pub-id-type=\"pmcid\">PMC9858257</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR103\"><label>103.</label><mixed-citation publication-type=\"other\">Kim S, Lee JH, Park EJ, Lee HS, Baik SH, Jeon TJ, et al. Prediction of microsatellite instability in colorectal cancer using a machine learning model based on PET/CT radiomics. Yonsei Med J. 2023;64(5):320.<pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.3349/ymj.2022.0548</pub-id><pub-id pub-id-type=\"pmcid\">PMC10151228</pub-id><pub-id pub-id-type=\"pmid\">37114635</pub-id></mixed-citation></ref><ref id=\"CR104\"><label>104.</label><citation-alternatives><element-citation id=\"ec-CR104\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Bodalal</surname><given-names>Z</given-names></name><name name-style=\"western\"><surname>Hong</surname><given-names>EK</given-names></name><name name-style=\"western\"><surname>Trebeschi</surname><given-names>S</given-names></name><name name-style=\"western\"><surname>Kurilova</surname><given-names>I</given-names></name><name name-style=\"western\"><surname>Landolfi</surname><given-names>F</given-names></name><name name-style=\"western\"><surname>Bogveradze</surname><given-names>N</given-names></name><etal/></person-group><article-title>Non-invasive CT radiomic biomarkers predict microsatellite stability status in colorectal cancer: a multicenter validation study</article-title><source>Eur Radiol Exp</source><year>2024</year><volume>8</volume><issue>1</issue><fpage>98</fpage><pub-id pub-id-type=\"doi\">10.1186/s41747-024-00484-8</pub-id><pub-id pub-id-type=\"pmid\">39186200</pub-id><pub-id pub-id-type=\"pmcid\">PMC11347521</pub-id></element-citation><mixed-citation id=\"mc-CR104\" publication-type=\"journal\">Bodalal Z, Hong EK, Trebeschi S, Kurilova I, Landolfi F, Bogveradze N, et al. Non-invasive CT radiomic biomarkers predict microsatellite stability status in colorectal cancer: a multicenter validation study. Eur Radiol Exp. 2024;8(1):98.<pub-id pub-id-type=\"pmid\">39186200</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1186/s41747-024-00484-8</pub-id><pub-id pub-id-type=\"pmcid\">PMC11347521</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR105\"><label>105.</label><citation-alternatives><element-citation id=\"ec-CR105\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Cao</surname><given-names>W</given-names></name><name name-style=\"western\"><surname>Hu</surname><given-names>H</given-names></name><name name-style=\"western\"><surname>Guo</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Qin</surname><given-names>Q</given-names></name><name name-style=\"western\"><surname>Lian</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Li</surname><given-names>J</given-names></name><etal/></person-group><article-title>CT-based deep learning model for the prediction of DNA mismatch repair deficient colorectal cancer: a diagnostic study</article-title><source>J Transl Med</source><year>2023</year><volume>21</volume><issue>1</issue><fpage>214</fpage><pub-id pub-id-type=\"doi\">10.1186/s12967-023-04023-8</pub-id><pub-id pub-id-type=\"pmid\">36949511</pub-id><pub-id pub-id-type=\"pmcid\">PMC10035255</pub-id></element-citation><mixed-citation id=\"mc-CR105\" publication-type=\"journal\">Cao W, Hu H, Guo J, Qin Q, Lian Y, Li J, et al. CT-based deep learning model for the prediction of DNA mismatch repair deficient colorectal cancer: a diagnostic study. J Transl Med. 2023;21(1):214.<pub-id pub-id-type=\"pmid\">36949511</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1186/s12967-023-04023-8</pub-id><pub-id pub-id-type=\"pmcid\">PMC10035255</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR106\"><label>106.</label><citation-alternatives><element-citation id=\"ec-CR106\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Jiang</surname><given-names>Z</given-names></name><name name-style=\"western\"><surname>Xie</surname><given-names>W</given-names></name><name name-style=\"western\"><surname>Zhou</surname><given-names>X</given-names></name><name name-style=\"western\"><surname>Pan</surname><given-names>W</given-names></name><name name-style=\"western\"><surname>Jiang</surname><given-names>S</given-names></name><name name-style=\"western\"><surname>Zhang</surname><given-names>X</given-names></name><etal/></person-group><article-title>A virtual biopsy study of microsatellite instability in gastric cancer based on deep learning radiomics</article-title><source>Insights Imaging</source><year>2023</year><volume>14</volume><issue>1</issue><fpage>104</fpage><pub-id pub-id-type=\"doi\">10.1186/s13244-023-01438-1</pub-id><pub-id pub-id-type=\"pmid\">37286810</pub-id><pub-id pub-id-type=\"pmcid\">PMC10247640</pub-id></element-citation><mixed-citation id=\"mc-CR106\" publication-type=\"journal\">Jiang Z, Xie W, Zhou X, Pan W, Jiang S, Zhang X, et al. A virtual biopsy study of microsatellite instability in gastric cancer based on deep learning radiomics. Insights Imaging. 2023;14(1):104.<pub-id pub-id-type=\"pmid\">37286810</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1186/s13244-023-01438-1</pub-id><pub-id pub-id-type=\"pmcid\">PMC10247640</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR107\"><label>107.</label><citation-alternatives><element-citation id=\"ec-CR107\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Niehues</surname><given-names>JM</given-names></name><name name-style=\"western\"><surname>Quirke</surname><given-names>P</given-names></name><name name-style=\"western\"><surname>West</surname><given-names>NP</given-names></name><name name-style=\"western\"><surname>Grabsch</surname><given-names>HI</given-names></name><name name-style=\"western\"><surname>van Treeck</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Schirris</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Generalizable biomarker prediction from cancer pathology slides with self-supervised deep learning: a retrospective multi-centric study</article-title><source>Cell Rep Med</source><year>2023</year><pub-id pub-id-type=\"doi\">10.1016/j.xcrm.2023.100980</pub-id><pub-id pub-id-type=\"pmid\">36958327</pub-id><pub-id pub-id-type=\"pmcid\">PMC10140458</pub-id></element-citation><mixed-citation id=\"mc-CR107\" publication-type=\"journal\">Niehues JM, Quirke P, West NP, Grabsch HI, van Treeck M, Schirris Y, et al. Generalizable biomarker prediction from cancer pathology slides with self-supervised deep learning: a retrospective multi-centric study. Cell Rep Med. 2023. 10.1016/j.xcrm.2023.100980.<pub-id pub-id-type=\"pmid\">36958327</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/j.xcrm.2023.100980</pub-id><pub-id pub-id-type=\"pmcid\">PMC10140458</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR108\"><label>108.</label><citation-alternatives><element-citation id=\"ec-CR108\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Wagner</surname><given-names>SJ</given-names></name><name name-style=\"western\"><surname>Reisenb&#252;chler</surname><given-names>D</given-names></name><name name-style=\"western\"><surname>West</surname><given-names>NP</given-names></name><name name-style=\"western\"><surname>Niehues</surname><given-names>JM</given-names></name><name name-style=\"western\"><surname>Zhu</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Foersch</surname><given-names>S</given-names></name><etal/></person-group><article-title>Transformer-based biomarker prediction from colorectal cancer histology: A large-scale multicentric study</article-title><source>Cancer Cell</source><year>2023</year><volume>41</volume><issue>9</issue><fpage>1650</fpage><lpage>1661</lpage><pub-id pub-id-type=\"doi\">10.1016/j.ccell.2023.08.002</pub-id><pub-id pub-id-type=\"pmid\">37652006</pub-id><pub-id pub-id-type=\"pmcid\">PMC10507381</pub-id></element-citation><mixed-citation id=\"mc-CR108\" publication-type=\"journal\">Wagner SJ, Reisenb&#252;chler D, West NP, Niehues JM, Zhu J, Foersch S, et al. Transformer-based biomarker prediction from colorectal cancer histology: A large-scale multicentric study. Cancer Cell. 2023;41(9):1650&#8211;61.<pub-id pub-id-type=\"pmid\">37652006</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/j.ccell.2023.08.002</pub-id><pub-id pub-id-type=\"pmcid\">PMC10507381</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR109\"><label>109.</label><citation-alternatives><element-citation id=\"ec-CR109\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Gerwert</surname><given-names>K</given-names></name><name name-style=\"western\"><surname>Sch&#246;rner</surname><given-names>S</given-names></name><name name-style=\"western\"><surname>Gro&#223;erueschkamp</surname><given-names>F</given-names></name><name name-style=\"western\"><surname>Kraeft</surname><given-names>AL</given-names></name><name name-style=\"western\"><surname>Schuhmacher</surname><given-names>D</given-names></name><name name-style=\"western\"><surname>Sternemann</surname><given-names>C</given-names></name><etal/></person-group><article-title>Fast and label-free automated detection of microsatellite status in early colon cancer using artificial intelligence integrated infrared imaging</article-title><source>Eur J Cancer</source><year>2023</year><volume>182</volume><fpage>122</fpage><lpage>31</lpage><pub-id pub-id-type=\"doi\">10.1016/j.ejca.2022.12.026</pub-id><pub-id pub-id-type=\"pmid\">36773401</pub-id></element-citation><mixed-citation id=\"mc-CR109\" publication-type=\"journal\">Gerwert K, Sch&#246;rner S, Gro&#223;erueschkamp F, Kraeft AL, Schuhmacher D, Sternemann C, et al. Fast and label-free automated detection of microsatellite status in early colon cancer using artificial intelligence integrated infrared imaging. Eur J Cancer. 2023;182:122&#8211;31.<pub-id pub-id-type=\"pmid\">36773401</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/j.ejca.2022.12.026</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR110\"><label>110.</label><citation-alternatives><element-citation id=\"ec-CR110\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Saillard</surname><given-names>C</given-names></name><name name-style=\"western\"><surname>Dubois</surname><given-names>R</given-names></name><name name-style=\"western\"><surname>Tchita</surname><given-names>O</given-names></name><name name-style=\"western\"><surname>Loiseau</surname><given-names>N</given-names></name><name name-style=\"western\"><surname>Garcia</surname><given-names>T</given-names></name><name name-style=\"western\"><surname>Adriansen</surname><given-names>A</given-names></name><etal/></person-group><article-title>Validation of MSIntuit as an AI-based pre-screening tool for MSI detection from colorectal cancer histology slides</article-title><source>Nat Commun</source><year>2023</year><volume>14</volume><issue>1</issue><fpage>6695</fpage><pub-id pub-id-type=\"doi\">10.1038/s41467-023-42453-6</pub-id><pub-id pub-id-type=\"pmid\">37932267</pub-id><pub-id pub-id-type=\"pmcid\">PMC10628260</pub-id></element-citation><mixed-citation id=\"mc-CR110\" publication-type=\"journal\">Saillard C, Dubois R, Tchita O, Loiseau N, Garcia T, Adriansen A, et al. Validation of MSIntuit as an AI-based pre-screening tool for MSI detection from colorectal cancer histology slides. Nat Commun. 2023;14(1):6695.<pub-id pub-id-type=\"pmid\">37932267</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1038/s41467-023-42453-6</pub-id><pub-id pub-id-type=\"pmcid\">PMC10628260</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR111\"><label>111.</label><citation-alternatives><element-citation id=\"ec-CR111\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Zamanitajeddin</surname><given-names>N</given-names></name><name name-style=\"western\"><surname>Jahanifar</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Bilal</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Eastwood</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Rajpoot</surname><given-names>N</given-names></name></person-group><article-title>Social network analysis of cell networks improves deep learning for prediction of molecular pathways and key mutations in colorectal cancer</article-title><source>Med Image Anal</source><year>2024</year><volume>93</volume><fpage>103071</fpage><pub-id pub-id-type=\"doi\">10.1016/j.media.2023.103071</pub-id><pub-id pub-id-type=\"pmid\">38199068</pub-id></element-citation><mixed-citation id=\"mc-CR111\" publication-type=\"journal\">Zamanitajeddin N, Jahanifar M, Bilal M, Eastwood M, Rajpoot N. Social network analysis of cell networks improves deep learning for prediction of molecular pathways and key mutations in colorectal cancer. Med Image Anal. 2024;93:103071.<pub-id pub-id-type=\"pmid\">38199068</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/j.media.2023.103071</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR112\"><label>112.</label><citation-alternatives><element-citation id=\"ec-CR112\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Chang</surname><given-names>X</given-names></name><name name-style=\"western\"><surname>Wang</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Zhang</surname><given-names>G</given-names></name><name name-style=\"western\"><surname>Yang</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Xi</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Xi</surname><given-names>C</given-names></name><etal/></person-group><article-title>Predicting colorectal cancer microsatellite instability with a self-attention-enabled convolutional neural network</article-title><source>Cell Rep Med</source><year>2023</year><pub-id pub-id-type=\"doi\">10.1016/j.xcrm.2022.100914</pub-id><pub-id pub-id-type=\"pmid\">36720223</pub-id><pub-id pub-id-type=\"pmcid\">PMC9975100</pub-id></element-citation><mixed-citation id=\"mc-CR112\" publication-type=\"journal\">Chang X, Wang J, Zhang G, Yang M, Xi Y, Xi C, et al. Predicting colorectal cancer microsatellite instability with a self-attention-enabled convolutional neural network. Cell Rep Med. 2023. 10.1016/j.xcrm.2022.100914.<pub-id pub-id-type=\"pmid\">36720223</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/j.xcrm.2022.100914</pub-id><pub-id pub-id-type=\"pmcid\">PMC9975100</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR113\"><label>113.</label><citation-alternatives><element-citation id=\"ec-CR113\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Echle</surname><given-names>A</given-names></name><name name-style=\"western\"><surname>Laleh</surname><given-names>NG</given-names></name><name name-style=\"western\"><surname>Quirke</surname><given-names>P</given-names></name><name name-style=\"western\"><surname>Grabsch</surname><given-names>H</given-names></name><name name-style=\"western\"><surname>Muti</surname><given-names>H</given-names></name><name name-style=\"western\"><surname>Saldanha</surname><given-names>O</given-names></name><etal/></person-group><article-title>Artificial intelligence for detection of microsatellite instability in colorectal cancer&#8211;a multicentric analysis of a pre-screening tool for clinical application</article-title><source>ESMO open</source><year>2022</year><volume>7</volume><issue>2</issue><fpage>100400</fpage><pub-id pub-id-type=\"doi\">10.1016/j.esmoop.2022.100400</pub-id><pub-id pub-id-type=\"pmid\">35247870</pub-id><pub-id pub-id-type=\"pmcid\">PMC9058894</pub-id></element-citation><mixed-citation id=\"mc-CR113\" publication-type=\"journal\">Echle A, Laleh NG, Quirke P, Grabsch H, Muti H, Saldanha O, et al. Artificial intelligence for detection of microsatellite instability in colorectal cancer&#8211;a multicentric analysis of a pre-screening tool for clinical application. ESMO open. 2022;7(2):100400.<pub-id pub-id-type=\"pmid\">35247870</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/j.esmoop.2022.100400</pub-id><pub-id pub-id-type=\"pmcid\">PMC9058894</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR114\"><label>114.</label><citation-alternatives><element-citation id=\"ec-CR114\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Saldanha</surname><given-names>OL</given-names></name><name name-style=\"western\"><surname>Quirke</surname><given-names>P</given-names></name><name name-style=\"western\"><surname>West</surname><given-names>NP</given-names></name><name name-style=\"western\"><surname>James</surname><given-names>JA</given-names></name><name name-style=\"western\"><surname>Loughrey</surname><given-names>MB</given-names></name><name name-style=\"western\"><surname>Grabsch</surname><given-names>HI</given-names></name><etal/></person-group><article-title>Swarm learning for decentralized artificial intelligence in cancer histopathology</article-title><source>Nat Med</source><year>2022</year><volume>28</volume><issue>6</issue><fpage>1232</fpage><lpage>9</lpage><pub-id pub-id-type=\"doi\">10.1038/s41591-022-01768-5</pub-id><pub-id pub-id-type=\"pmid\">35469069</pub-id><pub-id pub-id-type=\"pmcid\">PMC9205774</pub-id></element-citation><mixed-citation id=\"mc-CR114\" publication-type=\"journal\">Saldanha OL, Quirke P, West NP, James JA, Loughrey MB, Grabsch HI, et al. Swarm learning for decentralized artificial intelligence in cancer histopathology. Nat Med. 2022;28(6):1232&#8211;9.<pub-id pub-id-type=\"pmid\">35469069</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1038/s41591-022-01768-5</pub-id><pub-id pub-id-type=\"pmcid\">PMC9205774</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR115\"><label>115.</label><citation-alternatives><element-citation id=\"ec-CR115\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Lou</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Xu</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Sun</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Fang</surname><given-names>A</given-names></name><name name-style=\"western\"><surname>Liu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Ppsnet: an improved deep learning model for microsatellite instability high prediction in colorectal cancer from whole slide images</article-title><source>Comput Methods Programs Biomed</source><year>2022</year><volume>225</volume><fpage>107095</fpage><pub-id pub-id-type=\"doi\">10.1016/j.cmpb.2022.107095</pub-id><pub-id pub-id-type=\"pmid\">36057226</pub-id></element-citation><mixed-citation id=\"mc-CR115\" publication-type=\"journal\">Lou J, Xu J, Zhang Y, Sun Y, Fang A, Liu J, et al. Ppsnet: an improved deep learning model for microsatellite instability high prediction in colorectal cancer from whole slide images. Comput Methods Programs Biomed. 2022;225:107095.<pub-id pub-id-type=\"pmid\">36057226</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/j.cmpb.2022.107095</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR116\"><label>116.</label><citation-alternatives><element-citation id=\"ec-CR116\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Blake</surname><given-names>N</given-names></name><name name-style=\"western\"><surname>Gaifulina</surname><given-names>R</given-names></name><name name-style=\"western\"><surname>Griffin</surname><given-names>LD</given-names></name><name name-style=\"western\"><surname>Bell</surname><given-names>IM</given-names></name><name name-style=\"western\"><surname>Rodriguez-Justo</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Thomas</surname><given-names>GM</given-names></name></person-group><article-title>Deep learning applied to Raman Spectroscopy for the detection of microsatellite instability/MMR deficient colorectal cancer</article-title><source>Cancers (Basel)</source><year>2023</year><volume>15</volume><issue>6</issue><fpage>1720</fpage><pub-id pub-id-type=\"doi\">10.3390/cancers15061720</pub-id><pub-id pub-id-type=\"pmid\">36980606</pub-id><pub-id pub-id-type=\"pmcid\">PMC10046611</pub-id></element-citation><mixed-citation id=\"mc-CR116\" publication-type=\"journal\">Blake N, Gaifulina R, Griffin LD, Bell IM, Rodriguez-Justo M, Thomas GM. Deep learning applied to Raman Spectroscopy for the detection of microsatellite instability/MMR deficient colorectal cancer. Cancers (Basel). 2023;15(6):1720.<pub-id pub-id-type=\"pmid\">36980606</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.3390/cancers15061720</pub-id><pub-id pub-id-type=\"pmcid\">PMC10046611</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR117\"><label>117.</label><citation-alternatives><element-citation id=\"ec-CR117\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Schirris</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Gavves</surname><given-names>E</given-names></name><name name-style=\"western\"><surname>Nederlof</surname><given-names>I</given-names></name><name name-style=\"western\"><surname>Horlings</surname><given-names>HM</given-names></name><name name-style=\"western\"><surname>Teuwen</surname><given-names>J</given-names></name></person-group><article-title>DeepSMILE: Contrastive self-supervised pre-training benefits MSI and HRD classification directly from H &amp;E whole-slide images in colorectal and breast cancer</article-title><source>Med Image Anal</source><year>2022</year><volume>79</volume><fpage>102464</fpage><pub-id pub-id-type=\"doi\">10.1016/j.media.2022.102464</pub-id><pub-id pub-id-type=\"pmid\">35596966</pub-id></element-citation><mixed-citation id=\"mc-CR117\" publication-type=\"journal\">Schirris Y, Gavves E, Nederlof I, Horlings HM, Teuwen J. DeepSMILE: Contrastive self-supervised pre-training benefits MSI and HRD classification directly from H &amp;E whole-slide images in colorectal and breast cancer. Med Image Anal. 2022;79:102464.<pub-id pub-id-type=\"pmid\">35596966</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/j.media.2022.102464</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR118\"><label>118.</label><citation-alternatives><element-citation id=\"ec-CR118\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Tsai</surname><given-names>PC</given-names></name><name name-style=\"western\"><surname>Lee</surname><given-names>TH</given-names></name><name name-style=\"western\"><surname>Kuo</surname><given-names>KC</given-names></name><name name-style=\"western\"><surname>Su</surname><given-names>FY</given-names></name><name name-style=\"western\"><surname>Lee</surname><given-names>TLM</given-names></name><name name-style=\"western\"><surname>Marostica</surname><given-names>E</given-names></name><etal/></person-group><article-title>Histopathology images predict multi-omics aberrations and prognoses in colorectal cancer patients</article-title><source>Nat Commun</source><year>2023</year><volume>14</volume><issue>1</issue><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type=\"doi\">10.1038/s41467-023-37179-4</pub-id><pub-id pub-id-type=\"pmid\">37055393</pub-id><pub-id pub-id-type=\"pmcid\">PMC10102208</pub-id></element-citation><mixed-citation id=\"mc-CR118\" publication-type=\"journal\">Tsai PC, Lee TH, Kuo KC, Su FY, Lee TLM, Marostica E, et al. Histopathology images predict multi-omics aberrations and prognoses in colorectal cancer patients. Nat Commun. 2023;14(1):1&#8211;13.<pub-id pub-id-type=\"pmid\">37055393</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1038/s41467-023-37179-4</pub-id><pub-id pub-id-type=\"pmcid\">PMC10102208</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR119\"><label>119.</label><citation-alternatives><element-citation id=\"ec-CR119\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Fujii</surname><given-names>S</given-names></name><name name-style=\"western\"><surname>Kotani</surname><given-names>D</given-names></name><name name-style=\"western\"><surname>Hattori</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Nishihara</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Shikanai</surname><given-names>T</given-names></name><name name-style=\"western\"><surname>Hashimoto</surname><given-names>J</given-names></name><etal/></person-group><article-title>Rapid screening using pathomorphologic interpretation to detect BRAF V600E mutation and microsatellite instability in colorectal cancer</article-title><source>Clin Cancer Res</source><year>2022</year><volume>28</volume><issue>12</issue><fpage>2623</fpage><lpage>32</lpage><pub-id pub-id-type=\"doi\">10.1158/1078-0432.CCR-21-4391</pub-id><pub-id pub-id-type=\"pmid\">35363302</pub-id></element-citation><mixed-citation id=\"mc-CR119\" publication-type=\"journal\">Fujii S, Kotani D, Hattori M, Nishihara M, Shikanai T, Hashimoto J, et al. Rapid screening using pathomorphologic interpretation to detect BRAF V600E mutation and microsatellite instability in colorectal cancer. Clin Cancer Res. 2022;28(12):2623&#8211;32.<pub-id pub-id-type=\"pmid\">35363302</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1158/1078-0432.CCR-21-4391</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR120\"><label>120.</label><citation-alternatives><element-citation id=\"ec-CR120\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Wang</surname><given-names>CW</given-names></name><name name-style=\"western\"><surname>Muzakky</surname><given-names>H</given-names></name><name name-style=\"western\"><surname>Firdi</surname><given-names>NP</given-names></name><name name-style=\"western\"><surname>Liu</surname><given-names>TC</given-names></name><name name-style=\"western\"><surname>Lai</surname><given-names>PJ</given-names></name><name name-style=\"western\"><surname>Wang</surname><given-names>YC</given-names></name><etal/></person-group><article-title>Deep learning to assess microsatellite instability directly from histopathological whole slide images in endometrial cancer</article-title><source>NPJ Digit Med</source><year>2024</year><volume>7</volume><issue>1</issue><fpage>143</fpage><pub-id pub-id-type=\"doi\">10.1038/s41746-024-01131-7</pub-id><pub-id pub-id-type=\"pmid\">38811811</pub-id><pub-id pub-id-type=\"pmcid\">PMC11137095</pub-id></element-citation><mixed-citation id=\"mc-CR120\" publication-type=\"journal\">Wang CW, Muzakky H, Firdi NP, Liu TC, Lai PJ, Wang YC, et al. Deep learning to assess microsatellite instability directly from histopathological whole slide images in endometrial cancer. NPJ Digit Med. 2024;7(1):143.<pub-id pub-id-type=\"pmid\">38811811</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1038/s41746-024-01131-7</pub-id><pub-id pub-id-type=\"pmcid\">PMC11137095</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR121\"><label>121.</label><citation-alternatives><element-citation id=\"ec-CR121\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Hu</surname><given-names>Q</given-names></name><name name-style=\"western\"><surname>Rizvi</surname><given-names>AA</given-names></name><name name-style=\"western\"><surname>Schau</surname><given-names>G</given-names></name><name name-style=\"western\"><surname>Ingale</surname><given-names>K</given-names></name><name name-style=\"western\"><surname>Muller</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Baits</surname><given-names>R</given-names></name><etal/></person-group><article-title>Development and validation of a deep learning-based microsatellite instability predictor from prostate cancer whole-slide images</article-title><source>NPJ Precis Oncol</source><year>2024</year><volume>8</volume><issue>1</issue><fpage>88</fpage><pub-id pub-id-type=\"doi\">10.1038/s41698-024-00560-7</pub-id><pub-id pub-id-type=\"pmid\">38594360</pub-id><pub-id pub-id-type=\"pmcid\">PMC11004110</pub-id></element-citation><mixed-citation id=\"mc-CR121\" publication-type=\"journal\">Hu Q, Rizvi AA, Schau G, Ingale K, Muller Y, Baits R, et al. Development and validation of a deep learning-based microsatellite instability predictor from prostate cancer whole-slide images. NPJ Precis Oncol. 2024;8(1):88.<pub-id pub-id-type=\"pmid\">38594360</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1038/s41698-024-00560-7</pub-id><pub-id pub-id-type=\"pmcid\">PMC11004110</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR122\"><label>122.</label><citation-alternatives><element-citation id=\"ec-CR122\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Wang</surname><given-names>CW</given-names></name><name name-style=\"western\"><surname>Lee</surname><given-names>YC</given-names></name><name name-style=\"western\"><surname>Lin</surname><given-names>YJ</given-names></name><name name-style=\"western\"><surname>Firdi</surname><given-names>NP</given-names></name><name name-style=\"western\"><surname>Muzakky</surname><given-names>H</given-names></name><name name-style=\"western\"><surname>Liu</surname><given-names>TC</given-names></name><etal/></person-group><article-title>Deep learning can predict bevacizumab therapeutic effect and microsatellite instability directly from histology in epithelial ovarian cancer</article-title><source>Lab Invest</source><year>2023</year><volume>103</volume><issue>11</issue><fpage>100247</fpage><pub-id pub-id-type=\"doi\">10.1016/j.labinv.2023.100247</pub-id><pub-id pub-id-type=\"pmid\">37741509</pub-id></element-citation><mixed-citation id=\"mc-CR122\" publication-type=\"journal\">Wang CW, Lee YC, Lin YJ, Firdi NP, Muzakky H, Liu TC, et al. Deep learning can predict bevacizumab therapeutic effect and microsatellite instability directly from histology in epithelial ovarian cancer. Lab Invest. 2023;103(11):100247.<pub-id pub-id-type=\"pmid\">37741509</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/j.labinv.2023.100247</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR123\"><label>123.</label><citation-alternatives><element-citation id=\"ec-CR123\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Su</surname><given-names>F</given-names></name><name name-style=\"western\"><surname>Li</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Zhao</surname><given-names>X</given-names></name><name name-style=\"western\"><surname>Wang</surname><given-names>B</given-names></name><name name-style=\"western\"><surname>Hu</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Sun</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Interpretable tumor differentiation grade and microsatellite instability recognition in gastric cancer using deep learning</article-title><source>Lab Invest</source><year>2022</year><volume>102</volume><issue>6</issue><fpage>641</fpage><lpage>9</lpage><pub-id pub-id-type=\"doi\">10.1038/s41374-022-00742-6</pub-id><pub-id pub-id-type=\"pmid\">35177797</pub-id></element-citation><mixed-citation id=\"mc-CR123\" publication-type=\"journal\">Su F, Li J, Zhao X, Wang B, Hu Y, Sun Y, et al. Interpretable tumor differentiation grade and microsatellite instability recognition in gastric cancer using deep learning. Lab Invest. 2022;102(6):641&#8211;9.<pub-id pub-id-type=\"pmid\">35177797</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1038/s41374-022-00742-6</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR124\"><label>124.</label><citation-alternatives><element-citation id=\"ec-CR124\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Lee</surname><given-names>SH</given-names></name><name name-style=\"western\"><surname>Lee</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Jang</surname><given-names>HJ</given-names></name></person-group><article-title>Deep learning captures selective features for discrimination of microsatellite instability from pathologic tissue slides of gastric cancer</article-title><source>Int J Cancer</source><year>2023</year><volume>152</volume><issue>2</issue><fpage>298</fpage><lpage>307</lpage><pub-id pub-id-type=\"doi\">10.1002/ijc.34251</pub-id><pub-id pub-id-type=\"pmid\">36054320</pub-id></element-citation><mixed-citation id=\"mc-CR124\" publication-type=\"journal\">Lee SH, Lee Y, Jang HJ. Deep learning captures selective features for discrimination of microsatellite instability from pathologic tissue slides of gastric cancer. Int J Cancer. 2023;152(2):298&#8211;307.<pub-id pub-id-type=\"pmid\">36054320</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1002/ijc.34251</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR125\"><label>125.</label><citation-alternatives><element-citation id=\"ec-CR125\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Nowak</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Jabbar</surname><given-names>F</given-names></name><name name-style=\"western\"><surname>Rodewald</surname><given-names>AK</given-names></name><name name-style=\"western\"><surname>Gneo</surname><given-names>L</given-names></name><name name-style=\"western\"><surname>Tomasevic</surname><given-names>T</given-names></name><name name-style=\"western\"><surname>Harkin</surname><given-names>A</given-names></name><etal/></person-group><article-title>Single-cell AI-based detection and prognostic and predictive value of DNA mismatch repair deficiency in colorectal cancer</article-title><source>Cell Rep Med</source><year>2024</year><pub-id pub-id-type=\"doi\">10.1016/j.xcrm.2024.101727</pub-id><pub-id pub-id-type=\"pmid\">39293403</pub-id><pub-id pub-id-type=\"pmcid\">PMC11525017</pub-id></element-citation><mixed-citation id=\"mc-CR125\" publication-type=\"journal\">Nowak M, Jabbar F, Rodewald AK, Gneo L, Tomasevic T, Harkin A, et al. Single-cell AI-based detection and prognostic and predictive value of DNA mismatch repair deficiency in colorectal cancer. Cell Rep Med. 2024. 10.1016/j.xcrm.2024.101727.<pub-id pub-id-type=\"pmid\">39293403</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/j.xcrm.2024.101727</pub-id><pub-id pub-id-type=\"pmcid\">PMC11525017</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR126\"><label>126.</label><citation-alternatives><element-citation id=\"ec-CR126\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Jiang</surname><given-names>W</given-names></name><name name-style=\"western\"><surname>Mei</surname><given-names>WJ</given-names></name><name name-style=\"western\"><surname>Xu</surname><given-names>SY</given-names></name><name name-style=\"western\"><surname>Ling</surname><given-names>YH</given-names></name><name name-style=\"western\"><surname>Li</surname><given-names>WR</given-names></name><name name-style=\"western\"><surname>Kuang</surname><given-names>JB</given-names></name><etal/></person-group><article-title>Clinical actionability of triaging DNA mismatch repair deficient colorectal cancer from biopsy samples using deep learning</article-title><source>EBioMedicine</source><year>2022</year><pub-id pub-id-type=\"doi\">10.1016/j.ebiom.2022.104120</pub-id><pub-id pub-id-type=\"pmid\">35753152</pub-id><pub-id pub-id-type=\"pmcid\">PMC9240789</pub-id></element-citation><mixed-citation id=\"mc-CR126\" publication-type=\"journal\">Jiang W, Mei WJ, Xu SY, Ling YH, Li WR, Kuang JB, et al. Clinical actionability of triaging DNA mismatch repair deficient colorectal cancer from biopsy samples using deep learning. EBioMedicine. 2022. 10.1016/j.ebiom.2022.104120.<pub-id pub-id-type=\"pmid\">35753152</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/j.ebiom.2022.104120</pub-id><pub-id pub-id-type=\"pmcid\">PMC9240789</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR127\"><label>127.</label><citation-alternatives><element-citation id=\"ec-CR127\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Whangbo</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Lee</surname><given-names>YS</given-names></name><name name-style=\"western\"><surname>Kim</surname><given-names>YJ</given-names></name><name name-style=\"western\"><surname>Kim</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Kim</surname><given-names>KG</given-names></name></person-group><article-title>Predicting mismatch repair deficiency status in endometrial cancer through multi-resolution ensemble learning in digital pathology</article-title><source>Journal of Imaging Informatics in Medicine</source><year>2024</year><volume>37</volume><issue>4</issue><fpage>1674</fpage><lpage>82</lpage><pub-id pub-id-type=\"doi\">10.1007/s10278-024-00997-z</pub-id><pub-id pub-id-type=\"pmid\">38378964</pub-id><pub-id pub-id-type=\"pmcid\">PMC11300772</pub-id></element-citation><mixed-citation id=\"mc-CR127\" publication-type=\"journal\">Whangbo J, Lee YS, Kim YJ, Kim J, Kim KG. Predicting mismatch repair deficiency status in endometrial cancer through multi-resolution ensemble learning in digital pathology. Journal of Imaging Informatics in Medicine. 2024;37(4):1674&#8211;82.<pub-id pub-id-type=\"pmid\">38378964</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1007/s10278-024-00997-z</pub-id><pub-id pub-id-type=\"pmcid\">PMC11300772</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR128\"><label>128.</label><citation-alternatives><element-citation id=\"ec-CR128\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Umemoto</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Mariya</surname><given-names>T</given-names></name><name name-style=\"western\"><surname>Nambu</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Nagata</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Horimai</surname><given-names>T</given-names></name><name name-style=\"western\"><surname>Sugita</surname><given-names>S</given-names></name><etal/></person-group><article-title>Prediction of mismatch repair status in endometrial cancer from histological slide images using various deep learning-based algorithms</article-title><source>Cancers (Basel)</source><year>2024</year><volume>16</volume><issue>10</issue><fpage>1810</fpage><pub-id pub-id-type=\"doi\">10.3390/cancers16101810</pub-id><pub-id pub-id-type=\"pmid\">38791889</pub-id><pub-id pub-id-type=\"pmcid\">PMC11119770</pub-id></element-citation><mixed-citation id=\"mc-CR128\" publication-type=\"journal\">Umemoto M, Mariya T, Nambu Y, Nagata M, Horimai T, Sugita S, et al. Prediction of mismatch repair status in endometrial cancer from histological slide images using various deep learning-based algorithms. Cancers (Basel). 2024;16(10):1810.<pub-id pub-id-type=\"pmid\">38791889</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.3390/cancers16101810</pub-id><pub-id pub-id-type=\"pmcid\">PMC11119770</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR129\"><label>129.</label><citation-alternatives><element-citation id=\"ec-CR129\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Swaerts</surname><given-names>K</given-names></name><name name-style=\"western\"><surname>Dedeurwaerdere</surname><given-names>F</given-names></name><name name-style=\"western\"><surname>De Smet</surname><given-names>D</given-names></name><name name-style=\"western\"><surname>De Jaeger</surname><given-names>P</given-names></name><name name-style=\"western\"><surname>Martens</surname><given-names>GA</given-names></name></person-group><article-title>DeltaMSI: artificial intelligence-based modeling of microsatellite instability scoring on next-generation sequencing data</article-title><source>BMC Bioinformatics</source><year>2023</year><volume>24</volume><issue>1</issue><fpage>73</fpage><pub-id pub-id-type=\"doi\">10.1186/s12859-023-05186-3</pub-id><pub-id pub-id-type=\"pmid\">36859168</pub-id><pub-id pub-id-type=\"pmcid\">PMC9976396</pub-id></element-citation><mixed-citation id=\"mc-CR129\" publication-type=\"journal\">Swaerts K, Dedeurwaerdere F, De Smet D, De Jaeger P, Martens GA. DeltaMSI: artificial intelligence-based modeling of microsatellite instability scoring on next-generation sequencing data. BMC Bioinformatics. 2023;24(1):73.<pub-id pub-id-type=\"pmid\">36859168</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1186/s12859-023-05186-3</pub-id><pub-id pub-id-type=\"pmcid\">PMC9976396</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR130\"><label>130.</label><citation-alternatives><element-citation id=\"ec-CR130\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Chen</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Wang</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Zhao</surname><given-names>D</given-names></name><name name-style=\"western\"><surname>Li</surname><given-names>F</given-names></name><name name-style=\"western\"><surname>Wu</surname><given-names>H</given-names></name><name name-style=\"western\"><surname>Liu</surname><given-names>Q</given-names></name><etal/></person-group><article-title>MSINGB: a novel computational method based on NGBoost for identifying microsatellite instability status from tumor mutation annotation data</article-title><source>Interdiscip Sci Comput Life Sci</source><year>2023</year><volume>15</volume><issue>1</issue><fpage>100</fpage><lpage>110</lpage><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1007/s12539-022-00544-w</pub-id><pub-id pub-id-type=\"pmid\">36350503</pub-id></element-citation><mixed-citation id=\"mc-CR130\" publication-type=\"journal\">Chen J, Wang M, Zhao D, Li F, Wu H, Liu Q, et al. MSINGB: a novel computational method based on NGBoost for identifying microsatellite instability status from tumor mutation annotation data. Interdiscip Sci Comput Life Sci. 2023;15(1):100&#8211;10.<pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1007/s12539-022-00544-w</pub-id><pub-id pub-id-type=\"pmid\">36350503</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR131\"><label>131.</label><citation-alternatives><element-citation id=\"ec-CR131\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Cao</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Wang</surname><given-names>D</given-names></name><name name-style=\"western\"><surname>Wu</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Yao</surname><given-names>Z</given-names></name><name name-style=\"western\"><surname>Shen</surname><given-names>S</given-names></name><name name-style=\"western\"><surname>Niu</surname><given-names>C</given-names></name><etal/></person-group><article-title>MSI-XGNN: an explainable GNN computational framework integrating transcription-and methylation-level biomarkers for microsatellite instability detection</article-title><source>Brief Bioinform</source><year>2023</year><volume>24</volume><issue>6</issue><fpage>bbad362</fpage><pub-id pub-id-type=\"doi\">10.1093/bib/bbad362</pub-id><pub-id pub-id-type=\"pmid\">37833839</pub-id></element-citation><mixed-citation id=\"mc-CR131\" publication-type=\"journal\">Cao Y, Wang D, Wu J, Yao Z, Shen S, Niu C, et al. MSI-XGNN: an explainable GNN computational framework integrating transcription-and methylation-level biomarkers for microsatellite instability detection. Brief Bioinform. 2023;24(6):bbad362.<pub-id pub-id-type=\"pmid\">37833839</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1093/bib/bbad362</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR132\"><label>132.</label><citation-alternatives><element-citation id=\"ec-CR132\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Shi</surname><given-names>B</given-names></name><name name-style=\"western\"><surname>Wang</surname><given-names>W</given-names></name><name name-style=\"western\"><surname>Fang</surname><given-names>S</given-names></name><name name-style=\"western\"><surname>Wu</surname><given-names>S</given-names></name><name name-style=\"western\"><surname>Zhu</surname><given-names>L</given-names></name><name name-style=\"western\"><surname>Chen</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Raman spectroscopy analysis combined with computed tomography imaging to identify microsatellite instability in gastric cancers</article-title><source>Spectrochim Acta A Mol Biomol Spectrosc</source><year>2025</year><volume>325</volume><fpage>125062</fpage><pub-id pub-id-type=\"doi\">10.1016/j.saa.2024.125062</pub-id><pub-id pub-id-type=\"pmid\">39226670</pub-id></element-citation><mixed-citation id=\"mc-CR132\" publication-type=\"journal\">Shi B, Wang W, Fang S, Wu S, Zhu L, Chen Y, et al. Raman spectroscopy analysis combined with computed tomography imaging to identify microsatellite instability in gastric cancers. Spectrochim Acta A Mol Biomol Spectrosc. 2025;325:125062.<pub-id pub-id-type=\"pmid\">39226670</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/j.saa.2024.125062</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR133\"><label>133.</label><citation-alternatives><element-citation id=\"ec-CR133\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Qiu</surname><given-names>W</given-names></name><name name-style=\"western\"><surname>Yang</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Wang</surname><given-names>B</given-names></name><name name-style=\"western\"><surname>Yang</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Tian</surname><given-names>G</given-names></name><name name-style=\"western\"><surname>Wang</surname><given-names>P</given-names></name></person-group><article-title>Evaluating the microsatellite instability of colorectal cancer based on multimodal deep learning integrating histopathological and molecular data</article-title><source>Front Oncol</source><year>2022</year><volume>12</volume><fpage>925079</fpage><pub-id pub-id-type=\"doi\">10.3389/fonc.2022.925079</pub-id><pub-id pub-id-type=\"pmid\">35865460</pub-id><pub-id pub-id-type=\"pmcid\">PMC9295995</pub-id></element-citation><mixed-citation id=\"mc-CR133\" publication-type=\"journal\">Qiu W, Yang J, Wang B, Yang M, Tian G, Wang P. Evaluating the microsatellite instability of colorectal cancer based on multimodal deep learning integrating histopathological and molecular data. Front Oncol. 2022;12:925079.<pub-id pub-id-type=\"pmid\">35865460</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.3389/fonc.2022.925079</pub-id><pub-id pub-id-type=\"pmcid\">PMC9295995</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR134\"><label>134.</label><citation-alternatives><element-citation id=\"ec-CR134\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Ma</surname><given-names>KL</given-names></name><name name-style=\"western\"><surname>Mitchell</surname><given-names>TC</given-names></name><name name-style=\"western\"><surname>Dougher</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Sharon</surname><given-names>CE</given-names></name><name name-style=\"western\"><surname>Tortorello</surname><given-names>GN</given-names></name><name name-style=\"western\"><surname>Elder</surname><given-names>DE</given-names></name><etal/></person-group><article-title>Tumor-infiltrating lymphocytes in necrotic tumors after melanoma neoadjuvant anti-PD-1 therapy correlate with pathologic response and recurrence-free survival</article-title><source>Clin Cancer Res</source><year>2024</year><volume>30</volume><issue>21</issue><fpage>4987</fpage><lpage>94</lpage><pub-id pub-id-type=\"doi\">10.1158/1078-0432.CCR-23-3775</pub-id><pub-id pub-id-type=\"pmid\">39248505</pub-id><pub-id pub-id-type=\"pmcid\">PMC11539852</pub-id></element-citation><mixed-citation id=\"mc-CR134\" publication-type=\"journal\">Ma KL, Mitchell TC, Dougher M, Sharon CE, Tortorello GN, Elder DE, et al. Tumor-infiltrating lymphocytes in necrotic tumors after melanoma neoadjuvant anti-PD-1 therapy correlate with pathologic response and recurrence-free survival. Clin Cancer Res. 2024;30(21):4987&#8211;94.<pub-id pub-id-type=\"pmid\">39248505</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1158/1078-0432.CCR-23-3775</pub-id><pub-id pub-id-type=\"pmcid\">PMC11539852</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR135\"><label>135.</label><citation-alternatives><element-citation id=\"ec-CR135\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Wood</surname><given-names>SJ</given-names></name><name name-style=\"western\"><surname>Gao</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Lee</surname><given-names>JH</given-names></name><name name-style=\"western\"><surname>Chen</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Wang</surname><given-names>Q</given-names></name><name name-style=\"western\"><surname>Meisel</surname><given-names>JL</given-names></name><etal/></person-group><article-title>High tumor infiltrating lymphocytes are significantly associated with pathological complete response in triple negative breast cancer treated with neoadjuvant KEYNOTE-522 chemoimmunotherapy</article-title><source>Breast Cancer Res Treat</source><year>2024</year><volume>205</volume><issue>1</issue><fpage>193</fpage><lpage>9</lpage><pub-id pub-id-type=\"doi\">10.1007/s10549-023-07233-2</pub-id><pub-id pub-id-type=\"pmid\">38286889</pub-id></element-citation><mixed-citation id=\"mc-CR135\" publication-type=\"journal\">Wood SJ, Gao Y, Lee JH, Chen J, Wang Q, Meisel JL, et al. High tumor infiltrating lymphocytes are significantly associated with pathological complete response in triple negative breast cancer treated with neoadjuvant KEYNOTE-522 chemoimmunotherapy. Breast Cancer Res Treat. 2024;205(1):193&#8211;9.<pub-id pub-id-type=\"pmid\">38286889</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1007/s10549-023-07233-2</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR136\"><label>136.</label><citation-alternatives><element-citation id=\"ec-CR136\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Wolf</surname><given-names>GT</given-names></name><name name-style=\"western\"><surname>Liu</surname><given-names>S</given-names></name><name name-style=\"western\"><surname>Bellile</surname><given-names>E</given-names></name><name name-style=\"western\"><surname>Sartor</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Rozek</surname><given-names>L</given-names></name><name name-style=\"western\"><surname>Thomas</surname><given-names>D</given-names></name><etal/></person-group><article-title>Tumor infiltrating lymphocytes after neoadjuvant IRX-2 immunotherapy in oral squamous cell carcinoma: interim findings from the INSPIRE trial</article-title><source>Oral Oncol</source><year>2020</year><volume>111</volume><fpage>104928</fpage><pub-id pub-id-type=\"doi\">10.1016/j.oraloncology.2020.104928</pub-id><pub-id pub-id-type=\"pmid\">32738599</pub-id></element-citation><mixed-citation id=\"mc-CR136\" publication-type=\"journal\">Wolf GT, Liu S, Bellile E, Sartor M, Rozek L, Thomas D, et al. Tumor infiltrating lymphocytes after neoadjuvant IRX-2 immunotherapy in oral squamous cell carcinoma: interim findings from the INSPIRE trial. Oral Oncol. 2020;111:104928.<pub-id pub-id-type=\"pmid\">32738599</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/j.oraloncology.2020.104928</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR137\"><label>137.</label><citation-alternatives><element-citation id=\"ec-CR137\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Liu</surname><given-names>R</given-names></name><name name-style=\"western\"><surname>Yang</surname><given-names>F</given-names></name><name name-style=\"western\"><surname>Yin</surname><given-names>JY</given-names></name><name name-style=\"western\"><surname>Liu</surname><given-names>YZ</given-names></name><name name-style=\"western\"><surname>Zhang</surname><given-names>W</given-names></name><name name-style=\"western\"><surname>Zhou</surname><given-names>HH</given-names></name></person-group><article-title>Influence of tumor immune infiltration on immune checkpoint inhibitor therapeutic efficacy: a computational retrospective study</article-title><source>Front Immunol</source><year>2021</year><volume>12</volume><fpage>685370</fpage><pub-id pub-id-type=\"doi\">10.3389/fimmu.2021.685370</pub-id><pub-id pub-id-type=\"pmid\">34220837</pub-id><pub-id pub-id-type=\"pmcid\">PMC8248490</pub-id></element-citation><mixed-citation id=\"mc-CR137\" publication-type=\"journal\">Liu R, Yang F, Yin JY, Liu YZ, Zhang W, Zhou HH. Influence of tumor immune infiltration on immune checkpoint inhibitor therapeutic efficacy: a computational retrospective study. Front Immunol. 2021;12:685370.<pub-id pub-id-type=\"pmid\">34220837</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.3389/fimmu.2021.685370</pub-id><pub-id pub-id-type=\"pmcid\">PMC8248490</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR138\"><label>138.</label><citation-alternatives><element-citation id=\"ec-CR138\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Zheng</surname><given-names>DD</given-names></name><name name-style=\"western\"><surname>Li</surname><given-names>YY</given-names></name><name name-style=\"western\"><surname>Yuan</surname><given-names>XY</given-names></name><name name-style=\"western\"><surname>Lu</surname><given-names>JL</given-names></name><name name-style=\"western\"><surname>Zhang</surname><given-names>MF</given-names></name><name name-style=\"western\"><surname>Fu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Immune cell patterns before and after neoadjuvant immune checkpoint blockade combined with chemoradiotherapy in locally advanced esophageal squamous cell carcinoma</article-title><source>BMC Cancer</source><year>2024</year><volume>24</volume><issue>1</issue><fpage>649</fpage><pub-id pub-id-type=\"doi\">10.1186/s12885-024-12406-3</pub-id><pub-id pub-id-type=\"pmid\">38802821</pub-id><pub-id pub-id-type=\"pmcid\">PMC11129487</pub-id></element-citation><mixed-citation id=\"mc-CR138\" publication-type=\"journal\">Zheng DD, Li YY, Yuan XY, Lu JL, Zhang MF, Fu J, et al. Immune cell patterns before and after neoadjuvant immune checkpoint blockade combined with chemoradiotherapy in locally advanced esophageal squamous cell carcinoma. BMC Cancer. 2024;24(1):649.<pub-id pub-id-type=\"pmid\">38802821</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1186/s12885-024-12406-3</pub-id><pub-id pub-id-type=\"pmcid\">PMC11129487</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR139\"><label>139.</label><citation-alternatives><element-citation id=\"ec-CR139\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Yam</surname><given-names>C</given-names></name><name name-style=\"western\"><surname>Yen</surname><given-names>EY</given-names></name><name name-style=\"western\"><surname>Chang</surname><given-names>JT</given-names></name><name name-style=\"western\"><surname>Bassett</surname><given-names>RL</given-names></name><name name-style=\"western\"><surname>Alatrash</surname><given-names>G</given-names></name><name name-style=\"western\"><surname>Garber</surname><given-names>H</given-names></name><etal/></person-group><article-title>Immune phenotype and response to neoadjuvant therapy in triple-negative breast cancer</article-title><source>Clin Cancer Res</source><year>2021</year><volume>27</volume><issue>19</issue><fpage>5365</fpage><lpage>75</lpage><pub-id pub-id-type=\"doi\">10.1158/1078-0432.CCR-21-0144</pub-id><pub-id pub-id-type=\"pmid\">34253579</pub-id><pub-id pub-id-type=\"pmcid\">PMC8752638</pub-id></element-citation><mixed-citation id=\"mc-CR139\" publication-type=\"journal\">Yam C, Yen EY, Chang JT, Bassett RL Jr, Alatrash G, Garber H, et al. Immune phenotype and response to neoadjuvant therapy in triple-negative breast cancer. Clin Cancer Res. 2021;27(19):5365&#8211;75.<pub-id pub-id-type=\"pmid\">34253579</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1158/1078-0432.CCR-21-0144</pub-id><pub-id pub-id-type=\"pmcid\">PMC8752638</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR140\"><label>140.</label><citation-alternatives><element-citation id=\"ec-CR140\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Yamaguchi</surname><given-names>H</given-names></name><name name-style=\"western\"><surname>Hsu</surname><given-names>JM</given-names></name><name name-style=\"western\"><surname>Sun</surname><given-names>L</given-names></name><name name-style=\"western\"><surname>Wang</surname><given-names>SC</given-names></name><name name-style=\"western\"><surname>Hung</surname><given-names>MC</given-names></name></person-group><article-title>Advances and prospects of biomarkers for immune checkpoint inhibitors</article-title><source>Cell Rep Med</source><year>2024</year><pub-id pub-id-type=\"doi\">10.1016/j.xcrm.2024.101621</pub-id><pub-id pub-id-type=\"pmid\">38906149</pub-id><pub-id pub-id-type=\"pmcid\">PMC11293349</pub-id></element-citation><mixed-citation id=\"mc-CR140\" publication-type=\"journal\">Yamaguchi H, Hsu JM, Sun L, Wang SC, Hung MC. Advances and prospects of biomarkers for immune checkpoint inhibitors. Cell Rep Med. 2024. 10.1016/j.xcrm.2024.101621.<pub-id pub-id-type=\"pmid\">38906149</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/j.xcrm.2024.101621</pub-id><pub-id pub-id-type=\"pmcid\">PMC11293349</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR141\"><label>141.</label><citation-alternatives><element-citation id=\"ec-CR141\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Cheng</surname><given-names>N</given-names></name><name name-style=\"western\"><surname>Wang</surname><given-names>B</given-names></name><name name-style=\"western\"><surname>Xu</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Xue</surname><given-names>L</given-names></name><name name-style=\"western\"><surname>Ying</surname><given-names>J</given-names></name></person-group><article-title>Tumor stroma ratio, tumor stroma maturity, tumor-infiltrating immune cells in relation to prognosis, and neoadjuvant therapy response in esophagogastric junction adenocarcinoma</article-title><source>Virchows Arch</source><year>2024</year><pub-id pub-id-type=\"doi\">10.1007/s00428-024-03755-2</pub-id><pub-id pub-id-type=\"pmid\">38383941</pub-id></element-citation><mixed-citation id=\"mc-CR141\" publication-type=\"journal\">Cheng N, Wang B, Xu J, Xue L, Ying J. Tumor stroma ratio, tumor stroma maturity, tumor-infiltrating immune cells in relation to prognosis, and neoadjuvant therapy response in esophagogastric junction adenocarcinoma. Virchows Arch. 2024. 10.1007/s00428-024-03755-2.<pub-id pub-id-type=\"pmid\">38383941</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1007/s00428-024-03755-2</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR142\"><label>142.</label><citation-alternatives><element-citation id=\"ec-CR142\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Wang</surname><given-names>Q</given-names></name><name name-style=\"western\"><surname>Zhong</surname><given-names>W</given-names></name><name name-style=\"western\"><surname>Shen</surname><given-names>X</given-names></name><name name-style=\"western\"><surname>Hao</surname><given-names>Z</given-names></name><name name-style=\"western\"><surname>Wan</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Yang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Tertiary lymphoid structures predict survival and response to neoadjuvant therapy in locally advanced rectal cancer</article-title><source>NPJ Precis Oncol</source><year>2024</year><volume>8</volume><issue>1</issue><fpage>61</fpage><pub-id pub-id-type=\"doi\">10.1038/s41698-024-00533-w</pub-id><pub-id pub-id-type=\"pmid\">38431733</pub-id><pub-id pub-id-type=\"pmcid\">PMC10908779</pub-id></element-citation><mixed-citation id=\"mc-CR142\" publication-type=\"journal\">Wang Q, Zhong W, Shen X, Hao Z, Wan M, Yang X, et al. Tertiary lymphoid structures predict survival and response to neoadjuvant therapy in locally advanced rectal cancer. NPJ Precis Oncol. 2024;8(1):61.<pub-id pub-id-type=\"pmid\">38431733</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1038/s41698-024-00533-w</pub-id><pub-id pub-id-type=\"pmcid\">PMC10908779</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR143\"><label>143.</label><citation-alternatives><element-citation id=\"ec-CR143\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Krishnamoorthy</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Lenehan</surname><given-names>JG</given-names></name><name name-style=\"western\"><surname>Maleki Vareki</surname><given-names>S</given-names></name></person-group><article-title>Neoadjuvant immunotherapy for high-risk, resectable malignancies: scientific rationale and clinical challenges</article-title><source>JNCI J Natl Cancer Inst</source><year>2021</year><volume>113</volume><issue>7</issue><fpage>823</fpage><lpage>32</lpage><pub-id pub-id-type=\"doi\">10.1093/jnci/djaa216</pub-id><pub-id pub-id-type=\"pmid\">33432320</pub-id><pub-id pub-id-type=\"pmcid\">PMC8246900</pub-id></element-citation><mixed-citation id=\"mc-CR143\" publication-type=\"journal\">Krishnamoorthy M, Lenehan JG, Maleki Vareki S. Neoadjuvant immunotherapy for high-risk, resectable malignancies: scientific rationale and clinical challenges. JNCI J Natl Cancer Inst. 2021;113(7):823&#8211;32.<pub-id pub-id-type=\"pmid\">33432320</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1093/jnci/djaa216</pub-id><pub-id pub-id-type=\"pmcid\">PMC8246900</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR144\"><label>144.</label><citation-alternatives><element-citation id=\"ec-CR144\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Kang</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Zhang</surname><given-names>C</given-names></name><name name-style=\"western\"><surname>Zhong</surname><given-names>WZ</given-names></name></person-group><article-title>Neoadjuvant immunotherapy for non-small cell lung cancer: state of the art</article-title><source>Cancer Commun</source><year>2021</year><volume>41</volume><issue>4</issue><fpage>287</fpage><lpage>302</lpage><pub-id pub-id-type=\"doi\">10.1002/cac2.12153</pub-id><pub-id pub-id-type=\"pmcid\">PMC8045926</pub-id><pub-id pub-id-type=\"pmid\">33689225</pub-id></element-citation><mixed-citation id=\"mc-CR144\" publication-type=\"journal\">Kang J, Zhang C, Zhong WZ. Neoadjuvant immunotherapy for non-small cell lung cancer: state of the art. Cancer Commun. 2021;41(4):287&#8211;302.<pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1002/cac2.12153</pub-id><pub-id pub-id-type=\"pmcid\">PMC8045926</pub-id><pub-id pub-id-type=\"pmid\">33689225</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR145\"><label>145.</label><citation-alternatives><element-citation id=\"ec-CR145\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Wu</surname><given-names>R</given-names></name><name name-style=\"western\"><surname>Jia</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Li</surname><given-names>N</given-names></name><name name-style=\"western\"><surname>Lu</surname><given-names>X</given-names></name><name name-style=\"western\"><surname>Yao</surname><given-names>Z</given-names></name><name name-style=\"western\"><surname>Ma</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Evaluation of breast cancer tumor-infiltrating lymphocytes on ultrasound images based on a novel multi-cascade residual U-shaped network</article-title><source>Ultrasound Med Biol</source><year>2023</year><volume>49</volume><issue>11</issue><fpage>2398</fpage><lpage>406</lpage><pub-id pub-id-type=\"doi\">10.1016/j.ultrasmedbio.2023.08.003</pub-id><pub-id pub-id-type=\"pmid\">37634979</pub-id></element-citation><mixed-citation id=\"mc-CR145\" publication-type=\"journal\">Wu R, Jia Y, Li N, Lu X, Yao Z, Ma Y, et al. Evaluation of breast cancer tumor-infiltrating lymphocytes on ultrasound images based on a novel multi-cascade residual U-shaped network. Ultrasound Med Biol. 2023;49(11):2398&#8211;406.<pub-id pub-id-type=\"pmid\">37634979</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/j.ultrasmedbio.2023.08.003</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR146\"><label>146.</label><citation-alternatives><element-citation id=\"ec-CR146\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Jia</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Wu</surname><given-names>R</given-names></name><name name-style=\"western\"><surname>Lu</surname><given-names>X</given-names></name><name name-style=\"western\"><surname>Duan</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Zhu</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Ma</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Deep learning with transformer or convolutional neural network in the assessment of tumor-infiltrating lymphocytes (TILs) in breast cancer based on US images: a dual-center retrospective study</article-title><source>Cancers (Basel)</source><year>2023</year><volume>15</volume><issue>3</issue><fpage>838</fpage><pub-id pub-id-type=\"doi\">10.3390/cancers15030838</pub-id><pub-id pub-id-type=\"pmid\">36765796</pub-id><pub-id pub-id-type=\"pmcid\">PMC9913836</pub-id></element-citation><mixed-citation id=\"mc-CR146\" publication-type=\"journal\">Jia Y, Wu R, Lu X, Duan Y, Zhu Y, Ma Y, et al. Deep learning with transformer or convolutional neural network in the assessment of tumor-infiltrating lymphocytes (TILs) in breast cancer based on US images: a dual-center retrospective study. Cancers (Basel). 2023;15(3):838.<pub-id pub-id-type=\"pmid\">36765796</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.3390/cancers15030838</pub-id><pub-id pub-id-type=\"pmcid\">PMC9913836</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR147\"><label>147.</label><citation-alternatives><element-citation id=\"ec-CR147\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Zhang</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Li</surname><given-names>X</given-names></name><name name-style=\"western\"><surname>Zhou</surname><given-names>P</given-names></name><name name-style=\"western\"><surname>Zhang</surname><given-names>P</given-names></name><name name-style=\"western\"><surname>Wang</surname><given-names>G</given-names></name><name name-style=\"western\"><surname>Lin</surname><given-names>X</given-names></name></person-group><article-title>Prediction value study of breast cancer tumor infiltrating lymphocyte levels based on ultrasound imaging radiomics</article-title><source>Front Oncol</source><year>2024</year><volume>14</volume><fpage>1411261</fpage><pub-id pub-id-type=\"doi\">10.3389/fonc.2024.1411261</pub-id><pub-id pub-id-type=\"pmid\">38903726</pub-id><pub-id pub-id-type=\"pmcid\">PMC11187250</pub-id></element-citation><mixed-citation id=\"mc-CR147\" publication-type=\"journal\">Zhang M, Li X, Zhou P, Zhang P, Wang G, Lin X. Prediction value study of breast cancer tumor infiltrating lymphocyte levels based on ultrasound imaging radiomics. Front Oncol. 2024;14:1411261.<pub-id pub-id-type=\"pmid\">38903726</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.3389/fonc.2024.1411261</pub-id><pub-id pub-id-type=\"pmcid\">PMC11187250</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR148\"><label>148.</label><citation-alternatives><element-citation id=\"ec-CR148\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Hu</surname><given-names>L</given-names></name><name name-style=\"western\"><surname>Jin</surname><given-names>P</given-names></name><name name-style=\"western\"><surname>Xu</surname><given-names>W</given-names></name><name name-style=\"western\"><surname>Wang</surname><given-names>C</given-names></name><name name-style=\"western\"><surname>Huang</surname><given-names>P</given-names></name></person-group><article-title>Clinical and radiomics integrated nomogram for preoperative prediction of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer</article-title><source>Front Oncol</source><year>2024</year><volume>14</volume><fpage>1370466</fpage><pub-id pub-id-type=\"doi\">10.3389/fonc.2024.1370466</pub-id><pub-id pub-id-type=\"pmid\">38567151</pub-id><pub-id pub-id-type=\"pmcid\">PMC10985173</pub-id></element-citation><mixed-citation id=\"mc-CR148\" publication-type=\"journal\">Hu L, Jin P, Xu W, Wang C, Huang P. Clinical and radiomics integrated nomogram for preoperative prediction of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer. Front Oncol. 2024;14:1370466.<pub-id pub-id-type=\"pmid\">38567151</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.3389/fonc.2024.1370466</pub-id><pub-id pub-id-type=\"pmcid\">PMC10985173</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR149\"><label>149.</label><mixed-citation publication-type=\"other\">Lu X, Jia Y, Zhang H, Wu R, Zhao W, Yao Z, et&#160;al. Deep learning&#8211;based and BI-RADS guided radiomics model for tumour-infiltrating lymphocytes evaluation in breast cancer. Br J Radiol. 2024;p. tqae129.<pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1093/bjr/tqae129</pub-id><pub-id pub-id-type=\"pmid\">38995740</pub-id></mixed-citation></ref><ref id=\"CR150\"><label>150.</label><citation-alternatives><element-citation id=\"ec-CR150\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Su</surname><given-names>GH</given-names></name><name name-style=\"western\"><surname>Xiao</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Jiang</surname><given-names>L</given-names></name><name name-style=\"western\"><surname>Zheng</surname><given-names>RC</given-names></name><name name-style=\"western\"><surname>Wang</surname><given-names>H</given-names></name><name name-style=\"western\"><surname>Chen</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Radiomics features for assessing tumor-infiltrating lymphocytes correlate with molecular traits of triple-negative breast cancer</article-title><source>J Transl Med</source><year>2022</year><volume>20</volume><issue>1</issue><fpage>471</fpage><pub-id pub-id-type=\"doi\">10.1186/s12967-022-03688-x</pub-id><pub-id pub-id-type=\"pmid\">36243806</pub-id><pub-id pub-id-type=\"pmcid\">PMC9571493</pub-id></element-citation><mixed-citation id=\"mc-CR150\" publication-type=\"journal\">Su GH, Xiao Y, Jiang L, Zheng RC, Wang H, Chen Y, et al. Radiomics features for assessing tumor-infiltrating lymphocytes correlate with molecular traits of triple-negative breast cancer. J Transl Med. 2022;20(1):471.<pub-id pub-id-type=\"pmid\">36243806</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1186/s12967-022-03688-x</pub-id><pub-id pub-id-type=\"pmcid\">PMC9571493</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR151\"><label>151.</label><citation-alternatives><element-citation id=\"ec-CR151\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Jeon</surname><given-names>SH</given-names></name><name name-style=\"western\"><surname>Kim</surname><given-names>SW</given-names></name><name name-style=\"western\"><surname>Na</surname><given-names>K</given-names></name><name name-style=\"western\"><surname>Seo</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Sohn</surname><given-names>YM</given-names></name><name name-style=\"western\"><surname>Lim</surname><given-names>YJ</given-names></name></person-group><article-title>Radiomic models based on magnetic resonance imaging predict the spatial distribution of CD8+ tumor-infiltrating lymphocytes in breast cancer</article-title><source>Front Immunol</source><year>2022</year><volume>13</volume><fpage>1080048</fpage><pub-id pub-id-type=\"doi\">10.3389/fimmu.2022.1080048</pub-id><pub-id pub-id-type=\"pmid\">36601118</pub-id><pub-id pub-id-type=\"pmcid\">PMC9806253</pub-id></element-citation><mixed-citation id=\"mc-CR151\" publication-type=\"journal\">Jeon SH, Kim SW, Na K, Seo M, Sohn YM, Lim YJ. Radiomic models based on magnetic resonance imaging predict the spatial distribution of CD8+ tumor-infiltrating lymphocytes in breast cancer. Front Immunol. 2022;13:1080048.<pub-id pub-id-type=\"pmid\">36601118</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.3389/fimmu.2022.1080048</pub-id><pub-id pub-id-type=\"pmcid\">PMC9806253</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR152\"><label>152.</label><citation-alternatives><element-citation id=\"ec-CR152\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Qian</surname><given-names>H</given-names></name><name name-style=\"western\"><surname>Ren</surname><given-names>X</given-names></name><name name-style=\"western\"><surname>Xu</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Fang</surname><given-names>Z</given-names></name><name name-style=\"western\"><surname>Zhang</surname><given-names>R</given-names></name><name name-style=\"western\"><surname>Bu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Magnetic resonance imaging-based radiomics was used to evaluate the level of prognosis-related immune cell infiltration in breast cancer tumor microenvironment</article-title><source>BMC Med Imaging</source><year>2024</year><volume>24</volume><issue>1</issue><fpage>31</fpage><pub-id pub-id-type=\"doi\">10.1186/s12880-024-01212-9</pub-id><pub-id pub-id-type=\"pmid\">38308230</pub-id><pub-id pub-id-type=\"pmcid\">PMC10835863</pub-id></element-citation><mixed-citation id=\"mc-CR152\" publication-type=\"journal\">Qian H, Ren X, Xu M, Fang Z, Zhang R, Bu Y, et al. Magnetic resonance imaging-based radiomics was used to evaluate the level of prognosis-related immune cell infiltration in breast cancer tumor microenvironment. BMC Med Imaging. 2024;24(1):31.<pub-id pub-id-type=\"pmid\">38308230</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1186/s12880-024-01212-9</pub-id><pub-id pub-id-type=\"pmcid\">PMC10835863</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR153\"><label>153.</label><citation-alternatives><element-citation id=\"ec-CR153\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Ren</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Yang</surname><given-names>G</given-names></name><name name-style=\"western\"><surname>Song</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Zhang</surname><given-names>C</given-names></name><name name-style=\"western\"><surname>Yuan</surname><given-names>Y</given-names></name></person-group><article-title>Machine learning-based MRI radiomics for assessing the level of tumor infiltrating lymphocytes in oral tongue squamous cell carcinoma: a pilot study</article-title><source>BMC Med Imaging</source><year>2024</year><volume>24</volume><issue>1</issue><fpage>33</fpage><pub-id pub-id-type=\"doi\">10.1186/s12880-024-01210-x</pub-id><pub-id pub-id-type=\"pmid\">38317076</pub-id><pub-id pub-id-type=\"pmcid\">PMC10845803</pub-id></element-citation><mixed-citation id=\"mc-CR153\" publication-type=\"journal\">Ren J, Yang G, Song Y, Zhang C, Yuan Y. Machine learning-based MRI radiomics for assessing the level of tumor infiltrating lymphocytes in oral tongue squamous cell carcinoma: a pilot study. BMC Med Imaging. 2024;24(1):33.<pub-id pub-id-type=\"pmid\">38317076</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1186/s12880-024-01210-x</pub-id><pub-id pub-id-type=\"pmcid\">PMC10845803</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR154\"><label>154.</label><citation-alternatives><element-citation id=\"ec-CR154\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Huang</surname><given-names>H</given-names></name><name name-style=\"western\"><surname>Li</surname><given-names>Z</given-names></name><name name-style=\"western\"><surname>Wang</surname><given-names>D</given-names></name><name name-style=\"western\"><surname>Yang</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Jin</surname><given-names>H</given-names></name><name name-style=\"western\"><surname>Lu</surname><given-names>Z</given-names></name></person-group><article-title>Machine learning models based on quantitative dynamic contrast-enhanced MRI parameters assess the expression levels of CD3+, CD4+, and CD8+ tumor-infiltrating lymphocytes in advanced gastric carcinoma</article-title><source>Front Oncol</source><year>2024</year><volume>14</volume><fpage>1365550</fpage><pub-id pub-id-type=\"doi\">10.3389/fonc.2024.1365550</pub-id><pub-id pub-id-type=\"pmid\">38549936</pub-id><pub-id pub-id-type=\"pmcid\">PMC10973004</pub-id></element-citation><mixed-citation id=\"mc-CR154\" publication-type=\"journal\">Huang H, Li Z, Wang D, Yang Y, Jin H, Lu Z. Machine learning models based on quantitative dynamic contrast-enhanced MRI parameters assess the expression levels of CD3+, CD4+, and CD8+ tumor-infiltrating lymphocytes in advanced gastric carcinoma. Front Oncol. 2024;14:1365550.<pub-id pub-id-type=\"pmid\">38549936</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.3389/fonc.2024.1365550</pub-id><pub-id pub-id-type=\"pmcid\">PMC10973004</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR155\"><label>155.</label><citation-alternatives><element-citation id=\"ec-CR155\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Li</surname><given-names>G</given-names></name><name name-style=\"western\"><surname>Li</surname><given-names>L</given-names></name><name name-style=\"western\"><surname>Li</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Qian</surname><given-names>Z</given-names></name><name name-style=\"western\"><surname>Wu</surname><given-names>F</given-names></name><name name-style=\"western\"><surname>He</surname><given-names>Y</given-names></name><etal/></person-group><article-title>An MRI radiomics approach to predict survival and tumour-infiltrating macrophages in gliomas</article-title><source>Brain</source><year>2022</year><volume>145</volume><issue>3</issue><fpage>1151</fpage><lpage>61</lpage><pub-id pub-id-type=\"doi\">10.1093/brain/awab340</pub-id><pub-id pub-id-type=\"pmid\">35136934</pub-id><pub-id pub-id-type=\"pmcid\">PMC9050568</pub-id></element-citation><mixed-citation id=\"mc-CR155\" publication-type=\"journal\">Li G, Li L, Li Y, Qian Z, Wu F, He Y, et al. An MRI radiomics approach to predict survival and tumour-infiltrating macrophages in gliomas. Brain. 2022;145(3):1151&#8211;61.<pub-id pub-id-type=\"pmid\">35136934</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1093/brain/awab340</pub-id><pub-id pub-id-type=\"pmcid\">PMC9050568</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR156\"><label>156.</label><citation-alternatives><element-citation id=\"ec-CR156\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>He</surname><given-names>H</given-names></name><name name-style=\"western\"><surname>Jin</surname><given-names>Z</given-names></name><name name-style=\"western\"><surname>Dai</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Wang</surname><given-names>H</given-names></name><name name-style=\"western\"><surname>Sun</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Xu</surname><given-names>D</given-names></name></person-group><article-title>Computed tomography-based radiomics prediction of CTLA4 expression and prognosis in clear cell renal cell carcinoma</article-title><source>Cancer Med</source><year>2023</year><volume>12</volume><issue>6</issue><fpage>7627</fpage><lpage>38</lpage><pub-id pub-id-type=\"doi\">10.1002/cam4.5449</pub-id><pub-id pub-id-type=\"pmid\">36397666</pub-id><pub-id pub-id-type=\"pmcid\">PMC10067074</pub-id></element-citation><mixed-citation id=\"mc-CR156\" publication-type=\"journal\">He H, Jin Z, Dai J, Wang H, Sun J, Xu D. Computed tomography-based radiomics prediction of CTLA4 expression and prognosis in clear cell renal cell carcinoma. Cancer Med. 2023;12(6):7627&#8211;38.<pub-id pub-id-type=\"pmid\">36397666</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1002/cam4.5449</pub-id><pub-id pub-id-type=\"pmcid\">PMC10067074</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR157\"><label>157.</label><citation-alternatives><element-citation id=\"ec-CR157\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Li</surname><given-names>R</given-names></name><name name-style=\"western\"><surname>Bing</surname><given-names>X</given-names></name><name name-style=\"western\"><surname>Su</surname><given-names>X</given-names></name><name name-style=\"western\"><surname>Zhang</surname><given-names>C</given-names></name><name name-style=\"western\"><surname>Sun</surname><given-names>H</given-names></name><name name-style=\"western\"><surname>Dai</surname><given-names>Z</given-names></name><etal/></person-group><article-title>The potential value of dual-energy CT radiomics in evaluating CD8+, CD163+ and EquationSource IDSMA+ cells in the tumor microenvironment of clear cell renal cell carcinoma</article-title><source>Clin Transl Oncol</source><year>2025</year><volume>27</volume><issue>2</issue><fpage>716</fpage><lpage>726</lpage><pub-id pub-id-type=\"doi\">10.1007/s12094-024-03637-8</pub-id><pub-id pub-id-type=\"pmid\">39083142</pub-id></element-citation><mixed-citation id=\"mc-CR157\" publication-type=\"journal\">Li R, Bing X, Su X, Zhang C, Sun H, Dai Z, et al. The potential value of dual-energy CT radiomics in evaluating CD8+, CD163+ and SMA+ cells in the tumor microenvironment of clear cell renal cell carcinoma. Clin Transl Oncol. 2025;27(2):716&#8211;26.<pub-id pub-id-type=\"pmid\">39083142</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1007/s12094-024-03637-8</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR158\"><label>158.</label><citation-alternatives><element-citation id=\"ec-CR158\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Chen</surname><given-names>L</given-names></name><name name-style=\"western\"><surname>Chen</surname><given-names>L</given-names></name><name name-style=\"western\"><surname>Ni</surname><given-names>H</given-names></name><name name-style=\"western\"><surname>Shen</surname><given-names>L</given-names></name><name name-style=\"western\"><surname>Wei</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Xia</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Prediction of CD3 T cells and CD8 T cells expression levels in non-small cell lung cancer based on radiomic features of CT images</article-title><source>Front Oncol</source><year>2023</year><volume>13</volume><fpage>1104316</fpage><pub-id pub-id-type=\"doi\">10.3389/fonc.2023.1104316</pub-id><pub-id pub-id-type=\"pmid\">36860311</pub-id><pub-id pub-id-type=\"pmcid\">PMC9968855</pub-id></element-citation><mixed-citation id=\"mc-CR158\" publication-type=\"journal\">Chen L, Chen L, Ni H, Shen L, Wei J, Xia Y, et al. Prediction of CD3 T cells and CD8 T cells expression levels in non-small cell lung cancer based on radiomic features of CT images. Front Oncol. 2023;13:1104316.<pub-id pub-id-type=\"pmid\">36860311</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.3389/fonc.2023.1104316</pub-id><pub-id pub-id-type=\"pmcid\">PMC9968855</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR159\"><label>159.</label><citation-alternatives><element-citation id=\"ec-CR159\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Wu</surname><given-names>L</given-names></name><name name-style=\"western\"><surname>Li</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Ruan</surname><given-names>X</given-names></name><name name-style=\"western\"><surname>Ren</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Ping</surname><given-names>X</given-names></name><name name-style=\"western\"><surname>Chen</surname><given-names>B</given-names></name></person-group><article-title>Prediction of VEGF and EGFR expression in peripheral lung cancer based on the radiomics model of spectral CT enhanced images</article-title><source>Int J Gen Med</source><year>2022</year><volume>15</volume><fpage>6725</fpage><pub-id pub-id-type=\"doi\">10.2147/IJGM.S374002</pub-id><pub-id pub-id-type=\"pmid\">36039307</pub-id><pub-id pub-id-type=\"pmcid\">PMC9419990</pub-id></element-citation><mixed-citation id=\"mc-CR159\" publication-type=\"journal\">Wu L, Li J, Ruan X, Ren J, Ping X, Chen B. Prediction of VEGF and EGFR expression in peripheral lung cancer based on the radiomics model of spectral CT enhanced images. Int J Gen Med. 2022;15:6725.<pub-id pub-id-type=\"pmid\">36039307</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.2147/IJGM.S374002</pub-id><pub-id pub-id-type=\"pmcid\">PMC9419990</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR160\"><label>160.</label><citation-alternatives><element-citation id=\"ec-CR160\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Meng</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Zhang</surname><given-names>H</given-names></name><name name-style=\"western\"><surname>Li</surname><given-names>Q</given-names></name><name name-style=\"western\"><surname>Liu</surname><given-names>F</given-names></name><name name-style=\"western\"><surname>Fang</surname><given-names>X</given-names></name><name name-style=\"western\"><surname>Li</surname><given-names>J</given-names></name><etal/></person-group><article-title>Magnetic resonance radiomics and machine-learning models: an approach for evaluating tumor-stroma ratio in patients with pancreatic ductal adenocarcinoma</article-title><source>Acad Radiol</source><year>2022</year><volume>29</volume><issue>4</issue><fpage>523</fpage><lpage>35</lpage><pub-id pub-id-type=\"doi\">10.1016/j.acra.2021.08.013</pub-id><pub-id pub-id-type=\"pmid\">34563443</pub-id></element-citation><mixed-citation id=\"mc-CR160\" publication-type=\"journal\">Meng Y, Zhang H, Li Q, Liu F, Fang X, Li J, et al. Magnetic resonance radiomics and machine-learning models: an approach for evaluating tumor-stroma ratio in patients with pancreatic ductal adenocarcinoma. Acad Radiol. 2022;29(4):523&#8211;35.<pub-id pub-id-type=\"pmid\">34563443</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/j.acra.2021.08.013</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR161\"><label>161.</label><mixed-citation publication-type=\"other\">Liao H, Yuan J, Liu C, Zhang J, Yang Y, Liang H, et al. One novel transfer learning-based CLIP model combined with self-attention mechanism for differentiating the tumor-stroma ratio in pancreatic ductal adenocarcinoma. Radiol Med. 2024;(11):16. 10.1007/s11547-024-01902-y.<pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1007/s11547-024-01902-y</pub-id><pub-id pub-id-type=\"pmid\">39412688</pub-id></mixed-citation></ref><ref id=\"CR162\"><label>162.</label><citation-alternatives><element-citation id=\"ec-CR162\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Long</surname><given-names>S</given-names></name><name name-style=\"western\"><surname>Li</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Chen</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Zhong</surname><given-names>L</given-names></name><name name-style=\"western\"><surname>Dai</surname><given-names>G</given-names></name><name name-style=\"western\"><surname>Pan</surname><given-names>D</given-names></name><etal/></person-group><article-title>Transfer learning radiomic model predicts intratumoral tertiary lymphoid structures in hepatocellular carcinoma: a multicenter study</article-title><source>J Immunother Cancer</source><year>2025</year><volume>13</volume><issue>3</issue><fpage>e011126</fpage><pub-id pub-id-type=\"doi\">10.1136/jitc-2024-011126</pub-id><pub-id pub-id-type=\"pmid\">40037925</pub-id><pub-id pub-id-type=\"pmcid\">PMC11881188</pub-id></element-citation><mixed-citation id=\"mc-CR162\" publication-type=\"journal\">Long S, Li M, Chen J, Zhong L, Dai G, Pan D, et al. Transfer learning radiomic model predicts intratumoral tertiary lymphoid structures in hepatocellular carcinoma: a multicenter study. J Immunother Cancer. 2025;13(3):e011126.<pub-id pub-id-type=\"pmid\">40037925</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1136/jitc-2024-011126</pub-id><pub-id pub-id-type=\"pmcid\">PMC11881188</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR163\"><label>163.</label><citation-alternatives><element-citation id=\"ec-CR163\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Liu</surname><given-names>S</given-names></name><name name-style=\"western\"><surname>Amgad</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>More</surname><given-names>D</given-names></name><name name-style=\"western\"><surname>Rathore</surname><given-names>MA</given-names></name><name name-style=\"western\"><surname>Salgado</surname><given-names>R</given-names></name><name name-style=\"western\"><surname>Cooper</surname><given-names>LA</given-names></name></person-group><article-title>A panoptic segmentation dataset and deep-learning approach for explainable scoring of tumor-infiltrating lymphocytes</article-title><source>NPJ Breast Cancer</source><year>2024</year><volume>10</volume><issue>1</issue><fpage>52</fpage><pub-id pub-id-type=\"doi\">10.1038/s41523-024-00663-1</pub-id><pub-id pub-id-type=\"pmid\">38942745</pub-id><pub-id pub-id-type=\"pmcid\">PMC11213912</pub-id></element-citation><mixed-citation id=\"mc-CR163\" publication-type=\"journal\">Liu S, Amgad M, More D, Rathore MA, Salgado R, Cooper LA. A panoptic segmentation dataset and deep-learning approach for explainable scoring of tumor-infiltrating lymphocytes. NPJ Breast Cancer. 2024;10(1):52.<pub-id pub-id-type=\"pmid\">38942745</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1038/s41523-024-00663-1</pub-id><pub-id pub-id-type=\"pmcid\">PMC11213912</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR164\"><label>164.</label><citation-alternatives><element-citation id=\"ec-CR164\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Meirelles</surname><given-names>AL</given-names></name><name name-style=\"western\"><surname>Kurc</surname><given-names>T</given-names></name><name name-style=\"western\"><surname>Kong</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Ferreira</surname><given-names>R</given-names></name><name name-style=\"western\"><surname>Saltz</surname><given-names>JH</given-names></name><name name-style=\"western\"><surname>Teodoro</surname><given-names>G</given-names></name></person-group><article-title>Building efficient cnn architectures for histopathology images analysis: a case-study in tumor-infiltrating lymphocytes classification</article-title><source>Front Med</source><year>2022</year><volume>9</volume><fpage>894430</fpage><pub-id pub-id-type=\"doi\">10.3389/fmed.2022.894430</pub-id><pub-id pub-id-type=\"pmcid\">PMC9197439</pub-id><pub-id pub-id-type=\"pmid\">35712087</pub-id></element-citation><mixed-citation id=\"mc-CR164\" publication-type=\"journal\">Meirelles AL, Kurc T, Kong J, Ferreira R, Saltz JH, Teodoro G. Building efficient cnn architectures for histopathology images analysis: a case-study in tumor-infiltrating lymphocytes classification. Front Med. 2022;9:894430.<pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.3389/fmed.2022.894430</pub-id><pub-id pub-id-type=\"pmcid\">PMC9197439</pub-id><pub-id pub-id-type=\"pmid\">35712087</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR165\"><label>165.</label><citation-alternatives><element-citation id=\"ec-CR165\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Yosofvand</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Khan</surname><given-names>SY</given-names></name><name name-style=\"western\"><surname>Dhakal</surname><given-names>R</given-names></name><name name-style=\"western\"><surname>Nejat</surname><given-names>A</given-names></name><name name-style=\"western\"><surname>Moustaid-Moussa</surname><given-names>N</given-names></name><name name-style=\"western\"><surname>Rahman</surname><given-names>RL</given-names></name><etal/></person-group><article-title>Automated detection and scoring of tumor-infiltrating lymphocytes in breast cancer histopathology slides</article-title><source>Cancers (Basel)</source><year>2023</year><volume>15</volume><issue>14</issue><fpage>3635</fpage><pub-id pub-id-type=\"doi\">10.3390/cancers15143635</pub-id><pub-id pub-id-type=\"pmid\">37509295</pub-id><pub-id pub-id-type=\"pmcid\">PMC10377197</pub-id></element-citation><mixed-citation id=\"mc-CR165\" publication-type=\"journal\">Yosofvand M, Khan SY, Dhakal R, Nejat A, Moustaid-Moussa N, Rahman RL, et al. Automated detection and scoring of tumor-infiltrating lymphocytes in breast cancer histopathology slides. Cancers (Basel). 2023;15(14):3635.<pub-id pub-id-type=\"pmid\">37509295</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.3390/cancers15143635</pub-id><pub-id pub-id-type=\"pmcid\">PMC10377197</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR166\"><label>166.</label><citation-alternatives><element-citation id=\"ec-CR166\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Verdicchio</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Brancato</surname><given-names>V</given-names></name><name name-style=\"western\"><surname>Cavaliere</surname><given-names>C</given-names></name><name name-style=\"western\"><surname>Isgr&#242;</surname><given-names>F</given-names></name><name name-style=\"western\"><surname>Salvatore</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Aiello</surname><given-names>M</given-names></name></person-group><article-title>A pathomic approach for tumor-infiltrating lymphocytes classification on breast cancer digital pathology images</article-title><source>Heliyon</source><year>2023</year><pub-id pub-id-type=\"doi\">10.1016/j.heliyon.2023.e14371</pub-id><pub-id pub-id-type=\"pmid\">36950640</pub-id><pub-id pub-id-type=\"pmcid\">PMC10025040</pub-id></element-citation><mixed-citation id=\"mc-CR166\" publication-type=\"journal\">Verdicchio M, Brancato V, Cavaliere C, Isgr&#242; F, Salvatore M, Aiello M. A pathomic approach for tumor-infiltrating lymphocytes classification on breast cancer digital pathology images. Heliyon. 2023. 10.1016/j.heliyon.2023.e14371.<pub-id pub-id-type=\"pmid\">36950640</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/j.heliyon.2023.e14371</pub-id><pub-id pub-id-type=\"pmcid\">PMC10025040</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR167\"><label>167.</label><citation-alternatives><element-citation id=\"ec-CR167\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Shvetsov</surname><given-names>N</given-names></name><name name-style=\"western\"><surname>Gr&#248;nnesby</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Pedersen</surname><given-names>E</given-names></name><name name-style=\"western\"><surname>M&#248;llersen</surname><given-names>K</given-names></name><name name-style=\"western\"><surname>Busund</surname><given-names>LTR</given-names></name><name name-style=\"western\"><surname>Schwienbacher</surname><given-names>R</given-names></name><etal/></person-group><article-title>A pragmatic machine learning approach to quantify tumor-infiltrating lymphocytes in whole slide images</article-title><source>Cancers (Basel)</source><year>2022</year><volume>14</volume><issue>12</issue><fpage>2974</fpage><pub-id pub-id-type=\"doi\">10.3390/cancers14122974</pub-id><pub-id pub-id-type=\"pmid\">35740648</pub-id><pub-id pub-id-type=\"pmcid\">PMC9221016</pub-id></element-citation><mixed-citation id=\"mc-CR167\" publication-type=\"journal\">Shvetsov N, Gr&#248;nnesby M, Pedersen E, M&#248;llersen K, Busund LTR, Schwienbacher R, et al. A pragmatic machine learning approach to quantify tumor-infiltrating lymphocytes in whole slide images. Cancers (Basel). 2022;14(12):2974.<pub-id pub-id-type=\"pmid\">35740648</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.3390/cancers14122974</pub-id><pub-id pub-id-type=\"pmcid\">PMC9221016</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR168\"><label>168.</label><citation-alternatives><element-citation id=\"ec-CR168\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Abousamra</surname><given-names>S</given-names></name><name name-style=\"western\"><surname>Gupta</surname><given-names>R</given-names></name><name name-style=\"western\"><surname>Hou</surname><given-names>L</given-names></name><name name-style=\"western\"><surname>Batiste</surname><given-names>R</given-names></name><name name-style=\"western\"><surname>Zhao</surname><given-names>T</given-names></name><name name-style=\"western\"><surname>Shankar</surname><given-names>A</given-names></name><etal/></person-group><article-title>Deep learning-based mapping of tumor infiltrating lymphocytes in whole slide images of 23 types of cancer</article-title><source>Front Oncol</source><year>2022</year><volume>11</volume><issue>806603</issue><fpage>10</fpage><lpage>3389</lpage><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.3389/fonc.2021.806603</pub-id><pub-id pub-id-type=\"pmcid\">PMC8889499</pub-id><pub-id pub-id-type=\"pmid\">35251953</pub-id></element-citation><mixed-citation id=\"mc-CR168\" publication-type=\"journal\">Abousamra S, Gupta R, Hou L, Batiste R, Zhao T, Shankar A, et al. Deep learning-based mapping of tumor infiltrating lymphocytes in whole slide images of 23 types of cancer. Front Oncol. 2022;11(806603):10&#8211;3389.<pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.3389/fonc.2021.806603</pub-id><pub-id pub-id-type=\"pmcid\">PMC8889499</pub-id><pub-id pub-id-type=\"pmid\">35251953</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR169\"><label>169.</label><citation-alternatives><element-citation id=\"ec-CR169\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Machuca-Aguado</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Conde-Mart&#237;n</surname><given-names>AF</given-names></name><name name-style=\"western\"><surname>Alvarez-Mu&#241;oz</surname><given-names>A</given-names></name><name name-style=\"western\"><surname>Rodr&#237;guez-Zarco</surname><given-names>E</given-names></name><name name-style=\"western\"><surname>Polo-Velasco</surname><given-names>A</given-names></name><name name-style=\"western\"><surname>Rueda-Ramos</surname><given-names>A</given-names></name><etal/></person-group><article-title>Machine learning quantification of intraepithelial tumor-infiltrating lymphocytes as a significant prognostic factor in high-grade serous ovarian carcinomas</article-title><source>Int J Mol Sci</source><year>2023</year><volume>24</volume><issue>22</issue><fpage>16060</fpage><pub-id pub-id-type=\"doi\">10.3390/ijms242216060</pub-id><pub-id pub-id-type=\"pmid\">38003250</pub-id><pub-id pub-id-type=\"pmcid\">PMC10671555</pub-id></element-citation><mixed-citation id=\"mc-CR169\" publication-type=\"journal\">Machuca-Aguado J, Conde-Mart&#237;n AF, Alvarez-Mu&#241;oz A, Rodr&#237;guez-Zarco E, Polo-Velasco A, Rueda-Ramos A, et al. Machine learning quantification of intraepithelial tumor-infiltrating lymphocytes as a significant prognostic factor in high-grade serous ovarian carcinomas. Int J Mol Sci. 2023;24(22):16060.<pub-id pub-id-type=\"pmid\">38003250</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.3390/ijms242216060</pub-id><pub-id pub-id-type=\"pmcid\">PMC10671555</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR170\"><label>170.</label><citation-alternatives><element-citation id=\"ec-CR170\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Xu</surname><given-names>H</given-names></name><name name-style=\"western\"><surname>Cha</surname><given-names>YJ</given-names></name><name name-style=\"western\"><surname>Clemenceau</surname><given-names>JR</given-names></name><name name-style=\"western\"><surname>Choi</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Lee</surname><given-names>SH</given-names></name><name name-style=\"western\"><surname>Kang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Spatial analysis of tumor-infiltrating lymphocytes in histological sections using deep learning techniques predicts survival in colorectal carcinoma</article-title><source>The Journal of Pathology: Clinical Research</source><year>2022</year><volume>8</volume><issue>4</issue><fpage>327</fpage><lpage>39</lpage><pub-id pub-id-type=\"pmid\">35484698</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1002/cjp2.273</pub-id><pub-id pub-id-type=\"pmcid\">PMC9161341</pub-id></element-citation><mixed-citation id=\"mc-CR170\" publication-type=\"journal\">Xu H, Cha YJ, Clemenceau JR, Choi J, Lee SH, Kang J, et al. Spatial analysis of tumor-infiltrating lymphocytes in histological sections using deep learning techniques predicts survival in colorectal carcinoma. The Journal of Pathology: Clinical Research. 2022;8(4):327&#8211;39.<pub-id pub-id-type=\"pmid\">35484698</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1002/cjp2.273</pub-id><pub-id pub-id-type=\"pmcid\">PMC9161341</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR171\"><label>171.</label><citation-alternatives><element-citation id=\"ec-CR171\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Zheng</surname><given-names>Q</given-names></name><name name-style=\"western\"><surname>Yang</surname><given-names>R</given-names></name><name name-style=\"western\"><surname>Ni</surname><given-names>X</given-names></name><name name-style=\"western\"><surname>Yang</surname><given-names>S</given-names></name><name name-style=\"western\"><surname>Jiao</surname><given-names>P</given-names></name><name name-style=\"western\"><surname>Wu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Quantitative assessment of tumor-infiltrating lymphocytes using machine learning predicts survival in muscle-invasive bladder cancer</article-title><source>J Clin Med</source><year>2022</year><volume>11</volume><issue>23</issue><fpage>7081</fpage><pub-id pub-id-type=\"doi\">10.3390/jcm11237081</pub-id><pub-id pub-id-type=\"pmid\">36498655</pub-id><pub-id pub-id-type=\"pmcid\">PMC9739988</pub-id></element-citation><mixed-citation id=\"mc-CR171\" publication-type=\"journal\">Zheng Q, Yang R, Ni X, Yang S, Jiao P, Wu J, et al. Quantitative assessment of tumor-infiltrating lymphocytes using machine learning predicts survival in muscle-invasive bladder cancer. J Clin Med. 2022;11(23):7081.<pub-id pub-id-type=\"pmid\">36498655</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.3390/jcm11237081</pub-id><pub-id pub-id-type=\"pmcid\">PMC9739988</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR172\"><label>172.</label><citation-alternatives><element-citation id=\"ec-CR172\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Fassler</surname><given-names>DJ</given-names></name><name name-style=\"western\"><surname>Torre-Healy</surname><given-names>LA</given-names></name><name name-style=\"western\"><surname>Gupta</surname><given-names>R</given-names></name><name name-style=\"western\"><surname>Hamilton</surname><given-names>AM</given-names></name><name name-style=\"western\"><surname>Kobayashi</surname><given-names>S</given-names></name><name name-style=\"western\"><surname>Van Alsten</surname><given-names>SC</given-names></name><etal/></person-group><article-title>Spatial characterization of tumor-infiltrating lymphocytes and breast cancer progression</article-title><source>Cancers (Basel)</source><year>2022</year><volume>14</volume><issue>9</issue><fpage>2148</fpage><pub-id pub-id-type=\"doi\">10.3390/cancers14092148</pub-id><pub-id pub-id-type=\"pmid\">35565277</pub-id><pub-id pub-id-type=\"pmcid\">PMC9105398</pub-id></element-citation><mixed-citation id=\"mc-CR172\" publication-type=\"journal\">Fassler DJ, Torre-Healy LA, Gupta R, Hamilton AM, Kobayashi S, Van Alsten SC, et al. Spatial characterization of tumor-infiltrating lymphocytes and breast cancer progression. Cancers (Basel). 2022;14(9):2148.<pub-id pub-id-type=\"pmid\">35565277</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.3390/cancers14092148</pub-id><pub-id pub-id-type=\"pmcid\">PMC9105398</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR173\"><label>173.</label><citation-alternatives><element-citation id=\"ec-CR173\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Pan</surname><given-names>X</given-names></name><name name-style=\"western\"><surname>Lin</surname><given-names>H</given-names></name><name name-style=\"western\"><surname>Han</surname><given-names>C</given-names></name><name name-style=\"western\"><surname>Feng</surname><given-names>Z</given-names></name><name name-style=\"western\"><surname>Wang</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Lin</surname><given-names>J</given-names></name><etal/></person-group><article-title>Computerized tumor-infiltrating lymphocytes density score predicts survival of patients with resectable lung adenocarcinoma</article-title><source>iScience</source><year>2022</year><pub-id pub-id-type=\"doi\">10.1016/j.isci.2022.105605</pub-id><pub-id pub-id-type=\"pmid\">36505920</pub-id><pub-id pub-id-type=\"pmcid\">PMC9730047</pub-id></element-citation><mixed-citation id=\"mc-CR173\" publication-type=\"journal\">Pan X, Lin H, Han C, Feng Z, Wang Y, Lin J, et al. Computerized tumor-infiltrating lymphocytes density score predicts survival of patients with resectable lung adenocarcinoma. iScience. 2022. 10.1016/j.isci.2022.105605.<pub-id pub-id-type=\"pmid\">36505920</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/j.isci.2022.105605</pub-id><pub-id pub-id-type=\"pmcid\">PMC9730047</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR174\"><label>174.</label><citation-alternatives><element-citation id=\"ec-CR174\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Yang</surname><given-names>X</given-names></name><name name-style=\"western\"><surname>Li</surname><given-names>X</given-names></name><name name-style=\"western\"><surname>Xu</surname><given-names>H</given-names></name><name name-style=\"western\"><surname>Du</surname><given-names>S</given-names></name><name name-style=\"western\"><surname>Wang</surname><given-names>C</given-names></name><name name-style=\"western\"><surname>He</surname><given-names>H</given-names></name></person-group><article-title>Predicting CTLA4 expression and prognosis in clear cell renal cell carcinoma using a pathomics signature of histopathological images and machine learning</article-title><source>Heliyon</source><year>2024</year><pub-id pub-id-type=\"doi\">10.1016/j.heliyon.2024.e34877</pub-id><pub-id pub-id-type=\"pmid\">39145002</pub-id><pub-id pub-id-type=\"pmcid\">PMC11320204</pub-id></element-citation><mixed-citation id=\"mc-CR174\" publication-type=\"journal\">Yang X, Li X, Xu H, Du S, Wang C, He H. Predicting CTLA4 expression and prognosis in clear cell renal cell carcinoma using a pathomics signature of histopathological images and machine learning. Heliyon. 2024. 10.1016/j.heliyon.2024.e34877.<pub-id pub-id-type=\"pmid\">39145002</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/j.heliyon.2024.e34877</pub-id><pub-id pub-id-type=\"pmcid\">PMC11320204</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR175\"><label>175.</label><citation-alternatives><element-citation id=\"ec-CR175\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Firmbach</surname><given-names>D</given-names></name><name name-style=\"western\"><surname>Benz</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Kuritcyn</surname><given-names>P</given-names></name><name name-style=\"western\"><surname>Bruns</surname><given-names>V</given-names></name><name name-style=\"western\"><surname>Lang-Schwarz</surname><given-names>C</given-names></name><name name-style=\"western\"><surname>Stuebs</surname><given-names>FA</given-names></name><etal/></person-group><article-title>Tumor-stroma ratio in colorectal cancer&#8211;comparison between human estimation and automated assessment</article-title><source>Cancers (Basel)</source><year>2023</year><volume>15</volume><issue>10</issue><fpage>2675</fpage><pub-id pub-id-type=\"doi\">10.3390/cancers15102675</pub-id><pub-id pub-id-type=\"pmid\">37345012</pub-id><pub-id pub-id-type=\"pmcid\">PMC10216342</pub-id></element-citation><mixed-citation id=\"mc-CR175\" publication-type=\"journal\">Firmbach D, Benz M, Kuritcyn P, Bruns V, Lang-Schwarz C, Stuebs FA, et al. Tumor-stroma ratio in colorectal cancer&#8211;comparison between human estimation and automated assessment. Cancers (Basel). 2023;15(10):2675.<pub-id pub-id-type=\"pmid\">37345012</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.3390/cancers15102675</pub-id><pub-id pub-id-type=\"pmcid\">PMC10216342</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR176\"><label>176.</label><citation-alternatives><element-citation id=\"ec-CR176\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Xinsen</surname><given-names>L</given-names></name><name name-style=\"western\"><surname>Yang</surname><given-names>K</given-names></name><name name-style=\"western\"><surname>Bingzhi</surname><given-names>C</given-names></name><name name-style=\"western\"><surname>Xiuhong</surname><given-names>C</given-names></name><name name-style=\"western\"><surname>Xinling</surname><given-names>L</given-names></name><name name-style=\"western\"><surname>Xinyao</surname><given-names>X</given-names></name><etal/></person-group><article-title>Vague-Segment Technique: Automatic Computation of Tumor Stroma Ratio for Breast Cancer on Whole Slides</article-title><source>IEEE J Biomed Health Inform</source><year>2023</year><volume>28</volume><issue>2</issue><fpage>905</fpage><lpage>916</lpage><pub-id pub-id-type=\"doi\">10.1109/JBHI.2023.3341101</pub-id><pub-id pub-id-type=\"pmid\">38079367</pub-id></element-citation><mixed-citation id=\"mc-CR176\" publication-type=\"journal\">Xinsen L, Yang K, Bingzhi C, Xiuhong C, Xinling L, Xinyao X, et al. Vague-Segment Technique: Automatic Computation of Tumor Stroma Ratio for Breast Cancer on Whole Slides. IEEE J Biomed Health Inform. 2023;28(2):905&#8211;16.<pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1109/JBHI.2023.3341101</pub-id><pub-id pub-id-type=\"pmid\">38079367</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR177\"><label>177.</label><citation-alternatives><element-citation id=\"ec-CR177\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>van Rijthoven</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Obahor</surname><given-names>S</given-names></name><name name-style=\"western\"><surname>Pagliarulo</surname><given-names>F</given-names></name><name name-style=\"western\"><surname>van den Broek</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Schraml</surname><given-names>P</given-names></name><name name-style=\"western\"><surname>Moch</surname><given-names>H</given-names></name><etal/></person-group><article-title>Multi-resolution deep learning characterizes tertiary lymphoid structures and their prognostic relevance in solid tumors</article-title><source>Commun Med</source><year>2024</year><volume>4</volume><issue>1</issue><fpage>5</fpage><pub-id pub-id-type=\"doi\">10.1038/s43856-023-00421-7</pub-id><pub-id pub-id-type=\"pmid\">38182879</pub-id><pub-id pub-id-type=\"pmcid\">PMC10770129</pub-id></element-citation><mixed-citation id=\"mc-CR177\" publication-type=\"journal\">van Rijthoven M, Obahor S, Pagliarulo F, van den Broek M, Schraml P, Moch H, et al. Multi-resolution deep learning characterizes tertiary lymphoid structures and their prognostic relevance in solid tumors. Commun Med. 2024;4(1):5.<pub-id pub-id-type=\"pmid\">38182879</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1038/s43856-023-00421-7</pub-id><pub-id pub-id-type=\"pmcid\">PMC10770129</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR178\"><label>178.</label><citation-alternatives><element-citation id=\"ec-CR178\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Chen</surname><given-names>Z</given-names></name><name name-style=\"western\"><surname>Wang</surname><given-names>X</given-names></name><name name-style=\"western\"><surname>Jin</surname><given-names>Z</given-names></name><name name-style=\"western\"><surname>Li</surname><given-names>B</given-names></name><name name-style=\"western\"><surname>Jiang</surname><given-names>D</given-names></name><name name-style=\"western\"><surname>Wang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Deep learning on tertiary lymphoid structures in hematoxylin-eosin predicts cancer prognosis and immunotherapy response</article-title><source>NPJ Precis Oncol</source><year>2024</year><volume>8</volume><issue>1</issue><fpage>73</fpage><pub-id pub-id-type=\"doi\">10.1038/s41698-024-00579-w</pub-id><pub-id pub-id-type=\"pmid\">38519580</pub-id><pub-id pub-id-type=\"pmcid\">PMC10959936</pub-id></element-citation><mixed-citation id=\"mc-CR178\" publication-type=\"journal\">Chen Z, Wang X, Jin Z, Li B, Jiang D, Wang Y, et al. Deep learning on tertiary lymphoid structures in hematoxylin-eosin predicts cancer prognosis and immunotherapy response. NPJ Precis Oncol. 2024;8(1):73.<pub-id pub-id-type=\"pmid\">38519580</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1038/s41698-024-00579-w</pub-id><pub-id pub-id-type=\"pmcid\">PMC10959936</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR179\"><label>179.</label><citation-alternatives><element-citation id=\"ec-CR179\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Failmezger</surname><given-names>H</given-names></name><name name-style=\"western\"><surname>Zwing</surname><given-names>N</given-names></name><name name-style=\"western\"><surname>Tresch</surname><given-names>A</given-names></name><name name-style=\"western\"><surname>Korski</surname><given-names>K</given-names></name><name name-style=\"western\"><surname>Schmich</surname><given-names>F</given-names></name></person-group><article-title>Computational tumor infiltration phenotypes enable the spatial and genomic analysis of immune infiltration in colorectal cancer</article-title><source>Front Oncol</source><year>2021</year><volume>11</volume><fpage>552331</fpage><pub-id pub-id-type=\"doi\">10.3389/fonc.2021.552331</pub-id><pub-id pub-id-type=\"pmid\">33791196</pub-id><pub-id pub-id-type=\"pmcid\">PMC8006941</pub-id></element-citation><mixed-citation id=\"mc-CR179\" publication-type=\"journal\">Failmezger H, Zwing N, Tresch A, Korski K, Schmich F. Computational tumor infiltration phenotypes enable the spatial and genomic analysis of immune infiltration in colorectal cancer. Front Oncol. 2021;11:552331.<pub-id pub-id-type=\"pmid\">33791196</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.3389/fonc.2021.552331</pub-id><pub-id pub-id-type=\"pmcid\">PMC8006941</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR180\"><label>180.</label><citation-alternatives><element-citation id=\"ec-CR180\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Liu</surname><given-names>Z</given-names></name><name name-style=\"western\"><surname>Liu</surname><given-names>L</given-names></name><name name-style=\"western\"><surname>Weng</surname><given-names>S</given-names></name><name name-style=\"western\"><surname>Guo</surname><given-names>C</given-names></name><name name-style=\"western\"><surname>Dang</surname><given-names>Q</given-names></name><name name-style=\"western\"><surname>Xu</surname><given-names>H</given-names></name><etal/></person-group><article-title>Machine learning-based integration develops an immune-derived lncRNA signature for improving outcomes in colorectal cancer</article-title><source>Nat Commun</source><year>2022</year><volume>13</volume><issue>1</issue><fpage>816</fpage><pub-id pub-id-type=\"doi\">10.1038/s41467-022-28421-6</pub-id><pub-id pub-id-type=\"pmid\">35145098</pub-id><pub-id pub-id-type=\"pmcid\">PMC8831564</pub-id></element-citation><mixed-citation id=\"mc-CR180\" publication-type=\"journal\">Liu Z, Liu L, Weng S, Guo C, Dang Q, Xu H, et al. Machine learning-based integration develops an immune-derived lncRNA signature for improving outcomes in colorectal cancer. Nat Commun. 2022;13(1):816.<pub-id pub-id-type=\"pmid\">35145098</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1038/s41467-022-28421-6</pub-id><pub-id pub-id-type=\"pmcid\">PMC8831564</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR181\"><label>181.</label><citation-alternatives><element-citation id=\"ec-CR181\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Zhang</surname><given-names>N</given-names></name><name name-style=\"western\"><surname>Zhang</surname><given-names>H</given-names></name><name name-style=\"western\"><surname>Wu</surname><given-names>W</given-names></name><name name-style=\"western\"><surname>Zhou</surname><given-names>R</given-names></name><name name-style=\"western\"><surname>Li</surname><given-names>S</given-names></name><name name-style=\"western\"><surname>Wang</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Machine learning-based identification of tumor-infiltrating immune cell-associated lncRNAs for improving outcomes and immunotherapy responses in patients with low-grade glioma</article-title><source>Theranostics</source><year>2022</year><volume>12</volume><issue>13</issue><fpage>5931</fpage><pub-id pub-id-type=\"doi\">10.7150/thno.74281</pub-id><pub-id pub-id-type=\"pmid\">35966587</pub-id><pub-id pub-id-type=\"pmcid\">PMC9373811</pub-id></element-citation><mixed-citation id=\"mc-CR181\" publication-type=\"journal\">Zhang N, Zhang H, Wu W, Zhou R, Li S, Wang Z, et al. Machine learning-based identification of tumor-infiltrating immune cell-associated lncRNAs for improving outcomes and immunotherapy responses in patients with low-grade glioma. Theranostics. 2022;12(13):5931.<pub-id pub-id-type=\"pmid\">35966587</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.7150/thno.74281</pub-id><pub-id pub-id-type=\"pmcid\">PMC9373811</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR182\"><label>182.</label><citation-alternatives><element-citation id=\"ec-CR182\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Pan</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Jin</surname><given-names>X</given-names></name><name name-style=\"western\"><surname>Xu</surname><given-names>H</given-names></name><name name-style=\"western\"><surname>Hong</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Li</surname><given-names>F</given-names></name><name name-style=\"western\"><surname>Luo</surname><given-names>T</given-names></name><etal/></person-group><article-title>Developing a prognostic model using machine learning for disulfidptosis related lncRNA in lung adenocarcinoma</article-title><source>Sci Rep</source><year>2024</year><volume>14</volume><issue>1</issue><fpage>13113</fpage><pub-id pub-id-type=\"doi\">10.1038/s41598-024-63949-1</pub-id><pub-id pub-id-type=\"pmid\">38849442</pub-id><pub-id pub-id-type=\"pmcid\">PMC11161591</pub-id></element-citation><mixed-citation id=\"mc-CR182\" publication-type=\"journal\">Pan Y, Jin X, Xu H, Hong J, Li F, Luo T, et al. Developing a prognostic model using machine learning for disulfidptosis related lncRNA in lung adenocarcinoma. Sci Rep. 2024;14(1):13113.<pub-id pub-id-type=\"pmid\">38849442</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1038/s41598-024-63949-1</pub-id><pub-id pub-id-type=\"pmcid\">PMC11161591</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR183\"><label>183.</label><citation-alternatives><element-citation id=\"ec-CR183\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Peng</surname><given-names>Q</given-names></name><name name-style=\"western\"><surname>Tao</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Xu</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Shen</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Wang</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Jiao</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Lipid metabolism-associated genes serve as potential predictive biomarkers in neoadjuvant chemoradiotherapy combined with immunotherapy in rectal cancer</article-title><source>Transl Oncol</source><year>2024</year><volume>39</volume><fpage>101828</fpage><pub-id pub-id-type=\"doi\">10.1016/j.tranon.2023.101828</pub-id><pub-id pub-id-type=\"pmid\">38000147</pub-id><pub-id pub-id-type=\"pmcid\">PMC10709626</pub-id></element-citation><mixed-citation id=\"mc-CR183\" publication-type=\"journal\">Peng Q, Tao J, Xu Y, Shen Y, Wang Y, Jiao Y, et al. Lipid metabolism-associated genes serve as potential predictive biomarkers in neoadjuvant chemoradiotherapy combined with immunotherapy in rectal cancer. Transl Oncol. 2024;39:101828.<pub-id pub-id-type=\"pmid\">38000147</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/j.tranon.2023.101828</pub-id><pub-id pub-id-type=\"pmcid\">PMC10709626</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR184\"><label>184.</label><citation-alternatives><element-citation id=\"ec-CR184\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Wei</surname><given-names>F</given-names></name><name name-style=\"western\"><surname>Azuma</surname><given-names>K</given-names></name><name name-style=\"western\"><surname>Nakahara</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Saito</surname><given-names>H</given-names></name><name name-style=\"western\"><surname>Matsuo</surname><given-names>N</given-names></name><name name-style=\"western\"><surname>Tagami</surname><given-names>T</given-names></name><etal/></person-group><article-title>Machine learning for prediction of immunotherapeutic outcome in non-small-cell lung cancer based on circulating cytokine signatures</article-title><source>J Immunother Cancer</source><year>2023</year><volume>11</volume><issue>7</issue><fpage>e006788</fpage><pub-id pub-id-type=\"doi\">10.1136/jitc-2023-006788</pub-id><pub-id pub-id-type=\"pmid\">37433717</pub-id><pub-id pub-id-type=\"pmcid\">PMC10347453</pub-id></element-citation><mixed-citation id=\"mc-CR184\" publication-type=\"journal\">Wei F, Azuma K, Nakahara Y, Saito H, Matsuo N, Tagami T, et al. Machine learning for prediction of immunotherapeutic outcome in non-small-cell lung cancer based on circulating cytokine signatures. J Immunother Cancer. 2023;11(7):e006788.<pub-id pub-id-type=\"pmid\">37433717</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1136/jitc-2023-006788</pub-id><pub-id pub-id-type=\"pmcid\">PMC10347453</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR185\"><label>185.</label><citation-alternatives><element-citation id=\"ec-CR185\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Li</surname><given-names>N</given-names></name><name name-style=\"western\"><surname>Zhan</surname><given-names>X</given-names></name></person-group><article-title>Machine learning identifies Pan-cancer landscape of Nrf2 oxidative stress response pathway-related genes</article-title><source>Oxid Med Cell Longev</source><year>2022</year><volume>2022</volume><issue>1</issue><fpage>8450087</fpage><pub-id pub-id-type=\"doi\">10.1155/2022/8450087</pub-id><pub-id pub-id-type=\"pmid\">35242279</pub-id><pub-id pub-id-type=\"pmcid\">PMC8886747</pub-id></element-citation><mixed-citation id=\"mc-CR185\" publication-type=\"journal\">Li N, Zhan X. Machine learning identifies Pan-cancer landscape of Nrf2 oxidative stress response pathway-related genes. Oxid Med Cell Longev. 2022;2022(1):8450087.<pub-id pub-id-type=\"pmid\">35242279</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1155/2022/8450087</pub-id><pub-id pub-id-type=\"pmcid\">PMC8886747</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR186\"><label>186.</label><citation-alternatives><element-citation id=\"ec-CR186\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Ye</surname><given-names>G</given-names></name><name name-style=\"western\"><surname>Wu</surname><given-names>G</given-names></name><name name-style=\"western\"><surname>Zhang</surname><given-names>C</given-names></name><name name-style=\"western\"><surname>Wang</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Liu</surname><given-names>H</given-names></name><name name-style=\"western\"><surname>Song</surname><given-names>E</given-names></name><etal/></person-group><article-title>CT-based quantification of intratumoral heterogeneity for predicting pathologic complete response to neoadjuvant immunochemotherapy in non-small cell lung cancer</article-title><source>Front Immunol</source><year>2024</year><volume>15</volume><fpage>1414954</fpage><pub-id pub-id-type=\"doi\">10.3389/fimmu.2024.1414954</pub-id><pub-id pub-id-type=\"pmid\">38933281</pub-id><pub-id pub-id-type=\"pmcid\">PMC11199789</pub-id></element-citation><mixed-citation id=\"mc-CR186\" publication-type=\"journal\">Ye G, Wu G, Zhang C, Wang M, Liu H, Song E, et al. CT-based quantification of intratumoral heterogeneity for predicting pathologic complete response to neoadjuvant immunochemotherapy in non-small cell lung cancer. Front Immunol. 2024;15:1414954.<pub-id pub-id-type=\"pmid\">38933281</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.3389/fimmu.2024.1414954</pub-id><pub-id pub-id-type=\"pmcid\">PMC11199789</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR187\"><label>187.</label><citation-alternatives><element-citation id=\"ec-CR187\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Qu</surname><given-names>W</given-names></name><name name-style=\"western\"><surname>Chen</surname><given-names>C</given-names></name><name name-style=\"western\"><surname>Cai</surname><given-names>C</given-names></name><name name-style=\"western\"><surname>Gong</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Luo</surname><given-names>Q</given-names></name><name name-style=\"western\"><surname>Song</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Non-invasive prediction for pathologic complete response to neoadjuvant chemoimmunotherapy in lung cancer using CT-based deep learning: a multicenter study</article-title><source>Front Immunol</source><year>2024</year><volume>15</volume><fpage>1327779</fpage><pub-id pub-id-type=\"doi\">10.3389/fimmu.2024.1327779</pub-id><pub-id pub-id-type=\"pmid\">38596674</pub-id><pub-id pub-id-type=\"pmcid\">PMC11003263</pub-id></element-citation><mixed-citation id=\"mc-CR187\" publication-type=\"journal\">Qu W, Chen C, Cai C, Gong M, Luo Q, Song Y, et al. Non-invasive prediction for pathologic complete response to neoadjuvant chemoimmunotherapy in lung cancer using CT-based deep learning: a multicenter study. Front Immunol. 2024;15:1327779.<pub-id pub-id-type=\"pmid\">38596674</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.3389/fimmu.2024.1327779</pub-id><pub-id pub-id-type=\"pmcid\">PMC11003263</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR188\"><label>188.</label><citation-alternatives><element-citation id=\"ec-CR188\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Huang</surname><given-names>D</given-names></name><name name-style=\"western\"><surname>Lin</surname><given-names>C</given-names></name><name name-style=\"western\"><surname>Jiang</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Xin</surname><given-names>E</given-names></name><name name-style=\"western\"><surname>Xu</surname><given-names>F</given-names></name><name name-style=\"western\"><surname>Gan</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Radiomics model based on intratumoral and peritumoral features for predicting major pathological response in non-small cell lung cancer receiving neoadjuvant immunochemotherapy</article-title><source>Front Oncol</source><year>2024</year><volume>14</volume><fpage>1348678</fpage><pub-id pub-id-type=\"doi\">10.3389/fonc.2024.1348678</pub-id><pub-id pub-id-type=\"pmid\">38585004</pub-id><pub-id pub-id-type=\"pmcid\">PMC10996281</pub-id></element-citation><mixed-citation id=\"mc-CR188\" publication-type=\"journal\">Huang D, Lin C, Jiang Y, Xin E, Xu F, Gan Y, et al. Radiomics model based on intratumoral and peritumoral features for predicting major pathological response in non-small cell lung cancer receiving neoadjuvant immunochemotherapy. Front Oncol. 2024;14:1348678.<pub-id pub-id-type=\"pmid\">38585004</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.3389/fonc.2024.1348678</pub-id><pub-id pub-id-type=\"pmcid\">PMC10996281</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR189\"><label>189.</label><citation-alternatives><element-citation id=\"ec-CR189\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Liu</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Sui</surname><given-names>C</given-names></name><name name-style=\"western\"><surname>Bian</surname><given-names>H</given-names></name><name name-style=\"western\"><surname>Li</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Wang</surname><given-names>Z</given-names></name><name name-style=\"western\"><surname>Fu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Radiomics based on 18F-FDG PET/CT for prediction of pathological complete response to neoadjuvant therapy in non-small cell lung cancer</article-title><source>Front Oncol</source><year>2024</year><volume>14</volume><fpage>1425837</fpage><pub-id pub-id-type=\"doi\">10.3389/fonc.2024.1425837</pub-id><pub-id pub-id-type=\"pmid\">39132503</pub-id><pub-id pub-id-type=\"pmcid\">PMC11310012</pub-id></element-citation><mixed-citation id=\"mc-CR189\" publication-type=\"journal\">Liu J, Sui C, Bian H, Li Y, Wang Z, Fu J, et al. Radiomics based on 18F-FDG PET/CT for prediction of pathological complete response to neoadjuvant therapy in non-small cell lung cancer. Front Oncol. 2024;14:1425837.<pub-id pub-id-type=\"pmid\">39132503</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.3389/fonc.2024.1425837</pub-id><pub-id pub-id-type=\"pmcid\">PMC11310012</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR190\"><label>190.</label><citation-alternatives><element-citation id=\"ec-CR190\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Ye</surname><given-names>G</given-names></name><name name-style=\"western\"><surname>Wu</surname><given-names>G</given-names></name><name name-style=\"western\"><surname>Qi</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Li</surname><given-names>K</given-names></name><name name-style=\"western\"><surname>Wang</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Zhang</surname><given-names>C</given-names></name><etal/></person-group><article-title>Non-invasive multimodal CT deep learning biomarker to predict pathological complete response of non-small cell lung cancer following neoadjuvant immunochemotherapy: a multicenter study</article-title><source>J Immunother Cancer</source><year>2024</year><volume>12</volume><issue>9</issue><fpage>e009348</fpage><pub-id pub-id-type=\"doi\">10.1136/jitc-2024-009348</pub-id><pub-id pub-id-type=\"pmid\">39231545</pub-id><pub-id pub-id-type=\"pmcid\">PMC11409329</pub-id></element-citation><mixed-citation id=\"mc-CR190\" publication-type=\"journal\">Ye G, Wu G, Qi Y, Li K, Wang M, Zhang C, et al. Non-invasive multimodal CT deep learning biomarker to predict pathological complete response of non-small cell lung cancer following neoadjuvant immunochemotherapy: a multicenter study. J Immunother Cancer. 2024;12(9):e009348.<pub-id pub-id-type=\"pmid\">39231545</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1136/jitc-2024-009348</pub-id><pub-id pub-id-type=\"pmcid\">PMC11409329</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR191\"><label>191.</label><citation-alternatives><element-citation id=\"ec-CR191\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Han</surname><given-names>X</given-names></name><name name-style=\"western\"><surname>Wang</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Zheng</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Wang</surname><given-names>N</given-names></name><name name-style=\"western\"><surname>Wu</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Ding</surname><given-names>C</given-names></name><etal/></person-group><article-title>Delta-radiomics features for predicting the major pathological response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer</article-title><source>Eur Radiol</source><year>2024</year><volume>34</volume><issue>4</issue><fpage>2716</fpage><lpage>2726</lpage><pub-id pub-id-type=\"doi\">10.1007/s00330-023-10241-x</pub-id><pub-id pub-id-type=\"pmid\">37736804</pub-id></element-citation><mixed-citation id=\"mc-CR191\" publication-type=\"journal\">Han X, Wang M, Zheng Y, Wang N, Wu Y, Ding C, et al. Delta-radiomics features for predicting the major pathological response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer. Eur Radiol. 2024;34(4):2716&#8211;26.<pub-id pub-id-type=\"pmid\">37736804</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1007/s00330-023-10241-x</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR192\"><label>192.</label><citation-alternatives><element-citation id=\"ec-CR192\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Cui</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Lin</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Zhao</surname><given-names>Z</given-names></name><name name-style=\"western\"><surname>Long</surname><given-names>H</given-names></name><name name-style=\"western\"><surname>Zheng</surname><given-names>L</given-names></name><name name-style=\"western\"><surname>Lin</surname><given-names>X</given-names></name></person-group><article-title>Comprehensive 18F-FDG PET-based radiomics in elevating the pathological response to neoadjuvant immunochemotherapy for resectable stage III non-small-cell lung cancer: a pilot study</article-title><source>Front Immunol</source><year>2022</year><volume>13</volume><fpage>994917</fpage><pub-id pub-id-type=\"doi\">10.3389/fimmu.2022.994917</pub-id><pub-id pub-id-type=\"pmid\">36466929</pub-id><pub-id pub-id-type=\"pmcid\">PMC9713843</pub-id></element-citation><mixed-citation id=\"mc-CR192\" publication-type=\"journal\">Cui Y, Lin Y, Zhao Z, Long H, Zheng L, Lin X. Comprehensive 18F-FDG PET-based radiomics in elevating the pathological response to neoadjuvant immunochemotherapy for resectable stage III non-small-cell lung cancer: a pilot study. Front Immunol. 2022;13:994917.<pub-id pub-id-type=\"pmid\">36466929</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.3389/fimmu.2022.994917</pub-id><pub-id pub-id-type=\"pmcid\">PMC9713843</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR193\"><label>193.</label><citation-alternatives><element-citation id=\"ec-CR193\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Yang</surname><given-names>N</given-names></name><name name-style=\"western\"><surname>Yue</surname><given-names>HL</given-names></name><name name-style=\"western\"><surname>Zhang</surname><given-names>BH</given-names></name><name name-style=\"western\"><surname>Chen</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Chu</surname><given-names>Q</given-names></name><name name-style=\"western\"><surname>Wang</surname><given-names>JX</given-names></name><etal/></person-group><article-title>Predicting pathological response to neoadjuvant or conversion chemoimmunotherapy in stage IB-III non-small cell lung cancer patients using radiomic features</article-title><source>Thorac Cancer</source><year>2023</year><volume>14</volume><issue>28</issue><fpage>2869</fpage><lpage>76</lpage><pub-id pub-id-type=\"doi\">10.1111/1759-7714.15052</pub-id><pub-id pub-id-type=\"pmid\">37596822</pub-id><pub-id pub-id-type=\"pmcid\">PMC10542462</pub-id></element-citation><mixed-citation id=\"mc-CR193\" publication-type=\"journal\">Yang N, Yue HL, Zhang BH, Chen J, Chu Q, Wang JX, et al. Predicting pathological response to neoadjuvant or conversion chemoimmunotherapy in stage IB-III non-small cell lung cancer patients using radiomic features. Thorac Cancer. 2023;14(28):2869&#8211;76.<pub-id pub-id-type=\"pmid\">37596822</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1111/1759-7714.15052</pub-id><pub-id pub-id-type=\"pmcid\">PMC10542462</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR194\"><label>194.</label><citation-alternatives><element-citation id=\"ec-CR194\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>She</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>He</surname><given-names>B</given-names></name><name name-style=\"western\"><surname>Wang</surname><given-names>F</given-names></name><name name-style=\"western\"><surname>Zhong</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Wang</surname><given-names>T</given-names></name><name name-style=\"western\"><surname>Liu</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Deep learning for predicting major pathological response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer: a multicentre study</article-title><source>EBioMedicine</source><year>2022</year><pub-id pub-id-type=\"doi\">10.1016/j.ebiom.2022.104364</pub-id><pub-id pub-id-type=\"pmid\">36395737</pub-id><pub-id pub-id-type=\"pmcid\">PMC9672965</pub-id></element-citation><mixed-citation id=\"mc-CR194\" publication-type=\"journal\">She Y, He B, Wang F, Zhong Y, Wang T, Liu Z, et al. Deep learning for predicting major pathological response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer: a multicentre study. EBioMedicine. 2022. 10.1016/j.ebiom.2022.104364.<pub-id pub-id-type=\"pmid\">36395737</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/j.ebiom.2022.104364</pub-id><pub-id pub-id-type=\"pmcid\">PMC9672965</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR195\"><label>195.</label><citation-alternatives><element-citation id=\"ec-CR195\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Liu</surname><given-names>C</given-names></name><name name-style=\"western\"><surname>Zhao</surname><given-names>W</given-names></name><name name-style=\"western\"><surname>Xie</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Lin</surname><given-names>H</given-names></name><name name-style=\"western\"><surname>Hu</surname><given-names>X</given-names></name><name name-style=\"western\"><surname>Li</surname><given-names>C</given-names></name><etal/></person-group><article-title>Development and validation of a radiomics-based nomogram for predicting a major pathological response to neoadjuvant immunochemotherapy for patients with potentially resectable non-small cell lung cancer</article-title><source>Front Immunol</source><year>2023</year><volume>14</volume><fpage>1115291</fpage><pub-id pub-id-type=\"doi\">10.3389/fimmu.2023.1115291</pub-id><pub-id pub-id-type=\"pmid\">36875128</pub-id><pub-id pub-id-type=\"pmcid\">PMC9978193</pub-id></element-citation><mixed-citation id=\"mc-CR195\" publication-type=\"journal\">Liu C, Zhao W, Xie J, Lin H, Hu X, Li C, et al. Development and validation of a radiomics-based nomogram for predicting a major pathological response to neoadjuvant immunochemotherapy for patients with potentially resectable non-small cell lung cancer. Front Immunol. 2023;14:1115291.<pub-id pub-id-type=\"pmid\">36875128</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.3389/fimmu.2023.1115291</pub-id><pub-id pub-id-type=\"pmcid\">PMC9978193</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR196\"><label>196.</label><citation-alternatives><element-citation id=\"ec-CR196\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Wang</surname><given-names>F</given-names></name><name name-style=\"western\"><surname>Yang</surname><given-names>H</given-names></name><name name-style=\"western\"><surname>Chen</surname><given-names>W</given-names></name><name name-style=\"western\"><surname>Ruan</surname><given-names>L</given-names></name><name name-style=\"western\"><surname>Jiang</surname><given-names>T</given-names></name><name name-style=\"western\"><surname>Cheng</surname><given-names>L</given-names></name><etal/></person-group><article-title>A combined model using pre-treatment CT radiomics and clinicopathological features of non-small cell lung cancer to predict major pathological responses after neoadjuvant chemoimmunotherapy</article-title><source>Curr Probl Cancer</source><year>2024</year><volume>50</volume><fpage>101098</fpage><pub-id pub-id-type=\"doi\">10.1016/j.currproblcancer.2024.101098</pub-id><pub-id pub-id-type=\"pmid\">38704949</pub-id></element-citation><mixed-citation id=\"mc-CR196\" publication-type=\"journal\">Wang F, Yang H, Chen W, Ruan L, Jiang T, Cheng L, et al. A combined model using pre-treatment CT radiomics and clinicopathological features of non-small cell lung cancer to predict major pathological responses after neoadjuvant chemoimmunotherapy. Curr Probl Cancer. 2024;50:101098.<pub-id pub-id-type=\"pmid\">38704949</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/j.currproblcancer.2024.101098</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR197\"><label>197.</label><citation-alternatives><element-citation id=\"ec-CR197\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Li</surname><given-names>C</given-names></name><name name-style=\"western\"><surname>Zhou</surname><given-names>Z</given-names></name><name name-style=\"western\"><surname>Hou</surname><given-names>L</given-names></name><name name-style=\"western\"><surname>Hu</surname><given-names>K</given-names></name><name name-style=\"western\"><surname>Wu</surname><given-names>Z</given-names></name><name name-style=\"western\"><surname>Xie</surname><given-names>Y</given-names></name><etal/></person-group><article-title>A novel machine learning model for efficacy prediction of immunotherapy-chemotherapy in NSCLC based on CT radiomics</article-title><source>Comput Biol Med</source><year>2024</year><volume>178</volume><fpage>108638</fpage><pub-id pub-id-type=\"doi\">10.1016/j.compbiomed.2024.108638</pub-id><pub-id pub-id-type=\"pmid\">38897152</pub-id></element-citation><mixed-citation id=\"mc-CR197\" publication-type=\"journal\">Li C, Zhou Z, Hou L, Hu K, Wu Z, Xie Y, et al. A novel machine learning model for efficacy prediction of immunotherapy-chemotherapy in NSCLC based on CT radiomics. Comput Biol Med. 2024;178:108638.<pub-id pub-id-type=\"pmid\">38897152</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/j.compbiomed.2024.108638</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR198\"><label>198.</label><citation-alternatives><element-citation id=\"ec-CR198\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>She</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>He</surname><given-names>B</given-names></name><name name-style=\"western\"><surname>Wang</surname><given-names>F</given-names></name><name name-style=\"western\"><surname>Zhong</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Wang</surname><given-names>T</given-names></name><name name-style=\"western\"><surname>Liu</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Deep learning for predicting major pathological response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer: a multicentre study</article-title><source>EBioMedicine</source><year>2022</year><pub-id pub-id-type=\"doi\">10.1016/j.ebiom.2022.104364</pub-id><pub-id pub-id-type=\"pmid\">36395737</pub-id><pub-id pub-id-type=\"pmcid\">PMC9672965</pub-id></element-citation><mixed-citation id=\"mc-CR198\" publication-type=\"journal\">She Y, He B, Wang F, Zhong Y, Wang T, Liu Z, et al. Deep learning for predicting major pathological response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer: a multicentre study. EBioMedicine. 2022. 10.1016/j.ebiom.2022.104364.<pub-id pub-id-type=\"pmid\">36395737</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/j.ebiom.2022.104364</pub-id><pub-id pub-id-type=\"pmcid\">PMC9672965</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR199\"><label>199.</label><citation-alternatives><element-citation id=\"ec-CR199\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Zhao</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>He</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Yang</surname><given-names>X</given-names></name><name name-style=\"western\"><surname>Tian</surname><given-names>P</given-names></name><name name-style=\"western\"><surname>Zeng</surname><given-names>L</given-names></name><name name-style=\"western\"><surname>Huang</surname><given-names>K</given-names></name><etal/></person-group><article-title>Assessing treatment outcomes of chemoimmunotherapy in extensive-stage small cell lung cancer: an integrated clinical and radiomics approach</article-title><source>J Immunother Cancer</source><year>2023</year><volume>11</volume><issue>9</issue><fpage>e007492</fpage><pub-id pub-id-type=\"doi\">10.1136/jitc-2023-007492</pub-id><pub-id pub-id-type=\"pmid\">37730276</pub-id><pub-id pub-id-type=\"pmcid\">PMC10514620</pub-id></element-citation><mixed-citation id=\"mc-CR199\" publication-type=\"journal\">Zhao J, He Y, Yang X, Tian P, Zeng L, Huang K, et al. Assessing treatment outcomes of chemoimmunotherapy in extensive-stage small cell lung cancer: an integrated clinical and radiomics approach. J Immunother Cancer. 2023;11(9):e007492.<pub-id pub-id-type=\"pmid\">37730276</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1136/jitc-2023-007492</pub-id><pub-id pub-id-type=\"pmcid\">PMC10514620</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR200\"><label>200.</label><citation-alternatives><element-citation id=\"ec-CR200\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Wang</surname><given-names>JL</given-names></name><name name-style=\"western\"><surname>Tang</surname><given-names>LS</given-names></name><name name-style=\"western\"><surname>Zhong</surname><given-names>X</given-names></name><name name-style=\"western\"><surname>Wang</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Feng</surname><given-names>YJ</given-names></name><name name-style=\"western\"><surname>Zhang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>A machine learning radiomics based on enhanced computed tomography to predict neoadjuvant immunotherapy for resectable esophageal squamous cell carcinoma</article-title><source>Front Immunol</source><year>2024</year><volume>15</volume><fpage>1405146</fpage><pub-id pub-id-type=\"doi\">10.3389/fimmu.2024.1405146</pub-id><pub-id pub-id-type=\"pmid\">38947338</pub-id><pub-id pub-id-type=\"pmcid\">PMC11211602</pub-id></element-citation><mixed-citation id=\"mc-CR200\" publication-type=\"journal\">Wang JL, Tang LS, Zhong X, Wang Y, Feng YJ, Zhang Y, et al. A machine learning radiomics based on enhanced computed tomography to predict neoadjuvant immunotherapy for resectable esophageal squamous cell carcinoma. Front Immunol. 2024;15:1405146.<pub-id pub-id-type=\"pmid\">38947338</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.3389/fimmu.2024.1405146</pub-id><pub-id pub-id-type=\"pmcid\">PMC11211602</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR201\"><label>201.</label><citation-alternatives><element-citation id=\"ec-CR201\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Shi</surname><given-names>L</given-names></name><name name-style=\"western\"><surname>Li</surname><given-names>C</given-names></name><name name-style=\"western\"><surname>Bai</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Cao</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Zhao</surname><given-names>S</given-names></name><name name-style=\"western\"><surname>Chen</surname><given-names>X</given-names></name><etal/></person-group><article-title>CT radiomics to predict pathologic complete response after neoadjuvant immunotherapy plus chemoradiotherapy in locally advanced esophageal squamous cell carcinoma</article-title><source>Eur Radiol</source><year>2025</year><volume>35</volume><issue>3</issue><fpage>1594</fpage><lpage>1604</lpage><pub-id pub-id-type=\"doi\">10.1007/s00330-024-11141-4</pub-id><pub-id pub-id-type=\"pmid\">39470794</pub-id></element-citation><mixed-citation id=\"mc-CR201\" publication-type=\"journal\">Shi L, Li C, Bai Y, Cao Y, Zhao S, Chen X, et al. CT radiomics to predict pathologic complete response after neoadjuvant immunotherapy plus chemoradiotherapy in locally advanced esophageal squamous cell carcinoma. Eur Radiol. 2025;35(3):1594&#8211;604.<pub-id pub-id-type=\"pmid\">39470794</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1007/s00330-024-11141-4</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR202\"><label>202.</label><citation-alternatives><element-citation id=\"ec-CR202\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Kong</surname><given-names>W</given-names></name><name name-style=\"western\"><surname>Xu</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Huang</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Zhu</surname><given-names>K</given-names></name><name name-style=\"western\"><surname>Yao</surname><given-names>L</given-names></name><name name-style=\"western\"><surname>Wu</surname><given-names>K</given-names></name><etal/></person-group><article-title>CT-based habitat radiomics for predicting treatment response to neoadjuvant chemoimmunotherapy in esophageal cancer patients</article-title><source>Front Oncol</source><year>2024</year><volume>14</volume><fpage>1418252</fpage><pub-id pub-id-type=\"doi\">10.3389/fonc.2024.1418252</pub-id><pub-id pub-id-type=\"pmid\">39691599</pub-id><pub-id pub-id-type=\"pmcid\">PMC11649542</pub-id></element-citation><mixed-citation id=\"mc-CR202\" publication-type=\"journal\">Kong W, Xu J, Huang Y, Zhu K, Yao L, Wu K, et al. CT-based habitat radiomics for predicting treatment response to neoadjuvant chemoimmunotherapy in esophageal cancer patients. Front Oncol. 2024;14:1418252.<pub-id pub-id-type=\"pmid\">39691599</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.3389/fonc.2024.1418252</pub-id><pub-id pub-id-type=\"pmcid\">PMC11649542</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR203\"><label>203.</label><citation-alternatives><element-citation id=\"ec-CR203\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Zhang</surname><given-names>Z</given-names></name><name name-style=\"western\"><surname>Luo</surname><given-names>T</given-names></name><name name-style=\"western\"><surname>Yan</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Shen</surname><given-names>H</given-names></name><name name-style=\"western\"><surname>Tao</surname><given-names>K</given-names></name><name name-style=\"western\"><surname>Zeng</surname><given-names>J</given-names></name><etal/></person-group><article-title>Voxel-level radiomics and deep learning for predicting pathologic complete response in esophageal squamous cell carcinoma after neoadjuvant immunotherapy and chemotherapy</article-title><source>J Immunother Cancer</source><year>2025</year><volume>13</volume><issue>3</issue><fpage>e011149</fpage><pub-id pub-id-type=\"doi\">10.1136/jitc-2024-011149</pub-id><pub-id pub-id-type=\"pmid\">40090670</pub-id><pub-id pub-id-type=\"pmcid\">PMC11911808</pub-id></element-citation><mixed-citation id=\"mc-CR203\" publication-type=\"journal\">Zhang Z, Luo T, Yan M, Shen H, Tao K, Zeng J, et al. Voxel-level radiomics and deep learning for predicting pathologic complete response in esophageal squamous cell carcinoma after neoadjuvant immunotherapy and chemotherapy. J Immunother Cancer. 2025;13(3):e011149.<pub-id pub-id-type=\"pmid\">40090670</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1136/jitc-2024-011149</pub-id><pub-id pub-id-type=\"pmcid\">PMC11911808</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR204\"><label>204.</label><citation-alternatives><element-citation id=\"ec-CR204\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Ramtohul</surname><given-names>T</given-names></name><name name-style=\"western\"><surname>Lepagney</surname><given-names>V</given-names></name><name name-style=\"western\"><surname>Bonneau</surname><given-names>C</given-names></name><name name-style=\"western\"><surname>Jin</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Menet</surname><given-names>E</given-names></name><name name-style=\"western\"><surname>Sauge</surname><given-names>J</given-names></name><etal/></person-group><article-title>Use of pretreatment perfusion MRI-based intratumoral heterogeneity to predict pathologic response of triple-negative breast cancer to neoadjuvant chemoimmunotherapy</article-title><source>Radiology</source><year>2024</year><volume>312</volume><issue>3</issue><fpage>e240575</fpage><pub-id pub-id-type=\"doi\">10.1148/radiol.240575</pub-id><pub-id pub-id-type=\"pmid\">39225608</pub-id></element-citation><mixed-citation id=\"mc-CR204\" publication-type=\"journal\">Ramtohul T, Lepagney V, Bonneau C, Jin M, Menet E, Sauge J, et al. Use of pretreatment perfusion MRI-based intratumoral heterogeneity to predict pathologic response of triple-negative breast cancer to neoadjuvant chemoimmunotherapy. Radiology. 2024;312(3):e240575.<pub-id pub-id-type=\"pmid\">39225608</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1148/radiol.240575</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR205\"><label>205.</label><citation-alternatives><element-citation id=\"ec-CR205\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Seban</surname><given-names>RD</given-names></name><name name-style=\"western\"><surname>Arnaud</surname><given-names>E</given-names></name><name name-style=\"western\"><surname>Loirat</surname><given-names>D</given-names></name><name name-style=\"western\"><surname>Cabel</surname><given-names>L</given-names></name><name name-style=\"western\"><surname>Cottu</surname><given-names>P</given-names></name><name name-style=\"western\"><surname>Djerroudi</surname><given-names>L</given-names></name></person-group><article-title>18F]FDG PET/CT for predicting triple-negative breast cancer outcomes after neoadjuvant chemotherapy with or without pembrolizumab</article-title><source>Eur J Nucl Med Mol Imaging</source><year>2023</year><volume>50</volume><issue>13</issue><fpage>4024</fpage><lpage>35</lpage><pub-id pub-id-type=\"doi\">10.1007/s00259-023-06394-y</pub-id><pub-id pub-id-type=\"pmid\">37606858</pub-id></element-citation><mixed-citation id=\"mc-CR205\" publication-type=\"journal\">Seban RD, Arnaud E, Loirat D, Cabel L, Cottu P, Djerroudi L. 18F]FDG PET/CT for predicting triple-negative breast cancer outcomes after neoadjuvant chemotherapy with or without pembrolizumab. Eur J Nucl Med Mol Imaging. 2023;50(13):4024&#8211;35.<pub-id pub-id-type=\"pmid\">37606858</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1007/s00259-023-06394-y</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR206\"><label>206.</label><citation-alternatives><element-citation id=\"ec-CR206\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Lin</surname><given-names>P</given-names></name><name name-style=\"western\"><surname>Xie</surname><given-names>W</given-names></name><name name-style=\"western\"><surname>Li</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Zhang</surname><given-names>C</given-names></name><name name-style=\"western\"><surname>Wu</surname><given-names>H</given-names></name><name name-style=\"western\"><surname>Wan</surname><given-names>H</given-names></name><etal/></person-group><article-title>Intratumoral and peritumoral radiomics of MRIs predicts pathologic complete response to neoadjuvant chemoimmunotherapy in patients with head and neck squamous cell carcinoma</article-title><source>J Immunother Cancer</source><year>2024</year><volume>12</volume><issue>11</issue><fpage>e009616</fpage><pub-id pub-id-type=\"doi\">10.1136/jitc-2024-009616</pub-id><pub-id pub-id-type=\"pmid\">39500529</pub-id><pub-id pub-id-type=\"pmcid\">PMC11552555</pub-id></element-citation><mixed-citation id=\"mc-CR206\" publication-type=\"journal\">Lin P, Xie W, Li Y, Zhang C, Wu H, Wan H, et al. Intratumoral and peritumoral radiomics of MRIs predicts pathologic complete response to neoadjuvant chemoimmunotherapy in patients with head and neck squamous cell carcinoma. J Immunother Cancer. 2024;12(11):e009616.<pub-id pub-id-type=\"pmid\">39500529</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1136/jitc-2024-009616</pub-id><pub-id pub-id-type=\"pmcid\">PMC11552555</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR207\"><label>207.</label><citation-alternatives><element-citation id=\"ec-CR207\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Wang</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Zhang</surname><given-names>W</given-names></name><name name-style=\"western\"><surname>Chen</surname><given-names>L</given-names></name><name name-style=\"western\"><surname>Xie</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Zheng</surname><given-names>X</given-names></name><name name-style=\"western\"><surname>Jin</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Development of an interpretable deep learning model for pathological tumor response assessment after neoadjuvant therapy</article-title><source>Biol Proced Online</source><year>2024</year><volume>26</volume><issue>1</issue><fpage>10</fpage><pub-id pub-id-type=\"doi\">10.1186/s12575-024-00234-5</pub-id><pub-id pub-id-type=\"pmid\">38632527</pub-id><pub-id pub-id-type=\"pmcid\">PMC11022344</pub-id></element-citation><mixed-citation id=\"mc-CR207\" publication-type=\"journal\">Wang Y, Zhang W, Chen L, Xie J, Zheng X, Jin Y, et al. Development of an interpretable deep learning model for pathological tumor response assessment after neoadjuvant therapy. Biol Proced Online. 2024;26(1):10.<pub-id pub-id-type=\"pmid\">38632527</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1186/s12575-024-00234-5</pub-id><pub-id pub-id-type=\"pmcid\">PMC11022344</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR208\"><label>208.</label><citation-alternatives><element-citation id=\"ec-CR208\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Han</surname><given-names>D</given-names></name><name name-style=\"western\"><surname>Li</surname><given-names>H</given-names></name><name name-style=\"western\"><surname>Zheng</surname><given-names>X</given-names></name><name name-style=\"western\"><surname>Fu</surname><given-names>S</given-names></name><name name-style=\"western\"><surname>Wei</surname><given-names>R</given-names></name><name name-style=\"western\"><surname>Zhao</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Whole slide image-based weakly supervised deep learning for predicting major pathological response in non-small cell lung cancer following neoadjuvant chemoimmunotherapy: a multicenter, retrospective, cohort study</article-title><source>Front Immunol</source><year>2024</year><volume>15</volume><fpage>1453232</fpage><pub-id pub-id-type=\"doi\">10.3389/fimmu.2024.1453232</pub-id><pub-id pub-id-type=\"pmid\">39372403</pub-id><pub-id pub-id-type=\"pmcid\">PMC11449764</pub-id></element-citation><mixed-citation id=\"mc-CR208\" publication-type=\"journal\">Han D, Li H, Zheng X, Fu S, Wei R, Zhao Q, et al. Whole slide image-based weakly supervised deep learning for predicting major pathological response in non-small cell lung cancer following neoadjuvant chemoimmunotherapy: a multicenter, retrospective, cohort study. Front Immunol. 2024;15:1453232.<pub-id pub-id-type=\"pmid\">39372403</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.3389/fimmu.2024.1453232</pub-id><pub-id pub-id-type=\"pmcid\">PMC11449764</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR209\"><label>209.</label><citation-alternatives><element-citation id=\"ec-CR209\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Yehan</surname><given-names>Z</given-names></name><name name-style=\"western\"><surname>Sheng</surname><given-names>Q</given-names></name><name name-style=\"western\"><surname>Hong</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Jiayu</surname><given-names>L</given-names></name><name name-style=\"western\"><surname>Jun</surname><given-names>H</given-names></name><name name-style=\"western\"><surname>Juan</surname><given-names>J</given-names></name><etal/></person-group><article-title>To develop a prognostic model for neoadjuvant immunochemotherapy efficacy in esophageal squamous cell carcinoma by analyzing the immune microenvironment</article-title><source>Front Immunol</source><year>2024</year><volume>15</volume><fpage>1312380</fpage><pub-id pub-id-type=\"doi\">10.3389/fimmu.2024.1312380</pub-id><pub-id pub-id-type=\"pmid\">38726002</pub-id><pub-id pub-id-type=\"pmcid\">PMC11079241</pub-id></element-citation><mixed-citation id=\"mc-CR209\" publication-type=\"journal\">Yehan Z, Sheng Q, Hong Y, Jiayu L, Jun H, Juan J, et al. To develop a prognostic model for neoadjuvant immunochemotherapy efficacy in esophageal squamous cell carcinoma by analyzing the immune microenvironment. Front Immunol. 2024;15:1312380.<pub-id pub-id-type=\"pmid\">38726002</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.3389/fimmu.2024.1312380</pub-id><pub-id pub-id-type=\"pmcid\">PMC11079241</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR210\"><label>210.</label><citation-alternatives><element-citation id=\"ec-CR210\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Terada</surname><given-names>K</given-names></name><name name-style=\"western\"><surname>Yoshizawa</surname><given-names>A</given-names></name><name name-style=\"western\"><surname>Liu</surname><given-names>X</given-names></name><name name-style=\"western\"><surname>Ito</surname><given-names>H</given-names></name><name name-style=\"western\"><surname>Hamaji</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Menju</surname><given-names>T</given-names></name><etal/></person-group><article-title>Deep learning for predicting effect of neoadjuvant therapies in non-small cell lung carcinomas with histologic images</article-title><source>Mod Pathol</source><year>2023</year><volume>36</volume><issue>11</issue><fpage>100302</fpage><pub-id pub-id-type=\"doi\">10.1016/j.modpat.2023.100302</pub-id><pub-id pub-id-type=\"pmid\">37580019</pub-id></element-citation><mixed-citation id=\"mc-CR210\" publication-type=\"journal\">Terada K, Yoshizawa A, Liu X, Ito H, Hamaji M, Menju T, et al. Deep learning for predicting effect of neoadjuvant therapies in non-small cell lung carcinomas with histologic images. Mod Pathol. 2023;36(11):100302.<pub-id pub-id-type=\"pmid\">37580019</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/j.modpat.2023.100302</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR211\"><label>211.</label><citation-alternatives><element-citation id=\"ec-CR211\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Han</surname><given-names>Z</given-names></name><name name-style=\"western\"><surname>Zhang</surname><given-names>Z</given-names></name><name name-style=\"western\"><surname>Yang</surname><given-names>X</given-names></name><name name-style=\"western\"><surname>Li</surname><given-names>Z</given-names></name><name name-style=\"western\"><surname>Sang</surname><given-names>S</given-names></name><name name-style=\"western\"><surname>Islam</surname><given-names>MT</given-names></name><etal/></person-group><article-title>Development and interpretation of a pathomics-driven ensemble model for predicting the response to immunotherapy in gastric cancer</article-title><source>J Immunother Cancer</source><year>2024</year><volume>12</volume><issue>5</issue><fpage>e008927</fpage><pub-id pub-id-type=\"doi\">10.1136/jitc-2024-008927</pub-id><pub-id pub-id-type=\"pmid\">38749538</pub-id><pub-id pub-id-type=\"pmcid\">PMC11097892</pub-id></element-citation><mixed-citation id=\"mc-CR211\" publication-type=\"journal\">Han Z, Zhang Z, Yang X, Li Z, Sang S, Islam MT, et al. Development and interpretation of a pathomics-driven ensemble model for predicting the response to immunotherapy in gastric cancer. J Immunother Cancer. 2024;12(5):e008927.<pub-id pub-id-type=\"pmid\">38749538</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1136/jitc-2024-008927</pub-id><pub-id pub-id-type=\"pmcid\">PMC11097892</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR212\"><label>212.</label><citation-alternatives><element-citation id=\"ec-CR212\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Casarrubios</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Provencio</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Nadal</surname><given-names>E</given-names></name><name name-style=\"western\"><surname>Insa</surname><given-names>A</given-names></name><name name-style=\"western\"><surname>Del Rosario</surname><given-names>G-CM</given-names></name><name name-style=\"western\"><surname>L&#225;zaro-Quintela</surname><given-names>M</given-names></name><etal/></person-group><article-title>Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy</article-title><source>J Immunother Cancer</source><year>2022</year><volume>10</volume><issue>9</issue><fpage>e005320</fpage><pub-id pub-id-type=\"doi\">10.1136/jitc-2022-005320</pub-id><pub-id pub-id-type=\"pmid\">36171009</pub-id><pub-id pub-id-type=\"pmcid\">PMC9528578</pub-id></element-citation><mixed-citation id=\"mc-CR212\" publication-type=\"journal\">Casarrubios M, Provencio M, Nadal E, Insa A, Del Rosario G-CM, L&#225;zaro-Quintela M, et al. Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy. J Immunother Cancer. 2022;10(9):e005320.<pub-id pub-id-type=\"pmid\">36171009</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1136/jitc-2022-005320</pub-id><pub-id pub-id-type=\"pmcid\">PMC9528578</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR213\"><label>213.</label><citation-alternatives><element-citation id=\"ec-CR213\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Lu</surname><given-names>X</given-names></name><name name-style=\"western\"><surname>Gou</surname><given-names>Z</given-names></name><name name-style=\"western\"><surname>Chen</surname><given-names>H</given-names></name><name name-style=\"western\"><surname>Li</surname><given-names>L</given-names></name><name name-style=\"western\"><surname>Chen</surname><given-names>F</given-names></name><name name-style=\"western\"><surname>Bao</surname><given-names>C</given-names></name><etal/></person-group><article-title>Gene panel predicts neoadjuvant chemoimmunotherapy response and benefit from immunotherapy in HER2-negative breast cancer</article-title><source>J Immunother Cancer</source><year>2024</year><volume>12</volume><issue>8</issue><fpage>e009587</fpage><pub-id pub-id-type=\"doi\">10.1136/jitc-2024-009587</pub-id><pub-id pub-id-type=\"pmid\">39134345</pub-id><pub-id pub-id-type=\"pmcid\">PMC11337705</pub-id></element-citation><mixed-citation id=\"mc-CR213\" publication-type=\"journal\">Lu X, Gou Z, Chen H, Li L, Chen F, Bao C, et al. Gene panel predicts neoadjuvant chemoimmunotherapy response and benefit from immunotherapy in HER2-negative breast cancer. J Immunother Cancer. 2024;12(8):e009587.<pub-id pub-id-type=\"pmid\">39134345</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1136/jitc-2024-009587</pub-id><pub-id pub-id-type=\"pmcid\">PMC11337705</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR214\"><label>214.</label><citation-alternatives><element-citation id=\"ec-CR214\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Ji</surname><given-names>Z</given-names></name><name name-style=\"western\"><surname>Wang</surname><given-names>X</given-names></name><name name-style=\"western\"><surname>Xin</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Ma</surname><given-names>L</given-names></name><name name-style=\"western\"><surname>Zuo</surname><given-names>D</given-names></name><name name-style=\"western\"><surname>Li</surname><given-names>H</given-names></name><etal/></person-group><article-title>Multiomics reveals tumor microenvironment remodeling in locally advanced gastric and gastroesophageal junction cancer following neoadjuvant immunotherapy and chemotherapy</article-title><source>J Immunother Cancer</source><year>2024</year><volume>12</volume><issue>12</issue><fpage>e010041</fpage><pub-id pub-id-type=\"doi\">10.1136/jitc-2024-010041</pub-id><pub-id pub-id-type=\"pmid\">39653554</pub-id><pub-id pub-id-type=\"pmcid\">PMC11629098</pub-id></element-citation><mixed-citation id=\"mc-CR214\" publication-type=\"journal\">Ji Z, Wang X, Xin J, Ma L, Zuo D, Li H, et al. Multiomics reveals tumor microenvironment remodeling in locally advanced gastric and gastroesophageal junction cancer following neoadjuvant immunotherapy and chemotherapy. J Immunother Cancer. 2024;12(12):e010041.<pub-id pub-id-type=\"pmid\">39653554</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1136/jitc-2024-010041</pub-id><pub-id pub-id-type=\"pmcid\">PMC11629098</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR215\"><label>215.</label><citation-alternatives><element-citation id=\"ec-CR215\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Tang</surname><given-names>H</given-names></name><name name-style=\"western\"><surname>Yang</surname><given-names>Q</given-names></name><name name-style=\"western\"><surname>Tang</surname><given-names>Q</given-names></name><name name-style=\"western\"><surname>Li</surname><given-names>X</given-names></name><name name-style=\"western\"><surname>Ding</surname><given-names>W</given-names></name><name name-style=\"western\"><surname>Chen</surname><given-names>W</given-names></name></person-group><article-title>Integrated transcriptomics unravels implications of glycosylation-regulating signature in diagnosis, prognosis and therapeutic benefits of hepatocellular carcinoma</article-title><source>Comput Biol Med</source><year>2022</year><volume>148</volume><fpage>105886</fpage><pub-id pub-id-type=\"doi\">10.1016/j.compbiomed.2022.105886</pub-id><pub-id pub-id-type=\"pmid\">35973372</pub-id></element-citation><mixed-citation id=\"mc-CR215\" publication-type=\"journal\">Tang H, Yang Q, Tang Q, Li X, Ding W, Chen W. Integrated transcriptomics unravels implications of glycosylation-regulating signature in diagnosis, prognosis and therapeutic benefits of hepatocellular carcinoma. Comput Biol Med. 2022;148:105886.<pub-id pub-id-type=\"pmid\">35973372</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/j.compbiomed.2022.105886</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR216\"><label>216.</label><citation-alternatives><element-citation id=\"ec-CR216\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Liu</surname><given-names>L</given-names></name><name name-style=\"western\"><surname>Liang</surname><given-names>L</given-names></name><name name-style=\"western\"><surname>Luo</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Han</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Lu</surname><given-names>D</given-names></name><name name-style=\"western\"><surname>Cai</surname><given-names>R</given-names></name><etal/></person-group><article-title>Unveiling the power of gut microbiome in predicting neoadjuvant immunochemotherapy responses in esophageal squamous cell carcinoma</article-title><source>Research</source><year>2024</year><volume>7</volume><fpage>0529</fpage><pub-id pub-id-type=\"doi\">10.34133/research.0529</pub-id><pub-id pub-id-type=\"pmid\">39545038</pub-id><pub-id pub-id-type=\"pmcid\">PMC11562848</pub-id></element-citation><mixed-citation id=\"mc-CR216\" publication-type=\"journal\">Liu L, Liang L, Luo Y, Han J, Lu D, Cai R, et al. Unveiling the power of gut microbiome in predicting neoadjuvant immunochemotherapy responses in esophageal squamous cell carcinoma. Research. 2024;7:0529.<pub-id pub-id-type=\"pmid\">39545038</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.34133/research.0529</pub-id><pub-id pub-id-type=\"pmcid\">PMC11562848</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR217\"><label>217.</label><citation-alternatives><element-citation id=\"ec-CR217\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Wu</surname><given-names>C</given-names></name><name name-style=\"western\"><surname>Zhang</surname><given-names>G</given-names></name><name name-style=\"western\"><surname>Wang</surname><given-names>L</given-names></name><name name-style=\"western\"><surname>Hu</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Ju</surname><given-names>Z</given-names></name><name name-style=\"western\"><surname>Tao</surname><given-names>H</given-names></name><etal/></person-group><article-title>Spatial proteomic profiling elucidates immune determinants of neoadjuvant chemo-immunotherapy in esophageal squamous cell carcinoma</article-title><source>Oncogene</source><year>2024</year><volume>43</volume><issue>37</issue><fpage>2751</fpage><lpage>67</lpage><pub-id pub-id-type=\"doi\">10.1038/s41388-024-03123-z</pub-id><pub-id pub-id-type=\"pmid\">39122893</pub-id></element-citation><mixed-citation id=\"mc-CR217\" publication-type=\"journal\">Wu C, Zhang G, Wang L, Hu J, Ju Z, Tao H, et al. Spatial proteomic profiling elucidates immune determinants of neoadjuvant chemo-immunotherapy in esophageal squamous cell carcinoma. Oncogene. 2024;43(37):2751&#8211;67.<pub-id pub-id-type=\"pmid\">39122893</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1038/s41388-024-03123-z</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR218\"><label>218.</label><citation-alternatives><element-citation id=\"ec-CR218\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Zhang</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Zhu</surname><given-names>L</given-names></name><name name-style=\"western\"><surname>Liang</surname><given-names>S</given-names></name><name name-style=\"western\"><surname>Mao</surname><given-names>Z</given-names></name><name name-style=\"western\"><surname>Li</surname><given-names>X</given-names></name><name name-style=\"western\"><surname>Yang</surname><given-names>L</given-names></name><etal/></person-group><article-title>Pulmonary function test-related prognostic models in non-small cell lung cancer patients receiving neoadjuvant chemoimmunotherapy</article-title><source>Front Oncol</source><year>2024</year><volume>14</volume><fpage>1411436</fpage><pub-id pub-id-type=\"doi\">10.3389/fonc.2024.1411436</pub-id><pub-id pub-id-type=\"pmid\">38983930</pub-id><pub-id pub-id-type=\"pmcid\">PMC11231186</pub-id></element-citation><mixed-citation id=\"mc-CR218\" publication-type=\"journal\">Zhang M, Zhu L, Liang S, Mao Z, Li X, Yang L, et al. Pulmonary function test-related prognostic models in non-small cell lung cancer patients receiving neoadjuvant chemoimmunotherapy. Front Oncol. 2024;14:1411436.<pub-id pub-id-type=\"pmid\">38983930</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.3389/fonc.2024.1411436</pub-id><pub-id pub-id-type=\"pmcid\">PMC11231186</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR219\"><label>219.</label><citation-alternatives><element-citation id=\"ec-CR219\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Huang</surname><given-names>Q</given-names></name><name name-style=\"western\"><surname>Liu</surname><given-names>Z</given-names></name><name name-style=\"western\"><surname>Yu</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Rong</surname><given-names>Z</given-names></name><name name-style=\"western\"><surname>Wang</surname><given-names>P</given-names></name><name name-style=\"western\"><surname>Wang</surname><given-names>S</given-names></name><etal/></person-group><article-title>Prediction of response to neoadjuvant chemo-immunotherapy in patients with esophageal squamous cell carcinoma by a rapid breath test</article-title><source>Br J Cancer</source><year>2024</year><volume>130</volume><issue>4</issue><fpage>694</fpage><lpage>700</lpage><pub-id pub-id-type=\"doi\">10.1038/s41416-023-02547-w</pub-id><pub-id pub-id-type=\"pmid\">38177659</pub-id><pub-id pub-id-type=\"pmcid\">PMC10876947</pub-id></element-citation><mixed-citation id=\"mc-CR219\" publication-type=\"journal\">Huang Q, Liu Z, Yu Y, Rong Z, Wang P, Wang S, et al. Prediction of response to neoadjuvant chemo-immunotherapy in patients with esophageal squamous cell carcinoma by a rapid breath test. Br J Cancer. 2024;130(4):694&#8211;700.<pub-id pub-id-type=\"pmid\">38177659</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1038/s41416-023-02547-w</pub-id><pub-id pub-id-type=\"pmcid\">PMC10876947</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR220\"><label>220.</label><citation-alternatives><element-citation id=\"ec-CR220\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Wang</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Song</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Wang</surname><given-names>R</given-names></name><name name-style=\"western\"><surname>Wu</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Li</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Xu</surname><given-names>K</given-names></name><etal/></person-group><article-title>Clinical factors and major pathological response after neoadjuvant chemoimmunotherapy in potentially resectable lung squamous cell carcinoma</article-title><source>Front Oncol</source><year>2024</year><volume>14</volume><fpage>1265228</fpage><pub-id pub-id-type=\"doi\">10.3389/fonc.2024.1265228</pub-id><pub-id pub-id-type=\"pmid\">38680859</pub-id><pub-id pub-id-type=\"pmcid\">PMC11045983</pub-id></element-citation><mixed-citation id=\"mc-CR220\" publication-type=\"journal\">Wang Y, Song Y, Wang R, Wu Y, Li M, Xu K, et al. Clinical factors and major pathological response after neoadjuvant chemoimmunotherapy in potentially resectable lung squamous cell carcinoma. Front Oncol. 2024;14:1265228.<pub-id pub-id-type=\"pmid\">38680859</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.3389/fonc.2024.1265228</pub-id><pub-id pub-id-type=\"pmcid\">PMC11045983</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR221\"><label>221.</label><citation-alternatives><element-citation id=\"ec-CR221\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Hu</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Li</surname><given-names>X</given-names></name><name name-style=\"western\"><surname>Lin</surname><given-names>H</given-names></name><name name-style=\"western\"><surname>Lu</surname><given-names>B</given-names></name><name name-style=\"western\"><surname>Wang</surname><given-names>Q</given-names></name><name name-style=\"western\"><surname>Tong</surname><given-names>L</given-names></name><etal/></person-group><article-title>Easily applicable predictive score for MPR based on parameters before neoadjuvant chemoimmunotherapy in operable NSCLC: a single-center, ambispective, observational study</article-title><source>Int J Surg</source><year>2024</year><volume>110</volume><issue>4</issue><fpage>2275</fpage><lpage>87</lpage><pub-id pub-id-type=\"doi\">10.1097/JS9.0000000000001050</pub-id><pub-id pub-id-type=\"pmid\">38265431</pub-id><pub-id pub-id-type=\"pmcid\">PMC11020048</pub-id></element-citation><mixed-citation id=\"mc-CR221\" publication-type=\"journal\">Hu M, Li X, Lin H, Lu B, Wang Q, Tong L, et al. Easily applicable predictive score for MPR based on parameters before neoadjuvant chemoimmunotherapy in operable NSCLC: a single-center, ambispective, observational study. Int J Surg. 2024;110(4):2275&#8211;87.<pub-id pub-id-type=\"pmid\">38265431</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1097/JS9.0000000000001050</pub-id><pub-id pub-id-type=\"pmcid\">PMC11020048</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR222\"><label>222.</label><citation-alternatives><element-citation id=\"ec-CR222\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Feng</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Wang</surname><given-names>L</given-names></name><name name-style=\"western\"><surname>Yang</surname><given-names>X</given-names></name><name name-style=\"western\"><surname>Chen</surname><given-names>Q</given-names></name><name name-style=\"western\"><surname>Cheng</surname><given-names>X</given-names></name></person-group><article-title>Pathologic complete response prediction to neoadjuvant immunotherapy combined with chemotherapy in resectable locally advanced esophageal squamous cell carcinoma: real-world evidence from integrative inflammatory and nutritional scores</article-title><source>J Inflamm Res</source><year>2022</year><pub-id pub-id-type=\"doi\">10.2147/JIR.S367964</pub-id><pub-id pub-id-type=\"pmid\">35832830</pub-id><pub-id pub-id-type=\"pmcid\">PMC9271687</pub-id></element-citation><mixed-citation id=\"mc-CR222\" publication-type=\"journal\">Feng J, Wang L, Yang X, Chen Q, Cheng X. Pathologic complete response prediction to neoadjuvant immunotherapy combined with chemotherapy in resectable locally advanced esophageal squamous cell carcinoma: real-world evidence from integrative inflammatory and nutritional scores. J Inflamm Res. 2022. 10.2147/JIR.S367964.<pub-id pub-id-type=\"pmid\">35832830</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.2147/JIR.S367964</pub-id><pub-id pub-id-type=\"pmcid\">PMC9271687</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR223\"><label>223.</label><citation-alternatives><element-citation id=\"ec-CR223\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Han</surname><given-names>W</given-names></name><name name-style=\"western\"><surname>Weng</surname><given-names>K</given-names></name><name name-style=\"western\"><surname>Zhang</surname><given-names>P</given-names></name><name name-style=\"western\"><surname>Hong</surname><given-names>Z</given-names></name></person-group><article-title>Predictive value of systemic immune-inflammation index for pathological complete response in patients receiving neoadjuvant immunochemotherapy for locally advanced esophageal cancer</article-title><source>Front Surg</source><year>2023</year><volume>9</volume><fpage>1091601</fpage><pub-id pub-id-type=\"doi\">10.3389/fsurg.2022.1091601</pub-id><pub-id pub-id-type=\"pmid\">36684142</pub-id><pub-id pub-id-type=\"pmcid\">PMC9845901</pub-id></element-citation><mixed-citation id=\"mc-CR223\" publication-type=\"journal\">Han W, Weng K, Zhang P, Hong Z. Predictive value of systemic immune-inflammation index for pathological complete response in patients receiving neoadjuvant immunochemotherapy for locally advanced esophageal cancer. Front Surg. 2023;9:1091601.<pub-id pub-id-type=\"pmid\">36684142</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.3389/fsurg.2022.1091601</pub-id><pub-id pub-id-type=\"pmcid\">PMC9845901</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR224\"><label>224.</label><citation-alternatives><element-citation id=\"ec-CR224\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Zhai</surname><given-names>W</given-names></name><name name-style=\"western\"><surname>Zhang</surname><given-names>C</given-names></name><name name-style=\"western\"><surname>Duan</surname><given-names>F</given-names></name><name name-style=\"western\"><surname>Xie</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Dai</surname><given-names>S</given-names></name><name name-style=\"western\"><surname>Lin</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Dynamics of peripheral blood inflammatory index predict tumor pathological response and survival among patients with locally advanced non-small cell lung cancer who underwent neoadjuvant immunochemotherapy: a multi-cohort retrospective study</article-title><source>Front Immunol</source><year>2024</year><volume>15</volume><fpage>1422717</fpage><pub-id pub-id-type=\"doi\">10.3389/fimmu.2024.1422717</pub-id><pub-id pub-id-type=\"pmid\">39108262</pub-id><pub-id pub-id-type=\"pmcid\">PMC11300317</pub-id></element-citation><mixed-citation id=\"mc-CR224\" publication-type=\"journal\">Zhai W, Zhang C, Duan F, Xie J, Dai S, Lin Y, et al. Dynamics of peripheral blood inflammatory index predict tumor pathological response and survival among patients with locally advanced non-small cell lung cancer who underwent neoadjuvant immunochemotherapy: a multi-cohort retrospective study. Front Immunol. 2024;15:1422717.<pub-id pub-id-type=\"pmid\">39108262</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.3389/fimmu.2024.1422717</pub-id><pub-id pub-id-type=\"pmcid\">PMC11300317</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR225\"><label>225.</label><citation-alternatives><element-citation id=\"ec-CR225\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Zhai</surname><given-names>WY</given-names></name><name name-style=\"western\"><surname>Duan</surname><given-names>FF</given-names></name><name name-style=\"western\"><surname>Lin</surname><given-names>YB</given-names></name><name name-style=\"western\"><surname>Lin</surname><given-names>YB</given-names></name><name name-style=\"western\"><surname>Zhao</surname><given-names>ZR</given-names></name><name name-style=\"western\"><surname>Wang</surname><given-names>JY</given-names></name><etal/></person-group><article-title>Pan-immune-inflammatory value in patients with non-small-cell lung cancer undergoing neoadjuvant immunochemotherapy</article-title><source>J Inflamm Res</source><year>2023</year><pub-id pub-id-type=\"doi\">10.2147/JIR.S418276</pub-id><pub-id pub-id-type=\"pmid\">37576157</pub-id><pub-id pub-id-type=\"pmcid\">PMC10422963</pub-id></element-citation><mixed-citation id=\"mc-CR225\" publication-type=\"journal\">Zhai WY, Duan FF, Lin YB, Lin YB, Zhao ZR, Wang JY, et al. Pan-immune-inflammatory value in patients with non-small-cell lung cancer undergoing neoadjuvant immunochemotherapy. J Inflamm Res. 2023. 10.2147/JIR.S418276.<pub-id pub-id-type=\"pmid\">37576157</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.2147/JIR.S418276</pub-id><pub-id pub-id-type=\"pmcid\">PMC10422963</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR226\"><label>226.</label><citation-alternatives><element-citation id=\"ec-CR226\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Peng</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Zou</surname><given-names>D</given-names></name><name name-style=\"western\"><surname>Han</surname><given-names>L</given-names></name><name name-style=\"western\"><surname>Yin</surname><given-names>Z</given-names></name><name name-style=\"western\"><surname>Hu</surname><given-names>X</given-names></name></person-group><article-title>A support vector machine based on liquid immune profiling predicts major pathological response to chemotherapy plus anti-PD-1/PD-L1 as a neoadjuvant treatment for patients with resectable non-small cell lung cancer</article-title><source>Front Immunol</source><year>2021</year><volume>12</volume><fpage>778276</fpage><pub-id pub-id-type=\"doi\">10.3389/fimmu.2021.778276</pub-id><pub-id pub-id-type=\"pmid\">35095850</pub-id><pub-id pub-id-type=\"pmcid\">PMC8797141</pub-id></element-citation><mixed-citation id=\"mc-CR226\" publication-type=\"journal\">Peng J, Zou D, Han L, Yin Z, Hu X. A support vector machine based on liquid immune profiling predicts major pathological response to chemotherapy plus anti-PD-1/PD-L1 as a neoadjuvant treatment for patients with resectable non-small cell lung cancer. Front Immunol. 2021;12:778276.<pub-id pub-id-type=\"pmid\">35095850</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.3389/fimmu.2021.778276</pub-id><pub-id pub-id-type=\"pmcid\">PMC8797141</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR227\"><label>227.</label><citation-alternatives><element-citation id=\"ec-CR227\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Yang</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Yi</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Wang</surname><given-names>Z</given-names></name><name name-style=\"western\"><surname>Li</surname><given-names>S</given-names></name><name name-style=\"western\"><surname>Zhang</surname><given-names>B</given-names></name><name name-style=\"western\"><surname>Sang</surname><given-names>Z</given-names></name><etal/></person-group><article-title>A combined nomogram based on radiomics and hematology to predict the pathological complete response of neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma</article-title><source>BMC Cancer</source><year>2024</year><volume>24</volume><issue>1</issue><fpage>460</fpage><pub-id pub-id-type=\"doi\">10.1186/s12885-024-12239-0</pub-id><pub-id pub-id-type=\"pmid\">38609892</pub-id><pub-id pub-id-type=\"pmcid\">PMC11015586</pub-id></element-citation><mixed-citation id=\"mc-CR227\" publication-type=\"journal\">Yang Y, Yi Y, Wang Z, Li S, Zhang B, Sang Z, et al. A combined nomogram based on radiomics and hematology to predict the pathological complete response of neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma. BMC Cancer. 2024;24(1):460.<pub-id pub-id-type=\"pmid\">38609892</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1186/s12885-024-12239-0</pub-id><pub-id pub-id-type=\"pmcid\">PMC11015586</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR228\"><label>228.</label><citation-alternatives><element-citation id=\"ec-CR228\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Xu</surname><given-names>L</given-names></name><name name-style=\"western\"><surname>Si</surname><given-names>H</given-names></name><name name-style=\"western\"><surname>Zhuang</surname><given-names>F</given-names></name><name name-style=\"western\"><surname>Li</surname><given-names>C</given-names></name><name name-style=\"western\"><surname>Zhang</surname><given-names>L</given-names></name><name name-style=\"western\"><surname>Zhao</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Predicting therapeutic response to neoadjuvant immunotherapy based on an integration model in resectable stage IIIA (N2) non-small cell lung cancer</article-title><source>J Thorac Cardiovasc Surg</source><year>2025</year><volume>169</volume><issue>1</issue><fpage>242</fpage><lpage>253</lpage><pub-id pub-id-type=\"doi\">10.1016/j.jtcvs.2024.05.006</pub-id><pub-id pub-id-type=\"pmid\">38763304</pub-id></element-citation><mixed-citation id=\"mc-CR228\" publication-type=\"journal\">Xu L, Si H, Zhuang F, Li C, Zhang L, Zhao Y, et al. Predicting therapeutic response to neoadjuvant immunotherapy based on an integration model in resectable stage IIIA (N2) non-small cell lung cancer. J Thorac Cardiovasc Surg. 2025;169(1):242&#8211;53.<pub-id pub-id-type=\"pmid\">38763304</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/j.jtcvs.2024.05.006</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR229\"><label>229.</label><citation-alternatives><element-citation id=\"ec-CR229\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Qi</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Hu</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Lin</surname><given-names>C</given-names></name><name name-style=\"western\"><surname>Song</surname><given-names>G</given-names></name><name name-style=\"western\"><surname>Shi</surname><given-names>L</given-names></name><name name-style=\"western\"><surname>Zhu</surname><given-names>H</given-names></name></person-group><article-title>A preoperative predictive model based on multi-modal features to predict pathological complete response after neoadjuvant chemoimmunotherapy in esophageal cancer patients</article-title><source>Front Immunol</source><year>2025</year><volume>16</volume><fpage>1530279</fpage><pub-id pub-id-type=\"doi\">10.3389/fimmu.2025.1530279</pub-id><pub-id pub-id-type=\"pmid\">39958355</pub-id><pub-id pub-id-type=\"pmcid\">PMC11827421</pub-id></element-citation><mixed-citation id=\"mc-CR229\" publication-type=\"journal\">Qi Y, Hu Y, Lin C, Song G, Shi L, Zhu H. A preoperative predictive model based on multi-modal features to predict pathological complete response after neoadjuvant chemoimmunotherapy in esophageal cancer patients. Front Immunol. 2025;16:1530279.<pub-id pub-id-type=\"pmid\">39958355</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.3389/fimmu.2025.1530279</pub-id><pub-id pub-id-type=\"pmcid\">PMC11827421</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR230\"><label>230.</label><citation-alternatives><element-citation id=\"ec-CR230\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Nie</surname><given-names>F</given-names></name><name name-style=\"western\"><surname>Pei</surname><given-names>X</given-names></name><name name-style=\"western\"><surname>Du</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Shi</surname><given-names>W</given-names></name><name name-style=\"western\"><surname>Wang</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Feng</surname><given-names>L</given-names></name><etal/></person-group><article-title>Multiomics-based deep learning prediction of prognosis and therapeutic response in patients with extensive-stage small cell lung cancer receiving chemoimmunotherapy: a retrospective cohort study</article-title><source>Int J Gen Med</source><year>2025</year><pub-id pub-id-type=\"doi\">10.2147/IJGM.S506485</pub-id><pub-id pub-id-type=\"pmid\">40026810</pub-id><pub-id pub-id-type=\"pmcid\">PMC11869764</pub-id></element-citation><mixed-citation id=\"mc-CR230\" publication-type=\"journal\">Nie F, Pei X, Du J, Shi W, Wang J, Feng L, et al. Multiomics-based deep learning prediction of prognosis and therapeutic response in patients with extensive-stage small cell lung cancer receiving chemoimmunotherapy: a retrospective cohort study. Int J Gen Med. 2025. 10.2147/IJGM.S506485.<pub-id pub-id-type=\"pmid\">40026810</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.2147/IJGM.S506485</pub-id><pub-id pub-id-type=\"pmcid\">PMC11869764</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR231\"><label>231.</label><citation-alternatives><element-citation id=\"ec-CR231\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Gao</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Ventura-Diaz</surname><given-names>S</given-names></name><name name-style=\"western\"><surname>Wang</surname><given-names>X</given-names></name><name name-style=\"western\"><surname>He</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Xu</surname><given-names>Z</given-names></name><name name-style=\"western\"><surname>Weir</surname><given-names>A</given-names></name><etal/></person-group><article-title>An explainable longitudinal multi-modal fusion model for predicting neoadjuvant therapy response in women with breast cancer</article-title><source>Nat Commun</source><year>2024</year><volume>15</volume><issue>1</issue><fpage>9613</fpage><pub-id pub-id-type=\"doi\">10.1038/s41467-024-53450-8</pub-id><pub-id pub-id-type=\"pmid\">39511143</pub-id><pub-id pub-id-type=\"pmcid\">PMC11544255</pub-id></element-citation><mixed-citation id=\"mc-CR231\" publication-type=\"journal\">Gao Y, Ventura-Diaz S, Wang X, He M, Xu Z, Weir A, et al. An explainable longitudinal multi-modal fusion model for predicting neoadjuvant therapy response in women with breast cancer. Nat Commun. 2024;15(1):9613.<pub-id pub-id-type=\"pmid\">39511143</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1038/s41467-024-53450-8</pub-id><pub-id pub-id-type=\"pmcid\">PMC11544255</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR232\"><label>232.</label><mixed-citation publication-type=\"other\">Khanna NN, Maindarkar MA, Viswanathan V, Fernandes JFE, Paul S, Bhagawati M, et&#160;al. Economics of artificial intelligence in healthcare: diagnosis vs. treatment. In: Healthcare. vol.&#160;10. MDPI; 2022. p. 2493.<pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.3390/healthcare10122493</pub-id><pub-id pub-id-type=\"pmcid\">PMC9777836</pub-id><pub-id pub-id-type=\"pmid\">36554017</pub-id></mixed-citation></ref><ref id=\"CR233\"><label>233.</label><citation-alternatives><element-citation id=\"ec-CR233\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Askr</surname><given-names>H</given-names></name><name name-style=\"western\"><surname>Elgeldawi</surname><given-names>E</given-names></name><name name-style=\"western\"><surname>Aboul Ella</surname><given-names>H</given-names></name><name name-style=\"western\"><surname>Elshaier</surname><given-names>YA</given-names></name><name name-style=\"western\"><surname>Gomaa</surname><given-names>MM</given-names></name><name name-style=\"western\"><surname>Hassanien</surname><given-names>AE</given-names></name></person-group><article-title>Deep learning in drug discovery: an integrative review and future challenges</article-title><source>Artif Intell Rev</source><year>2023</year><volume>56</volume><issue>7</issue><fpage>5975</fpage><lpage>6037</lpage><pub-id pub-id-type=\"doi\">10.1007/s10462-022-10306-1</pub-id><pub-id pub-id-type=\"pmid\">36415536</pub-id><pub-id pub-id-type=\"pmcid\">PMC9669545</pub-id></element-citation><mixed-citation id=\"mc-CR233\" publication-type=\"journal\">Askr H, Elgeldawi E, Aboul Ella H, Elshaier YA, Gomaa MM, Hassanien AE. Deep learning in drug discovery: an integrative review and future challenges. Artif Intell Rev. 2023;56(7):5975&#8211;6037.<pub-id pub-id-type=\"pmid\">36415536</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1007/s10462-022-10306-1</pub-id><pub-id pub-id-type=\"pmcid\">PMC9669545</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR234\"><label>234.</label><citation-alternatives><element-citation id=\"ec-CR234\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Nam</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Kim</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Jung</surname><given-names>SH</given-names></name><name name-style=\"western\"><surname>Woerner</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Suh</surname><given-names>EH</given-names></name><name name-style=\"western\"><surname>Lee</surname><given-names>Dg</given-names></name><etal/></person-group><article-title>Harnessing artificial intelligence in multimodal omics data integration: paving the path for the next frontier in precision medicine</article-title><source>Annu Rev Biomed Data Sci</source><year>2024</year><pub-id pub-id-type=\"doi\">10.1146/annurev-biodatasci-102523-103801</pub-id><pub-id pub-id-type=\"pmid\">38768397</pub-id><pub-id pub-id-type=\"pmcid\">PMC11972123</pub-id></element-citation><mixed-citation id=\"mc-CR234\" publication-type=\"journal\">Nam Y, Kim J, Jung SH, Woerner J, Suh EH, Lee Dg, et al. Harnessing artificial intelligence in multimodal omics data integration: paving the path for the next frontier in precision medicine. Annu Rev Biomed Data Sci. 2024. 10.1146/annurev-biodatasci-102523-103801.<pub-id pub-id-type=\"pmid\">38768397</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1146/annurev-biodatasci-102523-103801</pub-id><pub-id pub-id-type=\"pmcid\">PMC11972123</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR235\"><label>235.</label><citation-alternatives><element-citation id=\"ec-CR235\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Cai</surname><given-names>Z</given-names></name><name name-style=\"western\"><surname>Poulos</surname><given-names>RC</given-names></name><name name-style=\"western\"><surname>Liu</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Zhong</surname><given-names>Q</given-names></name></person-group><article-title>Machine learning for multi-omics data integration in cancer</article-title><source>iScience</source><year>2022</year><pub-id pub-id-type=\"doi\">10.1016/j.isci.2022.103798</pub-id><pub-id pub-id-type=\"pmid\">35169688</pub-id><pub-id pub-id-type=\"pmcid\">PMC8829812</pub-id></element-citation><mixed-citation id=\"mc-CR235\" publication-type=\"journal\">Cai Z, Poulos RC, Liu J, Zhong Q. Machine learning for multi-omics data integration in cancer. iScience. 2022. 10.1016/j.isci.2022.103798.<pub-id pub-id-type=\"pmid\">35169688</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/j.isci.2022.103798</pub-id><pub-id pub-id-type=\"pmcid\">PMC8829812</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR236\"><label>236.</label><citation-alternatives><element-citation id=\"ec-CR236\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Acharya</surname><given-names>D</given-names></name><name name-style=\"western\"><surname>Mukhopadhyay</surname><given-names>A</given-names></name></person-group><article-title>A comprehensive review of machine learning techniques for multi-omics data integration: challenges and applications in precision oncology</article-title><source>Brief Funct Genomics</source><year>2024</year><volume>23</volume><issue>5</issue><fpage>549</fpage><lpage>60</lpage><pub-id pub-id-type=\"doi\">10.1093/bfgp/elae013</pub-id><pub-id pub-id-type=\"pmid\">38600757</pub-id></element-citation><mixed-citation id=\"mc-CR236\" publication-type=\"journal\">Acharya D, Mukhopadhyay A. A comprehensive review of machine learning techniques for multi-omics data integration: challenges and applications in precision oncology. Brief Funct Genomics. 2024;23(5):549&#8211;60.<pub-id pub-id-type=\"pmid\">38600757</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1093/bfgp/elae013</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR237\"><label>237.</label><citation-alternatives><element-citation id=\"ec-CR237\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Tuminello</surname><given-names>S</given-names></name><name name-style=\"western\"><surname>Sikavi</surname><given-names>D</given-names></name><name name-style=\"western\"><surname>Veluswamy</surname><given-names>R</given-names></name><name name-style=\"western\"><surname>Gamarra</surname><given-names>C</given-names></name><name name-style=\"western\"><surname>Lieberman-Cribbin</surname><given-names>W</given-names></name><name name-style=\"western\"><surname>Flores</surname><given-names>R</given-names></name><etal/></person-group><article-title>PD-L1 as a prognostic biomarker in surgically resectable non-small cell lung cancer: a meta-analysis</article-title><source>Transl Lung Cancer Res</source><year>2020</year><volume>9</volume><issue>4</issue><fpage>1343</fpage><pub-id pub-id-type=\"doi\">10.21037/tlcr-19-638</pub-id><pub-id pub-id-type=\"pmid\">32953509</pub-id><pub-id pub-id-type=\"pmcid\">PMC7481631</pub-id></element-citation><mixed-citation id=\"mc-CR237\" publication-type=\"journal\">Tuminello S, Sikavi D, Veluswamy R, Gamarra C, Lieberman-Cribbin W, Flores R, et al. PD-L1 as a prognostic biomarker in surgically resectable non-small cell lung cancer: a meta-analysis. Transl Lung Cancer Res. 2020;9(4):1343.<pub-id pub-id-type=\"pmid\">32953509</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.21037/tlcr-19-638</pub-id><pub-id pub-id-type=\"pmcid\">PMC7481631</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR238\"><label>238.</label><citation-alternatives><element-citation id=\"ec-CR238\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Strickler</surname><given-names>JH</given-names></name><name name-style=\"western\"><surname>Hanks</surname><given-names>BA</given-names></name><name name-style=\"western\"><surname>Khasraw</surname><given-names>M</given-names></name></person-group><article-title>Tumor mutational burden as a predictor of immunotherapy response: is more always better?</article-title><source>Clin Cancer Res</source><year>2021</year><volume>27</volume><issue>5</issue><fpage>1236</fpage><lpage>41</lpage><pub-id pub-id-type=\"doi\">10.1158/1078-0432.CCR-20-3054</pub-id><pub-id pub-id-type=\"pmid\">33199494</pub-id><pub-id pub-id-type=\"pmcid\">PMC9912042</pub-id></element-citation><mixed-citation id=\"mc-CR238\" publication-type=\"journal\">Strickler JH, Hanks BA, Khasraw M. Tumor mutational burden as a predictor of immunotherapy response: is more always better? Clin Cancer Res. 2021;27(5):1236&#8211;41.<pub-id pub-id-type=\"pmid\">33199494</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1158/1078-0432.CCR-20-3054</pub-id><pub-id pub-id-type=\"pmcid\">PMC9912042</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR239\"><label>239.</label><citation-alternatives><element-citation id=\"ec-CR239\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Tao</surname><given-names>W</given-names></name><name name-style=\"western\"><surname>Sun</surname><given-names>Q</given-names></name><name name-style=\"western\"><surname>Xu</surname><given-names>B</given-names></name><name name-style=\"western\"><surname>Wang</surname><given-names>R</given-names></name></person-group><article-title>Towards the prediction of responses to cancer immunotherapy: a multi-omics review</article-title><source>Life</source><year>2025</year><volume>15</volume><issue>2</issue><fpage>283</fpage><pub-id pub-id-type=\"doi\">10.3390/life15020283</pub-id><pub-id pub-id-type=\"pmid\">40003691</pub-id><pub-id pub-id-type=\"pmcid\">PMC11856636</pub-id></element-citation><mixed-citation id=\"mc-CR239\" publication-type=\"journal\">Tao W, Sun Q, Xu B, Wang R. Towards the prediction of responses to cancer immunotherapy: a multi-omics review. Life. 2025;15(2):283.<pub-id pub-id-type=\"pmid\">40003691</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.3390/life15020283</pub-id><pub-id pub-id-type=\"pmcid\">PMC11856636</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR240\"><label>240.</label><citation-alternatives><element-citation id=\"ec-CR240\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Venetis</surname><given-names>K</given-names></name><name name-style=\"western\"><surname>Frascarelli</surname><given-names>C</given-names></name><name name-style=\"western\"><surname>Bielo</surname><given-names>LB</given-names></name><name name-style=\"western\"><surname>Cursano</surname><given-names>G</given-names></name><name name-style=\"western\"><surname>Adorisio</surname><given-names>R</given-names></name><name name-style=\"western\"><surname>Ivanova</surname><given-names>M</given-names></name><etal/></person-group><article-title>Mismatch repair (MMR) and microsatellite instability (MSI) phenotypes across solid tumors: a comprehensive cBioPortal study on prevalence and prognostic impact</article-title><source>Eur J Cancer</source><year>2025</year><volume>217</volume><fpage>115233</fpage><pub-id pub-id-type=\"doi\">10.1016/j.ejca.2025.115233</pub-id><pub-id pub-id-type=\"pmid\">39827722</pub-id></element-citation><mixed-citation id=\"mc-CR240\" publication-type=\"journal\">Venetis K, Frascarelli C, Bielo LB, Cursano G, Adorisio R, Ivanova M, et al. Mismatch repair (MMR) and microsatellite instability (MSI) phenotypes across solid tumors: a comprehensive cBioPortal study on prevalence and prognostic impact. Eur J Cancer. 2025;217:115233.<pub-id pub-id-type=\"pmid\">39827722</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/j.ejca.2025.115233</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR241\"><label>241.</label><citation-alternatives><element-citation id=\"ec-CR241\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Zhu</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Zhao</surname><given-names>F</given-names></name><name name-style=\"western\"><surname>Li</surname><given-names>Z</given-names></name><name name-style=\"western\"><surname>Yu</surname><given-names>J</given-names></name></person-group><article-title>Current landscape and future directions of biomarkers for predicting responses to immune checkpoint inhibitors</article-title><source>Cancer Manag Res</source><year>2018</year><pub-id pub-id-type=\"doi\">10.2147/CMAR.S167400</pub-id><pub-id pub-id-type=\"pmid\">30122997</pub-id><pub-id pub-id-type=\"pmcid\">PMC6086110</pub-id></element-citation><mixed-citation id=\"mc-CR241\" publication-type=\"journal\">Zhu Y, Zhao F, Li Z, Yu J. Current landscape and future directions of biomarkers for predicting responses to immune checkpoint inhibitors. Cancer Manag Res. 2018. 10.2147/CMAR.S167400.<pub-id pub-id-type=\"pmid\">30122997</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.2147/CMAR.S167400</pub-id><pub-id pub-id-type=\"pmcid\">PMC6086110</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR242\"><label>242.</label><citation-alternatives><element-citation id=\"ec-CR242\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Li</surname><given-names>X</given-names></name><name name-style=\"western\"><surname>Wang</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Wang</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Yu</surname><given-names>X</given-names></name><name name-style=\"western\"><surname>Guo</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Sun</surname><given-names>T</given-names></name><etal/></person-group><article-title>Predictive and prognostic roles of pathological indicators for patients with breast cancer on neoadjuvant chemotherapy</article-title><source>J Breast Cancer</source><year>2019</year><volume>22</volume><issue>4</issue><fpage>497</fpage><lpage>521</lpage><pub-id pub-id-type=\"doi\">10.4048/jbc.2019.22.e49</pub-id><pub-id pub-id-type=\"pmid\">31897326</pub-id><pub-id pub-id-type=\"pmcid\">PMC6933033</pub-id></element-citation><mixed-citation id=\"mc-CR242\" publication-type=\"journal\">Li X, Wang M, Wang M, Yu X, Guo J, Sun T, et al. Predictive and prognostic roles of pathological indicators for patients with breast cancer on neoadjuvant chemotherapy. J Breast Cancer. 2019;22(4):497&#8211;521.<pub-id pub-id-type=\"pmid\">31897326</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.4048/jbc.2019.22.e49</pub-id><pub-id pub-id-type=\"pmcid\">PMC6933033</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR243\"><label>243.</label><mixed-citation publication-type=\"other\">Domenghino A, Walbert C, Birrer DL, Puhan MA, Clavien PA, consensus&#160;group Jury Heuskel Dieter 4 Man Nancy Kwan 5 Monteiro Jo&#227;o 6 Perellon Juan F 7 P&#233;rez Mart&#237;nez Sara 8 9 10 Seedat Soraya 11 Urbaniok Frank 12 13 Woodbridge&#160;Jayson O, et&#160;al. Consensus recommendations on how to assess the quality of surgical interventions. Nat Med. 2023;29(4):811&#8211;822.<pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1038/s41591-023-02237-3</pub-id><pub-id pub-id-type=\"pmid\">37069361</pub-id></mixed-citation></ref><ref id=\"CR244\"><label>244.</label><citation-alternatives><element-citation id=\"ec-CR244\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Cortazar</surname><given-names>P</given-names></name><name name-style=\"western\"><surname>Zhang</surname><given-names>L</given-names></name><name name-style=\"western\"><surname>Untch</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Mehta</surname><given-names>K</given-names></name><name name-style=\"western\"><surname>Costantino</surname><given-names>JP</given-names></name><name name-style=\"western\"><surname>Wolmark</surname><given-names>N</given-names></name><etal/></person-group><article-title>Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis</article-title><source>Lancet</source><year>2014</year><volume>384</volume><issue>9938</issue><fpage>164</fpage><lpage>72</lpage><pub-id pub-id-type=\"doi\">10.1016/S0140-6736(13)62422-8</pub-id><pub-id pub-id-type=\"pmid\">24529560</pub-id></element-citation><mixed-citation id=\"mc-CR244\" publication-type=\"journal\">Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164&#8211;72.<pub-id pub-id-type=\"pmid\">24529560</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/S0140-6736(13)62422-8</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR245\"><label>245.</label><citation-alternatives><element-citation id=\"ec-CR245\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Hellmann</surname><given-names>MD</given-names></name><name name-style=\"western\"><surname>Chaft</surname><given-names>JE</given-names></name><name name-style=\"western\"><surname>William</surname><given-names>WN</given-names></name><name name-style=\"western\"><surname>Rusch</surname><given-names>V</given-names></name><name name-style=\"western\"><surname>Pisters</surname><given-names>KM</given-names></name><name name-style=\"western\"><surname>Kalhor</surname><given-names>N</given-names></name><etal/></person-group><article-title>Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint</article-title><source>Lancet Oncol</source><year>2014</year><volume>15</volume><issue>1</issue><fpage>e42</fpage><lpage>e50</lpage><pub-id pub-id-type=\"doi\">10.1016/S1470-2045(13)70334-6</pub-id><pub-id pub-id-type=\"pmid\">24384493</pub-id><pub-id pub-id-type=\"pmcid\">PMC4734624</pub-id></element-citation><mixed-citation id=\"mc-CR245\" publication-type=\"journal\">Hellmann MD, Chaft JE, William WN, Rusch V, Pisters KM, Kalhor N, et al. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol. 2014;15(1):e42&#8211;50.<pub-id pub-id-type=\"pmid\">24384493</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/S1470-2045(13)70334-6</pub-id><pub-id pub-id-type=\"pmcid\">PMC4734624</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR246\"><label>246.</label><citation-alternatives><element-citation id=\"ec-CR246\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Dong</surname><given-names>F</given-names></name><name name-style=\"western\"><surname>Yan</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Zhang</surname><given-names>X</given-names></name><name name-style=\"western\"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Liu</surname><given-names>D</given-names></name><name name-style=\"western\"><surname>Pan</surname><given-names>X</given-names></name><etal/></person-group><article-title>Artificial intelligence-based predictive model for guidance on treatment strategy selection in oral and maxillofacial surgery</article-title><source>Heliyon</source><year>2024</year><pub-id pub-id-type=\"doi\">10.1016/j.heliyon.2024.e35742</pub-id><pub-id pub-id-type=\"pmid\">39170321</pub-id><pub-id pub-id-type=\"pmcid\">PMC11336844</pub-id></element-citation><mixed-citation id=\"mc-CR246\" publication-type=\"journal\">Dong F, Yan J, Zhang X, Zhang Y, Liu D, Pan X, et al. Artificial intelligence-based predictive model for guidance on treatment strategy selection in oral and maxillofacial surgery. Heliyon. 2024. 10.1016/j.heliyon.2024.e35742.<pub-id pub-id-type=\"pmid\">39170321</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/j.heliyon.2024.e35742</pub-id><pub-id pub-id-type=\"pmcid\">PMC11336844</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR247\"><label>247.</label><citation-alternatives><element-citation id=\"ec-CR247\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Waqas</surname><given-names>A</given-names></name><name name-style=\"western\"><surname>Naveed</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Shahnawaz</surname><given-names>W</given-names></name><name name-style=\"western\"><surname>Asghar</surname><given-names>S</given-names></name><name name-style=\"western\"><surname>Bui</surname><given-names>MM</given-names></name><name name-style=\"western\"><surname>Rasool</surname><given-names>G</given-names></name></person-group><article-title>Digital pathology and multimodal learning on oncology data</article-title><source>BJR|Artificial Intelligence</source><year>2024</year><volume>1</volume><issue>1</issue><fpage>ubae014</fpage><pub-id pub-id-type=\"doi\">10.1093/bjrai/ubae014</pub-id></element-citation><mixed-citation id=\"mc-CR247\" publication-type=\"journal\">Waqas A, Naveed J, Shahnawaz W, Asghar S, Bui MM, Rasool G. Digital pathology and multimodal learning on oncology data. BJR|Artificial Intelligence. 2024;1(1):ubae014.</mixed-citation></citation-alternatives></ref><ref id=\"CR248\"><label>248.</label><citation-alternatives><element-citation id=\"ec-CR248\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Rudin</surname><given-names>C</given-names></name></person-group><article-title>Stop explaining black box machine learning models for high stakes decisions and use interpretable models instead</article-title><source>Nat Mach Intell</source><year>2019</year><volume>1</volume><issue>5</issue><fpage>206</fpage><lpage>215</lpage><pub-id pub-id-type=\"doi\">10.1038/s42256-019-0048-x</pub-id><pub-id pub-id-type=\"pmid\">35603010</pub-id><pub-id pub-id-type=\"pmcid\">PMC9122117</pub-id></element-citation><mixed-citation id=\"mc-CR248\" publication-type=\"journal\">Rudin C. Stop explaining black box machine learning models for high stakes decisions and use interpretable models instead. Nat Mach Intell. 2019;1(5):206&#8211;15.<pub-id pub-id-type=\"pmid\">35603010</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1038/s42256-019-0048-x</pub-id><pub-id pub-id-type=\"pmcid\">PMC9122117</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR249\"><label>249.</label><citation-alternatives><element-citation id=\"ec-CR249\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Ghassemi</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Oakden-Rayner</surname><given-names>L</given-names></name><name name-style=\"western\"><surname>Beam</surname><given-names>AL</given-names></name></person-group><article-title>The false hope of current approaches to explainable artificial intelligence in health care</article-title><source>Lancet Digit Health</source><year>2021</year><volume>3</volume><issue>11</issue><fpage>e745</fpage><lpage>e750</lpage><pub-id pub-id-type=\"doi\">10.1016/S2589-7500(21)00208-9</pub-id><pub-id pub-id-type=\"pmid\">34711379</pub-id></element-citation><mixed-citation id=\"mc-CR249\" publication-type=\"journal\">Ghassemi M, Oakden-Rayner L, Beam AL. The false hope of current approaches to explainable artificial intelligence in health care. Lancet Digit Health. 2021;3(11):e745&#8211;50.<pub-id pub-id-type=\"pmid\">34711379</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/S2589-7500(21)00208-9</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR250\"><label>250.</label><citation-alternatives><element-citation id=\"ec-CR250\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Lu</surname><given-names>SC</given-names></name><name name-style=\"western\"><surname>Swisher</surname><given-names>CL</given-names></name><name name-style=\"western\"><surname>Chung</surname><given-names>C</given-names></name><name name-style=\"western\"><surname>Jaffray</surname><given-names>D</given-names></name><name name-style=\"western\"><surname>Sidey-Gibbons</surname><given-names>C</given-names></name></person-group><article-title>On the importance of interpretable machine learning predictions to inform clinical decision making in oncology</article-title><source>Front Oncol</source><year>2023</year><volume>13</volume><fpage>1129380</fpage><pub-id pub-id-type=\"doi\">10.3389/fonc.2023.1129380</pub-id><pub-id pub-id-type=\"pmid\">36925929</pub-id><pub-id pub-id-type=\"pmcid\">PMC10013157</pub-id></element-citation><mixed-citation id=\"mc-CR250\" publication-type=\"journal\">Lu SC, Swisher CL, Chung C, Jaffray D, Sidey-Gibbons C. On the importance of interpretable machine learning predictions to inform clinical decision making in oncology. Front Oncol. 2023;13:1129380.<pub-id pub-id-type=\"pmid\">36925929</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.3389/fonc.2023.1129380</pub-id><pub-id pub-id-type=\"pmcid\">PMC10013157</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR251\"><label>251.</label><citation-alternatives><element-citation id=\"ec-CR251\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Alzubaidi</surname><given-names>L</given-names></name><name name-style=\"western\"><surname>Zhang</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Humaidi</surname><given-names>AJ</given-names></name><name name-style=\"western\"><surname>Al-Dujaili</surname><given-names>A</given-names></name><name name-style=\"western\"><surname>Duan</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Al-Shamma</surname><given-names>O</given-names></name><etal/></person-group><article-title>Review of deep learning: concepts, CNN architectures, challenges, applications, future directions</article-title><source>J Big Data</source><year>2021</year><volume>8</volume><fpage>1</fpage><lpage>74</lpage><pub-id pub-id-type=\"doi\">10.1186/s40537-021-00444-8</pub-id><pub-id pub-id-type=\"pmid\">33816053</pub-id><pub-id pub-id-type=\"pmcid\">PMC8010506</pub-id></element-citation><mixed-citation id=\"mc-CR251\" publication-type=\"journal\">Alzubaidi L, Zhang J, Humaidi AJ, Al-Dujaili A, Duan Y, Al-Shamma O, et al. Review of deep learning: concepts, CNN architectures, challenges, applications, future directions. J Big Data. 2021;8:1&#8211;74.<pub-id pub-id-type=\"pmid\">33816053</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1186/s40537-021-00444-8</pub-id><pub-id pub-id-type=\"pmcid\">PMC8010506</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR252\"><label>252.</label><citation-alternatives><element-citation id=\"ec-CR252\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Marey</surname><given-names>A</given-names></name><name name-style=\"western\"><surname>Arjmand</surname><given-names>P</given-names></name><name name-style=\"western\"><surname>Alerab</surname><given-names>ADS</given-names></name><name name-style=\"western\"><surname>Eslami</surname><given-names>MJ</given-names></name><name name-style=\"western\"><surname>Saad</surname><given-names>AM</given-names></name><name name-style=\"western\"><surname>Sanchez</surname><given-names>N</given-names></name><etal/></person-group><article-title>Explainability, transparency and black box challenges of AI in radiology: impact on patient care in cardiovascular radiology</article-title><source>Egypt J Radiol Nucl Med</source><year>2024</year><volume>55</volume><issue>1</issue><fpage>183</fpage><pub-id pub-id-type=\"doi\">10.1186/s43055-024-01356-2</pub-id></element-citation><mixed-citation id=\"mc-CR252\" publication-type=\"journal\">Marey A, Arjmand P, Alerab ADS, Eslami MJ, Saad AM, Sanchez N, et al. Explainability, transparency and black box challenges of AI in radiology: impact on patient care in cardiovascular radiology. Egypt J Radiol Nucl Med. 2024;55(1):183.</mixed-citation></citation-alternatives></ref><ref id=\"CR253\"><label>253.</label><citation-alternatives><element-citation id=\"ec-CR253\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Vimbi</surname><given-names>V</given-names></name><name name-style=\"western\"><surname>Shaffi</surname><given-names>N</given-names></name><name name-style=\"western\"><surname>Mahmud</surname><given-names>M</given-names></name></person-group><article-title>Interpreting artificial intelligence models: a systematic review on the application of LIME and SHAP in Alzheimer&#8217;s disease detection</article-title><source>Brain Inform</source><year>2024</year><volume>11</volume><issue>1</issue><fpage>10</fpage><pub-id pub-id-type=\"doi\">10.1186/s40708-024-00222-1</pub-id><pub-id pub-id-type=\"pmid\">38578524</pub-id><pub-id pub-id-type=\"pmcid\">PMC10997568</pub-id></element-citation><mixed-citation id=\"mc-CR253\" publication-type=\"journal\">Vimbi V, Shaffi N, Mahmud M. Interpreting artificial intelligence models: a systematic review on the application of LIME and SHAP in Alzheimer&#8217;s disease detection. Brain Inform. 2024;11(1):10.<pub-id pub-id-type=\"pmid\">38578524</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1186/s40708-024-00222-1</pub-id><pub-id pub-id-type=\"pmcid\">PMC10997568</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR254\"><label>254.</label><citation-alternatives><element-citation id=\"ec-CR254\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Saranya</surname><given-names>A</given-names></name><name name-style=\"western\"><surname>Subhashini</surname><given-names>R</given-names></name></person-group><article-title>A systematic review of explainable artificial intelligence models and applications: recent developments and future trends</article-title><source>Decis Anal J</source><year>2023</year><volume>7</volume><fpage>100230</fpage><pub-id pub-id-type=\"doi\">10.1016/j.dajour.2023.100230</pub-id></element-citation><mixed-citation id=\"mc-CR254\" publication-type=\"journal\">Saranya A, Subhashini R. A systematic review of explainable artificial intelligence models and applications: recent developments and future trends. Decis Anal J. 2023;7:100230.</mixed-citation></citation-alternatives></ref><ref id=\"CR255\"><label>255.</label><citation-alternatives><element-citation id=\"ec-CR255\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Nahiduzzaman</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Abdulrazak</surname><given-names>LF</given-names></name><name name-style=\"western\"><surname>Kibria</surname><given-names>HB</given-names></name><name name-style=\"western\"><surname>Khandakar</surname><given-names>A</given-names></name><name name-style=\"western\"><surname>Ayari</surname><given-names>MA</given-names></name><name name-style=\"western\"><surname>Ahamed</surname><given-names>MF</given-names></name><etal/></person-group><article-title>A hybrid explainable model based on advanced machine learning and deep learning models for classifying brain tumors using MRI images</article-title><source>Sci Rep</source><year>2025</year><volume>15</volume><issue>1</issue><fpage>1649</fpage><pub-id pub-id-type=\"doi\">10.1038/s41598-025-85874-7</pub-id><pub-id pub-id-type=\"pmid\">39794374</pub-id><pub-id pub-id-type=\"pmcid\">PMC11724088</pub-id></element-citation><mixed-citation id=\"mc-CR255\" publication-type=\"journal\">Nahiduzzaman M, Abdulrazak LF, Kibria HB, Khandakar A, Ayari MA, Ahamed MF, et al. A hybrid explainable model based on advanced machine learning and deep learning models for classifying brain tumors using MRI images. Sci Rep. 2025;15(1):1649.<pub-id pub-id-type=\"pmid\">39794374</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1038/s41598-025-85874-7</pub-id><pub-id pub-id-type=\"pmcid\">PMC11724088</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR256\"><label>256.</label><citation-alternatives><element-citation id=\"ec-CR256\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Luca</surname><given-names>AR</given-names></name><name name-style=\"western\"><surname>Ursuleanu</surname><given-names>TF</given-names></name><name name-style=\"western\"><surname>Gheorghe</surname><given-names>L</given-names></name><name name-style=\"western\"><surname>Grigorovici</surname><given-names>R</given-names></name><name name-style=\"western\"><surname>Iancu</surname><given-names>S</given-names></name><name name-style=\"western\"><surname>Hlusneac</surname><given-names>M</given-names></name><etal/></person-group><article-title>Impact of quality, type and volume of data used by deep learning models in the analysis of medical images</article-title><source>Inf Med Unlocked</source><year>2022</year><volume>29</volume><fpage>100911</fpage><pub-id pub-id-type=\"doi\">10.1016/j.imu.2022.100911</pub-id></element-citation><mixed-citation id=\"mc-CR256\" publication-type=\"journal\">Luca AR, Ursuleanu TF, Gheorghe L, Grigorovici R, Iancu S, Hlusneac M, et al. Impact of quality, type and volume of data used by deep learning models in the analysis of medical images. Inf Med Unlocked. 2022;29:100911.</mixed-citation></citation-alternatives></ref><ref id=\"CR257\"><label>257.</label><citation-alternatives><element-citation id=\"ec-CR257\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Sarker</surname><given-names>IH</given-names></name></person-group><article-title>Deep learning: a comprehensive overview on techniques, taxonomy, applications and research directions</article-title><source>SN Comput Sci</source><year>2021</year><volume>2</volume><issue>6</issue><fpage>1</fpage><lpage>20</lpage><pub-id pub-id-type=\"doi\">10.1007/s42979-021-00815-1</pub-id><pub-id pub-id-type=\"pmcid\">PMC8372231</pub-id><pub-id pub-id-type=\"pmid\">34426802</pub-id></element-citation><mixed-citation id=\"mc-CR257\" publication-type=\"journal\">Sarker IH. Deep learning: a comprehensive overview on techniques, taxonomy, applications and research directions. SN Comput Sci. 2021;2(6):1&#8211;20.<pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1007/s42979-021-00815-1</pub-id><pub-id pub-id-type=\"pmcid\">PMC8372231</pub-id><pub-id pub-id-type=\"pmid\">34426802</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR258\"><label>258.</label><citation-alternatives><element-citation id=\"ec-CR258\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Zhao</surname><given-names>Z</given-names></name><name name-style=\"western\"><surname>Alzubaidi</surname><given-names>L</given-names></name><name name-style=\"western\"><surname>Zhang</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Duan</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Gu</surname><given-names>Y</given-names></name></person-group><article-title>A comparison review of transfer learning and self-supervised learning: definitions, applications, advantages and limitations</article-title><source>Expert Syst Appl</source><year>2024</year><volume>242</volume><fpage>122807</fpage><pub-id pub-id-type=\"doi\">10.1016/j.eswa.2023.122807</pub-id></element-citation><mixed-citation id=\"mc-CR258\" publication-type=\"journal\">Zhao Z, Alzubaidi L, Zhang J, Duan Y, Gu Y. A comparison review of transfer learning and self-supervised learning: definitions, applications, advantages and limitations. Expert Syst Appl. 2024;242:122807.</mixed-citation></citation-alternatives></ref><ref id=\"CR259\"><label>259.</label><citation-alternatives><element-citation id=\"ec-CR259\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Yan</surname><given-names>R</given-names></name><name name-style=\"western\"><surname>Qu</surname><given-names>L</given-names></name><name name-style=\"western\"><surname>Wei</surname><given-names>Q</given-names></name><name name-style=\"western\"><surname>Huang</surname><given-names>SC</given-names></name><name name-style=\"western\"><surname>Shen</surname><given-names>L</given-names></name><name name-style=\"western\"><surname>Rubin</surname><given-names>DL</given-names></name><etal/></person-group><article-title>Label-efficient self-supervised federated learning for tackling data heterogeneity in medical imaging</article-title><source>IEEE Trans Med Imaging</source><year>2023</year><volume>42</volume><issue>7</issue><fpage>1932</fpage><lpage>43</lpage><pub-id pub-id-type=\"doi\">10.1109/TMI.2022.3233574</pub-id><pub-id pub-id-type=\"pmid\">37018314</pub-id><pub-id pub-id-type=\"pmcid\">PMC10880587</pub-id></element-citation><mixed-citation id=\"mc-CR259\" publication-type=\"journal\">Yan R, Qu L, Wei Q, Huang SC, Shen L, Rubin DL, et al. Label-efficient self-supervised federated learning for tackling data heterogeneity in medical imaging. IEEE Trans Med Imaging. 2023;42(7):1932&#8211;43.<pub-id pub-id-type=\"pmid\">37018314</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1109/TMI.2022.3233574</pub-id><pub-id pub-id-type=\"pmcid\">PMC10880587</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR260\"><label>260.</label><citation-alternatives><element-citation id=\"ec-CR260\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Kim</surname><given-names>MJ</given-names></name><name name-style=\"western\"><surname>Kim</surname><given-names>SH</given-names></name><name name-style=\"western\"><surname>Kim</surname><given-names>SM</given-names></name><name name-style=\"western\"><surname>Nam</surname><given-names>JH</given-names></name><name name-style=\"western\"><surname>Hwang</surname><given-names>YB</given-names></name><name name-style=\"western\"><surname>Lim</surname><given-names>YJ</given-names></name></person-group><article-title>The advent of domain adaptation into artificial intelligence for gastrointestinal endoscopy and medical imaging</article-title><source>Diagnostics</source><year>2023</year><volume>13</volume><issue>19</issue><fpage>3023</fpage><pub-id pub-id-type=\"doi\">10.3390/diagnostics13193023</pub-id><pub-id pub-id-type=\"pmid\">37835766</pub-id><pub-id pub-id-type=\"pmcid\">PMC10572560</pub-id></element-citation><mixed-citation id=\"mc-CR260\" publication-type=\"journal\">Kim MJ, Kim SH, Kim SM, Nam JH, Hwang YB, Lim YJ. The advent of domain adaptation into artificial intelligence for gastrointestinal endoscopy and medical imaging. Diagnostics. 2023;13(19):3023.<pub-id pub-id-type=\"pmid\">37835766</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.3390/diagnostics13193023</pub-id><pub-id pub-id-type=\"pmcid\">PMC10572560</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR261\"><label>261.</label><citation-alternatives><element-citation id=\"ec-CR261\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Sinha</surname><given-names>S</given-names></name><name name-style=\"western\"><surname>Lee</surname><given-names>YM</given-names></name></person-group><article-title>Challenges with developing and deploying AI models and applications in industrial systems</article-title><source>Discov Artif Intell</source><year>2024</year><volume>4</volume><issue>1</issue><fpage>55</fpage><pub-id pub-id-type=\"doi\">10.1007/s44163-024-00151-2</pub-id></element-citation><mixed-citation id=\"mc-CR261\" publication-type=\"journal\">Sinha S, Lee YM. Challenges with developing and deploying AI models and applications in industrial systems. Discov Artif Intell. 2024;4(1):55.</mixed-citation></citation-alternatives></ref><ref id=\"CR262\"><label>262.</label><citation-alternatives><element-citation id=\"ec-CR262\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Suwannaphong</surname><given-names>T</given-names></name><name name-style=\"western\"><surname>Jovan</surname><given-names>F</given-names></name><name name-style=\"western\"><surname>Craddock</surname><given-names>I</given-names></name><name name-style=\"western\"><surname>McConville</surname><given-names>R</given-names></name></person-group><article-title>Optimising TinyML with quantization and distillation of transformer and mamba models for indoor localisation on edge devices</article-title><source>Sci Rep</source><year>2025</year><volume>15</volume><issue>1</issue><fpage>10081</fpage><pub-id pub-id-type=\"doi\">10.1038/s41598-025-94205-9</pub-id><pub-id pub-id-type=\"pmid\">40128553</pub-id><pub-id pub-id-type=\"pmcid\">PMC11933347</pub-id></element-citation><mixed-citation id=\"mc-CR262\" publication-type=\"journal\">Suwannaphong T, Jovan F, Craddock I, McConville R. Optimising TinyML with quantization and distillation of transformer and mamba models for indoor localisation on edge devices. Sci Rep. 2025;15(1):10081.<pub-id pub-id-type=\"pmid\">40128553</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1038/s41598-025-94205-9</pub-id><pub-id pub-id-type=\"pmcid\">PMC11933347</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR263\"><label>263.</label><citation-alternatives><element-citation id=\"ec-CR263\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Molla</surname><given-names>G</given-names></name><name name-style=\"western\"><surname>Bitew</surname><given-names>M</given-names></name></person-group><article-title>Revolutionizing personalized medicine: synergy with multi-omics data generation, main hurdles, and future perspectives</article-title><source>Biomedicines</source><year>2024</year><volume>12</volume><issue>12</issue><fpage>2750</fpage><pub-id pub-id-type=\"doi\">10.3390/biomedicines12122750</pub-id><pub-id pub-id-type=\"pmid\">39767657</pub-id><pub-id pub-id-type=\"pmcid\">PMC11673561</pub-id></element-citation><mixed-citation id=\"mc-CR263\" publication-type=\"journal\">Molla G, Bitew M. Revolutionizing personalized medicine: synergy with multi-omics data generation, main hurdles, and future perspectives. Biomedicines. 2024;12(12):2750.<pub-id pub-id-type=\"pmid\">39767657</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.3390/biomedicines12122750</pub-id><pub-id pub-id-type=\"pmcid\">PMC11673561</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR264\"><label>264.</label><citation-alternatives><element-citation id=\"ec-CR264\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Vanguri</surname><given-names>RS</given-names></name><name name-style=\"western\"><surname>Luo</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Aukerman</surname><given-names>AT</given-names></name><name name-style=\"western\"><surname>Egger</surname><given-names>JV</given-names></name><name name-style=\"western\"><surname>Fong</surname><given-names>CJ</given-names></name><name name-style=\"western\"><surname>Horvat</surname><given-names>N</given-names></name><etal/></person-group><article-title>Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L) 1 blockade in patients with non-small cell lung cancer</article-title><source>Nat Cancer</source><year>2022</year><volume>3</volume><issue>10</issue><fpage>1151</fpage><lpage>64</lpage><pub-id pub-id-type=\"doi\">10.1038/s43018-022-00416-8</pub-id><pub-id pub-id-type=\"pmid\">36038778</pub-id><pub-id pub-id-type=\"pmcid\">PMC9586871</pub-id></element-citation><mixed-citation id=\"mc-CR264\" publication-type=\"journal\">Vanguri RS, Luo J, Aukerman AT, Egger JV, Fong CJ, Horvat N, et al. Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L) 1 blockade in patients with non-small cell lung cancer. Nat Cancer. 2022;3(10):1151&#8211;64.<pub-id pub-id-type=\"pmid\">36038778</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1038/s43018-022-00416-8</pub-id><pub-id pub-id-type=\"pmcid\">PMC9586871</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR265\"><label>265.</label><citation-alternatives><element-citation id=\"ec-CR265\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Putrama</surname><given-names>IM</given-names></name><name name-style=\"western\"><surname>Martinek</surname><given-names>P</given-names></name></person-group><article-title>Heterogeneous data integration: challenges and opportunities</article-title><source>Data Brief</source><year>2024</year><pub-id pub-id-type=\"doi\">10.1016/j.dib.2024.110853</pub-id><pub-id pub-id-type=\"pmid\">39286416</pub-id><pub-id pub-id-type=\"pmcid\">PMC11402636</pub-id></element-citation><mixed-citation id=\"mc-CR265\" publication-type=\"journal\">Putrama IM, Martinek P. Heterogeneous data integration: challenges and opportunities. Data Brief. 2024. 10.1016/j.dib.2024.110853.<pub-id pub-id-type=\"pmid\">39286416</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/j.dib.2024.110853</pub-id><pub-id pub-id-type=\"pmcid\">PMC11402636</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR266\"><label>266.</label><citation-alternatives><element-citation id=\"ec-CR266\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Hyun</surname><given-names>JW</given-names></name><name name-style=\"western\"><surname>Li</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Huang</surname><given-names>C</given-names></name><name name-style=\"western\"><surname>Styner</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Lin</surname><given-names>W</given-names></name><name name-style=\"western\"><surname>Zhu</surname><given-names>H</given-names></name></person-group><article-title>STGP: spatio-temporal Gaussian process models for longitudinal neuroimaging data</article-title><source>Neuroimage</source><year>2016</year><volume>134</volume><fpage>550</fpage><lpage>62</lpage><pub-id pub-id-type=\"doi\">10.1016/j.neuroimage.2016.04.023</pub-id><pub-id pub-id-type=\"pmid\">27103140</pub-id><pub-id pub-id-type=\"pmcid\">PMC4912881</pub-id></element-citation><mixed-citation id=\"mc-CR266\" publication-type=\"journal\">Hyun JW, Li Y, Huang C, Styner M, Lin W, Zhu H. STGP: spatio-temporal Gaussian process models for longitudinal neuroimaging data. Neuroimage. 2016;134:550&#8211;62.<pub-id pub-id-type=\"pmid\">27103140</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/j.neuroimage.2016.04.023</pub-id><pub-id pub-id-type=\"pmcid\">PMC4912881</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR267\"><label>267.</label><citation-alternatives><element-citation id=\"ec-CR267\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Liu</surname><given-names>C</given-names></name><name name-style=\"western\"><surname>Liu</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Liu</surname><given-names>T</given-names></name><name name-style=\"western\"><surname>Lin</surname><given-names>H</given-names></name><name name-style=\"western\"><surname>Huang</surname><given-names>CB</given-names></name><etal/></person-group><article-title>Attention is all you need: utilizing attention in AI-enabled drug discovery</article-title><source>Brief Bioinform</source><year>2024</year><volume>25</volume><issue>1</issue><fpage>bbad467</fpage><pub-id pub-id-type=\"doi\">10.1093/bib/bbad467</pub-id><pub-id pub-id-type=\"pmcid\">PMC10772984</pub-id><pub-id pub-id-type=\"pmid\">38189543</pub-id></element-citation><mixed-citation id=\"mc-CR267\" publication-type=\"journal\">Zhang Y, Liu C, Liu M, Liu T, Lin H, Huang CB, et al. Attention is all you need: utilizing attention in AI-enabled drug discovery. Brief Bioinform. 2024;25(1):bbad467.<pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1093/bib/bbad467</pub-id><pub-id pub-id-type=\"pmcid\">PMC10772984</pub-id><pub-id pub-id-type=\"pmid\">38189543</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR268\"><label>268.</label><citation-alternatives><element-citation id=\"ec-CR268\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Liu</surname><given-names>Z</given-names></name><name name-style=\"western\"><surname>Hu</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Qiu</surname><given-names>Z</given-names></name><name name-style=\"western\"><surname>Niu</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Zhou</surname><given-names>D</given-names></name><name name-style=\"western\"><surname>Li</surname><given-names>X</given-names></name><etal/></person-group><article-title>Cross-modal attention network for retinal disease classification based on multi-modal images</article-title><source>Biomed Opt Express</source><year>2024</year><volume>15</volume><issue>6</issue><fpage>3699</fpage><lpage>714</lpage><pub-id pub-id-type=\"doi\">10.1364/BOE.516764</pub-id><pub-id pub-id-type=\"pmid\">38867787</pub-id><pub-id pub-id-type=\"pmcid\">PMC11166426</pub-id></element-citation><mixed-citation id=\"mc-CR268\" publication-type=\"journal\">Liu Z, Hu Y, Qiu Z, Niu Y, Zhou D, Li X, et al. Cross-modal attention network for retinal disease classification based on multi-modal images. Biomed Opt Express. 2024;15(6):3699&#8211;714.<pub-id pub-id-type=\"pmid\">38867787</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1364/BOE.516764</pub-id><pub-id pub-id-type=\"pmcid\">PMC11166426</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR269\"><label>269.</label><citation-alternatives><element-citation id=\"ec-CR269\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Norori</surname><given-names>N</given-names></name><name name-style=\"western\"><surname>Hu</surname><given-names>Q</given-names></name><name name-style=\"western\"><surname>Aellen</surname><given-names>FM</given-names></name><name name-style=\"western\"><surname>Faraci</surname><given-names>FD</given-names></name><name name-style=\"western\"><surname>Tzovara</surname><given-names>A</given-names></name></person-group><article-title>Addressing bias in big data and AI for health care: a call for open science</article-title><source>Patterns</source><year>2021</year><pub-id pub-id-type=\"doi\">10.1016/j.patter.2021.100347</pub-id><pub-id pub-id-type=\"pmid\">34693373</pub-id><pub-id pub-id-type=\"pmcid\">PMC8515002</pub-id></element-citation><mixed-citation id=\"mc-CR269\" publication-type=\"journal\">Norori N, Hu Q, Aellen FM, Faraci FD, Tzovara A. Addressing bias in big data and AI for health care: a call for open science. Patterns. 2021. 10.1016/j.patter.2021.100347.<pub-id pub-id-type=\"pmid\">34693373</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/j.patter.2021.100347</pub-id><pub-id pub-id-type=\"pmcid\">PMC8515002</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR270\"><label>270.</label><citation-alternatives><element-citation id=\"ec-CR270\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Arora</surname><given-names>A</given-names></name><name name-style=\"western\"><surname>Alderman</surname><given-names>JE</given-names></name><name name-style=\"western\"><surname>Palmer</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Ganapathi</surname><given-names>S</given-names></name><name name-style=\"western\"><surname>Laws</surname><given-names>E</given-names></name><name name-style=\"western\"><surname>Mccradden</surname><given-names>MD</given-names></name><etal/></person-group><article-title>The value of standards for health datasets in artificial intelligence-based applications</article-title><source>Nat Med</source><year>2023</year><volume>29</volume><issue>11</issue><fpage>2929</fpage><lpage>38</lpage><pub-id pub-id-type=\"doi\">10.1038/s41591-023-02608-w</pub-id><pub-id pub-id-type=\"pmid\">37884627</pub-id><pub-id pub-id-type=\"pmcid\">PMC10667100</pub-id></element-citation><mixed-citation id=\"mc-CR270\" publication-type=\"journal\">Arora A, Alderman JE, Palmer J, Ganapathi S, Laws E, Mccradden MD, et al. The value of standards for health datasets in artificial intelligence-based applications. Nat Med. 2023;29(11):2929&#8211;38.<pub-id pub-id-type=\"pmid\">37884627</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1038/s41591-023-02608-w</pub-id><pub-id pub-id-type=\"pmcid\">PMC10667100</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR271\"><label>271.</label><citation-alternatives><element-citation id=\"ec-CR271\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Ueda</surname><given-names>D</given-names></name><name name-style=\"western\"><surname>Kakinuma</surname><given-names>T</given-names></name><name name-style=\"western\"><surname>Fujita</surname><given-names>S</given-names></name><name name-style=\"western\"><surname>Kamagata</surname><given-names>K</given-names></name><name name-style=\"western\"><surname>Fushimi</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Ito</surname><given-names>R</given-names></name><etal/></person-group><article-title>Fairness of artificial intelligence in healthcare: review and recommendations</article-title><source>Jpn J Radiol</source><year>2024</year><volume>42</volume><issue>1</issue><fpage>3</fpage><lpage>15</lpage><pub-id pub-id-type=\"doi\">10.1007/s11604-023-01474-3</pub-id><pub-id pub-id-type=\"pmid\">37540463</pub-id><pub-id pub-id-type=\"pmcid\">PMC10764412</pub-id></element-citation><mixed-citation id=\"mc-CR271\" publication-type=\"journal\">Ueda D, Kakinuma T, Fujita S, Kamagata K, Fushimi Y, Ito R, et al. Fairness of artificial intelligence in healthcare: review and recommendations. Jpn J Radiol. 2024;42(1):3&#8211;15.<pub-id pub-id-type=\"pmid\">37540463</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1007/s11604-023-01474-3</pub-id><pub-id pub-id-type=\"pmcid\">PMC10764412</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR272\"><label>272.</label><citation-alternatives><element-citation id=\"ec-CR272\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Cross</surname><given-names>JL</given-names></name><name name-style=\"western\"><surname>Choma</surname><given-names>MA</given-names></name><name name-style=\"western\"><surname>Onofrey</surname><given-names>JA</given-names></name></person-group><article-title>Bias in medical AI: implications for clinical decision-making</article-title><source>PLoS Digit Health</source><year>2024</year><volume>3</volume><issue>11</issue><fpage>e0000651</fpage><pub-id pub-id-type=\"doi\">10.1371/journal.pdig.0000651</pub-id><pub-id pub-id-type=\"pmid\">39509461</pub-id><pub-id pub-id-type=\"pmcid\">PMC11542778</pub-id></element-citation><mixed-citation id=\"mc-CR272\" publication-type=\"journal\">Cross JL, Choma MA, Onofrey JA. Bias in medical AI: implications for clinical decision-making. PLoS Digit Health. 2024;3(11):e0000651.<pub-id pub-id-type=\"pmid\">39509461</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1371/journal.pdig.0000651</pub-id><pub-id pub-id-type=\"pmcid\">PMC11542778</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR273\"><label>273.</label><citation-alternatives><element-citation id=\"ec-CR273\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Hasanzadeh</surname><given-names>F</given-names></name><name name-style=\"western\"><surname>Josephson</surname><given-names>CB</given-names></name><name name-style=\"western\"><surname>Waters</surname><given-names>G</given-names></name><name name-style=\"western\"><surname>Adedinsewo</surname><given-names>D</given-names></name><name name-style=\"western\"><surname>Azizi</surname><given-names>Z</given-names></name><name name-style=\"western\"><surname>White</surname><given-names>JA</given-names></name></person-group><article-title>Bias recognition and mitigation strategies in artificial intelligence healthcare applications</article-title><source>NPJ Digit Med</source><year>2025</year><volume>8</volume><issue>1</issue><fpage>154</fpage><pub-id pub-id-type=\"doi\">10.1038/s41746-025-01503-7</pub-id><pub-id pub-id-type=\"pmid\">40069303</pub-id><pub-id pub-id-type=\"pmcid\">PMC11897215</pub-id></element-citation><mixed-citation id=\"mc-CR273\" publication-type=\"journal\">Hasanzadeh F, Josephson CB, Waters G, Adedinsewo D, Azizi Z, White JA. Bias recognition and mitigation strategies in artificial intelligence healthcare applications. NPJ Digit Med. 2025;8(1):154.<pub-id pub-id-type=\"pmid\">40069303</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1038/s41746-025-01503-7</pub-id><pub-id pub-id-type=\"pmcid\">PMC11897215</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR274\"><label>274.</label><citation-alternatives><element-citation id=\"ec-CR274\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Agarwal</surname><given-names>R</given-names></name><name name-style=\"western\"><surname>Bjarnadottir</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Rhue</surname><given-names>L</given-names></name><name name-style=\"western\"><surname>Dugas</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Crowley</surname><given-names>K</given-names></name><name name-style=\"western\"><surname>Clark</surname><given-names>J</given-names></name><etal/></person-group><article-title>Addressing algorithmic bias and the perpetuation of health inequities: an AI bias aware framework</article-title><source>Health Policy Technol</source><year>2023</year><volume>12</volume><issue>1</issue><fpage>100702</fpage><pub-id pub-id-type=\"doi\">10.1016/j.hlpt.2022.100702</pub-id></element-citation><mixed-citation id=\"mc-CR274\" publication-type=\"journal\">Agarwal R, Bjarnadottir M, Rhue L, Dugas M, Crowley K, Clark J, et al. Addressing algorithmic bias and the perpetuation of health inequities: an AI bias aware framework. Health Policy Technol. 2023;12(1):100702.</mixed-citation></citation-alternatives></ref><ref id=\"CR275\"><label>275.</label><citation-alternatives><element-citation id=\"ec-CR275\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Murdoch</surname><given-names>B</given-names></name></person-group><article-title>Privacy and artificial intelligence: challenges for protecting health information in a new era</article-title><source>BMC Med Ethics</source><year>2021</year><volume>22</volume><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type=\"doi\">10.1186/s12910-021-00687-3</pub-id><pub-id pub-id-type=\"pmid\">34525993</pub-id><pub-id pub-id-type=\"pmcid\">PMC8442400</pub-id></element-citation><mixed-citation id=\"mc-CR275\" publication-type=\"journal\">Murdoch B. Privacy and artificial intelligence: challenges for protecting health information in a new era. BMC Med Ethics. 2021;22:1&#8211;5.<pub-id pub-id-type=\"pmid\">34525993</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1186/s12910-021-00687-3</pub-id><pub-id pub-id-type=\"pmcid\">PMC8442400</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR276\"><label>276.</label><citation-alternatives><element-citation id=\"ec-CR276\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Narayan</surname><given-names>SM</given-names></name><name name-style=\"western\"><surname>Kohli</surname><given-names>N</given-names></name><name name-style=\"western\"><surname>Martin</surname><given-names>MM</given-names></name></person-group><article-title>Addressing contemporary threats in anonymised healthcare data using privacy engineering</article-title><source>NPJ Digit Med</source><year>2025</year><volume>8</volume><issue>1</issue><fpage>145</fpage><pub-id pub-id-type=\"doi\">10.1038/s41746-025-01520-6</pub-id><pub-id pub-id-type=\"pmid\">40050672</pub-id><pub-id pub-id-type=\"pmcid\">PMC11885643</pub-id></element-citation><mixed-citation id=\"mc-CR276\" publication-type=\"journal\">Narayan SM, Kohli N, Martin MM. Addressing contemporary threats in anonymised healthcare data using privacy engineering. NPJ Digit Med. 2025;8(1):145.<pub-id pub-id-type=\"pmid\">40050672</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1038/s41746-025-01520-6</pub-id><pub-id pub-id-type=\"pmcid\">PMC11885643</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR277\"><label>277.</label><citation-alternatives><element-citation id=\"ec-CR277\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Han</surname><given-names>D</given-names></name><name name-style=\"western\"><surname>Babaei</surname><given-names>R</given-names></name><name name-style=\"western\"><surname>Zhao</surname><given-names>S</given-names></name><name name-style=\"western\"><surname>Cheng</surname><given-names>S</given-names></name></person-group><article-title>Exploring the efficacy of learning techniques in model extraction attacks on image classifiers: a comparative study</article-title><source>Appl Sci</source><year>2024</year><volume>14</volume><issue>9</issue><fpage>3785</fpage><pub-id pub-id-type=\"doi\">10.3390/app14093785</pub-id></element-citation><mixed-citation id=\"mc-CR277\" publication-type=\"journal\">Han D, Babaei R, Zhao S, Cheng S. Exploring the efficacy of learning techniques in model extraction attacks on image classifiers: a comparative study. Appl Sci. 2024;14(9):3785.</mixed-citation></citation-alternatives></ref><ref id=\"CR278\"><label>278.</label><citation-alternatives><element-citation id=\"ec-CR278\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Khalid</surname><given-names>N</given-names></name><name name-style=\"western\"><surname>Qayyum</surname><given-names>A</given-names></name><name name-style=\"western\"><surname>Bilal</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Al-Fuqaha</surname><given-names>A</given-names></name><name name-style=\"western\"><surname>Qadir</surname><given-names>J</given-names></name></person-group><article-title>Privacy-preserving artificial intelligence in healthcare: techniques and applications</article-title><source>Comput Biol Med</source><year>2023</year><volume>158</volume><fpage>106848</fpage><pub-id pub-id-type=\"doi\">10.1016/j.compbiomed.2023.106848</pub-id><pub-id pub-id-type=\"pmid\">37044052</pub-id></element-citation><mixed-citation id=\"mc-CR278\" publication-type=\"journal\">Khalid N, Qayyum A, Bilal M, Al-Fuqaha A, Qadir J. Privacy-preserving artificial intelligence in healthcare: techniques and applications. Comput Biol Med. 2023;158:106848.<pub-id pub-id-type=\"pmid\">37044052</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/j.compbiomed.2023.106848</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR279\"><label>279.</label><citation-alternatives><element-citation id=\"ec-CR279\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Gu</surname><given-names>X</given-names></name><name name-style=\"western\"><surname>Sabrina</surname><given-names>F</given-names></name><name name-style=\"western\"><surname>Fan</surname><given-names>Z</given-names></name><name name-style=\"western\"><surname>Sohail</surname><given-names>S</given-names></name></person-group><article-title>A review of privacy enhancement methods for federated learning in healthcare systems</article-title><source>Int J Environ Res Public Health</source><year>2023</year><volume>20</volume><issue>15</issue><fpage>6539</fpage><pub-id pub-id-type=\"doi\">10.3390/ijerph20156539</pub-id><pub-id pub-id-type=\"pmid\">37569079</pub-id><pub-id pub-id-type=\"pmcid\">PMC10418741</pub-id></element-citation><mixed-citation id=\"mc-CR279\" publication-type=\"journal\">Gu X, Sabrina F, Fan Z, Sohail S. A review of privacy enhancement methods for federated learning in healthcare systems. Int J Environ Res Public Health. 2023;20(15):6539.<pub-id pub-id-type=\"pmid\">37569079</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.3390/ijerph20156539</pub-id><pub-id pub-id-type=\"pmcid\">PMC10418741</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR280\"><label>280.</label><citation-alternatives><element-citation id=\"ec-CR280\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Aziz</surname><given-names>R</given-names></name><name name-style=\"western\"><surname>Banerjee</surname><given-names>S</given-names></name><name name-style=\"western\"><surname>Bouzefrane</surname><given-names>S</given-names></name><name name-style=\"western\"><surname>Le Vinh</surname><given-names>T</given-names></name></person-group><article-title>Exploring homomorphic encryption and differential privacy techniques towards secure federated learning paradigm</article-title><source>Future Internet</source><year>2023</year><volume>15</volume><issue>9</issue><fpage>310</fpage><pub-id pub-id-type=\"doi\">10.3390/fi15090310</pub-id></element-citation><mixed-citation id=\"mc-CR280\" publication-type=\"journal\">Aziz R, Banerjee S, Bouzefrane S, Le Vinh T. Exploring homomorphic encryption and differential privacy techniques towards secure federated learning paradigm. Future Internet. 2023;15(9):310.</mixed-citation></citation-alternatives></ref><ref id=\"CR281\"><label>281.</label><citation-alternatives><element-citation id=\"ec-CR281\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Schmidt</surname><given-names>A</given-names></name></person-group><article-title>Regulatory challenges in healthcare IT: Ensuring compliance with HIPAA and GDPR</article-title><source>Acad J Sci Technol</source><year>2020</year><volume>3</volume><issue>1</issue><fpage>1</fpage><lpage>7</lpage></element-citation><mixed-citation id=\"mc-CR281\" publication-type=\"journal\">Schmidt A. Regulatory challenges in healthcare IT: Ensuring compliance with HIPAA and GDPR. Acad J Sci Technol. 2020;3(1):1&#8211;7.</mixed-citation></citation-alternatives></ref><ref id=\"CR282\"><label>282.</label><citation-alternatives><element-citation id=\"ec-CR282\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Zhang</surname><given-names>B</given-names></name><name name-style=\"western\"><surname>Zhong</surname><given-names>H</given-names></name><name name-style=\"western\"><surname>Han</surname><given-names>B</given-names></name></person-group><article-title>Neoadjuvant immunotherapy for patients with non-small cell lung cancer&#8211;is a new era coming?</article-title><source>JAMA Oncol</source><year>2023</year><volume>9</volume><issue>3</issue><fpage>301</fpage><lpage>2</lpage><pub-id pub-id-type=\"doi\">10.1001/jamaoncol.2022.6898</pub-id><pub-id pub-id-type=\"pmid\">36701143</pub-id></element-citation><mixed-citation id=\"mc-CR282\" publication-type=\"journal\">Zhang B, Zhong H, Han B. Neoadjuvant immunotherapy for patients with non-small cell lung cancer&#8211;is a new era coming? JAMA Oncol. 2023;9(3):301&#8211;2.<pub-id pub-id-type=\"pmid\">36701143</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1001/jamaoncol.2022.6898</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR283\"><label>283.</label><citation-alternatives><element-citation id=\"ec-CR283\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Rouanne</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Bajorin</surname><given-names>DF</given-names></name><name name-style=\"western\"><surname>Hannan</surname><given-names>R</given-names></name><name name-style=\"western\"><surname>Galsky</surname><given-names>MD</given-names></name><name name-style=\"western\"><surname>Williams</surname><given-names>SB</given-names></name><name name-style=\"western\"><surname>Necchi</surname><given-names>A</given-names></name><etal/></person-group><article-title>Rationale and outcomes for neoadjuvant immunotherapy in urothelial carcinoma of the bladder</article-title><source>Eur Urol Oncol</source><year>2020</year><volume>3</volume><issue>6</issue><fpage>728</fpage><lpage>38</lpage><pub-id pub-id-type=\"doi\">10.1016/j.euo.2020.06.009</pub-id><pub-id pub-id-type=\"pmid\">33177001</pub-id></element-citation><mixed-citation id=\"mc-CR283\" publication-type=\"journal\">Rouanne M, Bajorin DF, Hannan R, Galsky MD, Williams SB, Necchi A, et al. Rationale and outcomes for neoadjuvant immunotherapy in urothelial carcinoma of the bladder. Eur Urol Oncol. 2020;3(6):728&#8211;38.<pub-id pub-id-type=\"pmid\">33177001</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/j.euo.2020.06.009</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR284\"><label>284.</label><citation-alternatives><element-citation id=\"ec-CR284\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Nanda</surname><given-names>R</given-names></name><name name-style=\"western\"><surname>Liu</surname><given-names>MC</given-names></name><name name-style=\"western\"><surname>Yau</surname><given-names>C</given-names></name><name name-style=\"western\"><surname>Shatsky</surname><given-names>R</given-names></name><name name-style=\"western\"><surname>Pusztai</surname><given-names>L</given-names></name><name name-style=\"western\"><surname>Wallace</surname><given-names>A</given-names></name><etal/></person-group><article-title>Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial</article-title><source>JAMA Oncol</source><year>2020</year><volume>6</volume><issue>5</issue><fpage>676</fpage><lpage>84</lpage><pub-id pub-id-type=\"doi\">10.1001/jamaoncol.2019.6650</pub-id><pub-id pub-id-type=\"pmid\">32053137</pub-id><pub-id pub-id-type=\"pmcid\">PMC7058271</pub-id></element-citation><mixed-citation id=\"mc-CR284\" publication-type=\"journal\">Nanda R, Liu MC, Yau C, Shatsky R, Pusztai L, Wallace A, et al. Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial. JAMA Oncol. 2020;6(5):676&#8211;84.<pub-id pub-id-type=\"pmid\">32053137</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1001/jamaoncol.2019.6650</pub-id><pub-id pub-id-type=\"pmcid\">PMC7058271</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR285\"><label>285.</label><citation-alternatives><element-citation id=\"ec-CR285\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Li</surname><given-names>Y</given-names></name><name name-style=\"western\"><surname>Wu</surname><given-names>X</given-names></name><name name-style=\"western\"><surname>Fang</surname><given-names>D</given-names></name><name name-style=\"western\"><surname>Luo</surname><given-names>Y</given-names></name></person-group><article-title>Informing immunotherapy with multi-omics driven machine learning</article-title><source>NPJ Digit Med</source><year>2024</year><volume>7</volume><issue>1</issue><fpage>67</fpage><pub-id pub-id-type=\"doi\">10.1038/s41746-024-01043-6</pub-id><pub-id pub-id-type=\"pmid\">38486092</pub-id><pub-id pub-id-type=\"pmcid\">PMC10940614</pub-id></element-citation><mixed-citation id=\"mc-CR285\" publication-type=\"journal\">Li Y, Wu X, Fang D, Luo Y. Informing immunotherapy with multi-omics driven machine learning. NPJ Digit Med. 2024;7(1):67.<pub-id pub-id-type=\"pmid\">38486092</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1038/s41746-024-01043-6</pub-id><pub-id pub-id-type=\"pmcid\">PMC10940614</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR286\"><label>286.</label><citation-alternatives><element-citation id=\"ec-CR286\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Xie</surname><given-names>T</given-names></name><name name-style=\"western\"><surname>Huang</surname><given-names>A</given-names></name><name name-style=\"western\"><surname>Yan</surname><given-names>H</given-names></name><name name-style=\"western\"><surname>Ju</surname><given-names>X</given-names></name><name name-style=\"western\"><surname>Xiang</surname><given-names>L</given-names></name><name name-style=\"western\"><surname>Yuan</surname><given-names>J</given-names></name></person-group><article-title>Artificial intelligence: illuminating the depths of the tumor microenvironment</article-title><source>J Transl Med</source><year>2024</year><volume>22</volume><issue>1</issue><fpage>799</fpage><pub-id pub-id-type=\"doi\">10.1186/s12967-024-05609-6</pub-id><pub-id pub-id-type=\"pmid\">39210368</pub-id><pub-id pub-id-type=\"pmcid\">PMC11360846</pub-id></element-citation><mixed-citation id=\"mc-CR286\" publication-type=\"journal\">Xie T, Huang A, Yan H, Ju X, Xiang L, Yuan J. Artificial intelligence: illuminating the depths of the tumor microenvironment. J Transl Med. 2024;22(1):799.<pub-id pub-id-type=\"pmid\">39210368</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1186/s12967-024-05609-6</pub-id><pub-id pub-id-type=\"pmcid\">PMC11360846</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR287\"><label>287.</label><mixed-citation publication-type=\"other\">Ligero M, El&#160;Nahhas OS, Aldea M, Kather JN. Artificial intelligence-based biomarkers for treatment decisions in oncology. Trends in Cancer. 2025.<pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/j.trecan.2024.12.001</pub-id><pub-id pub-id-type=\"pmid\">39814650</pub-id></mixed-citation></ref><ref id=\"CR288\"><label>288.</label><citation-alternatives><element-citation id=\"ec-CR288\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Niso</surname><given-names>G</given-names></name><name name-style=\"western\"><surname>Botvinik-Nezer</surname><given-names>R</given-names></name><name name-style=\"western\"><surname>Appelhoff</surname><given-names>S</given-names></name><name name-style=\"western\"><surname>De La Vega</surname><given-names>A</given-names></name><name name-style=\"western\"><surname>Esteban</surname><given-names>O</given-names></name><name name-style=\"western\"><surname>Etzel</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Open and reproducible neuroimaging: from study inception to publication</article-title><source>Neuroimage</source><year>2022</year><volume>263</volume><fpage>119623</fpage><pub-id pub-id-type=\"doi\">10.1016/j.neuroimage.2022.119623</pub-id><pub-id pub-id-type=\"pmid\">36100172</pub-id><pub-id pub-id-type=\"pmcid\">PMC10008521</pub-id></element-citation><mixed-citation id=\"mc-CR288\" publication-type=\"journal\">Niso G, Botvinik-Nezer R, Appelhoff S, De La Vega A, Esteban O, Etzel JA, et al. Open and reproducible neuroimaging: from study inception to publication. Neuroimage. 2022;263:119623.<pub-id pub-id-type=\"pmid\">36100172</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1016/j.neuroimage.2022.119623</pub-id><pub-id pub-id-type=\"pmcid\">PMC10008521</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR289\"><label>289.</label><citation-alternatives><element-citation id=\"ec-CR289\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Beam</surname><given-names>AL</given-names></name><name name-style=\"western\"><surname>Manrai</surname><given-names>AK</given-names></name><name name-style=\"western\"><surname>Ghassemi</surname><given-names>M</given-names></name></person-group><article-title>Challenges to the reproducibility of machine learning models in health care</article-title><source>JAMA</source><year>2020</year><volume>323</volume><issue>4</issue><fpage>305</fpage><lpage>6</lpage><pub-id pub-id-type=\"doi\">10.1001/jama.2019.20866</pub-id><pub-id pub-id-type=\"pmid\">31904799</pub-id><pub-id pub-id-type=\"pmcid\">PMC7335677</pub-id></element-citation><mixed-citation id=\"mc-CR289\" publication-type=\"journal\">Beam AL, Manrai AK, Ghassemi M. Challenges to the reproducibility of machine learning models in health care. JAMA. 2020;323(4):305&#8211;6.<pub-id pub-id-type=\"pmid\">31904799</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1001/jama.2019.20866</pub-id><pub-id pub-id-type=\"pmcid\">PMC7335677</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR290\"><label>290.</label><citation-alternatives><element-citation id=\"ec-CR290\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Shiferaw</surname><given-names>KB</given-names></name><name name-style=\"western\"><surname>Roloff</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Balaur</surname><given-names>I</given-names></name><name name-style=\"western\"><surname>Welter</surname><given-names>D</given-names></name><name name-style=\"western\"><surname>Waltemath</surname><given-names>D</given-names></name><name name-style=\"western\"><surname>Zeleke</surname><given-names>AA</given-names></name></person-group><article-title>Guidelines and standard frameworks for artificial intelligence in medicine: a systematic review</article-title><source>JAMIA Open</source><year>2025</year><volume>8</volume><issue>1</issue><fpage>ooae155</fpage><pub-id pub-id-type=\"doi\">10.1093/jamiaopen/ooae155</pub-id><pub-id pub-id-type=\"pmid\">39759773</pub-id><pub-id pub-id-type=\"pmcid\">PMC11700560</pub-id></element-citation><mixed-citation id=\"mc-CR290\" publication-type=\"journal\">Shiferaw KB, Roloff M, Balaur I, Welter D, Waltemath D, Zeleke AA. Guidelines and standard frameworks for artificial intelligence in medicine: a systematic review. JAMIA Open. 2025;8(1):ooae155.<pub-id pub-id-type=\"pmid\">39759773</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1093/jamiaopen/ooae155</pub-id><pub-id pub-id-type=\"pmcid\">PMC11700560</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR291\"><label>291.</label><citation-alternatives><element-citation id=\"ec-CR291\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Heil</surname><given-names>BJ</given-names></name><name name-style=\"western\"><surname>Hoffman</surname><given-names>MM</given-names></name><name name-style=\"western\"><surname>Markowetz</surname><given-names>F</given-names></name><name name-style=\"western\"><surname>Lee</surname><given-names>SI</given-names></name><name name-style=\"western\"><surname>Greene</surname><given-names>CS</given-names></name><name name-style=\"western\"><surname>Hicks</surname><given-names>SC</given-names></name></person-group><article-title>Reproducibility standards for machine learning in the life sciences</article-title><source>Nat Methods</source><year>2021</year><volume>18</volume><issue>10</issue><fpage>1132</fpage><lpage>5</lpage><pub-id pub-id-type=\"doi\">10.1038/s41592-021-01256-7</pub-id><pub-id pub-id-type=\"pmid\">34462593</pub-id><pub-id pub-id-type=\"pmcid\">PMC9131851</pub-id></element-citation><mixed-citation id=\"mc-CR291\" publication-type=\"journal\">Heil BJ, Hoffman MM, Markowetz F, Lee SI, Greene CS, Hicks SC. Reproducibility standards for machine learning in the life sciences. Nat Methods. 2021;18(10):1132&#8211;5.<pub-id pub-id-type=\"pmid\">34462593</pub-id><pub-id pub-id-type=\"doi\" assigning-authority=\"pmc\">10.1038/s41592-021-01256-7</pub-id><pub-id pub-id-type=\"pmcid\">PMC9131851</pub-id></mixed-citation></citation-alternatives></ref><ref id=\"CR292\"><label>292.</label><citation-alternatives><element-citation id=\"ec-CR292\" publication-type=\"journal\"><person-group person-group-type=\"author\"><name name-style=\"western\"><surname>Tsay</surname><given-names>J</given-names></name><name name-style=\"western\"><surname>Braz</surname><given-names>A</given-names></name><name name-style=\"western\"><surname>Hirzel</surname><given-names>M</given-names></name><name name-style=\"western\"><surname>Shinnar</surname><given-names>A</given-names></name><name name-style=\"western\"><surname>Mummert</surname><given-names>T</given-names></name></person-group><article-title>Extracting enhanced artificial intelligence model metadata from software repositories</article-title><source>Empir Software Eng</source><year>2022</year><volume>27</volume><issue>7</issue><fpage>176</fpage><pub-id pub-id-type=\"doi\">10.1007/s10664-022-10206-6</pub-id></element-citation><mixed-citation id=\"mc-CR292\" publication-type=\"journal\">Tsay J, Braz A, Hirzel M, Shinnar A, Mummert T. Extracting enhanced artificial intelligence model metadata from software repositories. Empir Software Eng. 2022;27(7):176.</mixed-citation></citation-alternatives></ref></ref-list></back></article></pmc-articleset>",
  "text": "pmc Cancer Cell Int Cancer Cell Int 96 cancell Cancer Cell International 1475-2867 BMC PMC12673801 PMC12673801.1 12673801 12673801 41339875 10.1186/s12935-025-04063-8 4063 1 Review AI-based neoadjuvant immunotherapy response prediction across pan-cancer: a comprehensive review Deng Yishu 1 2 3 4 Li Tailin 1 2 3 4 Wang Yunze 1 2 3 4 Chen Silin 1 2 3 4 Tang Feilong 5 6 Zhu Taoyu 1 2 3 4 Ran Jiayi 1 2 3 4 Yang Bo 1 2 3 4 Zhang Xiaohan 1 2 3 4 Xu Ruijie 1 2 3 4 Ray Manas K. 7 Zhang Yimin 1307020@zju.edu.cn 8 9 Chen Shuifang chen-sf@zju.edu.cn 10 11 Liu Jian JianL@intl.zju.edu.cn 1 2 3 4 1 https://ror.org/00a2xv884 grid.13402.34 0000 0004 1759 700X Department of Respiratory and Critical Care Medicine, the Second Affiliated Hospital, and Centre for Infection Immunity and Cancer (IIC) of Zhejiang University-University of Edinburgh Institute (ZJU-UoE Institute), Zhejiang University School of Medicine, Zhejiang University, Hangzhou, Zhejiang China 2 https://ror.org/01nrxwf90 grid.4305.2 0000 0004 1936 7988 Biomedical Sciences, Edinburgh Medical School, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK 3 Zhejiang Key Laboratory of Medical Imaging Artificial Intelligence, 310058 Hangzhou, China 4 Biomedical and Health Translational Research Center of Zhejiang Province, Haining, China 5 https://ror.org/02bfwt286 grid.1002.3 0000 0004 1936 7857 Monash University, Melbourne, Australia 6 https://ror.org/03snqfa66 grid.444464.2 0000 0001 0650 0848 Mohamed bin Zayed University of AI, Abu Dhabi, UAE 7 https://ror.org/00j4k1h63 grid.280664.e 0000 0001 2110 5790 Gene Editing and Mouse Model Core Facility, NIEHS, Research Triangle Park, USA 8 https://ror.org/00325dg83 State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang China 9 https://ror.org/00j2a7k55 grid.411870.b 0000 0001 0063 8301 Department of Infectious Diseases, Affiliated Haining Hospital of Jiaxing University, Haining People&#8217;s Hospital, Jiaxing, Zhejiang China 10 https://ror.org/05m1p5x56 grid.452661.2 0000 0004 1803 6319 First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang China 11 https://ror.org/02ez0zm48 grid.459988.1 Department of Respiratory Diseases, Haining People&#8217;s Hospital, Haining, Zhejiang China 3 12 2025 2025 25 478344 430 15 4 2025 23 10 2025 03 12 2025 04 12 2025 05 12 2025 &#169; The Author(s) 2025 2025 https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ . Neoadjuvant immunotherapy (NIT) has emerged as a transformative treatment strategy across various cancer types. However, due to the significant heterogeneity of tumors, patients exhibit highly variable responses to NIT, making the accurate preoperative identification of those who would benefit a pressing clinical challenge. In recent years, artificial intelligence (AI), particularly machine learning (ML) and deep learning (DL), has opened new pathways for predicting treatment response. AI-driven approaches have the ability to extract latent features from high-dimensional, multimodal oncological data, facilitating the construction of efficient predictive models that can optimize individualized treatment strategies. In this review, we systematically summarize existing AI-driven computational approaches for NIT response prediction, categorizing them into indirect and direct predictive paradigms. The indirect paradigm predicts clinically validated surrogate biomarkers to infer therapeutic response to NIT. In contrast, the direct paradigm leverages AI to analyze high-throughput data and establish data-driven biomarkers that directly predict clinical endpoints of NIT. Additionally, we categorize existing AI predictive models based on data modalities, spanning radiomics, pathomics, genomics, and multi-omics approaches, each providing distinct insights into tumor characteristics and treatment response. Despite notable progress, current predictive models still face significant challenges, which we broadly classify into biomarker-based and AI-based limitations. We further discuss potential strategies to address these challenges. This review systematically summarizes recent AI-based predictive models for NIT response across cancer types. By offering a structured analysis of current methodologies and challenges, we aim to guide future research and accelerate the integration of AI into precision immunotherapy. Keywords Neoadjuvant immunotherapy Artificial intelligence Multi-omics Biomarkers Response prediction The Intramural Research Program ES102425 The Natural Science Foundation (NSF) of China 82172899 The Natural Science Foundation of Zhejiang Province LR22H160002 Noncommunicable Chronic Diseases-National Science and Technology Major Project 2023ZD0502900/ 2023ZD0502902 Dr. Li Dak Sum Yip Yio Chin Development Fund for Regenerative Medicine, Zhejiang University, the Open Fund of Zhejiang Provincial Key Laboratory of Pulmonology KF202302 the Haining People&#8217;s Hospital Tertiary-A Public Hospital Establishment Project Municipal Finance Support Fund the Joint University-Local Cooperation Fund between ZJU-UoE Institute and Haining People&#8217;s Hospital pmc-status-qastatus 0 pmc-status-live yes pmc-status-embargo no pmc-status-released yes pmc-prop-open-access yes pmc-prop-olf no pmc-prop-manuscript no pmc-prop-legally-suppressed no pmc-prop-has-pdf yes pmc-prop-has-supplement no pmc-prop-pdf-only no pmc-prop-suppress-copyright no pmc-prop-is-real-version no pmc-prop-is-scanned-article no pmc-prop-preprint no pmc-prop-in-epmc yes issue-copyright-statement &#169; BioMed Central Ltd., part of Springer Nature 2025 Introduction Immunotherapy, particularly immune checkpoint inhibitors (ICIs), has emerged as a significant breakthrough in cancer treatment. By targeting programmed cell death protein 1 (PD-1), its ligand PD-L1, and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), ICIs can relieve the immune suppression exerted by tumor cells, restoring the effector functions of T cells and thereby effectively promoting the clearance of tumor cells [ 1 ]. However, the application of immunotherapy in resectable cancers remains an area of active exploration. Neoadjuvant immunotherapy (NIT) is an innovative treatment strategy that primarily involves the use of ICIs before surgery to eliminate potential micrometastases or microtumor foci, thus reducing tumor burden and lowering the risk of postoperative recurrence [ 2 ]. Preliminary clinical data have shown favorable pathological response rates for NIT across various tumor types. Despite these promising results, current clinical research still faces the challenge of accurately predicting which patients will benefit from NIT [ 3 ]. Therefore, the precise identification of patients who are most likely to benefit from NIT remains a significant challenge in clinical practice, necessitating the development of accurate predictive models to identify potential responders and optimize treatment strategies before therapy begins. The tumor characteristics of cancer patients can be characterized by a variety of data modalities, each contributing valuable insights into different aspects of tumor biology and the immune status [ 4 ]. These include radiological images, digitized histopathological slides, genomic sequencing, proteomic profiles, epigenomic modifications, and microbiome features [ 5 ]. Radiological imaging provides critical details on tumor size, shape, and location, while histopathological slides offer information about tumor-infiltrating immune cells and microenvironment characteristics. Genomic sequencing, through techniques such as whole-genome sequencing and targeted gene panels, identifies specific genetic mutations and alterations that drive tumor progression and immune evasion. Transcriptomics examines gene expression at the RNA level by analyzing the complete set of transcripts, including mRNA and non-coding RNA, to reveal cellular functions and regulatory mechanisms. Proteomic profiling, which analyzes protein expression in the tumor and its microenvironment, reveals biomarkers associated with tumor metastasis and immune suppression. Microbiome data explore the role of microbial communities in modulating immune responses. Epigenomic modifications, including DNA methylation, histone modifications, and chromatin accessibility, provide insights into gene regulation within both the tumor and immune microenvironment, influencing tumor behavior and immune escape mechanisms [ 5 , 6 ]. The integration of these data allows for a more comprehensive understanding of tumors. However, these diverse data sources are inherently complex, often exhibiting high dimensionality, non-linearity, and heterogeneity, making it difficult to accurately model them using traditional human observation and statistical analysis [ 7 ]. This complexity underscores the limitations of conventional methods, which struggle to account for intricate relationships between tumor biology, immune function, and treatment outcomes. In contrast, artificial intelligence (AI) technologies, particularly machine learning (ML) and deep learning (DL), offer a promising solution by efficiently processing and analyzing these large, heterogeneous datasets [ 8 ]. These techniques can uncover hidden, non-linear patterns between multi-dimensional patient data and their treatment outcomes, resulting in more accurate and generalized predictions of NIT efficacy and helping to tailor personalized treatment strategies. In this review, we provide the comprehensive and structured review of existing AI-based predictive models for assessing NIT efficacy. Specifically, we introduce a new taxonomy that classifies current approaches into two principal paradigms. The indirect paradigm infers therapeutic response by predicting clinically validated surrogate biomarkers such as PD-L1 expression, tumor mutational burden (TMB), microsatellite instability (MSI), and the tumor microenvironment (TME) features. In contrast, the direct paradigm leverages AI-driven algorithms to model clinical treatment endpoints directly, including major pathological response (MPR), pathological complete response (pCR), and progression-free survival (PFS). Furthermore, we subgroup these predictive models according to the data modality&#8212;distinguishing between single-omics and multi-omics frameworks&#8212;to emphasize the strengths of AI in capturing complex biological signals through feature extraction and data integration. Despite significant advances, AI-based computational approaches for NIT prediction remain limited by several challenges and we outline key future directions to address these limitations. Overcoming these barriers will be critical for enhancing the clinical translation of AI models and advancing precision oncology in the NIT landscape. Comparison with existing reviews Several reviews have been published on the application of AI in predicting immunotherapy outcomes. However, our review distinguishes itself in several key aspects. Firstly, while many existing reviews broadly examine AI in immunotherapy, our work specifically focuses on NIT. This narrower scope highlights a clinically significant and rapidly evolving treatment setting, where accurate prediction is particularly critical for guiding patient selection and optimizing perioperative strategies, thereby distinguishing our review from prior surveys that address immunotherapy in general [ 9 &#8211; 13 ]. Secondly, unlike reviews that concentrate on specific cancer types, our study adopts a pan-cancer perspective, providing a more comprehensive overview of AI-driven prediction methods across multiple malignancies. This broader scope allows us to identify cross-cancer patterns and insights that would remain hidden in single-entity surveys [ 14 &#8211; 18 ]. Thirdly, while earlier reviews often confine themselves to a single biomarker class or a specific data modality, our framework embraces both direct prediction of clinical outcomes and indirect prediction via validated biomarkers, without being restricted to one omics layer or biomarker type [ 19 &#8211; 26 ]. Finally, our review is organized in a structured manner with comparative tables that clearly summarize study attributes such as data modality, cohort size, validation strategy, and performance metrics, thereby facilitating transparent cross-study comparison and synthesis. Together, these perspectives underscore the novelty of our review and provide readers with a structured, integrative, and clinically relevant overview of AI-based prediction in NIT. Fig. 1 Historical evolution of artificial intelligence and representative algorithm architectures. ( A ) Timeline illustrating the major developmental phases of AI, from symbolic logic and expert systems (1950s), through machine learning (1980s) and deep learning (2000s), to the current foundation model (2020s). ( B ) Schematic representations of classical ML algorithms, including LR, KNN, SVM, RF, and GBDT. ( C ) Architectures of widely used DL models, specifically MLP, CNN, RNN, Transformer, and GNN AI foundations in cancer research AI, a branch of computer science (CS), is dedicated to replicating human intelligence to enable machines to learn and reason autonomously [ 27 ]. Its evolution can be categorized into four distinct stages (Fig. 1 A). From the 1950&#8201;s to the 1980&#8201;s, research was dominated by symbolic reasoning and expert systems, though progress was limited by insufficient computational resources and data. Between the 1980&#8201;s and the 2000&#8201;s, the adoption of statistical learning marked a shift towards data-driven methods, leading to notable advances in ML [ 28 ]. Since the 2000&#8201;s, the emergence of DL has significantly improved AI capabilities, particularly in CV and complex decision-making. Entering the 2020&#8201;s, AI has transitioned into the foundation model era, exemplified by large-scale pre-trained systems such as generative pre-trained transformer (GPT), contrastive language-Image pre-training (CLIP), and segment anything model (SAM) [ 29 ]. Trained on massive datasets using self-supervised learning, these models exhibit strong generalizability and adaptability across tasks [ 28 ]. These advancements have laid a robust foundation for the integration of AI into complex real-world domains [ 30 ]. These advancements have laid a solid foundation for integrating AI into complex real-world domains. Among these, AI has been applied to biomedical predictive analytics problems. For example, machine learning models have been used to analyze time-series data from wearable devices, such as heart rate monitors, electrocardiograms, and fitness trackers. These models can predict cardiovascular events, like heart attacks, by detecting abnormalities in heart rhythms and other physiological signals [ 31 ]. Additionally, graph neural networks are being utilized to predict how molecules interact with biological targets [ 32 ]. These models analyze extensive chemical and biological datasets to identify promising compounds for drug development or repurposing. Machine learning (ML), a subfield of artificial intelligence (AI), involves constructing mathematical models that enable computers to identify patterns from data and make predictions or decisions without explicit programming [ 33 ]. Among commonly used ML algorithms, logistic regression (LR) is a classic statistical model for binary classification, widely applied in tasks such as disease risk prediction, treatment response evaluation, and survival analysis [ 34 ]. K-Nearest Neighbors (KNN), a non-parametric algorithm based on sample similarity (e.g., Euclidean distance), is valued for its simplicity and interpretability [ 35 ]. Support Vector Machines (SVMs) construct optimal hyperplanes to separate classes, demonstrating robust performance in high-dimensional biomedical data [ 36 ]. Random Forests (RFs), as ensemble methods combining multiple decision trees, improve model robustness and generalization. They are frequently employed in clinical outcome prediction and disease risk assessment, especially in settings with heterogeneous, multidimensional clinical data [ 37 ]. Gradient Boosted Decision Trees (GBDTs) iteratively correct prediction errors to build strong learners, showing effectiveness in genomic feature selection and personalized treatment modeling, particularly when dealing with small but high-quality datasets [ 38 ]. While conventional ML approaches provide interpretable models with lower computational costs, they heavily depend on handcrafted feature engineering, which may lead to the loss of critical information [ 39 ]. However, DL, another branch of AI, overcomes the limitations of traditional ML methods by leveraging multi-layered neural networks to automatically extract hierarchical features from data [ 39 ]. DL models typically contain multiple hidden layers that abstract data features from low to high levels. Its primary advantage lies in its powerful feature learning capability, particularly in processing large-scale, complex, unstructured data ( e.g. , image and speech data), where it exhibits exceptional performance (Fig. 1 C). Specifically, multi-layer perceptrons (MLPs), as fundamental feedforward networks, capture non-linear relationships and serve as the basis for more advanced architectures [ 40 ]. Convolutional Neural Networks (CNNs) are among the most commonly used DL models, particularly for medical image analysis. In NIT, CNNs are widely applied for automated tumor image analysis, such as tumor detection, segmentation, classification, and evaluation of immune microenvironments. CNNs can progressively capture both local and global features of tumor images, enabling precise classification or regression analyses that inform clinical decision-making [ 41 ]. Besides, recurrent neural networks (RNNs) are particularly suited for handling sequential data. In genomics, RNNs have been applied to tasks such as predicting gene expression from promoter sequences by incorporating context information across nucleotide positions [ 41 ]. Unlike CNNs, which rely on convolutional operations to extract local features, vision transformers (ViTs) employ self-attention mechanisms that enable global feature modeling across the entire image. This architecture not only facilitates efficient parallel computation but also enhances the model&#8217;s ability to capture long-range dependencies. Consequently, ViTs have demonstrated strong performance in complex visual tasks such as tumor subtyping, segmentation, and multi-modal image fusion [ 42 ]. Also, graph neural networks (GNNs) are gaining traction in medical AI, particularly in modeling relational data, such as protein interactions, molecular structures, and patient networks [ 42 ]. Indirect biomarker-based prediction methods PD-L1 As a key immune-regulatory molecule, elevated PD-L1 expression is thought to enhance the tumor&#8217;s sensitivity to immune checkpoint blockade, which could improve the likelihood of therapeutic benefit [ 43 ]. Extensive clinical trials have consistently demonstrated that tumors with high PD-L1 expression ( \\documentclass[12pt]{minimal} \\usepackage{amsmath} \\usepackage{wasysym} \\usepackage{amsfonts} \\usepackage{amssymb} \\usepackage{amsbsy} \\usepackage{mathrsfs} \\usepackage{upgreek} \\setlength{\\oddsidemargin}{-69pt} \\begin{document}$$\\ge$$\\end{document} 1%) tend to achieve higher rates of MPR or pCR following NIT or neoadjuvant chemoimmunotherapy (NCIT), suggesting an indirect association between PD-L1 levels and treatment response [ 44 &#8211; 49 ]. Therefore, PD-L1 expression is considered a viable indirect biomarker for predicting potential benefits from NIT, contributing to improved preoperative treatment stratification and patient selection. By automating the quantification of PD-L1 expression with exceptional precision, AI models mitigate the inherent variability of manual assessment and provide a means to capture the dynamic spatiotemporal heterogeneity of tumors [ 20 ]. This technological advance could significantly enhance the accuracy of patient selection and ultimately enable more refined, evidence-based decision-making in the clinical application of NIT. A systematic literature search was conducted, followed by independent screening and quality assessment by two researchers, leading to the inclusion of 19 studies that met the predefined criteria and focused on PD-L1 as a biomarker. Among these, 18 studies employed a single-omics approach, with radiomics-driven analyses comprising 10 studies (55.6%), pathomics-based investigations accounting for six studies (33.3%), and genomics-focused research representing two studies (11.1%) (Tab. 1 , Fig. 2 ). Herein, a model built with data from a single type of omics (e.g., radiomics, pathomics, genomics, etc.) is referred to as a single-omics model. In contrast, a model built using data from two or more omics layers is classified as a multi-omics model. Single omics-based methods Radiomics Using an unbiased search approach, we included 10 AI-based radiomics studies focused on lung, bladder, gastric, and breast cancers, with seven studies centered on lung cancer [ 50 &#8211; 59 ]. Five retrospective studies in lung cancers have demonstrated that CT-based models are effective in predicting PD-L1 expression, with AUC values exceeding 0.75. Following this progression, another NSCLC study introduced a hybrid radiomics model that integrated delta-radiomics and DL features with mathematical models and replaced eight original model features with non-linear fitting parameters, which indicates its high prediction accuracy (cross-validation AUC of 0.91) [ 51 ]. While the majority of previous studies have been concentrated on primary lung cancer, a particular investigation by Mei&#223;ner et al. [ 59 ] provides a novel non-invasive assessment method for predicting PD-L1 expression in brain metastases from NSCLC. They proposed a radiomics-based model on intracranial PD-L1 expression, which, using stratified cross-validation, achieved an AUC of 0.84 in external validation, demonstrating its ability to accurately predict intracranial PD-L1 expression in NSCLC patients with brain metastases. Furthermore, AI-driven radiomics has also shown broad potential in other cancers. Notably, one study in advanced BC found that subgroup analysis revealed the radiomics model&#8217;s independence from IHC-based PD-L1 status, tumor metastatic load, and molecular subtypes, emphasizing its significant value in the automated quantification of PD-L1 expression [ 53 ]. These studies highlight the emerging potential of radiomics in predicting PD-L1 expression, particularly in lung cancer, and underscore ongoing efforts to refine model algorithms. Pathomics We conducted an unbiased selection of five studies, focusing on NSCLC, esophageal squamous cell carcinoma (ESCC), BC, and glioblastoma (GBM) [ 60 &#8211; 65 ]. Nearly all of the AI models employed CNN and RNN as core methodologies. Among these, the largest study involved 3,376 BC patients and utilized automated analysis of H&amp;E-stained tissue slide images to predict PD-L1 expression levels, achieving AUC values ranging from 0.91 to 0.93 [ 62 ]. Moreover, two retrospective studies on NSCLC focused on the automated analysis of PD-L1 IHC images labeled with 22C3 and SP263 antibodies. These studies applied a CNN-based PD-L1 tumor proportion score (TPS) model, demonstrating high consistency with pathologist-calculated TPS results ( \\documentclass[12pt]{minimal} \\usepackage{amsmath} \\usepackage{wasysym} \\usepackage{amsfonts} \\usepackage{amssymb} \\usepackage{amsbsy} \\usepackage{mathrsfs} \\usepackage{upgreek} \\setlength{\\oddsidemargin}{-69pt} \\begin{document}$$\\text {R}&gt; 0.950$$\\end{document} ), further validating the reliability of this model for automated PD-L1 expression assessment [ 60 , 61 ]. Besides NSCLC, another study on GBM developed an ML model based on Raman histopathology. Leveraging a machine learning classifier (MLC), the model successfully visualized PD-L1 expression in glioma cells, CD8 + T cells, macrophages, and normal cells, achieving an average accuracy of 0.990. This method not only accurately delineated tumor-normal tissue boundaries but also completed the entire process&#8212;from signal collection to image visualization&#8212;in just 30 minutes, showcasing its remarkable potential for rapid and efficient analysis [ 64 ]. Overall, AI-based models show strong potential in automated PD-L1 assessment across various cancers, utilizing diverse pathological inputs to enhance accuracy. Others AI methods have been successfully applied to genomics for predicting PD-L1 expression in cancer. Two multicenter, retrospective studies have demonstrated the potential of AI in predicting durable clinical benefit and survival outcomes in NSCLC patients, achieving exceptional predictive accuracy ( \\documentclass[12pt]{minimal} \\usepackage{amsmath} \\usepackage{wasysym} \\usepackage{amsfonts} \\usepackage{amssymb} \\usepackage{amsbsy} \\usepackage{mathrsfs} \\usepackage{upgreek} \\setlength{\\oddsidemargin}{-69pt} \\begin{document}$$\\text {AUC}&gt; 0.80$$\\end{document} ) [ 66 , 67 ]. These studies underscore the effectiveness of AI techniques in forecasting PD-L1 expression to predict patient outcomes. Multi-omics-based methods In AI-based studies on PD-L1 biomarkers, the integration of multiple input data types has proven to be a powerful approach, leveraging the distinct advantages of various omics to enhance prediction accuracy. In a study on gastric cancer (GC), PD-L1 was used as a supplementary biomarker for evaluating immune responses, combined with radiomics and pathomics to assess the efficacy of anti-HER2 therapy in conjunction with immunotherapy [ 68 ]. Specifically, in another study involving 57 NSCLC patients, Byeon et al. (2022) [ 69 ] developed a multi-omics ML model that incorporated sequencing data, IHC images, demographic information, and clinical data. By combining these diverse data types, the model was able to capture the intricate relationships between gene expression, tumor immune microenvironment features, and cancer-specific intrinsic gene signatures, thus providing a precise prediction of immune treatment efficacy (AUC = 0.957). These multi-omics studies centered around PD-L1 highlight the significant potential of AI-driven models in advancing precision medicine and improving therapeutic outcomes. Fig. 2 AI-based single- and multi-omics computational frameworks for pan-cancer NIT response prediction through surrogate biomarker (outer) and direct modeling (inner) TMB TMB reflects the overall quantity of somatic mutations within a tumor genome and has emerged as a potential biomarker for prognostic assessment and immunotherapy response prediction [ 70 ]. TMB is closely associated with tumor immunogenicity, as higher mutational loads increase the likelihood of neoantigen generation, thereby enhancing tumor visibility to the host immune system [ 71 ]. Clinical evidence across multiple studies indicates that tumors with high TMB (TMB-H) are more likely to exhibit substantial pathological regression and tumor shrinkage following NIT, with a strong correlation between TMB-H status and favorable immune responses [ 72 &#8211; 74 ]. Consequently, TMB-H is increasingly recognized as a viable biomarker to benefit from NIT. A systematic literature search was conducted, followed by independent screening and quality assessment by two researchers, resulting in the inclusion of 15 studies that met the predefined criteria and focused on TMB as a biomarker. Of these, 14 studies adopted a single-omics approach, with radiomics-driven analyses comprising five studies (35.7%), pathomics-based investigations accounting for seven studies (50%), genomics-focused research representing one studies (7.14%), and transcriptomics-focused research representing one studies (6.7%) (Tab. 1 , Fig. 2 ). Single omics-based methods Radiomics Through an unbiased search approach, we identified five studies validating the capability of AI-based radiomics models in assessing TMB, spanning endometrial cancer, lung adenocarcinoma, NSCLC, and low-grade glioma (LGG) cohorts [ 75 &#8211; 79 ]. Among these studies, He et al. (2020) [ 77 ] developed a CNN model based on CT imaging to create a DL-based radiomics biomarker, which can accurately differentiate patients with high or low pre-treatment TMB status (AUC 0.8). They observed that the DL radiomics biomarkers also potentially predict the treatment responses to ICIs in NSCLC patients (AUC = 0.81), which also supports TMB as an efficacy biomarker of immunotherapy. In endometrial cancer, Veeraraghavan et al. (2020) [ 75 ] utilized radiomic features from contrast-enhanced CT images to capture tumor morphology and explore the differences in features across various tumor regions and subpopulations. Based on these features, they successfully developed an ML model robustly assessing TMB status (AUC = 0.87) and further observed that peritumoral features are closely correlated with TMB status. Additionally, another study leverages ML algorithms for MRI radiomics model development and achieved TMB evaluation in lower-grade glioma cohorts [ 78 ]. Overall, radiomics demonstrates significant potential as a valuable adjunct for TMB classification, providing sufficient information to guide clinical decision-making in immunotherapy, despite the inherent tumor heterogeneity. Pathomics We conducted an unbiased selection of six AI-based pathology studies, covering various cancer types, including colorectal cancer (CRC), renal cell carcinoma (RCC), glioma, bladder cancer (BLCA), and GC [ 80 &#8211; 85 ], [?]. All of these studies utilized data sourced from the TCGA database, with the images processed using H&amp;E staining for subsequent analysis. Also, nearly all studies have opted for CNN-based deep learning models, specifically utilizing architectures such as ResNet18, ResNet50, VGG19, and InceptionNet for image analysis. Notably, in a glioma study, a graph convolutional neural network-based (GCNN) framework was employed to identify pathological features on WSIs of H&amp;E stained tumor biopsies. The DL model can both classify patients into high and low TMB groups and stratify glioma patients based on their overall survival (OS), demonstrating a strong association between TMB-related histopathological features from H&amp;E staining and overall survival [ 82 ]. Furthermore, a multicenter study on BLCA demonstrated that DL-driven spatial analysis of WSI can reliably predict TMB-H and TIL level, another therapeutic biomarker for NIT as elaborated in the following sections. The study also observed that TMB-H patients with lower spatial heterogeneity of TMB and enriched TILs show improved OS [ 84 ]. Overall, AI-based pathology research effectively correlates stratified TMB-related features with clinical outcomes, marking a significant advancement in predicting therapeutic efficacy across cancers. Others We also reviewed three additional genomics-based studies, two of which focused on pan-cancer analysis rather than a single cancer type [ 86 &#8211; 88 ]. One pan-cancer study highlighted that the relationship between TMB and OS is not always monotonic, revealing more complex dynamics in certain cancer types. Using a dual-threshold approach combined with a Na&#239;ve Bayes (NB)-based machine learning model, this study leveraged large-scale pan-cancer data to capture nuanced interactions between TMB and cancer stem cell characteristics, deepening our understanding of TMB as a biomarker [ 88 ]. Multi-omics-based methods A growing number of studies are now exploring the predictive potential of TMB through multi-omics data combined with AI. In a study by Wang et al. (2022) [ 89 ], a multi-omics model was developed to predict TMB status in lung adenocarcinoma (LUAD) patients by integrating gene expression, miRNA profiles, CpG methylation, and pathological tissue images. This approach enables more precise TMB prediction by capturing nuanced epigenetic changes in the tumor microenvironment, promoting prognostic accuracy. Also, the features selected from these mutational and epigenetic profiles could inspire the rationale and design of simplified clinical assays, such as qRT-PCR, enhancing patient stratification and treatment selection. However, further research is required to refine multi-omics integration methods and validate their applicability in larger, multi-center cohorts. MSI/dMMR When the mismatch repair (MMR) system becomes dysfunctional, the accumulation of mismatches leads to genomic instability, including an increase in indels within microsatellite regions [ 90 ]. This results in tumors typically exhibiting a higher mutational burden and tumor antigen presentation, associated with better efficacy in immunotherapy. A substantial number of clinical trials have demonstrated that, compared to microsatellite stability (MSS)/proficient MMR tumors, MSI/deficient MMR (dMMR) tumors generally exhibit a higher pathological response rate to NIT or NCIT across multiple cancer types [ 91 &#8211; 97 ]. Therefore, MSI/dMMR is considered a viable biomarker for predicting the benefit of NIT. Following a systematic search based on predefined criteria, and subsequent independent screening and quality assessment by two reviewers, we ultimately included 37 studies that employed AI to evaluate MSI/dMMR status in cancer patients. Of these, nine (24.3%) were radiomics-based, 23 (62.2%) were pathology-based, three (8.1%) were genomics-based, and two (5.4%) utilized multi-omics approaches (Tab. 1 , Fig. 2 ). Single omics-based methods Radiomics Recent studies have validated the potential of imaging-based AI models for the non-invasive prediction of MSI and dMMR. Through an unbiased literature review, we identified nine relevant studies, the majority of which were retrospective analyses conducted on large cohorts of over 100 patients [ 98 &#8211; 106 ]. The primary imaging modalities used in these studies included MRI (n=5) and CT or PET/CT (n=4). ML algorithms, including SVM, LR, and KNN, were employed in five studies, while DL was applied in four. CRC remains the most commonly studied cancer, accounting for more than half of the studies (n=5). Other cancer types investigated include EMC [ 98 , 100 , 101 ] and GC [ 106 ]. Nearly all studies reported satisfactory performance, with an area AUC value greater than 0.8. Notably, Wang et al. [ 101 ] developed a composite model that integrates features extracted from diffusion-weighted imaging (DWI) MRI via CNN with traditional radiomics, clinical parameters, and apparent diffusion coefficient (ADC) values. The model demonstrated excellent predictive performance in an endometrial cancer cohort, highlighting the significant advantages and clinical potential of multi-level, multimodal feature fusion in the non-invasive prediction of MSI. Pathomics AI models are applied to predict tumor MSI or dMMR status from pathological slides, thereby aiding in individualized NIT regimens. By undergoing a comprehensive literature retrieval, we identified 18 studies focused on AI-based MSI prediction using pathomics features, of which 70% were conducted within CRC cohorts (n=13), while the remaining studies involved endometrial cancer (EMC), prostate cancer, epithelial ovarian cancer (EOC) and GC [ 107 &#8211; 124 ]. Regardless of cancer type, nearly all studies were retrospective analyses conducted on large cohorts of over 100 patients. In CRC research, 12 studies have demonstrated the robustness of DL models utilizing H&amp;E WSIs for MSI prediction, consistently achieving AUC values greater than 0.85. Among these studies, one study notably proposed an innovative multi-center collaboration approach. Specifically, the study from Saldanha et al.[ 114 ] is the first to successfully apply a swarm learning (SL) framework to a large-scale, multicenter cancer histopathology image dataset comprising over 5,000 patients. Without requiring data sharing and while fully preserving data privacy, the study enabled cross-institutional collaborative training of AI models to predict MSI in CRC. This approach overcomes the reliance on centralized data aggregation typical of conventional AI training and addresses critical barriers related to ethics, legal constraints, and data sovereignty in clinical research. The SL-trained models outperformed most locally trained counterparts. They achieved performance comparable to models trained on pooled datasets, demonstrating strong data efficiency and promising potential for real-world clinical application. Meanwhile, several studies have successfully developed models for predicting MSI in CRC using other types of pathology data. For example, two studies demonstrated that DL models based on infrared imaging and Raman spectroscopy features of tumor biopsies were able to distinguish between MSI and MSS in CRC cohorts [ 109 , 116 ]. In other cancer types, all five studies reported DL models can automatically extract features from H&amp;E WSIs and differentiate patients with MSS or MSI with robust performance, indicating that DL models based on H&amp;E WSI are both more commonly studied across various cancer types. Besides MSI, we identified four studies that applied DL models based on tumor tissue sections to directly predict the MMR status in CRC [ 125 , 126 ] and EMC [ 127 , 128 ]. While these studies are also primarily constructed upon H&amp;E WSIs (n = 3), Nowak et al. [ 125 ] developed a DL&#8211;based model that predicts dMMR status in CRC using IHC images of MMR proteins, enabling single-cell&#8211;level assessment of protein expression. In two independent clinical trial cohorts, the model demonstrated excellent predictive performance (AUC = 0.86), achieving over 75% specificity at 98% sensitivity, with a positive predictive value of \\documentclass[12pt]{minimal} \\usepackage{amsmath} \\usepackage{wasysym} \\usepackage{amsfonts} \\usepackage{amssymb} \\usepackage{amsbsy} \\usepackage{mathrsfs} \\usepackage{upgreek} \\setlength{\\oddsidemargin}{-69pt} \\begin{document}$$\\ge 98\\%$$\\end{document} for the most common somatic dMMR subtype. Further validation in the SCOT trial confirmed the prognostic significance of dMMR status in patients treated with oxaliplatin. In summary, H&amp;E WSIs are the most extensively studied input for ML and DL models in predicting MSI/dMMR. AI models have demonstrated robust performance in predicting MSI/dMMR status across multiple cancer types, reducing the burden of pathological workload. While the majority of models are trained and validated in CRC cohorts, AI has shown efficacy in MSI/dMMR predictions across various cancers such as EMC, prostate cancer (PC), and EOC. Others Compared to traditional PCR-based methods, next-generation sequencing (NGS)-based computational approaches have emerged as promising alternatives for detecting MSI. These methods are less labor-intensive and allow for the simultaneous analysis of multiple samples and loci. However, a major limitation of conventional NGS-based MSI detection is the requirement for matched normal tissue, which serves as a reference to examine aligned reads&#8212;an approach that is computationally intensive and often impractical in clinical settings. To address this, ML algorithms have been developed to predict MSI directly from tumor samples, eliminating the need for normal-tumor pairings. For instance, Swaerts et al. [ 129 ] introduced DeltaMSI, an ML tool that infers MSI status based on raw indel distributions across microsatellite loci. Similarly, Chen et al. [ 130 ] proposed MSINGB, a model based on next-generation boosting (NGBoost) that utilizes tumor mutation annotation data. Both tools demonstrated excellent predictive performance, achieving AUCs of 0.95 and 0.999, respectively. In addition to ML-based methods, DL approaches have also been explored. One study proposes a novel and explainable GNN framework, which, for the first time, integrates RNA expression and DNA methylation data to predict MSI status. The model enables high-performance MSI detection using tumor-only samples, eliminating the need for matched normal tissue. It also identifies key MSI-associated biomarkers with potential relevance to immunotherapy, providing both predictive accuracy and biological interpretability [ 131 ]. Multi-omics-based methods Two studies have developed multi-omics AI models for MSI prediction by integrating data from different omics sources [ 132 , 133 ]. Shi et al. [ 132 ] developed a multi-omics integrative model that combines Raman spectroscopy data from formalin-fixed paraffin-embedded (FFPE) tumor slides with preoperative CT imaging to accurately classify MSI status in gastric cancer. The model incorporates a newly proposed Euclidean Distance Raman Spectroscopy algorithm, which effectively mitigates signal variability caused by tumor heterogeneity. Among various machine learning approaches, the EDRS-based model achieved the highest classification accuracy (94.6%). Compared to the Raman-only model (AUC = 0.871), the multi-modal model demonstrated superior performance in distinguishing MSI from MSS tumors (AUC = 0.914), offering a novel and promising strategy for precise NIT prediction. Another study proposed a multimodal DL model for predicting MSI in CRC [ 133 ]. It demonstrated robustness in MSI classification with H&amp;E WSIs alone (AUC=0.809) but can be further enhanced by integrating DNA methylation data (AUC=0.952). Interestingly, combining WSIs with multiple molecular data types (mRNA, miRNA, lncRNA, DNA methylation, and CNV) resulted in lower performance. The study attributed this to the noise from irrelevant features or overlapping information across omics data, which diluted the model&#8217;s focus. Overall, while combining multiple omics holds the potential to improve model efficacy, the addition of heterogeneous data can introduce noise and thus requires careful selection. TME Characteristics of the TME, particularly infiltrating immune cells such as TILs and CD8 + T cells, have been widely studied as predictors of immunotherapy benefit and shown to correlate with NIT response rates in clinical trials [ 134 &#8211; 139 ]. Also, tumor-stromal ratio (TSR), tertiary lymphoid structure (TLS), molecular markers including CTLA-4, and vascular endothelial growth factor (VEGF), have been reported to reflect ICI therapeutic outcomes [ 140 ], with growing evidence suggesting their potential as predictive parameters of NIT outcomes [ 141 &#8211; 144 ]. The integration of AI holds promise for directly predicting TME components from imaging features, thereby potentially guiding the use of NIT. Following a systematic search based on predefined criteria, followed by independent screening and quality assessment by two reviewers, we ultimately included 34 studies that utilized AI to evaluate components of the TME related to the benefits of NIT in cancer patients. Among these, 18 studies (52.9%) were radiomics-driven, while 16 studies (47.1%) were pathomics-driven (Tab. 1 , Fig. 2 ). Single omics-based methods Radiomics Through an unbiased literature search, we identified 18 studies involving AI models based on radiomics for evaluating TME profiles that are correlated to NIT efficacy. All of these studies were retrospective, with a large proportion of the data originating from single-center cohorts (n=10). Approximately half of the studies focused on BC (n=8), while the remaining studies covered oral tongue squamous cell carcinoma (OTSCC), GC, glioma, clear cell RCC (ccRCC), lung cancer, pancreatic ductal adenocarcinoma (PDAC) and hepatocellular carcinoma (HCC) [ 145 &#8211; 162 ]. The primary objective of these radiomics models was to predict immune cell infiltration within the TME, particularly TILs (n=7). Most researches focus on the imaging data from BC patients (n=6)[ 145 &#8211; 150 ]. Additionally, six studies utilized radiomics to evaluate other immune or stromal cell populations within the TME, all employing ML techniques[ 151 , 152 , 154 , 155 , 157 , 158 ]. Four of these studies used MRI radiomics, while the other two employed CT radiomics. These studies were based on various cancer cohorts and predicted different TME cell populations, highlighting the broad applicability of AI models based on MRI and CT radiomics in predicting TME cellular composition. Interestingly, even within the same study, models built with the same sample group and algorithm showed significant differences in performance when predicting various infiltrating cell populations. For example, in a study of an NSCLC cohort, the ML model based on radiomics predicted \\documentclass[12pt]{minimal} \\usepackage{amsmath} \\usepackage{wasysym} \\usepackage{amsfonts} \\usepackage{amssymb} \\usepackage{amsbsy} \\usepackage{mathrsfs} \\usepackage{upgreek} \\setlength{\\oddsidemargin}{-69pt} \\begin{document}$${CD3}^+$$\\end{document} and \\documentclass[12pt]{minimal} \\usepackage{amsmath} \\usepackage{wasysym} \\usepackage{amsfonts} \\usepackage{amssymb} \\usepackage{amsbsy} \\usepackage{mathrsfs} \\usepackage{upgreek} \\setlength{\\oddsidemargin}{-69pt} \\begin{document}$${CD8}^+$$\\end{document} infiltrating cells with AUCs of 0.943 and 0.837, respectively, which may reflect the distinct distribution patterns of these cells within the TME [ 158 ]. As important TME features associated with immunotherapy efficacy, the TSR and TLS can also be assessed through AI models based on radiomics [ 160 &#8211; 162 ]. For instance, a recent multicenter study in an HCC cohort validated the feasibility of non-invasive TLS quantification using an MRI-based radiomic model with transfer learning, achieving high predictive accuracy and demonstrating clinical relevance in survival stratification and treatment response evaluation [ 162 ]. In addition to cellular composition, radiomics has also been employed to predict the expression levels of certain molecular biomarkers within the TME. For example, He et al. [ 156 ] and Wu et al. [ 159 ] developed machine learning models based on CT radiomics to predict the expression levels of CTLA-4, VEGF, and EGFR in ccRCC and peripheral lung cancer, respectively. In conclusion, radiomics models, when combined with ML or DL techniques, effectively predict TME features associated with NIT efficacy, including cellular populations and molecular biomarkers. Pathomics In the field of TME analysis, traditional methods for evaluating TILs have long relied on pathologists manually interpreting H&amp;E-stained slides. This visually-based approach is not only time-consuming and labor-intensive but is also prone to inter-observer variability, limiting the reproducibility of results and significantly hindering its widespread application in clinical practice. AI technology, particularly its breakthroughs in automating TME component quantification, offers a novel solution for TIL assessment. Through a literature review, we identified 11 relevant studies that validated the feasibility of AI algorithms in TIL evaluation [ 163 &#8211; 173 ]. All studies retrospectively collected H&amp;E-stained slide data, with the majority of the data coming from multi-center cohorts (n=8). Among them, seven studies established DL models, while four employed ML models, all demonstrating excellent TIL assessment capabilities across various cancer cohorts. Notably, a model developed by Abousamra et al. [ 168 ] was trained on a large dataset of 7,983 pathological slides, enabling reliable evaluation of TILs across 23 different cancer types. Similarly, another study proposed a generalizable model for tumor-infiltrating lymphocytes classification across multiple cancer types by introducing a CNN simplification approach&#8212;Network Auto-Reduction&#8212;that substantially reduces computational cost (up to \\documentclass[12pt]{minimal} \\usepackage{amsmath} \\usepackage{wasysym} \\usepackage{amsfonts} \\usepackage{amssymb} \\usepackage{amsbsy} \\usepackage{mathrsfs} \\usepackage{upgreek} \\setlength{\\oddsidemargin}{-69pt} \\begin{document}$$4\\times$$\\end{document} fewer FLOPs) without sacrificing classification accuracy, thereby enabling efficient large-scale digital pathology analysis [ 164 ]. In addition to TILs, more pathomics-based AI models have been developed to predict other features of TME components. For example, Yang et al. [ 174 ] developed an ML model that predicts the expression of CTLA-4 in the TME from H&amp;E WSIs in ccRCC patients. The CTLA-4 signature generated by the model was also effective in predicting the prognosis of ccRCC patients. Furthermore, four studies proposed DL models that were capable of assessing TSR and TLS from H&amp;E slides [ 175 &#8211; 178 ]. To illustrate, Lian et al. [ 176 ] and Firmbach et al. [ 175 ] developed DL models for accurate TSR evaluation in CRC and BC cohorts. The rest two DL models were also built with H&amp;E WSIs for TLS quantification but were valid across multiple cancer types [ 177 , 178 ]. Overall, AI models based on pathology have the potential for reproducible and automated assessment of TME components. Currently, the primary focus is on TILs, and these models are expected to guide clinical practice for NIT. Multi-omics-based methods Compared to established immunotherapy biomarkers such as PD-L1 and MSI, relatively few studies have focused on predicting TME parameters associated with response to NIT, particularly through the integration of multi-omics data. Although certain TME indicators have recently gained recognition in clinical trials and translational research as potential predictors of immunotherapy efficacy, the development of AI models targeting these markers remains limited. In particular, multi-omics-based models capable of capturing the complex interplay within the TME are still scarce. For instance, Failmezger et al. developed a multi-omics computational framework that integrates spatial pathology and transcriptomic data to characterize tumor immune infiltration in colorectal cancer [ 179 ]. Specifically, the study applied a fused LASSO logistic regression model to classify spatial tumor infiltration phenotypes based on point pattern analysis of immune cell distributions from IHC-stained tissue sections, capturing intra-tumor heterogeneity in immune infiltration. These spatial phenotypes were then linked to genomic features by employing a support vector machine to derive predictive gene signatures from patient-matched transcriptomic data. The resulting model enabled accurate inference of spatial immune infiltration status from gene expression profiles alone and was successfully validated in an independent cohort. Furthermore, the study revealed significant associations between spatial infiltration patterns and common colorectal cancer mutations, highlighting the biological relevance of spatial immune heterogeneity in the tumor microenvironment. In the future, as more TME indicators are adopted in clinical practice, we anticipate that additional AI prediction models will be developed to offer a more comprehensive predictive approach for NIT. Other biomarkers In recent years, biomarkers for predicting immunotherapy efficacy, particularly in NIT applications, have garnered significant attention. Alongside traditional biomarkers, emerging markers such as genes, cytokines, non-coding RNAs, and DNA methylation are being explored. AI-driven methods play a crucial role in identifying and developing these biomarkers, advancing precision medicine. Through a systematic review, we identified three studies that investigate immune-related lncRNAs as biomarkers across various cancer types, including CRC, LGG, and LUAD (Tab. 1 ) [ 180 &#8211; 182 ]. They underscore the exceptional stability and accuracy of immune-related lncRNAs, which are intricately associated with crucial aspects of tumors, including their stage, grade, and prognosis, positioning them as potentially powerful biomarkers in oncology. Specifically in LGG patients, a random survival forest (RSF)-based ML model revealed that lncRNAs related to tumor-infiltrating immune cells were significantly associated with immune characteristics such as MSI, TMB, CD8, and interferon- \\documentclass[12pt]{minimal} \\usepackage{amsmath} \\usepackage{wasysym} \\usepackage{amsfonts} \\usepackage{amssymb} \\usepackage{amsbsy} \\usepackage{mathrsfs} \\usepackage{upgreek} \\setlength{\\oddsidemargin}{-69pt} \\begin{document}$$\\gamma$$\\end{document} , which were validated in internal datasets [ 180 ]. Also, a study on LUAD demonstrated that lncRNAs effectively stratify patients and forecast OS, outperforming 95 established GBM biomarkers in prediction accuracy [ 182 ]. Moreover, gene expression levels have emerged as promising biomarkers for predicting the efficacy [ 183 &#8211; 185 ]. Particularly, in a study on a small CRC cohort, SREBF2 was demonstrated to be closely associated with multiple immune infiltrating cells and immunotherapy-related genes. However, the underlying mechanisms of SREBF2 and its clinical therapeutic effectiveness require validation through large-scale clinical trials and biological experiments [ 183 ]. These findings highlight the growing potential of emerging biomarkers&#8212;particularly those related to immune characteristics and tumor biology&#8212;revealing new insights into immunotherapy efficacy and driving the enhancement of treatment outcomes in NIT strategies. Table 1 Summary of studies on indirect biomarker-based prediction Ref. Author (Year) Biomarker Omics Cancer type Data source Analysis type Total patients Training set Validation set Testing set AI model Prediction performance [ 50 ] Wang et al. (2022) PD-L1 Radiomics NSCLC Multicenter Retrospective 4404 3629 873 818 DL: NLP/LASSO AUC: 0.80 [ 51 ] Jin et al. (2023) PD-L1 Radiomics LC Multicenter Prospective 104 97 - 46 DL: CNN AUC: 0.91 (cross-validation)&#8722;0.85 (external validation) [ 52 ] Saad et al. (2023) PD-L1 Radiomics NSCLC Multicenter Retrospective 976 60% 10% 30% DL C-index: 0.70 (clinical model)&#8722;0.75 (composite model) [ 53 ] Zhao et al. (2023) PD-L1 Radiomics BC Multicenter Retrospective 240 171 - 69 ML AUC: 0.99 (training)&#8722;0.96 (validation) [ 54 ] Wang et al. (2023) PD-L1 Radiomics GC Multicenter Retrospective 249 168 39 42 DL: MLP/CNN AUC: 0.81 [ 55 ] Mu et al. (2021) PD-L1 Radiomics LC Multicenter Retrospective - 284 116 117 DL: SResCNN AUC: 0.89, Sensitivity: 84.7%, Specificity: 80.4% [ 56 ] Tian et al. (2021) PD-L1 Radiomics NSCLC Multicenter Retrospective 939 750 93 96 DL: CNN/KNN AUC: 0.78 (training)&#8722;0.71 (validation)-and 0.76 (testing) [ 57 ] Cao et al. (2024) PD-L1 Radiomics BC Multicenter Retrospective 183 70% - 30% ML: SVM/RF AUC: 0.92 (training)&#8722;0.75 (validation) [ 58 ] Ronrick et al. (2024) PD-L1 Radiomics LC Multicenter Retrospective 189 132 - 57 DL: CNN AUC: 0.83 [ 59 ] Mei&#223;ner et al. (2023) PD-L1 Radiomics NSCLC Multicenter Retrospective 53 36 - 17 ML: RF/SVM/CNN AUC: 0.83 &#177; 0.18 (training)&#8722;0.84 (testing) [ 60 ] Cheng et al. (2023) PD-L1 Pathomics NSCLC Singlecenter Retrospective 1288 627 577 84 DL: CNN Accuracy: 96.4%, Specificity: 96.8% [ 61 ] Wu et al. (2022) PD-L1 Pathomics NSCLC Multicenter Retrospective 239 173 - 78 DL: CNN Accuracy: 93.3%, Specificity: 96.4% [ 62 ] Shamai et al. (2022) PD-L1 Pathomics BC Multicenter Retrospective 3376 2516 - 860 DL: CNN AUC: 0.91&#8211;0.93.91.93 [ 63 ] Li et al. (2024) PD-L1 Pathomics ESCC Singlecenter Retrospective 324 WSIs 227 WSIs - 97 WSIs DL: ViR-RNN AUC: 0.92, C-index: 0.81 [ 64 ] Zhou et al. (2024) PD-L1 Pathomics GBM Singlecenter Prospective - 80% - 20% ML: MLC-based Raman histopathology/SVM/RF/GBT Accuracy: 99%, Concordance: 84.3 % [ 65 ] Jin et al. (2024) PD-L1 Pathomics Pan-cancer Multicenter Retrospective 6715 60% 15% 25% DL: MITLS AUC: 0.83 [ 66 ] Peng et al. (2022) PD-L1 Genomics NSCLC Multicenter Retrospective 915 611 - 304 DL: CNN AUC: 0.97 [ 67 ] Wiesweg et al. (2020) PD-L1 Genomics NSCLC Multicenter Retrospective 67 55 22 16 ML: SVM/RF HR: 0.46 [ 68 ] Chen et al. (2024) PD-L1 Multi-omics GC Multicenter Retrospective 429 271 - 39 DL: Transformer/MnasNet AUC: 0.82 (anti-HER2)&#8722;0.91 (combined with PD-L1) [ 69 ] Byeon et al. (2022) PD-L1 Multi-omics NSCLC Singlecenter Retrospective 57 - - - ML: RF/SVM/CNN AUC: 0.96 [ 75 ] Veeraraghavan et al. (2020) TMB/dMMR Radiomics EC Singlecenter Retrospective 150 105 - 45 ML: RF AUC: 0.87 (TMB)&#8722;0.78 (dMMR) [ 76 ] Wang et al. (2019) TMB Radiomics LUAD Singlecenter Retrospective 51 41 - 20 ML: SVM AUC: 0.67 [ 77 ] He et al. (2020) TMB Radiomics NSCLC Multicenter Retrospective 327 236 26 65 DL: 3D-densenet/CNN AUC: 0.85 (training)&#8722;0.81 (testing) [ 78 ] Lam et al. (2022) TMB Radiomics LGG Multicenter Retrospective 75 63 - 42 ML: Light Gradient Boosting Machine Accuracy: 79.4% [ 79 ] Hoshino et al. (2022) TMB Radiomics CRC Singlecenter Retrospective 24 70% - 30% ML: RF AUC: 0.92, Accuracy: 87.5%, Sensitivity: 87.5%, Specificity: 85.7% [ 80 ] Shimada et al. (2021) TMB Pathomics CRC Multicenter Retrospective - 201 - 77 DL: ResNet/InceptionNet/CNN AUC: 0.93 [ 81 ] Zheng et al. (2024) TMB Pathomics RCC Multicenter Retrospective 513 350 - 163 DL: self-supervised attention-based instance learning AUC: 0.83 &#177; 0.02 [ 82 ] Sun et al. (2023) TMB Pathomics Gliomas Multicenter Retrospective 856 619 - 237 DL: GCNN HR: 4.81 (training)&#8722;4.00 (validation) [ 83 ] Huang et al. (2022) TMB Pathomics CRC Multicenter Retrospective 509 - - - DL: ResNet/CNN/MLP AUC: 0.82, Accuracy: 87.2%, Precision: 74.8% [ 84 ] Xu et al. (2022) TMB Pathomics BC Multicenter Retrospective 386 - - - DL: CNN/SVM/RF HR: 3.30 [ 85 ] Li et al. (2024) TMB Pathomics GC Multicenter Retrospective 450 362 - 88 DL: ResNet AUC: 0.75 (training)&#8722;0.97 (testing) [?] Liu et al. (2024) TMB Pathomics ccCRC Multicenter Retrospective 264 198 - 66 ML: LR AUC: 0.65 (training)&#8722;0.67 (validation) [ 86 ] Sanjaya et al. (2023) TMB Genomics Pan-Cancer Multicenter Retrospective 2,587 - - - DL: DNN/MuAt/RF Accuracy: 97% [ 87 ] Nassar et al. (2021) TMB Genomics BC Multicenter Retrospective 58 90% - 10% ML: RF/SVM/KNN Positive expression [OR =0.35, 95% CI: 0.04&#8211;2.98.04.98] [ 88 ] Zhang et al. (2022) TMB Transcriptomics Pan-Cancer Multicenter Retrospective 722 620 154 149 ML: RF/SVM/NB AUC: 0.71 (validation and testing) [ 89 ] Wang et al. (2022) TMB Multi-omics LC Multicenter Retrospective 517 70% - 30% ML: RF/SVM AUC: 0.91 (training)&#8722;0.86 (validation) [ 98 ] Jia et al. (2024) MSI Radiomics EMC Multicenter Retrospective 225 158 67 132 ML: SVM/LR/KNN/NB/RF AUC: 0.86&#8211;0.90.86.90 (SVM), 0.62&#8211;0.68.62.68 (KNN), 0.81&#8211;0.82.81.82 (RF) [ 99 ] Xing et al. (2024) MSI Radiomics RC Singlecenter Retrospective 308 - - - ML: KNN AUC: 0.85 [ 100 ] Li et al. (2023) MSI Radiomics EMC Multicenter Retrospective 82 60 - 22 ML: LR AUC: 0.83 (radiomics)&#8722;0.89 (radiomics+clinical data) [ 101 ] Wang et al. (2024) MSI Radiomics EMC Singlecenter Retrospective 116 81 - 35 DL: CNN AUC: 0.87 (DL)&#8722;0.99 (combined) [ 102 ] Zhang et al. (2023) MSI Radiomics RC Singlecenter Retrospective 383 268 - 115 ML: LR AUC: 0.83 (training)&#8722;0.74 (testing) [ 103 ] Kim et al. (2023) MSI Radiomics CRC Singlecenter Retrospective 233 139 - 94 ML: LR AUC: 0.87 (training)&#8722;0.82 (testing) [ 104 ] Bodalal. et al. (2024) MSI Radiomics CRC Multicenter Retrospective 243 191 - 52 ML AUC: 0.69 (radiomics)&#8722;0.78 (combined with clinical data) [ 105 ] Cao et al. (2023) MSI Radiomics CRC Multicenter Retrospective 1812 1124 482 206 DL: Resnet/GPR AUC: 0.99 (training)&#8722;0.92 (testing) [ 106 ] Jiang et al. (2023) MSI Radiomics GC Singlecenter Retrospective 223 167 - 56 DL: MLP AUC: 0.88 (training)&#8722;0.80 (testing) [ 107 ] Niehues et al. (2023) MSI Pathomics CRC Multicenter Retrospective 4638 2190 - 2448 DL: SSL-attMIL AUC: 0.94 [ 108 ] Wagner et al. (2023) MSI Pathomics CRC Multicenter Retrospective 13689 8181 - 889 DL: Transformer AUC: 0.97, Sensitivity: 99% [ 109 ] Gerwert et al. (2023) MSI Pathomics CC Multicenter Retrospective 629 273 218 138 DL: CNN AUC: 0.90 [ 110 ] Saillard et al. (2023) MSI Pathomics CRC Multicenter Retrospective 1034 434 - 600 DL: MLP AUC: 0.88 [ 111 ] Zamanitajeddin et al. (2024) MSI Pathomics CRC Multicenter NA 549 slides 502 slides - 47 slides DL: MIL/Social Network Analysis AUC: 0.99 [ 112 ] Chang et al. (2023) MSI Pathomics CRC Multicenter Retrospective 1884WSIs 1107WSIs 157WSIs 620WSIs DL: Resnet AUC: 0.95 [ 113 ] Echle et al. (2022) MSI Pathomics CRC Multicenter Retrospective 8343 7538 - 805 DL: Resnet AUC: 0.74&#8211;0.96.74.96 [ 114 ] Saldanha et al. (2022) MSI Pathomics CRC Multicenter Retrospective 6820 3741 - 2579 ML: Swarm Learning AUC: 0.80&#8211;0.82.80.82 [ 115 ] Lou et al. (2022) MSI Pathomics CRC Multicenter Retrospective 144 87 37 20 DL: PPsNet AUC: 0.94, Accuracy: 87.28% [ 116 ] Blake et al. (2023) MSI Pathomics CRC NA Retrospective 1490 spectra - - - DL/ML: CNN/SVM/PCA-LDA AUC: 0.65&#8211;0.75.65.75 [ 117 ] Schirris et al. (2022) MSI Pathomics CRC/BC Multicenter Retrospective 360 260 - 100 DL: CNN/MIL AUC: 0.87 [ 118 ] Tsai et al. (2023) MSI Pathomics CRC Multicenter NA 1888 60% 20% 20% DL: CNN/Transformer AUC: 0.76&#8211;0.88.76.88 [ 119 ] Fujii et al. (2022) MSI Pathomics CRC NA Retrospective 1657 986 248 423 DL: Resnet AUC: 0.86&#8211;0.92.86.92 [ 120 ] Wang et al. (2024) MSI Pathomics EMC Multicenter Retrospective 529 353 - 176 DL Accuracy: 84%&#8722;94%, Precision: 81%&#8722;93% [ 121 ] Hu et al. (2024) MSI Pathomics PC Singlecenter Retrospective 5538 4015 173 1350 DL: attMIL AUC: 0.78 (validation)&#8722;0.72 (testing) [ 122 ] Wang et al. (2023) MSI Pathomics EOC Multicenter Retrospective 1160 472 248 440 DL: MIL/RNN Accuracy: 77%, Sensitivity: 84%, Specificity: 67% [ 123 ] Su et al. (2022) MSI Pathomics GC Singlecenter Retrospective 467WSIs 348WSIs 88WSIs 31WSIs DL: Resnet Accuracy: 83.9%&#8722;86.4% [ 124 ] Lee et al. (2023) MSI Pathomics GC Multicenter Retrospective 714 331 102 383 DL: CNN AUC: 0.89&#8211;0.90.89.90 [ 125 ] Nowak et al. (2024) dMMR Pathomics CRC Multicenter NA 3547 2352 - 1195 DL AUC: 0.98 [ 126 ] Jiang et al. (2022) dMMR Pathomics CRC Multicenter Retrospective 1215WSIs 441WSIs - 774WSIs DL: Densenet/MIL AUC: 0.77&#8211;0.88.77.88 [ 127 ] Whangbo et al. (2024) dMMR Pathomics EMC Singlecenter Retrospective 1168WSIs 934WSIs - 234WSIs DL: GAN/CNN AUC: 0.77&#8211;0.82.77.82 [ 128 ] Umemoto et al. (2024) dMMR Pathomics EMC Singlecenter Retrospective 114 70% 15% 15% DL: Resnet AUC: 0.91 [ 129 ] Swaerts et al. (2023) MSI Genomics Pan-cancer Singlecenter Retrospective 1188 1072 - 116 ML: LR/SVM AUC: 0.95 [ 130 ] Chen et al. (2023) MSI Genomics Pan-cancer Multicenter Retrospective 2285 1432 - 853 ML: NGBoost AUC: 0.99 [ 131 ] Cao et al. (2023) MSI Genomics Pan-cancer Multicenter Retrospective 7446 639 - 6807 DL: GNN/Catboost AUC: 0.91&#8211;0.99.91.99 [ 132 ] Shi et al. (2025) MSI Multiomics GC Singlecenter NA 37 - - - ML: KNN/RF/ELM AUC: 0.91 [ 133 ] Qiu et al. (2022) MSI Multiomics CRC NA Retrospective 353 282 - 71 DL: Resnet AUC: 0.81 (pathomics)&#8722;0.95 (combined) [ 145 ] Wu et al. (2023) TIL Radiomics BC Multicenter Retrospective 494 60% 20% 20% DL AUC: 0.89 [ 146 ] Jia et al. (2023) TIL Radiomics BC Multicenter Retrospective 494 298 98 98 DL: CNN AUC: 0.87 [ 147 ] Zhang et al. (2024) TIL Radiomics BC Singlecenter Retrospective 185 111 - 74 ML: LASSO/LR AUC: 0.80 (radiomics)&#8722;0.84 (combined with ultrasound features) [ 148 ] Hu et al. (2024) TIL Radiomics BC Singlecenter Retrospective 145 70% - 30% ML: LASSO AUC: 0.84 (radiomics)&#8722;0.85 (combined with clinical data) [ 149 ] Lu et al. (2024) TIL Radiomics BC Singlecenter Retrospective 378 80% - 20% ML: LASSO/LR AUC: 0.87(radiomics)&#8722;0.89 (combined with clinical data) [ 150 ] Su et al. (2022) TIL Radiomics BC Singlecenter Retrospective 139 98 - 41 ML: Elastic Net Regression/LR AUC: 0.87 (training)&#8722;0.79 (testing) [ 151 ] Jeon et al. (2022) CD8 TILs Radiomics BC Singlecenter Retrospective 182 137 - 45 ML: LASSO AUC: 0.97&#8211;0.99.97.99 [ 152 ] Qian et al. (2024) Immune Cell Infiltration Radiomics BC Multicenter Retrospective 73 70% - 30% ML: LASSO/LR AUC: 0.82 (peri-tumor)&#8722;0.84 (combined) [ 153 ] Ren et al. (2024) TIL Radiomics OTSCC Singlecenter Retrospective 68 90% - 10% ML: LR/SVM/RF AUC: 0.85 (LR), 0.82 (SVM), 0.81 (RF) [ 154 ] Huang et al. (2024) CD3, CD4, and CD8 TILs Radiomics GC Singlecenter Retrospective 103 90% - 10% ML: RF/LR AUC: 0.81&#8211;0.87.81.87 (CD3, LR), 0.90&#8211;0.91.90.91 (CD4, RF), 0.90&#8211;0.97.90.97 (CD8, RF) [ 155 ] Li et al. (2022) Tumour-infiltrating macrophages Radiomics Glioma Multicenter Ambispective 652 167 - 485 ML: RF/DL NA [ 156 ] He et al. (2023) CTLA-4 Radiomics ccRCC NA Retrospective 102 90% - 10% ML: SVM AUC: 0.72 (validation)&#8722;0.77 (testing) [ 157 ] Li et al. (2025) CD8, CD163 and SMA cells in TME Radiomics ccRCC Multicenter Retrospective 100 69 18 17 ML: LASSO/LR AUC: 0.87 (CD8), 0.90 (CD163), 0.86 (SMA) [ 158 ] Chen et al. (2023) CD3 and CD8 T Cells Radiomics NSCLC Singlecenter Retrospective 105 70% - 30% ML: LASSO AUC: 0.94 (CD3), 0.84 (CD8) [ 159 ] Wu et al. (2022) VEGF and EGFR Radiomics LC Singlecenter Retrospective 73 - - - ML: LR AUC: 0.87 (VEGF), 0.95 (EGFR) [ 160 ] Meng et al. (2022) TSR Radiomics PDAC Singlecenter Retrospective 148 110 - 38 ML: LASSO/XGBoost AUC: 0.82 (training)&#8722;0.78 (testing) [ 161 ] Liao et al. (2024) TSR Radiomics PDAC Multicenter Retrospective 207 70% - 30% DL: CNN/Transformer/self-attention AUC: 0.90&#8211;0.98.90.98 [ 162 ] Long et al. (2025) TLS Radiomics HCC Multicenter Retrospective 660 307 76 277 ML AUC: 0.90 (training)&#8722;0.85 (validation)&#8722;0.85 (testing) [ 163 ] Liu et al. (2024) TIL Pathomics BC Multicenter NA 125 80% - 20% DL: U-Net AUC: 0.93 [ 164 ] Meirelles et al. (2022) TIL Pathomics Pan-cancer NA NA 61WSI 56WSIs - 5WSIs DL: Resnet NA [ 165 ] Yosofvand et al. (2023) TIL Pathomics BC Singlecenter Retrospective 63WSIs 80% - 20% DL: U-Net/R-CNN Accuracy: 98.1% [ 166 ] Verdicchio et al. (2023) TIL Pathomics BC Multicenter NA 151WSIs 70% - 30% ML: LASSO/RF/DT AUC: 0.86 (training)&#8722;0.86 (testing) [ 167 ] Shevtsov et al. (2022) TIL Pathomics NSCLC Multicenter Retrospective 87 - - - DL: HoVer-Net Precision&gt;90% [ 168 ] Abousamara et al. (2022) TIL Pathomics Pan-cancer Multicenter Retrospective 353411 patches 351272 patches - 2139 patches DL: CNN Accuracy: 89% [ 169 ] Machuca-Aguado et al. (2023) TIL Pathomics EOC Singlecenter Retrospective 76 - - - ML NA [ 170 ] Xu et al. (2022) TIL Pathomics CRC Multicenter Retrospective 43440 tiles 80% 10% 10% DL: Resnet Accuracy: 80.1% [ 171 ] Zheng et al. (2022) TIL Pathomics BC Multicenter Retrospective 380 133 - 247 ML NA [ 172 ] Fassler et al. (2022) TIL Pathomics BC Multicenter NA 2015 2015 - 911 ML NA [ 173 ] Pan et al. (2022) TIL Pathomics LUAD Multicenter Retrospective 793 276 - 517 DL NA [ 174 ] Yang et al. (2024) CTLA-4 Pathomics ccRCC NA NA 354 70% - 30% ML: mRMR/REF/GBM AUC: 0.74 [ 175 ] Firmbach et al. (2023) TSR Pathomics CRC Singlecenter Retrospective 33WSIs 23WSIs 4WSIs 6WSIs DL: BPN/U-Net Accuracy: 86.5% (BPN), 86.7% (U-Net) [ 176 ] Xinsen et al. (2023) TSR Pathomics BC Multicenter NA 80WSIs 56WSIs - 24WSIs DL: U-Net/Transformer Dice-coef: 0.88, IOU-metric: 0.80 [ 177 ] Rijthoven et al. (2024) TLS Pathomics Pan-cancer Multicenter Retrospective 1024WSIs 188WSIs 69WSIs 767WSIs DL: HoVer-Net NA [ 178 ] Chen et al. (2024) TLS Pathomics Pan-cancer Multicenter Retrospective 65 70% 10% 20% DL: Encoder-decoder AUC: 0.98 (training)&#8722;0.99 (validation)&#8722;0.97 (testing) [ 179 ] Failmezger et al. (2021) TIL Multi-omics CRC Multicenter Retrospective 80 80% - 20% ML: LR/SVM Accuracy: 85% [ 180 ] Liu et al. (2022) lncRNA Transcriptomics CRC Multicenter Retrospective 2277 791 - 232 ML: RF/SVF/LASSO/Cox AUC: 0.75 [ 181 ] Zhang et al. (2022) lncRNA Transcriptomics LGG Multicenter Retrospective 932 518 169 168 ML: RSF NA [ 182 ] Pan et al. (2024) lncRNA Transcriptomics LUAD Multicenter Retrospective 916 - - 27 ML: LASSO/RSF AUC: 0.75 (1 year)&#8722;0.72 (2/3 years) [ 183 ] Peng et al. (2024) Lipid metabolism-associated genes Genomics RC Multicenter Retrospective NA (datasets) - - - ML: SVM-RFE/RF AUC: 0.68 [ 184 ] Wei et al. (2023) Cytokines Proteomics NSCLC Multicenter Retrospective 222 123 - 99 ML: RSF C-index: 0.76 (training)&#8722;0.76 (validation) [ 185 ] Li et al. (2022) NRF2 Genomics Pan-cancer Multicenter Retrospective NA (datasets) - - - ML; RSF/LASSO/Cox AUC: 0.77 AUC, Area Under the Curve; C-Index, Concordance index; CI, Confidence Interval; HR, Hazard Ratio; OR, Odds Ratio; NA, Not Available Direct biomarker-based prediction methods Single omics-based methods In recent studies, multiple categories of omics data have been used to build models that directly predict the benefits of NIT or NCIT. The integration of AI further facilitates feature identification and response prediction. Through an unbiased search, we identified 40 studies that applied AI to develop single-omics models for predicting the outcomes of NIT or NCIT. More than half of these studies (n=21) relied on patient radiomics data, while the remaining models were constructed using clinical assays, hematology, transcriptomics, pathology, proteomics, and microbiomics data. Most models predicted outcomes such as MPR (n=14) or pCR (n=15) following neoadjuvant treatment, with others predicting indicators like PFS. Radiomics-based models were predominantly established in lung cancer populations (n=14), likely reflecting the widespread application of imaging screening in lung cancer management (Tab. 2 ). This suggests that, irrespective of the type of omics input, integrated predictive efforts have primarily focused on lung cancer. This finding aligns with the high incidence of lung cancer and the increasing adoption of NIT in this patient population. Additionally, we observed that radiomics data were mostly derived from multicenter studies, whereas single-center data were more common in models using other omics. This difference highlights the adoption and relative prevalence of multicenter collaborations when utilizing imaging data. (Fig. 2 ). Radiomics We report 21 studies focused on imaging and histology-based approaches for NIT efficacy prediction, with 14 studies specifically targeting lung cancer, and others addressing various cancers, including ESCC, triple-negative breast cancer (TNBC), and head and neck squamous cell carcinoma (HNSCC) [ 186 &#8211; 206 ]. Among these studies, CT imaging serves as a widely used input, particularly in the prediction of lung cancer treatments. For instance, Han et al. [ 191 ] notably developed a predictive model based on conventional CT imaging in NSCLC cohorts, incorporating innovative delta-radiomics methods to capture dynamic changes in imaging features during treatment. Unlike traditional static image analysis, delta-radiomics quantifies the variation in CT image characteristics before and after treatment, offering a more comprehensive reflection of tumor biology and its response to therapy. Specifically, significant tumor regression in certain areas post-treatment, especially when compared to pre-treatment images, is often considered a marker of favorable prognosis. These dynamic features further enhanced the accuracy of MPR prediction ( \\documentclass[12pt]{minimal} \\usepackage{amsmath} \\usepackage{wasysym} \\usepackage{amsfonts} \\usepackage{amssymb} \\usepackage{amsbsy} \\usepackage{mathrsfs} \\usepackage{upgreek} \\setlength{\\oddsidemargin}{-69pt} \\begin{document}$$\\text {AUC}&gt; 0.8$$\\end{document} ), demonstrating the high accuracy and predictive power of delta-radiomics in evaluating MPR [ 191 ]. Similarly, radiomics features derived from [18F]-FDG PET/CT imaging were employed to predict pathological responses in patients with resectable stage III NSCLC, achieving an AUC of 0.925 [ 189 ]. This further indicates that the combination of PET/CT imaging&#8217;s quantitative assessment of tumor metabolic activity with radiomics methods provides a more comprehensive and highly accurate prediction. Incorporating AI methodologies prompt biological insights, as a study predicting the pCR to NIT in NSCLC revealed that higher DL scores were associated with substantially enriched cell proliferation and metabolic pathways, as well as increased infiltration of activated immune cells, including B cells, natural killer cells, and T helper 17 (Th17) cells [ 187 ]. These biological findings underscore the critical role of tumor and TME dynamics in therapeutic responses, highlighting the potential of integrating imaging and biological data to more precisely forecast the efficacy of NIT. While current research primarily focuses on lung cancer, there is a growing exploration of the potential of AI-driven radiomics modeling in other cancer types as well. For instance, Kong et al. [ 202 ] introduced a novel CT-based habitat radiomics approach for predicting treatment response to NCIT in ESCC. This method clusters conventional radiomic features into distinct habitats and models each cluster independently. Results further indicated that the habitat-based model outperforms traditional radiomics analysis models, highlighting its superior predictive capability and providing a more nuanced understanding of tumor biology [ 202 ]. This emphasizes the immense potential of radiomics-based AI models and single omics data in predicting NIT therapeutic outcomes in pan-cancer treatment. Pathomics Five Studies have validated the feasibility of AI models based on the pathological profiles of patient tissue biopsies to directly predict the efficacy of NIT across different cancer types, like NSCLC, ESCC, and GC [ 207 &#8211; 211 ]. For example, Han et al. [ 208 ] developed a DL model predicting MPR of NIT in NSCLC cohorts from pathomics features on H&amp;E-stained tumor sections. The study compared various DL algorithms in model construction and utilized gradient-weighted class activation mapping (Grad-CAM) for model explanation. Similarly, another study reported a Transformer framework that automatically identifies pathological features on WSIs of H&amp;E-stained tumor sections and predicts residual tumor percentage in ESCC patients taking NIT [ 207 ]. Besides H&amp;E WSIs, one study reported an ML model based on multiple immunofluorescence (mIF) profiles of immune cell surface markers ( e.g. , CD8) and immune checkpoints ( e.g. , PD-L1) to predict the MPR of NIT in ESCC cohorts [ 209 ]. With an ambispective design, the model was trained in a retrospective cohort but validated in a prospective cohort with reliable performance (AUC = 0.832). In addition, leveraging LASSO for feature selection, the model construction indicates that PD-L1 and CD3 levels are associated with NIT benefits, consistent with the predictive value of PD-L1 expression in NIT, as discussed previously. Transcriptomics In patients receiving NIT, gene expression differences between responders and non-responders have been identified, particularly among genes related to the TME [ 212 ]. ML algorithms are employed to select the differentially expressed genes (DEGs) most closely associated with treatment efficacy and to develop predictive models. For example, two studies constructed ML models using DEGs derived from pre-treatment RNA-seq data, reliably predicting pCR and MPR following NIT in HER2-negative BC and Gastric and Gastroesophageal Junction Cancer (GGJC) (AUC = 0.841 and 1, respectively) [ 213 , 214 ]. However, the latter study had a very small sample size. Both studies also revealed that an inflammatory TME is correlated with improved treatment outcomes. Furthermore, one study built a model based solely on glycosylation-related gene features identified from RNA-seq data, which was able to screen for potential beneficiaries of neoadjuvant therapy in HCC [ 215 ]. This model-building process also highlighted the potential role of glycosylation in modulating the TME and NIT response, warranting further investigation. Microbiomics AI algorithms have been applied to identify gut microbiome features associated with treatment efficacy in patients undergoing NIT or NCIT, leading to the development of predictive models for selecting likely responders [ 216 ]. In this study, researchers analyzed the 16S rRNA sequences of patients with ESCC receiving NCIT and observed significant differences in the gut microbiome between responders and non-responders. They used the Extreme Gradient Boosting (XGBoost) algorithm to determine the microbial features most relevant to treatment outcomes and then applied the LightGBM algorithm to construct a predictive model that reliably identified responders (AUC = 0.868). This study not only validated the potential of microbial biomarkers in predicting NIT outcomes but also revealed that enrichment of short-chain fatty acid-producing bacteria is associated with favorable responses, whereas a higher abundance of potential pathogenic microbes ( e.g. , Veillonella) is enriched in non-responders. Proteomics Proteomic characteristics of certain TME markers, such as expression levels and spatial distribution, have been found to correlate with patient responses to NIT or NCIT, making them valuable inputs for AI-based predictive models. For instance, one study utilized mass cytometry to assess the spatial distribution of various protein markers within the TME, including those associated with epithelial cells, endothelial cells, stromal cells, immune cells, cytokines, and immune checkpoints [ 217 ]. Feature selection was conducted using an SVM algorithm, followed by model construction with an RF algorithm, resulting in excellent predictive performance for NCIT response (AUC = 0.97). Moreover, the feature selection process provided important biological insights, identifying that CD8 + T cells and B cells within TLS, as well as inflammatory macrophages in fibrotic regions, were associated with favorable treatment responses. Others We identified nine studies developed ML models that predict NIT or NCIT outcomes leveraging rapid clinical test or blood-based parameters [ 218 &#8211; 226 ]. Among studies leveraging hematological profiles for model construction, six focused on predicting MPR, pCR, and PFS in NSCLC patients treated with NIT, whereas the rest two studies aimed at predicting NCIT pCR in ESCC cohorts. In these studies, features screened for prediction were either individual hematological parameters or inflammation scores calculated by integrating these parameters, sometimes combined with clinical pathological data such as cancer stage and smoking status. Despite the different hematological features selected, including immune cell ratios ( e.g. , neutrophil-to-lymphocyte ratio (NLR) and monocyte-to-lymphocyte ratio (MLR)), specific immune cell types ( e.g. , CD3 + CD56 + natural killer T cells), and other indicators such as neutrophil percentage (NEUT%) and PD-L1 expression levels, most of these models demonstrated reliable predictive efficacy in large cohorts of over 100 patients. Besides laboratory hematology analysis, one study validates the feasibility of establishing a prediction model based on a rapid breathing test. Huang et al. [ 219 ] proposed an innovative ML model that identified high-pressure photon ionization time-of-flight mass spectrometry (HPPI-TOFMS) features in patient respiratory samples, capable of distinguishing responders from non-responders to NCIT in ESCC cohorts (AUC = 0.86). Collectively, these studies confirm that ML models can predict responses to NIT using clinical test data, providing a fast, cost-effective, and less invasive approach. Multi-omics-based methods Multi-omics AI models that integrate omics features from different dimensions have the potential to provide a more accurate method for predicting responses to NIT or NCIT. We report five relevant studies [ 227 &#8211; 231 ]. Among these studies, Xu et al. [ 228 ] developed a composite model that combines DL-based CT radiomics scores, the mutation counts in ctDNA, and clinical data. It had robust prediction for MPR in a prospective cohort of NSCLC patients undergoing NCIT (AUC = 0.82) and outperformed single-omics DL models in the same cohort (AUC = 0.703). Another study leverages SVM to construct three single-omics models and a multi-omics model predicting NCIT pCR in esophageal cancer cohorts. The single-omics models were developed individually based on CT images (AUC = 0.70), WSIs of H&amp;E-stained tumor biopsies (AUC = 0.77), and clinical data (AUC = 0.63). In contrast, the multi-omics models integrating all three inputs achieved superior performance in predicting performance (AUC = 0.89) [ 229 ]. Similarly, Nie et al. [ 230 ] combined CT radiomics and pathomics inputs in a model predicting NCIT therapeutic responses in extensive-stage small cell lung cancer (ES-SCLC). A combined model based on radiomics and hematological parameters has also been developed, as another study by Yang et al. [ 227 ] proposed an ML model that leverages CT images and laboratory blood tests to predict NCIT pCR in ESCC patients. Consistent with the aforementioned multi-omics approaches, the integrated model in the ES-SCLC and ESCC studies outperformed single omics methodologies in the same cohorts [ 227 , 230 ]. Besides combining omics input, one study notably developed an open-source longitudinal MLP model for predicting the outcomes of BC neoadjuvant therapy [ 231 ]. The model combined longitudinal MRI imaging and clinical parameters, achieving superior performance in predicting pCR (AUC = 0.852). Consistent with the above studies, the model integrating the two categories of input (AUC = 0.934) outperformed the radiomics (AUC = 0.874) and hematology models (AUC = 0.772). Collectively, AI algorithms showed feasibility in combining various inputs for enhancing the prediction of NIT clinical endpoints. However, current research remains focused on limited cancer types and omics categories, highlighting the need for broader validation across diverse tumor types and integration of additional omics layers (Tab. 2 , Fig. 2 ). Table 2 Summary of studies on direct biomarker-based prediction Ref. Author (Year) Omics Cancer type Data source Predictive marker Analysis type Total patients Training set Validation set Testing set AI model Prediction performance [ 186 ] Ye et al. (2024) Radiomics NSCLC Multicenter pCR Retrospective 178 108 - 70 ML/DL AUC: 0.78, Accuracy: 81.5% [ 187 ] Qu et al. (2024) Radiomics LC Multicenter pCR Retrospective 248 104 69 75 DL: CNN AUC: 0.78 (training)&#8722;0.74 (validation) [ 188 ] Huang et al. (2024) Radiomics NSCLC Multicenter MPR Retrospective 148 105 - 43 ML/DL: SVM/CNN AUC: 0.81 (training)&#8722;0.77 (testing) [ 189 ] Liu et al. (2024) Radiomics NSCLC Multicenter pCR Retrospective 106 74 - 32 ML: SVM/RF AUC: 0.93 (training)&#8722;0.86 (testing) [ 190 ] Ye et al. (2024) Radiomics NSCLC Multicenter pCR Retrospective 113 80% - 20% DL: CNN AUC: 0.86 [ 191 ] Han et al. (2024) Radiomics NSCLC Multicenter MPR Retrospective 204 164 21 21 DL: CNN AUC: 0.77 (training)&#8722;0.73 (validation)&#8722;0.83 (testing) [ 192 ] Cui et al. (2022) Radiomics NSCLC Singlecenter pCR Pilot study 50 30 - 19 ML/DL AUC: 0.85; Accuracy: 83%; Sensitivity: 80%, Specificity: 85% [ 193 ] Yang et al. (2023) Radiomics NSCLC Multicenter pCR Retrospective 110 77 - 33 ML: LASSO AUC: 0.85; Accuracy: 81%; Specificity: 81%; Sensitivity: 83% [ 194 ] She et al. (2022) Radiomics NSCLC Multicenter MPR Retrospective 274 142 61 71 DL: CNN AUC: 0.73 (training)&#8722;0.72 (testing) [ 196 ] Wang et al. (2024) Radiomics NSCLC Multicenter MPR Retrospective 211 148 - 63 ML: LASSO AUC: 0.70 (training)&#8722;0.60 (testing) [ 197 ] Li et al. (2024) Radiomics NSCLC Singlecenter PFS Retrospective 60 - - - ML: SVM Accuracy: 92.3%, Specificity: 96.6% [ 198 ] Han et al. (2024) Radiomics NSCLC Multicenter MPR Retrospective 186 105 45 36 DL AUC: 0.99 [ 199 ] Zhao et al. (2024) Radiomics SCLC Multicenter PFS Retrospective 379 253 51 75 ML: LASSO AUC: 0.73 (training)&#8722;0.66 (validation)&#8722;0.73 (testing) [ 200 ] Wang et al. (2024) Radiomics ESCC Multicenter MPR Retrospective 82 57 - 25 ML: SVM/RF/LASSO AUC: 0.93 (training)&#8722;0.85 (testing) [ 201 ] Shi et al. (2024) Radiomics ESCC Multicenter pCR Retrospective 105 75% - 25% ML AUC: 0.89 (training)&#8722;0.80 (testing) [ 202 ] Kong et al. (2024) Radiomics ESCC Multicenter pCR Retrospective 112 85 - 27 ML: LASSO/LR AUC: 0.90 [ 203 ] Zhang et al. (2025) Radiomics ESCC Multicenter pCR Retrospective 741 469 118 120 DL: 3D-ResNet/ViT AUC: 0.91 (traning)&#8722;0.83 (validation) [ 204 ] Ramtohulet al. (2024) Radiomics TNBC Multicenter pCR Prospective - 112 - 83 ML: LASSO AUC: 0.86 [ 205 ] Seban et al. (2023) Radiomics TNBC Multicenter pCR Retrospective 191 70% - 30% ML: SVM/RF OR: 3.7 [95% CI 1.3&#8211;12.4] [ 206 ] Lin et al. (2024) Radiomics HNSCC Multicenter pCR Retrospective 172 84 37 51 ML: LASSO AUC: 0.90 (training)&#8722;0.85 (testing) [ 207 ] Wang et al. (2024) Pathomics ESCC Singlecenter Residual Tumor Percentages Retrospective 451 225WSIs 30WSIs 196WSIs DL: Transformer \\documentclass[12pt]{minimal} \\usepackage{amsmath} \\usepackage{wasysym} \\usepackage{amsfonts} \\usepackage{amssymb} \\usepackage{amsbsy} \\usepackage{mathrsfs} \\usepackage{upgreek} \\setlength{\\oddsidemargin}{-69pt} \\begin{document}$$\\text {R}^2$$\\end{document} : 0.84 [ 208 ] Han et al. (2024) Pathomics NSCLC Multicenter MPR Retrospective 186 105 45 36 DL: DenseNet/XGBoost AUC: 0.99 (training)&#8722;0.81 (validation)&#8722;0.82 (testing) [ 209 ] Yehan et al. (2024) Pathomics ESCC Singlecenter MPR Ambispective 78 30 - 48 ML: LASSO/LR AUC: 0.93 (training)&#8722;0.83 (testing) [ 210 ] Terada et al. (2023) Pathomics NSCLC Multicenter MPR Retrospective 125 55 - 70 DL: CNN Accuracy: 0.86 (cross-validation) [ 211 ] Han et al. (2024) Pathomics GC Multicenter PFS Retrospective 584 130 44 99 ML: RF/KNN AUC: 0.98 (training)&#8722;0.92 (validation) [ 213 ] Lu et al. (2024) Transcriptomics BC Multicenter pCR Retrospective 195 69 71 55 ML:Boruta/SVM-RFE/XGBoost AUC: 0.93 (training)&#8722;0.86 (validation)&#8722;0.84 (testing) [ 214 ] Ji et al. (2024) Transcriptomics GGJC Singlecenter MPR NA 30 - - - ML: LASSO AUC: 1 [ 215 ] Tang et al. (2022) Transcriptomics HC Multicenter Responders/Non-responders NA 1332 364 - 379 ML: LASSO/SVM Accuracy: 72.4% [ 218 ] Zhang et al. (2024) Clinical Test and Hematology NSCLC Singlecenter PFS Retrospective 175 50% - 50% ML: LASSO AUC: 0.74 (1 year)&#8722;0.81 (2 years)&#8722;0.79 (3 years) [ 219 ] Huang et al. (2024) Clinical Test ESCC Singlecenter Responders/Non-responders Ambispective 133 70% - 30% ML AUC: 0.86 (training)&#8722;0.85 (testing) [ 220 ] Wang et al. (2024) Clinical Test and Hematology LUSC Singlecenter MPR Retrospective 91 - - - ML: LR AUC: 0.91 [ 221 ] Hu et al. (2024) Hematology NSCLC Singlecenter MPR Ambispective 206 166 - 40 ML: LASSO/LR AUC: 0.77 (training)&#8722;0.75 (validation)&#8722;0.84 (testing) [ 222 ] Feng et al. (2022) Hematology ESCC Singlecenter pCR Retrospective 285 200 - 85 ML: LASSO/LR C-index: 0.76 (training) &#8722;0.81 (testing) [ 223 ] Han et al. (2023) Hematology ESCC Singlecenter pCR Retrospective 97 70% - 30% ML: LASSO/LR AUC: 0.72 (training)&#8722;0.82 (testing) [ 224 ] Zhai et al. (2024) Hematology NSCLC Multicenter MPR Retrospective 173 147 - 26 ML: LASSO AUC: 0.80 (training) &#8722;0.82 (testing) [ 225 ] Zhai et al. (2023) Hematology NSCLC Singlecenter pCR Retrospective 128 - - - ML: LASSO AUC: 0.74 [ 226 ] Peng et al. (2021) Hematology NSCLC Singlecenter MPR Prospective 211 127 - 84 ML: LASSO/SVM AUC: 0.95 (training)&#8722;0.94 (testing) [ 216 ] Liu et al. (2024) Microbiomics ESCC Singlecenter Responders/Non-responders Retrospective 68 80% - 20% ML: XGBoost AUC: 0.87 (training)&#8722;0.77 (validation)&#8722;0.76 (testing) [ 217 ] Wu et al. (2024) Proteomics ESCC Singlecenter Drug Response NA 55 70% - 30% ML: RF/GLM AUC: 0.97 [ 227 ] Yang et al. (2024) Multi-omics ESCC Singlecenter pCR Retrospective 164 80% - 20% ML: LASSO AUC: 0.77 (hematology)&#8722;0.87 (radiomics)&#8722;0.93 (combined) [ 228 ] Xu et al. (2025) Multi-omics NSCLC Singlecenter MPR Prospective 45 - - - DL AUC: 0.70 (DL)&#8722;0.82 (combined) [ 229 ] Qi et al. (2025) Multi-omics ESCC Singlecenter pCR Retrospective 223 75% - 25% ML: SVM AUC: 0.99 (training)&#8722;0.89 (testing) [ 230 ] Nie et al. (2025) Multi-omics SCLC Multicenter PFS/OS Retrospective 309 - - - ML: RF AUC: 0.76 (training)&#8722;0.90 (validation) [ 231 ] Gao et al. (2024) Multi-omics BC Multicenter pCR Retrospective 3352 80% - 20% DL: MLP AUC: 0.85 Discussion Research quenstions and main findings Q1: How has AI currently been applied to predicting pan-cancer NIT therapeutic outcomes? We systematically reviewed AI-based models developed to predict therapeutic outcomes of NIT across cancer types, and categorized them into indirect and direct prediction paradigms. The indirect approach leverages AI to infer the status of established biomarkers, such as PD-L1, TMB, MSI, and TME features, based on omics data, thereby enabling stratification of patient response. In contrast, the direct paradigm involves constructing computational biomarkers or AI-derived scores directly from patient data to predict clinical endpoints such as pCR, MPR, and PFS, or to distinguish responders from non-responders. Current research in this field reveals several trends. First, AI-based predictions of conventional immunotherapy biomarkers have reached accuracies comparable to expert-level assessments; however, models targeting emerging TME features linked to NIT therapeutic outcomes, such as TLS, remain underrepresented. Second, direct prediction models are primarily concentrated in cancers with higher prevalence and NIT practice, particularly lung cancer, and tend to focus on short-term endpoints. Third, most models remain in the preclinical stage, with limited prospective and multi-center validation, posing a major barrier to clinical translation. Q2: What are the data categories and sources in AI prediction model development? Across studies, regardless of the prediction objective, the most commonly used input modalities are routine clinical imaging and H&amp;E-stained histopathology slides. This likely reflects their low acquisition cost, widespread availability, and standardized presence in clinical workflows. In addition to these conventional inputs, a number of studies have begun to explore novel data sources, such as Raman spectroscopy features from tumor sections, gut microbiome profiles, and spatial proteomics of the TME, to improve the prediction of both biomarker status and clinical outcomes. In terms of data sources, public repositories such as TCGA are frequently used for developing indirect prediction models, offering foundational multi-omics data for biomarker inference. In contrast, direct prediction models often rely on patient-level data obtained from clinical trials or institutional cohorts. Due to ethical and privacy constraints, such data are typically confidential and not publicly shared, which may explain the predominance of single-center studies in this domain. Furthermore, the vast majority of studies, irrespective of predictive targets or data modalities, employ retrospective study designs. In the research of leveraging AI for predicting treatment response, a retrospective study examines existing data collected in the past, often from patient records or databases, to investigate study outcomes. In contrast, a prospective study involves collecting new data moving forward, where participants are followed over time, and data is gathered as particular events occur or treatments are administered. This trend reflects the exploratory nature of NIT research, where prospective trials remain logistically challenging due to the requirements of patient recruitment, long-term follow-up, regulatory approval, and substantial funding. Retrospective designs, by contrast, allow efficient use of existing real-world datasets to rapidly test hypotheses and identify potential predictive features, thereby laying the groundwork for future high-quality prospective validation. Q3: How do AI-based models differ from conventional biomarker assessment and therapeutic prediction models? Traditional biomarker assessment methods are often costly, labor-intensive, and heavily reliant on clinical expertise. These processes are not only time-consuming but also subject to inter-observer variability and human bias. For example, manual delineation of TILs on histopathological slides frequently suffers from inconsistent accuracy and reproducibility [ 167 ]. In contrast, the integration of AI technologies has introduced significant advantages in this domain. AI enables rapid and automated evaluation of biomarker status, particularly in tasks involving image interpretation and histopathological analysis. Beyond efficiency and scalability, AI-based approaches offer the potential to more comprehensively predict patient response to NIT. By identifying informative features from high-dimensional data, these models may facilitate the discovery of novel biomarkers and enhance our understanding of the underlying biological mechanisms of NIT efficacy. In addition, AI holds promise for reducing labor and time costs associated with conventional biomarker evaluation pipelines [ 232 , 233 ]. AI models and conventional therapeutic prediction models differ significantly in terms of necessary validation schemes due to their complexity, data requirements, and interpretability. AI models rely on large, high-dimensional datasets, including multiple omics layers, and often function as &#8220;black boxes&#8221;. This necessitates not only internal validation (e.g., cross-validation) for model evaluation and optimization, but also external validation on independent datasets to ensure generalizability and reproducibility. By contrast, conventional prediction models typically rely on more direct data input with fewer variables and smaller datasets. These models typically focus on more easily interpretable features like clinical parameters and are more generalizable. Therefore, a single internal validation may suffice if the model is well-understood and used in consistent clinical contexts. Q4: What are the characteristics and potential of multi-omics models? Multi-omics models offer a distinct advantage in their ability to simultaneously integrate heterogeneous data across different modalities, dimensions, and time points. By leveraging the complementary nature of these data types, such models can provide a more holistic and nuanced characterization of patient status [ 7 , 234 ]. Our synthesis of current literature indicates that, within the same patient cohorts, multi-omics models usually outperform their single-omics counterparts in predictive accuracy, underscoring the value of multi-source data integration. Moreover, AI algorithms are particularly well-suited for multi-omics integration, as they can automatically identify complex and subtle associations across diverse feature dimensions [ 235 , 236 ]. This capability not only enhances predictive performance but also holds promise for uncovering previously unrecognized biological interactions, potentially shedding light on the mechanisms underlying response to NIT. However, Current models predominantly rely on readily accessible data types. Moreover, despite the potential of data integration approaches, studies employing multi-omics strategies remain relatively limited, reflecting a practical emphasis on feasibility over breadth. This may be attributed to limitations posed by both NIT clinical landscape and AI algorithmic issues, which will be further elaborated in the following sections. Biomarker-related limitations and future directions Indirect Biomarkers Although NIT has demonstrated promising clinical outcomes, the identification and validation of reliable indirect biomarkers remain a significant challenge. Several biomarkers, including PD-L1 expression, TMB, and MSI, have been investigated for predicting NIT efficacy, but their clinical applicability is limited by various constraints. For example, PD-L1 expression, while integrated into clinical decision-making, exhibits inconsistent predictive value due to factors such as intra-tumoral heterogeneity, variability in IHC scoring, and differences in testing platforms [ 44 , 49 , 237 ]. TMB, however, lacks universally accepted thresholds across different tumor types and does not always correlate with effective anti-tumor immune responses [ 238 , 239 ]. MSI is a robust predictor of immunotherapy response in CRC, whereas its relevance in other malignancies is limited due to its lower prevalence [ 240 ]. TME characteristics such as TIL, TLS, and CTLA-4 expression, have been identified to reflect NIT response in clinical, yet fewer studies validated their robustness as therapeutic biomarkers or explored AI-driven automated assessment of these components. Furthermore, the absence of large, diverse patient cohorts for biomarker validation impedes the generalization and widespread clinical implementation of these biomarkers [ 241 ]. To address these challenges, future research should focus on improving the reliability, standardization, and regulatory approval of indirect biomarkers. Additionally, integrating AI-driven approaches into biomarker discovery could accelerate the identification of novel predictive markers from complex multi-omics data and inspire biological insights. Direct Biomarkers Direct prediction models based on pre-treatment data mainly focus on short-term NIT outcomes such as pCR and MPR, which offer early efficacy signals but fail to capture long-term risks and benefits better reflected by PFS and OS, such as recurrence and metastasis [ 242 , 243 ]. Moreover, evidence suggests that the correlation between short-term indicators and long-term treatment outcomes can vary across individuals and cancer types [ 244 , 245 ]. However, research focusing on long-term treatment indicators remains relatively limited in the context of NIT. Our analysis indicates that the majority of direct prediction studies have been conducted on NSCLC and ESCC cohorts. As NIT continues to gain traction in other cancer types, such as BC, there is a clear need for the development of prediction models for these underrepresented cohorts. The expansion of NIT research will help validate indirect prediction models and contribute to more diversified datasets for model construction. To advance direct prediction models, it is essential to prioritize the collection of long-term follow-up data from diverse patient populations. Additionally, the development of integrated learning models that combine preoperative imaging, pathological assessments, and postoperative outcomes holds significant promise for more accurate predictions of long-term treatment responses [ 246 , 247 ]. AI-related limitations and future directions Interpretability and Trustworthiness AI models, particularly DL and ML, often function as black boxes, making it difficult to understand how they arrive at their decisions [ 248 , 249 ]. Traditional models like decision trees, random forests, and logistic regression offer better interpretability, providing explicit decision rules or feature importance scores [ 250 ]. In contrast, DL models such as CNNs and Transformer-based architectures extract highly abstract representations, which are challenging to explain [ 251 ]. This lack of interpretability raises trust issues, particularly in healthcare, where clinicians must understand why a model makes a specific prediction before using it in decision-making. Regulatory bodies like the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) also require transparent explanations of how AI models function in medical applications [ 252 ]. To address these challenges, Explainable AI (XAI) methods such as Shapley Additive Explanations (SHAP), Local Interpretable Model-agnostic Explanations (LIME), and saliency maps provide post-hoc explanations [ 39 , 253 , 254 ]. Hybrid models, which combine deep learning with interpretable techniques (e.g., CNNs with decision trees), could further help build trust and transparency among healthcare professionals and regulators [ 255 ]. Generalization and Scalability AI models in healthcare often face challenges related to generalization and scalability due to variability in data sources, patient demographics, and imaging techniques. A model trained on one dataset may not perform well when applied to another institution or demographic, due to differences in imaging protocols, scanner types, or clinical documentation styles [ 256 ]. Furthermore, many AI models, particularly DL models, require large amounts of labeled data for training, which can be hard to obtain for rare diseases or underrepresented populations [ 257 ]. Techniques such as domain adaptation, transfer learning, self-supervised learning, and federated learning are emerging to improve generalization by reducing the dependency on large, labeled datasets and enabling models to learn robust features across diverse settings [ 258 &#8211; 260 ]. Scalability remains a challenge, especially in resource-limited environments where access to high-performance computing (HPC) infrastructure may be restricted [ 261 ]. To address this, lightweight neural networks, knowledge distillation, and edge AI solutions could improve scalability by enabling AI deployment on local clinical devices with fewer computational resources [ 262 ]. Multi-source Data Integration AI has the potential to integrate multi-omics data to improve predictive accuracy and aid in biomarker discovery, whereas multi-omics models are underrepresented in research [ 263 ]. Multi-omics models tend to outperform single-omics models, capturing the complex, multi-factorial nature of diseases [ 227 , 264 ]. In addition, integrating longitudinal data, such as treatment response measurements taken at multiple time points, could enhance predictions of patient outcomes over time [ 246 , 247 ]. However, difficulties remain in aligning and merging heterogeneous data types, particularly data temporally or spatially misaligned [ 265 ]. Therefore, future research should focus on robust data fusion methods that can effectively combine multi-omics and longitudinal data, minimizing noise and misalignment. Advanced techniques such as spatiotemporal models can capture the temporal dynamics inherent in longitudinal data, offering more accurate representations of disease progression or treatment responses [ 266 ]. Attention mechanisms like self-attention and cross-modal attention could also enhance model performance by allowing the model to focus on the most informative features from each data modality, leading to more reliable predictions [ 267 , 268 ]. Bias and Fairness AI models trained on biased datasets can lead to unfair and inaccurate predictions, disproportionately affecting underrepresented patient populations [ 269 ]. In the case of NIT prediction, many publicly available medical datasets primarily feature data from high-income countries, introducing ethnic, geographic, and socioeconomic biases [ 270 ]. Moreover, biases in data collection, such as disparities in imaging quality between well-funded and resource-limited healthcare settings, can further exacerbate these issues [ 271 , 272 ]. To mitigate bias, it is crucial to ensure that training datasets are diverse and representative of different demographic groups. Additionally, AI models should be evaluated using fairness-aware metrics like equalized odds and disparate impact analysis to ensure that they perform equitably across different subpopulations. Methods like adversarial debiasing, reweighting strategies, and subgroup-aware training can help reduce bias during model development [ 273 ]. Regulatory agencies may also mandate fairness audits as part of AI model validation to promote equitable healthcare outcomes in immunotherapy predictions [ 274 ]. Security and Privacy Medical AI relies on sensitive data, making security and privacy critical concerns, as are vulnerable to data breaches, adversarial attacks, and model inversion [ 275 , 276 ]. Adversarial perturbations, like malicious modifications to medical images, can manipulate AI predictions, thereby harming model performance and compromising patient safety. Similarly, model extraction attacks can allow unauthorized entities to replicate proprietary AI models, posing risks of intellectual property theft and misuse [ 277 ]. Therefore, researchers may adopt adversarial defense mechanisms such as adversarial training and robust model architectures [ 278 ]. Privacy-preserving techniques like differential privacy and homomorphic encryption offer promising solutions to ensure patient data remains protected while enabling collaborative model development across institutions [ 279 , 280 ]. Furthermore, adherence to regulatory frameworks such as the General Data Protection Regulation (GDPR) and Health Insurance Portability and Accountability Act (HIPAA) is essential to safeguard patient data in AI development [ 281 ]. Future research should focus on enhancing privacy-preserving algorithms and secure multi-party computation to enable safe, large-scale AI training without compromising patient confidentiality. Conclusion In summary, the application of AI in predicting the efficacy of NIT represents a transformative advancement in precision immunotherapy. By leveraging diverse oncological data, AI-driven models have demonstrated the potential to accurately screen for NIT potential beneficiaries. In this review, we systematically categorized existing AI-based approaches into indirect prediction paradigms, which infer treatment response through clinically established biomarkers, and direct prediction paradigms, which utilize AI to define data-driven biomarkers that are directly linked to clinical endpoints. Despite these advancements, two main challenges remain spanning from the biomarker robustness to AI algorithmic issues that jointly hinder AI application in NIT efficacy prediction. Addressing these issues is essential for advancing medical AI in precision oncology. Abbreviations 3D-DenseNet Three-dimensional dense convolutional neural network ACC Accuracy ADC Apparent diffusion coefficient AI Artificial intelligence ATAC-seq Assay for transposase-accessible chromatin sequencing attMIL Attention-based multiple instance learning AUC Area under the curve BC Breast cancer BLCA Bladder cancer CATBOOST Categorical boosting CD163 Cluster of differentiation 163 CD3 Cluster of differentiation 3 CD4 Cluster of differentiation 4 CD8 Cluster of differentiation 8 ChIP-seq Chromatin immunoprecipitation sequencing CLIP Contrastive language-image pre-training C-Index Concordance index CNVs Copy number variations CNN Convolutional neural network CONCH Contrastive learning-based network for histopathology CONSORT-AI Consolidated standards of reporting trials &#8211; artificial intelligence CRC Colorectal cancer CS Computer science CT Computed tomography CTLA-4 Cytotoxic T-lymphocyte-associated protein 4 ctDNA Circulating tumor DNA CV Computer vision dMMR Deficient mismatch repair DL Deep learning DNA Deoxyribonucleic acid DNN Deep neural network DWI Diffusion-weighted imaging EHRs Electronic health records EGFR Epidermal growth factor receptor EOC Epithelial ovarian cancer EMC Endometrial cancer EMA European medicines agency ENCODE Encyclopedia of DNA elements ESCC Esophageal squamous cell carcinoma ES-SCLC Extensive-stage small cell lung cancer FDA Food and drug administration FFPP Formalin-fixed paraffin-embedded F1-score F1 score FN False negative FP False positive FPR False positive rate GBDT Gradient boosted decision trees GBM Glioblastoma GC Gastric cancer GC-MS Gas chromatography&#8211;mass spectrometry GEO Gene expression omnibus GGJC Gastric and gastroesophageal junction cancer GLM Generalized linear model GNN Graph neural network gnomAD Genome aggregation database GPR Gaussian process regression GPT Generative pre-trained transformer HC Hepatocellular carcinoma HIPAA Health insurance portability and accountability act HMDB Human metabolome database HNSCC Head and neck Squamous cell carcinoma HR Hazard ratio ICGC International cancer genome consortium ICI Immune checkpoint inhibitor IHC Immunohistochemistry IOU Intersection over union KNN K-nearest neighbors LASSO Least absolute shrinkage and selection operator LC Lung cancer LC-MS Liquid chromatography&#8211;mass spectrometry LDA Linear discriminant analysis LGG Low-grade glioma LIME Local interpretable model-agnostic explanations lncRNA Long non-coding RNA LR Logistic regression LUAD Lung adenocarcinoma LUSC Lung squamous cell carcinoma MIL Multiple instance learning ML Machine learning MLC Machine learning classifier MLP Multi-layer perceptron MITLS Multi-instance transformer learning system MLR Monocyte-to-lymphocyte ratio MMR Mismatch repair mRNA Messenger RNA MRI Magnetic resonance imaging MS Mass spectrometry MSI Microsatellite instability MSS Microsatellite stability MuAt Mutation attention NIT Neoadjuvant immunotherapy NB Na&#239;ve bayes NCIT Neoadjuvant chemoimmunotherapy NKT cells Natural killer T cells NLR Neutrophil-to-lymphocyte ratio NLP Natural language processing NMR Nuclear magnetic resonance NSCLC Non-small cell lung cancer OR Odds ratio OS Overall survival PACS Picture archiving and communication system Pan-Cancer Pan-cancer PCA Principal component analysis PCR Polymerase chain reaction pCR Pathological complete response PEOS Population, exposure, outcomes, and study design PD-1 Programmed cell death protein 1 PD-L1 Programmed cell death 1 ligand 1 PDAC Pancreatic ductal adenocarcinoma PET Positron emission tomography PET/CT Positron emission tomography/Computed tomography PFS Progression-free survival PPsNet Patch-wise pretrained segmentation network PTM Post-translational modification qRT-PCR quantitative Reverse transcription polymerase chain reaction RC Rectal cancer RF Random forest RNN Recurrent neural network RSF Random survival forest SAM Segment anything model SCLC Small cell lung cancer SMA Smooth muscle actin SNP Single nucleotide polymorphism SSL Semi-supervised learning SSL-attMIL Self-supervised learning attention-based multiple instance learning SREBF2 Sterol regulatory element binding transcription factor 2 SVM Support vector machine TCGA The cancer genome atlas TCIA The cancer imaging archive TILs Tumor-infiltrating lymphocytes TLS Tertiary lymphoid structures TMB Tumor mutational burden TN True negative TNBC Triple-negative breast cancer TP True positive TPR True positive rate TPS Tumor proportion score TSR Tumor-stroma ratio Th17 T helper 17 UK Biobank United kingdom biobank UL Unsupervised learning UNI Unified network for representation learning VEGF Vascular endothelial growth factor ViTs Vision transformers WES Whole-exome sequencing WGS Whole-genome sequencing WSIs Whole slide images XGBoost Extreme gradient boosting Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Yishu Deng, Tailin Li, Yunze Wang and Silin Chen contributed equally to this work. Acknowledgements This work was supported by grants to Dr. Jian Liu from the Natural Science Foundation (NSF) of China (General Grant: 82172899 and 82472637), the NSF of Zhejiang Province (Distinguished Young Scholars: LR22H160002), Noncommunicable Chronic Diseases-National Science and Technology Major Project (2023ZD0502900/2023ZD0502902 and 2023ZD0507500/2023ZD0507501), Dr. Li Dak Sum &amp; Yip Yio Chin Development Fund for Regenerative Medicine, Zhejiang University, the Open Fund of Zhejiang Provincial Key Laboratory of Pulmonology (Grant No. KF202302), and Zhejiang Provincial Key R&amp;D Program of China (Grant No. 2025C02091). We also acknowledge support from the Haining People&#8217;s Hospital Tertiary-A Public Hospital Establishment Project Municipal Finance Support Fund, and the Joint University-Local Cooperation Fund between ZJU-UoE Institute and Haining People&#8217;s Hospital. We are grateful to the support by the Intramural Research Program, ES102425 to Dr. Manas K. Ray. Principal Supervisor Jian Liu led the work.The Zhejiang University &#8211; University of Edinburgh Institute (ZJE) undergraduate authors, such as Yishu Deng, Tailin Li, Taoyu Zhu, Jiayi Ran, Bo Yang, and Xiaohan Zhang, gratefully acknowledged the profound impact of the ZJE HDRC3A (Human Disease: From Research to Clinic 3A) course, whose innovative pedagogical framework was instrumental in developing the critical perspective and interdisciplinary approach essential for this comprehensive review. The conceptualization and critical analysis presented in this review were directly shaped by the research-driven and AI-enhanced learning paradigm of the HDRC3A course. We also acknowledge the help of members in JL's lab. We thank the Biomed-X Laboratory of 2.EInstitute, School of Medicine, Zhejiang University, for continuous support. Author contributions YD, TL, YW, and SC contributed to the conceptualization of the study, literature collection, manuscript preparation, and figure generation. SC, YZ, and JL provided critical supports. JL oversaw the project and provided critical supervision. All authors contributed to the preparation, writing, and editing of the manuscript. All authors reviewed and approved the final version of the manuscript. No generative AI has been used in the writing of the manuscript. Data availability No datasets were generated or analysed during the current study. Declarations Competing interests The authors declare no competing interests. References 1. Salas-Benito D P&#233;rez-Gracia JL Ponz-Sarvis&#233; M Rodriguez-Ruiz ME Mart&#237;nez-Forero I Casta&#241;&#243;n E Paradigms on immunotherapy combinations with chemotherapy Cancer Discov 2021 11 6 1353 67 10.1158/2159-8290.CD-20-1312 33712487 Salas-Benito D, P&#233;rez-Gracia JL, Ponz-Sarvis&#233; M, Rodriguez-Ruiz ME, Mart&#237;nez-Forero I, Casta&#241;&#243;n E, et al. Paradigms on immunotherapy combinations with chemotherapy. Cancer Discov. 2021;11(6):1353&#8211;67. 33712487 10.1158/2159-8290.CD-20-1312 2. Jiang S Liu Y Zheng H Zhang L Zhao H Sang X Evolutionary patterns and research frontiers in neoadjuvant immunotherapy: a bibliometric analysis Int J Surg 2023 109 9 2774 83 10.1097/JS9.0000000000000492 37216225 PMC10498839 Jiang S, Liu Y, Zheng H, Zhang L, Zhao H, Sang X, et al. Evolutionary patterns and research frontiers in neoadjuvant immunotherapy: a bibliometric analysis. Int J Surg. 2023;109(9):2774&#8211;83. 37216225 10.1097/JS9.0000000000000492 PMC10498839 3. Alizadeh AA Aranda V Bardelli A Blanpain C Bock C Borowski C Toward understanding and exploiting tumor heterogeneity Nat Med 2015 21 8 846 53 10.1038/nm.3915 26248267 PMC4785013 Alizadeh AA, Aranda V, Bardelli A, Blanpain C, Bock C, Borowski C, et al. Toward understanding and exploiting tumor heterogeneity. Nat Med. 2015;21(8):846&#8211;53. 26248267 10.1038/nm.3915 PMC4785013 4. O&#8217;Donnell JS Hoefsmit EP Smyth MJ Blank CU Teng MW The promise of neoadjuvant immunotherapy and surgery for cancer treatment Clin Cancer Res 2019 25 19 5743 51 10.1158/1078-0432.CCR-18-2641 31040150 O&#8217;Donnell JS, Hoefsmit EP, Smyth MJ, Blank CU, Teng MW. The promise of neoadjuvant immunotherapy and surgery for cancer treatment. Clin Cancer Res. 2019;25(19):5743&#8211;51. 31040150 10.1158/1078-0432.CCR-18-2641 5. Menyh&#225;rt O Gy&#337;rffy B Multi-omics approaches in cancer research with applications in tumor subtyping, prognosis, and diagnosis Comput Struct Biotechnol J 2021 19 949 60 10.1016/j.csbj.2021.01.009 33613862 PMC7868685 Menyh&#225;rt O, Gy&#337;rffy B. Multi-omics approaches in cancer research with applications in tumor subtyping, prognosis, and diagnosis. Comput Struct Biotechnol J. 2021;19:949&#8211;60. 33613862 10.1016/j.csbj.2021.01.009 PMC7868685 6. He X, Liu X, Zuo F, Shi H, Jing J. Artificial intelligence-based multi-omics analysis fuels cancer precision medicine. In: Seminars in Cancer Biology. vol.&#160;88. Elsevier; 2023. p. 187&#8211;200. 10.1016/j.semcancer.2022.12.009 36596352 7. Chakraborty S Sharma G Karmakar S Banerjee S Multi-OMICS approaches in cancer biology: new era in cancer therapy Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 2024 1870 5 167120 10.1016/j.bbadis.2024.167120 38484941 Chakraborty S, Sharma G, Karmakar S, Banerjee S. Multi-OMICS approaches in cancer biology: new era in cancer therapy. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. 2024;1870(5):167120. 38484941 10.1016/j.bbadis.2024.167120 8. Bhinder B Gilvary C Madhukar NS Elemento O Artificial intelligence in cancer research and precision medicine Cancer Discov 2021 11 4 900 15 10.1158/2159-8290.CD-21-0090 33811123 PMC8034385 Bhinder B, Gilvary C, Madhukar NS, Elemento O. Artificial intelligence in cancer research and precision medicine. Cancer Discov. 2021;11(4):900&#8211;15. 33811123 10.1158/2159-8290.CD-21-0090 PMC8034385 9. Yang Y Zhao Y Liu X Huang J Elsevier Artificial intelligence for prediction of response to cancer immunotherapy Semin Cancer Biol 2022 87 137 147 10.1016/j.semcancer.2022.11.008 36372326 Yang Y, Zhao Y, Liu X, Huang J, Elsevier. Artificial intelligence for prediction of response to cancer immunotherapy. Semin Cancer Biol. 2022;87:137&#8211;47. 36372326 10.1016/j.semcancer.2022.11.008 10. Xie J Luo X Deng X Tang Y Tian W Cheng H Advances in artificial intelligence to predict cancer immunotherapy efficacy Front Immunol 2023 13 1076883 10.3389/fimmu.2022.1076883 36685496 PMC9845588 Xie J, Luo X, Deng X, Tang Y, Tian W, Cheng H, et al. Advances in artificial intelligence to predict cancer immunotherapy efficacy. Front Immunol. 2023;13:1076883. 36685496 10.3389/fimmu.2022.1076883 PMC9845588 11. Ghaffari Laleh N Ligero M Perez-Lopez R Kather JN Facts and hopes on the use of artificial intelligence for predictive immunotherapy biomarkers in cancer Clin Cancer Res 2023 29 2 316 23 10.1158/1078-0432.CCR-22-0390 36083132 Ghaffari Laleh N, Ligero M, Perez-Lopez R, Kather JN. Facts and hopes on the use of artificial intelligence for predictive immunotherapy biomarkers in cancer. Clin Cancer Res. 2023;29(2):316&#8211;23. 36083132 10.1158/1078-0432.CCR-22-0390 12. Zhou X Qu M Tebon P Jiang X Wang C Xue Y Screening cancer immunotherapy: when engineering approaches meet artificial intelligence Adv Sci 2020 7 19 2001447 10.1002/advs.202001447 PMC7539186 33042756 Zhou X, Qu M, Tebon P, Jiang X, Wang C, Xue Y, et al. Screening cancer immunotherapy: when engineering approaches meet artificial intelligence. Adv Sci. 2020;7(19):2001447. 10.1002/advs.202001447 PMC7539186 33042756 13. Pilard C Ancion M Delvenne P Jerusalem G Hubert P Herfs M Cancer immunotherapy: it&#8217;s time to better predict patients&#8217; response Br J Cancer 2021 125 7 927 38 10.1038/s41416-021-01413-x 34112949 PMC8476530 Pilard C, Ancion M, Delvenne P, Jerusalem G, Hubert P, Herfs M. Cancer immunotherapy: it&#8217;s time to better predict patients&#8217; response. Br J Cancer. 2021;125(7):927&#8211;38. 34112949 10.1038/s41416-021-01413-x PMC8476530 14. Yin X, Liao H, Yun H, Lin N, Li S, Xiang Y, et&#160;al. Artificial intelligence-based prediction of clinical outcome in immunotherapy and targeted therapy of lung cancer. In: Seminars in cancer biology. vol.&#160;86. Elsevier; 2022. p. 146&#8211;159. 10.1016/j.semcancer.2022.08.002 35963564 15. Gao Q Yang L Lu M Jin R Ye H Ma T The artificial intelligence and machine learning in lung cancer immunotherapy J Hematol Oncol 2023 16 1 55 10.1186/s13045-023-01456-y 37226190 PMC10207827 Gao Q, Yang L, Lu M, Jin R, Ye H, Ma T. The artificial intelligence and machine learning in lung cancer immunotherapy. J Hematol Oncol. 2023;16(1):55. 37226190 10.1186/s13045-023-01456-y PMC10207827 16. Wang Z, Liu Y, Niu X. Application of artificial intelligence for improving early detection and prediction of therapeutic outcomes for gastric cancer in the era of precision oncology. In: Seminars in Cancer Biology. vol.&#160;93. Elsevier; 2023. p. 83&#8211;96. 10.1016/j.semcancer.2023.04.009 37116818 17. Zhang W, Song LN, You YF, Qi FN, Cui XH, Yi MX, et&#160;al. Application of artificial intelligence in the prediction of immunotherapy efficacy in hepatocellular carcinoma: Current status and prospects. Artif Intel Gastroenterol. 2024;5(1). 18. Li J Dan K Ai J Machine learning in the prediction of immunotherapy response and prognosis of melanoma: a systematic review and meta-analysis Front Immunol 2024 15 1281940 10.3389/fimmu.2024.1281940 38835779 PMC11148209 Li J, Dan K, Ai J. Machine learning in the prediction of immunotherapy response and prognosis of melanoma: a systematic review and meta-analysis. Front Immunol. 2024;15:1281940. 38835779 10.3389/fimmu.2024.1281940 PMC11148209 19. Mei T Wang T Zhou Q Multi-omics and artificial intelligence predict clinical outcomes of immunotherapy in non-small cell lung cancer patients Clin Exp Med 2024 24 1 60 10.1007/s10238-024-01324-0 38554212 PMC10981593 Mei T, Wang T, Zhou Q. Multi-omics and artificial intelligence predict clinical outcomes of immunotherapy in non-small cell lung cancer patients. Clin Exp Med. 2024;24(1):60. 38554212 10.1007/s10238-024-01324-0 PMC10981593 20. Jin W Luo Q When artificial intelligence meets PD-1/PD-L1 inhibitors: population screening, response prediction and efficacy evaluation Comput Biol Med 2022 145 105499 10.1016/j.compbiomed.2022.105499 35439641 Jin W, Luo Q. When artificial intelligence meets PD-1/PD-L1 inhibitors: population screening, response prediction and efficacy evaluation. Comput Biol Med. 2022;145:105499. 35439641 10.1016/j.compbiomed.2022.105499 21. Hildebrand LA Pierce CJ Dennis M Paracha M Maoz A Artificial intelligence for histology-based detection of microsatellite instability and prediction of response to immunotherapy in colorectal cancer Cancers (Basel) 2021 13 3 391 10.3390/cancers13030391 33494280 PMC7864494 Hildebrand LA, Pierce CJ, Dennis M, Paracha M, Maoz A. Artificial intelligence for histology-based detection of microsatellite instability and prediction of response to immunotherapy in colorectal cancer. Cancers (Basel). 2021;13(3):391. 33494280 10.3390/cancers13030391 PMC7864494 22. Bera K Braman N Gupta A Velcheti V Madabhushi A Predicting cancer outcomes with radiomics and artificial intelligence in radiology Nat Rev Clin Oncol 2022 19 2 132 46 10.1038/s41571-021-00560-7 34663898 PMC9034765 Bera K, Braman N, Gupta A, Velcheti V, Madabhushi A. Predicting cancer outcomes with radiomics and artificial intelligence in radiology. Nat Rev Clin Oncol. 2022;19(2):132&#8211;46. 34663898 10.1038/s41571-021-00560-7 PMC9034765 23. Dercle L McGale J Sun S Marabelle A Yeh R Deutsch E Artificial intelligence and radiomics: fundamentals, applications, and challenges in immunotherapy J Immunother Cancer 2022 10 9 e005292 10.1136/jitc-2022-005292 36180071 PMC9528623 Dercle L, McGale J, Sun S, Marabelle A, Yeh R, Deutsch E, et al. Artificial intelligence and radiomics: fundamentals, applications, and challenges in immunotherapy. J Immunother Cancer. 2022;10(9):e005292. 36180071 10.1136/jitc-2022-005292 PMC9528623 24. Kothari G Role of radiomics in predicting immunotherapy response J Med Imaging Radiat Oncol 2022 66 4 575 591 10.1111/1754-9485.13426 35581928 PMC9323544 Kothari G. Role of radiomics in predicting immunotherapy response. J Med Imaging Radiat Oncol. 2022;66(4):575&#8211;91. 35581928 10.1111/1754-9485.13426 PMC9323544 25. Wu M Zhang Y Zhang Y Liu Y Wu M Ye Z Imaging-based biomarkers for predicting and evaluating cancer immunotherapy response Radiology: Imaging Cancer 2019 1 2 e190031 33778682 10.1148/rycan.2019190031 PMC7983749 Wu M, Zhang Y, Zhang Y, Liu Y, Wu M, Ye Z. Imaging-based biomarkers for predicting and evaluating cancer immunotherapy response. Radiology: Imaging Cancer. 2019;1(2):e190031. 33778682 10.1148/rycan.2019190031 PMC7983749 26. Fu X Sahai E Wilkins A Application of digital pathology-based advanced analytics of tumour microenvironment organisation to predict prognosis and therapeutic response J Pathol 2023 260 5 578 91 10.1002/path.6153 37551703 PMC10952145 Fu X, Sahai E, Wilkins A. Application of digital pathology-based advanced analytics of tumour microenvironment organisation to predict prognosis and therapeutic response. J Pathol. 2023;260(5):578&#8211;91. 37551703 10.1002/path.6153 PMC10952145 27. Pareek A Lungren MP Halabi SS The requirements for performing artificial-intelligence-related research and model development Pediatr Radiol 2022 52 11 2094 100 10.1007/s00247-022-05483-8 35996023 Pareek A, Lungren MP, Halabi SS. The requirements for performing artificial-intelligence-related research and model development. Pediatr Radiol. 2022;52(11):2094&#8211;100. 35996023 10.1007/s00247-022-05483-8 28. Wang H Fu T Du Y Gao W Huang K Liu Z Scientific discovery in the age of artificial intelligence Nature 2023 620 7972 47 60 10.1038/s41586-023-06221-2 37532811 Wang H, Fu T, Du Y, Gao W, Huang K, Liu Z, et al. Scientific discovery in the age of artificial intelligence. Nature. 2023;620(7972):47&#8211;60. 37532811 10.1038/s41586-023-06221-2 29. Awais M Naseer M Khan S Anwer RM Cholakkal H Shah M Foundation models defining a new era in vision: a survey and outlook IEEE Trans Pattern Anal Mach Intell 2025 10.1109/TPAMI.2024.3506283 40030979 Awais M, Naseer M, Khan S, Anwer RM, Cholakkal H, Shah M, et al. Foundation models defining a new era in vision: a survey and outlook. IEEE Trans Pattern Anal Mach Intell. 2025. 10.1109/TPAMI.2024.3506283. 40030979 10.1109/TPAMI.2024.3506283 30. Stanfill MH Marc DT Health information management: implications of artificial intelligence on healthcare data and information management Yearb Med Inform 2019 28 01 056 64 10.1055/s-0039-1677913 PMC6697524 31419816 Stanfill MH, Marc DT. Health information management: implications of artificial intelligence on healthcare data and information management. Yearb Med Inform. 2019;28(01):056&#8211;64. 10.1055/s-0039-1677913 PMC6697524 31419816 31. Kundrick J Naniwadekar A Singla V Kancharla K Bhonsale A Voigt A Machine learning applied to wearable fitness tracker data and the risk of hospitalizations and cardiovascular events Am J Prev Cardiol 2025 10.1016/j.ajpc.2025.101006 40496758 PMC12149649 Kundrick J, Naniwadekar A, Singla V, Kancharla K, Bhonsale A, Voigt A, et al. Machine learning applied to wearable fitness tracker data and the risk of hospitalizations and cardiovascular events. Am J Prev Cardiol. 2025. 10.1016/j.ajpc.2025.101006. 40496758 10.1016/j.ajpc.2025.101006 PMC12149649 32. Abbas K Hao C Yong X Hasan MK Islam S Rahman AHA Graph neural network-based drug-drug interaction prediction Sci Rep 2025 15 1 30340 10.1038/s41598-025-12936-1 40830547 PMC12365209 Abbas K, Hao C, Yong X, Hasan MK, Islam S, Rahman AHA. Graph neural network-based drug-drug interaction prediction. Sci Rep. 2025;15(1):30340. 40830547 10.1038/s41598-025-12936-1 PMC12365209 33. Greener JG Kandathil SM Moffat L Jones DT A guide to machine learning for biologists Nat Rev Mol Cell Biol 2022 23 1 40 55 10.1038/s41580-021-00407-0 34518686 Greener JG, Kandathil SM, Moffat L, Jones DT. A guide to machine learning for biologists. Nat Rev Mol Cell Biol. 2022;23(1):40&#8211;55. 34518686 10.1038/s41580-021-00407-0 34. Schober P Vetter TR Logistic regression in medical research Anesthesia &amp; Analgesia 2021 132 2 365 366 10.1213/ANE.0000000000005247 33449558 PMC7785709 Schober P, Vetter TR. Logistic regression in medical research. Anesthesia &amp; Analgesia. 2021;132(2):365&#8211;6. 33449558 10.1213/ANE.0000000000005247 PMC7785709 35. Nicola S, Chirila OS, Stoicu-Tivadar L. Recovery Gestures Classification Using KNN and LDA Models. In: Telehealth Ecosystems in Practice. IOS Press; 2023. p. 58&#8211;62. 10.3233/SHTI230739 37869806 36. Dong J Yang L Liu C Cheng W Wang W Support vector machine embedding discriminative dictionary pair learning for pattern classification Neural Netw 2022 155 498 511 10.1016/j.neunet.2022.08.031 36166977 Dong J, Yang L, Liu C, Cheng W, Wang W. Support vector machine embedding discriminative dictionary pair learning for pattern classification. Neural Netw. 2022;155:498&#8211;511. 36166977 10.1016/j.neunet.2022.08.031 37. Hu J Szymczak S A review on longitudinal data analysis with random forest Brief Bioinform 2023 24 2 bbad002 10.1093/bib/bbad002 36653905 PMC10025446 Hu J, Szymczak S. A review on longitudinal data analysis with random forest. Brief Bioinform. 2023;24(2):bbad002. 36653905 10.1093/bib/bbad002 PMC10025446 38. Seto H Oyama A Kitora S Toki H Yamamoto R Kotoku J Gradient boosting decision tree becomes more reliable than logistic regression in predicting probability for diabetes with big data Sci Rep 2022 12 1 15889 10.1038/s41598-022-20149-z 36220875 PMC9553945 Seto H, Oyama A, Kitora S, Toki H, Yamamoto R, Kotoku J, et al. Gradient boosting decision tree becomes more reliable than logistic regression in predicting probability for diabetes with big data. Sci Rep. 2022;12(1):15889. 36220875 10.1038/s41598-022-20149-z PMC9553945 39. Van der Velden BH Kuijf HJ Gilhuijs KG Viergever MA Explainable artificial intelligence (XAI) in deep learning-based medical image analysis Med Image Anal 2022 79 102470 10.1016/j.media.2022.102470 35576821 Van der Velden BH, Kuijf HJ, Gilhuijs KG, Viergever MA. Explainable artificial intelligence (XAI) in deep learning-based medical image analysis. Med Image Anal. 2022;79:102470. 35576821 10.1016/j.media.2022.102470 40. V&#238;rgolici O, Virgolici H. Predicting Prediabetes Using Simple a Multi-Layer Perceptron Neural Network Model. In: ICIMTH; 2023. p. 168&#8211;171. 10.3233/SHTI230453 37386987 41. You Y Lu C Wang W Tang CK Relative CNN-RNN: learning relative atmospheric visibility from images IEEE Trans Image Process 2018 28 1 45 55 10.1109/TIP.2018.2857219 30028702 You Y, Lu C, Wang W, Tang CK. Relative CNN-RNN: learning relative atmospheric visibility from images. IEEE Trans Image Process. 2018;28(1):45&#8211;55. 30028702 10.1109/TIP.2018.2857219 42. Jahan I, Chowdhury ME, Vranic S, Al&#160;Saady RM, Kabir S, Pranto ZH, et&#160;al. Deep learning and vision transformers-based framework for breast cancer and subtype identification. Neural Comput Appl. 2025;p. 1&#8211;20. 43. Topalian SL Taube JM Pardoll DM Neoadjuvant checkpoint blockade for cancer immunotherapy Science 2020 367 6477 eaax0182 10.1126/science.aax0182 32001626 PMC7789854 Topalian SL, Taube JM, Pardoll DM. Neoadjuvant checkpoint blockade for cancer immunotherapy. Science. 2020;367(6477):eaax0182. 32001626 10.1126/science.aax0182 PMC7789854 44. Deng H Zhao Y Cai X Chen H Cheng B Zhong R PD-L1 expression and tumor mutation burden as pathological response biomarkers of neoadjuvant immunotherapy for early-stage non-small cell lung cancer: a systematic review and meta-analysis Crit Rev Oncol Hematol 2022 170 103582 10.1016/j.critrevonc.2022.103582 35031441 Deng H, Zhao Y, Cai X, Chen H, Cheng B, Zhong R, et al. PD-L1 expression and tumor mutation burden as pathological response biomarkers of neoadjuvant immunotherapy for early-stage non-small cell lung cancer: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2022;170:103582. 35031441 10.1016/j.critrevonc.2022.103582 45. Wu J Xia X Gong L Huang S Zheng H Qiao G Neoadjuvant chemoimmunotherapy for small cell carcinoma of the esophagus: clinical efficacy and biomarker exploration Hum Vaccin Immunother 2024 20 1 2370085 10.1080/21645515.2024.2370085 38967227 PMC11229733 Wu J, Xia X, Gong L, Huang S, Zheng H, Qiao G, et al. Neoadjuvant chemoimmunotherapy for small cell carcinoma of the esophagus: clinical efficacy and biomarker exploration. Hum Vaccin Immunother. 2024;20(1):2370085. 38967227 10.1080/21645515.2024.2370085 PMC11229733 46. Sharma P Stecklein SR Yoder R Staley JM Schwensen K O&#8217;Dea A Clinical and biomarker findings of neoadjuvant pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer: NeoPACT phase 2 clinical trial JAMA Oncol 2024 10 2 227 35 10.1001/jamaoncol.2023.5033 37991778 PMC10666040 Sharma P, Stecklein SR, Yoder R, Staley JM, Schwensen K, O&#8217;Dea A, et al. Clinical and biomarker findings of neoadjuvant pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer: NeoPACT phase 2 clinical trial. JAMA Oncol. 2024;10(2):227&#8211;35. 37991778 10.1001/jamaoncol.2023.5033 PMC10666040 47. Liu SY Dong S Yang XN Liao RQ Jiang BY Wang Q Neoadjuvant nivolumab with or without platinum-doublet chemotherapy based on PD-L1 expression in resectable NSCLC (CTONG1804): a multicenter open-label phase II study Signal Transduct Target Ther 2023 8 1 442 10.1038/s41392-023-01700-4 38057314 PMC10700550 Liu SY, Dong S, Yang XN, Liao RQ, Jiang BY, Wang Q, et al. Neoadjuvant nivolumab with or without platinum-doublet chemotherapy based on PD-L1 expression in resectable NSCLC (CTONG1804): a multicenter open-label phase II study. Signal Transduct Target Ther. 2023;8(1):442. 38057314 10.1038/s41392-023-01700-4 PMC10700550 48. Mittendorf EA Zhang H Barrios CH Saji S Jung KH Hegg R Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial Lancet 2020 396 10257 1090 100 10.1016/S0140-6736(20)31953-X 32966830 Mittendorf EA, Zhang H, Barrios CH, Saji S, Jung KH, Hegg R, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet. 2020;396(10257):1090&#8211;100. 32966830 10.1016/S0140-6736(20)31953-X 49. Gao S Li N Gao S Xue Q Ying J Wang S Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC J Thorac Oncol 2020 15 5 816 26 10.1016/j.jtho.2020.01.017 32036071 Gao S, Li N, Gao S, Xue Q, Ying J, Wang S, et al. Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC. J Thorac Oncol. 2020;15(5):816&#8211;26. 32036071 10.1016/j.jtho.2020.01.017 50. Wang CD Ma JC Shao J Zhang S Liu Z Yu Y Predicting EGFR and PD-L1 Status in NSCLC Patients Using Multitask AI System Based on CT Images Front Immunol 2022 13 813072 10.3389/fimmu.2022.813072 35250988 PMC8895233 Wang CD, Ma JC, Shao J, Zhang S, Liu Z, Yu Y, et al. Predicting EGFR and PD-L1 Status in NSCLC Patients Using Multitask AI System Based on CT Images. Front Immunol. 2022;13:813072. 10.3389/fimmu.2022.813072. 35250988 10.3389/fimmu.2022.813072 PMC8895233 51. Jin W Tian Y Xuzhang W Zhu H Zou N Shen L Non-linear modifications enhance prediction of pathological response to pre-operative PD-1 blockade in lung cancer: a longitudinal hybrid radiological model Pharmacol Res 2023 198 106992 10.1016/j.phrs.2023.106992 37977237 Jin W, Tian Y, Xuzhang W, Zhu H, Zou N, Shen L, et al. Non-linear modifications enhance prediction of pathological response to pre-operative PD-1 blockade in lung cancer: a longitudinal hybrid radiological model. Pharmacol Res. 2023;198:106992. 37977237 10.1016/j.phrs.2023.106992 52. Saad MZB Hong L Aminu M Vokes NI Chen PJ Saleh Jahromi M Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study The Lancet Digital Health 2023 5 7 e404 e420 10.1016/S2589-7500(23)00082-1 37268451 PMC10330920 Saad MZB, Hong L, Aminu M, Vokes NI, Chen PJ, Saleh Jahromi M, et al. Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study. The Lancet Digital Health. 2023;5(7):e404&#8211;20. 10.1016/S2589-7500(23)00082-1. 37268451 10.1016/S2589-7500(23)00082-1 PMC10330920 53. Zhao J Sun Z Yu Y Yuan Z Lin Y Tan Y Radiomic and clinical data integration using machine learning predict the efficacy of anti-PD-1 antibodies-based combinational treatment in advanced breast cancer: a multicentered study J Immunother Cancer 2023 11 5 e006514 10.1136/jitc-2022-006514 37217246 PMC10230987 Zhao J, Sun Z, Yu Y, Yuan Z, Lin Y, Tan Y, et al. Radiomic and clinical data integration using machine learning predict the efficacy of anti-PD-1 antibodies-based combinational treatment in advanced breast cancer: a multicentered study. J Immunother Cancer. 2023;11(5):e006514. 37217246 10.1136/jitc-2022-006514 PMC10230987 54. Wang X Jiang Y Chen H Zhang T Han Z Chen C Cancer immunotherapy response prediction from multi-modal clinical and image data using semi-supervised deep learning Radiother Oncol 2023 186 109793 10.1016/j.radonc.2023.109793 37414254 Wang X, Jiang Y, Chen H, Zhang T, Han Z, Chen C, et al. Cancer immunotherapy response prediction from multi-modal clinical and image data using semi-supervised deep learning. Radiother Oncol. 2023;186:109793. 37414254 10.1016/j.radonc.2023.109793 55. Mu W Jiang L Shi Y Tunali I Gray JE Katsoulakis E Non-invasive measurement of PD-L1 status and prediction of immunotherapy response using deep learning of PET/CT images J Immunother Cancer 2021 9 6 e002118 10.1136/jitc-2020-002118 34135101 PMC8211060 Mu W, Jiang L, Shi Y, Tunali I, Gray JE, Katsoulakis E, et al. Non-invasive measurement of PD-L1 status and prediction of immunotherapy response using deep learning of PET/CT images. J Immunother Cancer. 2021;9(6):e002118. 34135101 10.1136/jitc-2020-002118 PMC8211060 56. Tian P He B Mu W Liu K Liu L Zeng H Assessing PD-L1 expression in non-small cell lung cancer and predicting responses to immune checkpoint inhibitors using deep learning on computed tomography images Theranostics 2021 11 5 2098 10.7150/thno.48027 33500713 PMC7797686 Tian P, He B, Mu W, Liu K, Liu L, Zeng H, et al. Assessing PD-L1 expression in non-small cell lung cancer and predicting responses to immune checkpoint inhibitors using deep learning on computed tomography images. Theranostics. 2021;11(5):2098. 33500713 10.7150/thno.48027 PMC7797686 57. Cao Y Zhu H Li Z Liu C Ye J CT image-based radiomic analysis for detecting PD-L1 expression status in bladder cancer patients Acad Radiol 2024 31 9 3678 87 10.1016/j.acra.2024.02.047 38556431 Cao Y, Zhu H, Li Z, Liu C, Ye J. CT image-based radiomic analysis for detecting PD-L1 expression status in bladder cancer patients. Acad Radiol. 2024;31(9):3678&#8211;87. 38556431 10.1016/j.acra.2024.02.047 58. Da-Ano R Andrade-Miranda G Tankyevych O Visvikis D Conze PH Rest CCL Automated PD-L1 status prediction in lung cancer with multi-modal PET/CT fusion Sci Rep 2024 14 1 16720 10.1038/s41598-024-66487-y 39030240 PMC11271510 Da-Ano R, Andrade-Miranda G, Tankyevych O, Visvikis D, Conze PH, Rest CCL. Automated PD-L1 status prediction in lung cancer with multi-modal PET/CT fusion. Sci Rep. 2024;14(1):16720. 39030240 10.1038/s41598-024-66487-y PMC11271510 59. Mei&#223;ner AK Gutsche R Galldiks N Kocher M J&#252;nger ST Eich ML Radiomics for the non-invasive prediction of PD-L1 expression in patients with brain metastases secondary to non-small cell lung cancer J Neurooncol 2023 163 3 597 605 10.1007/s11060-023-04367-7 37382806 PMC10393847 Mei&#223;ner AK, Gutsche R, Galldiks N, Kocher M, J&#252;nger ST, Eich ML, et al. Radiomics for the non-invasive prediction of PD-L1 expression in patients with brain metastases secondary to non-small cell lung cancer. J Neurooncol. 2023;163(3):597&#8211;605. 37382806 10.1007/s11060-023-04367-7 PMC10393847 60. Cheng G Zhang F Xing Y Hu X Zhang H Chen S Artificial intelligence-assisted score analysis for predicting the expression of the immunotherapy biomarker PD-L1 in lung cancer Front Immunol 2022 13 893198 10.3389/fimmu.2022.893198 35844508 PMC9286729 Cheng G, Zhang F, Xing Y, Hu X, Zhang H, Chen S, et al. Artificial intelligence-assisted score analysis for predicting the expression of the immunotherapy biomarker PD-L1 in lung cancer. Front Immunol. 2022;13:893198. 35844508 10.3389/fimmu.2022.893198 PMC9286729 61. Wu J Liu C Liu X Sun W Li L Gao N Artificial intelligence-assisted system for precision diagnosis of PD-L1 expression in non-small cell lung cancer Mod Pathol 2022 35 3 403 11 10.1038/s41379-021-00904-9 34518630 Wu J, Liu C, Liu X, Sun W, Li L, Gao N, et al. Artificial intelligence-assisted system for precision diagnosis of PD-L1 expression in non-small cell lung cancer. Mod Pathol. 2022;35(3):403&#8211;11. 34518630 10.1038/s41379-021-00904-9 62. Shamai G Livne A Pol&#243;nia A Sabo E Cretu A Bar-Sela G Deep learning-based image analysis predicts PD-L1 status from H &amp;E-stained histopathology images in breast cancer Nat Commun 2022 13 1 6753 10.1038/s41467-022-34275-9 36347854 PMC9643479 Shamai G, Livne A, Pol&#243;nia A, Sabo E, Cretu A, Bar-Sela G, et al. Deep learning-based image analysis predicts PD-L1 status from H &amp;E-stained histopathology images in breast cancer. Nat Commun. 2022;13(1):6753. 36347854 10.1038/s41467-022-34275-9 PMC9643479 63. Li B Qin W Yang L Li H Jiang C Yao Y From pixels to patient care: deep learning-enabled pathomics signature offers precise outcome predictions for immunotherapy in esophageal squamous cell cancer J Transl Med 2024 22 1 195 10.1186/s12967-024-04997-z 38388379 PMC10885627 Li B, Qin W, Yang L, Li H, Jiang C, Yao Y, et al. From pixels to patient care: deep learning-enabled pathomics signature offers precise outcome predictions for immunotherapy in esophageal squamous cell cancer. J Transl Med. 2024;22(1):195. 38388379 10.1186/s12967-024-04997-z PMC10885627 64. Zhou QQ Guo J Wang Z Li J Chen M Xu Q Rapid visualization of PD-L1 expression level in glioblastoma immune microenvironment via machine learning cascade-based Raman histopathology J Adv Res 2024 65 257 71 10.1016/j.jare.2023.12.002 38072311 PMC11519053 Zhou QQ, Guo J, Wang Z, Li J, Chen M, Xu Q, et al. Rapid visualization of PD-L1 expression level in glioblastoma immune microenvironment via machine learning cascade-based Raman histopathology. J Adv Res. 2024;65:257&#8211;71. 38072311 10.1016/j.jare.2023.12.002 PMC11519053 65. Jin D Liang S Shmatko A Arnold A Horst D Gr&#252;newald TG Teacher-student collaborated multiple instance learning for pan-cancer PDL1 expression prediction from histopathology slides Nat Commun 2024 15 1 3063 10.1038/s41467-024-46764-0 38594278 PMC11004138 Jin D, Liang S, Shmatko A, Arnold A, Horst D, Gr&#252;newald TG, et al. Teacher-student collaborated multiple instance learning for pan-cancer PDL1 expression prediction from histopathology slides. Nat Commun. 2024;15(1):3063. 38594278 10.1038/s41467-024-46764-0 PMC11004138 66. Peng J Zhang J Zou D Xiao L Ma H Zhang X Deep learning to estimate durable clinical benefit and prognosis from patients with non-small cell lung cancer treated with PD-1/PD-L1 blockade Front Immunol 2022 13 960459 10.3389/fimmu.2022.960459 36420269 PMC9677530 Peng J, Zhang J, Zou D, Xiao L, Ma H, Zhang X, et al. Deep learning to estimate durable clinical benefit and prognosis from patients with non-small cell lung cancer treated with PD-1/PD-L1 blockade. Front Immunol. 2022;13:960459. 36420269 10.3389/fimmu.2022.960459 PMC9677530 67. Wiesweg M Mairinger F Reis H Goetz M Kollmeier J Misch D Machine learning reveals a PD-L1-independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression context Eur J Cancer 2020 140 76 85 10.1016/j.ejca.2020.09.015 33059196 Wiesweg M, Mairinger F, Reis H, Goetz M, Kollmeier J, Misch D, et al. Machine learning reveals a PD-L1-independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression context. Eur J Cancer. 2020;140:76&#8211;85. 33059196 10.1016/j.ejca.2020.09.015 68. Chen Z Chen Y Sun Y Tang L Zhang L Hu Y Predicting gastric cancer response to anti-HER2 therapy or anti-HER2 combined immunotherapy based on multi-modal data Signal Transduct Target Ther 2024 9 1 222 10.1038/s41392-024-01932-y 39183247 PMC11345439 Chen Z, Chen Y, Sun Y, Tang L, Zhang L, Hu Y, et al. Predicting gastric cancer response to anti-HER2 therapy or anti-HER2 combined immunotherapy based on multi-modal data. Signal Transduct Target Ther. 2024;9(1):222. 39183247 10.1038/s41392-024-01932-y PMC11345439 69. Byeon HE Haam S Han JH Lee HW Koh YW Intrinsic and extrinsic transcriptional profiles that affect the clinical response to PD-1 inhibitors in patients with non-small cell lung cancer Cancers (Basel) 2022 15 1 197 10.3390/cancers15010197 36612193 PMC9818269 Byeon HE, Haam S, Han JH, Lee HW, Koh YW. Intrinsic and extrinsic transcriptional profiles that affect the clinical response to PD-1 inhibitors in patients with non-small cell lung cancer. Cancers (Basel). 2022;15(1):197. 36612193 10.3390/cancers15010197 PMC9818269 70. Jardim DL Goodman A de Melo GD Kurzrock R The challenges of tumor mutational burden as an immunotherapy biomarker Cancer Cell 2021 39 2 154 173 10.1016/j.ccell.2020.10.001 33125859 PMC7878292 Jardim DL, Goodman A, de Melo GD, Kurzrock R. The challenges of tumor mutational burden as an immunotherapy biomarker. Cancer Cell. 2021;39(2):154&#8211;73. 33125859 10.1016/j.ccell.2020.10.001 PMC7878292 71. Palmeri M Mehnert J Silk A Jabbour S Ganesan S Popli P Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers ESMO Open 2022 7 1 100336 10.1016/j.esmoop.2021.100336 34953399 PMC8717431 Palmeri M, Mehnert J, Silk A, Jabbour S, Ganesan S, Popli P, et al. Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers. ESMO Open. 2022;7(1):100336. 34953399 10.1016/j.esmoop.2021.100336 PMC8717431 72. Li S Yu W Xie F Luo H Liu Z Lv W Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer Nat Commun 2023 14 1 8 10.1038/s41467-022-35431-x 36596787 PMC9810618 Li S, Yu W, Xie F, Luo H, Liu Z, Lv W, et al. Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer. Nat Commun. 2023;14(1):8. 36596787 10.1038/s41467-022-35431-x PMC9810618 73. Zhang G Yuan J Pan C Xu Q Cui X Zhang J Multi-omics analysis uncovers tumor ecosystem dynamics during neoadjuvant toripalimab plus nab-paclitaxel and S-1 for esophageal squamous cell carcinoma: a single-center, open-label, single-arm phase 2 trial EBioMedicine 2023 10.1016/j.ebiom.2023.104515 36921563 PMC10024111 Zhang G, Yuan J, Pan C, Xu Q, Cui X, Zhang J, et al. Multi-omics analysis uncovers tumor ecosystem dynamics during neoadjuvant toripalimab plus nab-paclitaxel and S-1 for esophageal squamous cell carcinoma: a single-center, open-label, single-arm phase 2 trial. EBioMedicine. 2023. 10.1016/j.ebiom.2023.104515. 36921563 10.1016/j.ebiom.2023.104515 PMC10024111 74. Mino-Kenudson M Schalper K Cooper W Dacic S Hirsch FR Jain D Predictive biomarkers for immunotherapy in lung cancer: perspective from the International Association for the Study of Lung Cancer Pathology Committee J Thorac Oncol 2022 17 12 1335 54 10.1016/j.jtho.2022.09.109 36184066 Mino-Kenudson M, Schalper K, Cooper W, Dacic S, Hirsch FR, Jain D, et al. Predictive biomarkers for immunotherapy in lung cancer: perspective from the International Association for the Study of Lung Cancer Pathology Committee. J Thorac Oncol. 2022;17(12):1335&#8211;54. 36184066 10.1016/j.jtho.2022.09.109 75. Veeraraghavan H Friedman CF DeLair DF Nin&#269;evi&#263; J Himoto Y Bruni SG Machine learning-based prediction of microsatellite instability and high tumor mutation burden from contrast-enhanced computed tomography in endometrial cancers Sci Rep 2020 10 1 17769 10.1038/s41598-020-72475-9 33082371 PMC7575573 Veeraraghavan H, Friedman CF, DeLair DF, Nin&#269;evi&#263; J, Himoto Y, Bruni SG, et al. Machine learning-based prediction of microsatellite instability and high tumor mutation burden from contrast-enhanced computed tomography in endometrial cancers. Sci Rep. 2020;10(1):17769. 33082371 10.1038/s41598-020-72475-9 PMC7575573 76. Wang X Kong C Xu W Yang S Shi D Zhang J Decoding tumor mutation burden and driver mutations in early stage lung adenocarcinoma using CT-based radiomics signature Thorac Cancer 2019 10 10 1904 12 10.1111/1759-7714.13163 31414580 PMC6775017 Wang X, Kong C, Xu W, Yang S, Shi D, Zhang J, et al. Decoding tumor mutation burden and driver mutations in early stage lung adenocarcinoma using CT-based radiomics signature. Thorac Cancer. 2019;10(10):1904&#8211;12. 31414580 10.1111/1759-7714.13163 PMC6775017 77. He B Dong D She Y Zhou C Fang M Zhu Y Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker J Immunother Cancer 2020 8 2 e000550 10.1136/jitc-2020-000550 32636239 PMC7342823 He B, Dong D, She Y, Zhou C, Fang M, Zhu Y, et al. Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker. J Immunother Cancer. 2020;8(2):e000550. 32636239 10.1136/jitc-2020-000550 PMC7342823 78. Lam LHT Chu NT Tran TO Do DT Le NQK A radiomics-based machine learning model for prediction of tumor mutational burden in lower-grade gliomas Cancers (Basel) 2022 14 14 3492 10.3390/cancers14143492 35884551 PMC9324877 Lam LHT, Chu NT, Tran TO, Do DT, Le NQK. A radiomics-based machine learning model for prediction of tumor mutational burden in lower-grade gliomas. Cancers (Basel). 2022;14(14):3492. 35884551 10.3390/cancers14143492 PMC9324877 79. Hoshino I Yokota H Iwatate Y Mori Y Kuwayama N Ishige F Prediction of the differences in tumor mutation burden between primary and metastatic lesions by radiogenomics Cancer Sci 2022 113 1 229 39 10.1111/cas.15173 34689378 PMC8748253 Hoshino I, Yokota H, Iwatate Y, Mori Y, Kuwayama N, Ishige F, et al. Prediction of the differences in tumor mutation burden between primary and metastatic lesions by radiogenomics. Cancer Sci. 2022;113(1):229&#8211;39. 34689378 10.1111/cas.15173 PMC8748253 80. Shimada Y Okuda S Watanabe Y Tajima Y Nagahashi M Ichikawa H Histopathological characteristics and artificial intelligence for predicting tumor mutational burden-high colorectal cancer J Gastroenterol 2021 56 6 547 59 10.1007/s00535-021-01789-w 33909150 Shimada Y, Okuda S, Watanabe Y, Tajima Y, Nagahashi M, Ichikawa H, et al. Histopathological characteristics and artificial intelligence for predicting tumor mutational burden-high colorectal cancer. J Gastroenterol. 2021;56(6):547&#8211;59. 33909150 10.1007/s00535-021-01789-w 81. Zheng Q Wang X Yang R Fan J Yuan J Liu X Predicting tumor mutation burden and VHL mutation from renal cancer pathology slides with self-supervised deep learning Cancer Med 2024 13 16 e70112 10.1002/cam4.70112 39166457 PMC11336896 Zheng Q, Wang X, Yang R, Fan J, Yuan J, Liu X, et al. Predicting tumor mutation burden and VHL mutation from renal cancer pathology slides with self-supervised deep learning. Cancer Med. 2024;13(16):e70112. 39166457 10.1002/cam4.70112 PMC11336896 82. Sun C Luo T Liu Z Ge J Shao L Liu X Tumor mutation burden-related histopathologic features for predicting overall survival in gliomas using graph deep learning Am J Pathol 2023 193 12 2111 21 10.1016/j.ajpath.2023.08.015 37741452 Sun C, Luo T, Liu Z, Ge J, Shao L, Liu X, et al. Tumor mutation burden-related histopathologic features for predicting overall survival in gliomas using graph deep learning. Am J Pathol. 2023;193(12):2111&#8211;21. 37741452 10.1016/j.ajpath.2023.08.015 83. Huang K Lin B Liu J Liu Y Li J Tian G Predicting colorectal cancer tumor mutational burden from histopathological images and clinical information using multi-modal deep learning Bioinformatics 2022 38 22 5108 15 10.1093/bioinformatics/btac641 36130268 Huang K, Lin B, Liu J, Liu Y, Li J, Tian G, et al. Predicting colorectal cancer tumor mutational burden from histopathological images and clinical information using multi-modal deep learning. Bioinformatics. 2022;38(22):5108&#8211;15. 36130268 10.1093/bioinformatics/btac641 84. Xu H Clemenceau JR Park S Choi J Lee SH Hwang TH Spatial heterogeneity and organization of tumor mutation burden with immune infiltrates within tumors based on whole slide images correlated with patient survival in bladder cancer J Pathol Inform 2022 13 100105 10.1016/j.jpi.2022.100105 36268064 PMC9577053 Xu H, Clemenceau JR, Park S, Choi J, Lee SH, Hwang TH. Spatial heterogeneity and organization of tumor mutation burden with immune infiltrates within tumors based on whole slide images correlated with patient survival in bladder cancer. J Pathol Inform. 2022;13:100105. 36268064 10.1016/j.jpi.2022.100105 PMC9577053 85. Li J Liu H Liu W Zong P Huang K Li Z Predicting gastric cancer tumor mutational burden from histopathological images using multimodal deep learning Brief Funct Genomics 2024 23 3 228 38 10.1093/bfgp/elad032 37525540 Li J, Liu H, Liu W, Zong P, Huang K, Li Z, et al. Predicting gastric cancer tumor mutational burden from histopathological images using multimodal deep learning. Brief Funct Genomics. 2024;23(3):228&#8211;38. 37525540 10.1093/bfgp/elad032 86. Sanjaya P Maljanen K Katainen R Waszak SM Aaltonen LA Stegle O Mutation-attention (MuAt): deep representation learning of somatic mutations for tumour typing and subtyping Genome Med 2023 15 1 47 10.1186/s13073-023-01204-4 37420249 PMC10326961 Sanjaya P, Maljanen K, Katainen R, Waszak SM, Aaltonen LA, Stegle O, et al. Mutation-attention (MuAt): deep representation learning of somatic mutations for tumour typing and subtyping. Genome Med. 2023;15(1):47. 37420249 10.1186/s13073-023-01204-4 PMC10326961 87. Nassar A Lymona AM Lotfy MM Youssef ASED Mohanad M Manie TM Tumor mutation burden prediction model in Egyptian breast cancer patients based on next generation sequencing Asian Pac J Cancer Prev 2021 22 7 2053 10.31557/APJCP.2021.22.7.2053 34319027 PMC8607104 Nassar A, Lymona AM, Lotfy MM, Youssef ASED, Mohanad M, Manie TM, et al. Tumor mutation burden prediction model in Egyptian breast cancer patients based on next generation sequencing. Asian Pac J Cancer Prev. 2021;22(7):2053. 34319027 10.31557/APJCP.2021.22.7.2053 PMC8607104 88. Zhang Z Wang ZX Chen YX Wu HX Yin L Zhao Q Integrated analysis of single-cell and bulk RNA sequencing data reveals a pan-cancer stemness signature predicting immunotherapy response Genome Med 2022 14 1 45 10.1186/s13073-022-01050-w 35488273 PMC9052621 Zhang Z, Wang ZX, Chen YX, Wu HX, Yin L, Zhao Q, et al. Integrated analysis of single-cell and bulk RNA sequencing data reveals a pan-cancer stemness signature predicting immunotherapy response. Genome Med. 2022;14(1):45. 35488273 10.1186/s13073-022-01050-w PMC9052621 89. Wang J Chen P Su M Zhong G Zhang S Gou D Integrative modeling of multiomics data for predicting tumor mutation burden in patients with lung cancer BioMed Res Int 2022 2022 1 2698190 10.1155/2022/2698190 35097114 PMC8794677 Wang J, Chen P, Su M, Zhong G, Zhang S, Gou D. Integrative modeling of multiomics data for predicting tumor mutation burden in patients with lung cancer. BioMed Res Int. 2022;2022(1):2698190. 35097114 10.1155/2022/2698190 PMC8794677 90. Ozer M Vegivinti CTR Syed M Ferrell ME Gonzalez Gomez C Cheng S Neoadjuvant immunotherapy for patients with dMMR/MSI-high gastrointestinal cancers: a changing paradigm Cancers (Basel) 2023 15 15 3833 10.3390/cancers15153833 37568648 PMC10417711 Ozer M, Vegivinti CTR, Syed M, Ferrell ME, Gonzalez Gomez C, Cheng S, et al. Neoadjuvant immunotherapy for patients with dMMR/MSI-high gastrointestinal cancers: a changing paradigm. Cancers (Basel). 2023;15(15):3833. 37568648 10.3390/cancers15153833 PMC10417711 91. Zhang X Wu T Cai X Dong J Xia C Zhou Y Neoadjuvant immunotherapy for MSI-H/dMMR locally advanced colorectal cancer: new strategies and unveiled opportunities Front Immunol 2022 13 795972 10.3389/fimmu.2022.795972 35371084 PMC8968082 Zhang X, Wu T, Cai X, Dong J, Xia C, Zhou Y, et al. Neoadjuvant immunotherapy for MSI-H/dMMR locally advanced colorectal cancer: new strategies and unveiled opportunities. Front Immunol. 2022;13:795972. 35371084 10.3389/fimmu.2022.795972 PMC8968082 92. Zhang Z Cheng S Gong J Lu M Zhou J Zhang X Efficacy and safety of neoadjuvant immunotherapy in patients with microsatellite instability-high gastrointestinal malignancies: A case series Eur J Surg Oncol 2020 46 10 e33 e39 10.1016/j.ejso.2020.06.034 32732092 Zhang Z, Cheng S, Gong J, Lu M, Zhou J, Zhang X, et al. Efficacy and safety of neoadjuvant immunotherapy in patients with microsatellite instability-high gastrointestinal malignancies: A case series. Eur J Surg Oncol. 2020;46(10):e33&#8211;9. 32732092 10.1016/j.ejso.2020.06.034 93. Ludford K Ho WJ Thomas JV Raghav KP Murphy MB Fleming ND Neoadjuvant pembrolizumab in localized microsatellite instability high/deficient mismatch repair solid tumors J Clin Oncol 2023 41 12 2181 90 10.1200/JCO.22.01351 36623241 PMC10489404 Ludford K, Ho WJ, Thomas JV, Raghav KP, Murphy MB, Fleming ND, et al. Neoadjuvant pembrolizumab in localized microsatellite instability high/deficient mismatch repair solid tumors. J Clin Oncol. 2023;41(12):2181&#8211;90. 36623241 10.1200/JCO.22.01351 PMC10489404 94. Pei F Wu J Zhao Y He W Yao Q Huang M Single-agent neoadjuvant immunotherapy with a PD-1 antibody in locally advanced mismatch repair-deficient or microsatellite instability-high colorectal cancer Clin Colorectal Cancer 2023 22 1 85 91 36528470 10.1016/j.clcc.2022.11.004 Pei F, Wu J, Zhao Y, He W, Yao Q, Huang M, et al. Single-agent neoadjuvant immunotherapy with a PD-1 antibody in locally advanced mismatch repair-deficient or microsatellite instability-high colorectal cancer. Clin Colorectal Cancer. 2023;22(1):85&#8211;91. 36528470 10.1016/j.clcc.2022.11.004 95. Liu L Woo Y D&#8217;Apuzzo M Melstrom L Raoof M Liang Y Immunotherapy-based neoadjuvant treatment of advanced microsatellite instability-high gastric cancer: a case series J Natl Compr Canc Netw 2022 20 8 857 65 10.6004/jnccn.2022.7023 35948034 Liu L, Woo Y, D&#8217;Apuzzo M, Melstrom L, Raoof M, Liang Y, et al. Immunotherapy-based neoadjuvant treatment of advanced microsatellite instability-high gastric cancer: a case series. J Natl Compr Canc Netw. 2022;20(8):857&#8211;65. 35948034 10.6004/jnccn.2022.7023 96. Andr&#233; T Tougeron D Piessen G de La Fouchardi&#232;re C Louvet C Adenis A Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: the GERCOR NEONIPIGA phase II study J Clin Oncol 2023 41 2 255 65 10.1200/JCO.22.00686 35969830 PMC9839243 Andr&#233; T, Tougeron D, Piessen G, de La Fouchardi&#232;re C, Louvet C, Adenis A, et al. Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: the GERCOR NEONIPIGA phase II study. J Clin Oncol. 2023;41(2):255&#8211;65. 35969830 10.1200/JCO.22.00686 PMC9839243 97. Sahin IH Zhang J Saridogan T Gorantla V Rhree J Malhotra M Neoadjuvant immune checkpoint inhibitor therapy for patients with microsatellite instability-high colorectal cancer: shedding light on the future JCO Oncol Pract 2023 19 5 251 9 10.1200/OP.22.00762 36862965 Sahin IH, Zhang J, Saridogan T, Gorantla V, Rhree J, Malhotra M, et al. Neoadjuvant immune checkpoint inhibitor therapy for patients with microsatellite instability-high colorectal cancer: shedding light on the future. JCO Oncol Pract. 2023;19(5):251&#8211;9. 36862965 10.1200/OP.22.00762 98. Jia Y Hou L Zhao J Ren J Li D Li H Radiomics analysis of multiparametric MRI for preoperative prediction of microsatellite instability status in endometrial cancer: a dual-center study Front Oncol 2024 14 1333020 10.3389/fonc.2024.1333020 38347846 PMC10860747 Jia Y, Hou L, Zhao J, Ren J, Li D, Li H, et al. Radiomics analysis of multiparametric MRI for preoperative prediction of microsatellite instability status in endometrial cancer: a dual-center study. Front Oncol. 2024;14:1333020. 38347846 10.3389/fonc.2024.1333020 PMC10860747 99. Xing X Li D Peng J Shu Z Zhang Y Song Q A combinatorial MRI sequence-based radiomics model for preoperative prediction of microsatellite instability status in rectal cancer Sci Rep 2024 14 1 11760 10.1038/s41598-024-62584-0 38783014 PMC11116457 Xing X, Li D, Peng J, Shu Z, Zhang Y, Song Q. A combinatorial MRI sequence-based radiomics model for preoperative prediction of microsatellite instability status in rectal cancer. Sci Rep. 2024;14(1):11760. 38783014 10.1038/s41598-024-62584-0 PMC11116457 100. Li Q Xia Y Li M Tang W Zhang M Zhao Z Radiogenomics for predicting microsatellite instability status and PD-L1 expression with machine learning in endometrial cancers: a multicenter study Heliyon 2023 10.1016/j.heliyon.2023.e23166 38149198 PMC10750045 Li Q, Xia Y, Li M, Tang W, Zhang M, Zhao Z, et al. Radiogenomics for predicting microsatellite instability status and PD-L1 expression with machine learning in endometrial cancers: a multicenter study. Heliyon. 2023. 10.1016/j.heliyon.2023.e23166. 38149198 10.1016/j.heliyon.2023.e23166 PMC10750045 101. Wang J Song P Zhang M Liu W Zeng X Chen N A prediction model based on deep learning and radiomics features of DWI for the assessment of microsatellite instability in endometrial cancer Cancer Med 2024 13 16 e70046 10.1002/cam4.70046 39171859 PMC11339853 Wang J, Song P, Zhang M, Liu W, Zeng X, Chen N, et al. A prediction model based on deep learning and radiomics features of DWI for the assessment of microsatellite instability in endometrial cancer. Cancer Med. 2024;13(16):e70046. 39171859 10.1002/cam4.70046 PMC11339853 102. Zhang Y Liu J Wu C Peng J Wei Y Cui S Preoperative prediction of microsatellite instability in rectal cancer using five machine learning algorithms based on multiparametric MRI radiomics Diagnostics 2023 13 2 269 10.3390/diagnostics13020269 36673079 PMC9858257 Zhang Y, Liu J, Wu C, Peng J, Wei Y, Cui S. Preoperative prediction of microsatellite instability in rectal cancer using five machine learning algorithms based on multiparametric MRI radiomics. Diagnostics. 2023;13(2):269. 36673079 10.3390/diagnostics13020269 PMC9858257 103. Kim S, Lee JH, Park EJ, Lee HS, Baik SH, Jeon TJ, et al. Prediction of microsatellite instability in colorectal cancer using a machine learning model based on PET/CT radiomics. Yonsei Med J. 2023;64(5):320. 10.3349/ymj.2022.0548 PMC10151228 37114635 104. Bodalal Z Hong EK Trebeschi S Kurilova I Landolfi F Bogveradze N Non-invasive CT radiomic biomarkers predict microsatellite stability status in colorectal cancer: a multicenter validation study Eur Radiol Exp 2024 8 1 98 10.1186/s41747-024-00484-8 39186200 PMC11347521 Bodalal Z, Hong EK, Trebeschi S, Kurilova I, Landolfi F, Bogveradze N, et al. Non-invasive CT radiomic biomarkers predict microsatellite stability status in colorectal cancer: a multicenter validation study. Eur Radiol Exp. 2024;8(1):98. 39186200 10.1186/s41747-024-00484-8 PMC11347521 105. Cao W Hu H Guo J Qin Q Lian Y Li J CT-based deep learning model for the prediction of DNA mismatch repair deficient colorectal cancer: a diagnostic study J Transl Med 2023 21 1 214 10.1186/s12967-023-04023-8 36949511 PMC10035255 Cao W, Hu H, Guo J, Qin Q, Lian Y, Li J, et al. CT-based deep learning model for the prediction of DNA mismatch repair deficient colorectal cancer: a diagnostic study. J Transl Med. 2023;21(1):214. 36949511 10.1186/s12967-023-04023-8 PMC10035255 106. Jiang Z Xie W Zhou X Pan W Jiang S Zhang X A virtual biopsy study of microsatellite instability in gastric cancer based on deep learning radiomics Insights Imaging 2023 14 1 104 10.1186/s13244-023-01438-1 37286810 PMC10247640 Jiang Z, Xie W, Zhou X, Pan W, Jiang S, Zhang X, et al. A virtual biopsy study of microsatellite instability in gastric cancer based on deep learning radiomics. Insights Imaging. 2023;14(1):104. 37286810 10.1186/s13244-023-01438-1 PMC10247640 107. Niehues JM Quirke P West NP Grabsch HI van Treeck M Schirris Y Generalizable biomarker prediction from cancer pathology slides with self-supervised deep learning: a retrospective multi-centric study Cell Rep Med 2023 10.1016/j.xcrm.2023.100980 36958327 PMC10140458 Niehues JM, Quirke P, West NP, Grabsch HI, van Treeck M, Schirris Y, et al. Generalizable biomarker prediction from cancer pathology slides with self-supervised deep learning: a retrospective multi-centric study. Cell Rep Med. 2023. 10.1016/j.xcrm.2023.100980. 36958327 10.1016/j.xcrm.2023.100980 PMC10140458 108. Wagner SJ Reisenb&#252;chler D West NP Niehues JM Zhu J Foersch S Transformer-based biomarker prediction from colorectal cancer histology: A large-scale multicentric study Cancer Cell 2023 41 9 1650 1661 10.1016/j.ccell.2023.08.002 37652006 PMC10507381 Wagner SJ, Reisenb&#252;chler D, West NP, Niehues JM, Zhu J, Foersch S, et al. Transformer-based biomarker prediction from colorectal cancer histology: A large-scale multicentric study. Cancer Cell. 2023;41(9):1650&#8211;61. 37652006 10.1016/j.ccell.2023.08.002 PMC10507381 109. Gerwert K Sch&#246;rner S Gro&#223;erueschkamp F Kraeft AL Schuhmacher D Sternemann C Fast and label-free automated detection of microsatellite status in early colon cancer using artificial intelligence integrated infrared imaging Eur J Cancer 2023 182 122 31 10.1016/j.ejca.2022.12.026 36773401 Gerwert K, Sch&#246;rner S, Gro&#223;erueschkamp F, Kraeft AL, Schuhmacher D, Sternemann C, et al. Fast and label-free automated detection of microsatellite status in early colon cancer using artificial intelligence integrated infrared imaging. Eur J Cancer. 2023;182:122&#8211;31. 36773401 10.1016/j.ejca.2022.12.026 110. Saillard C Dubois R Tchita O Loiseau N Garcia T Adriansen A Validation of MSIntuit as an AI-based pre-screening tool for MSI detection from colorectal cancer histology slides Nat Commun 2023 14 1 6695 10.1038/s41467-023-42453-6 37932267 PMC10628260 Saillard C, Dubois R, Tchita O, Loiseau N, Garcia T, Adriansen A, et al. Validation of MSIntuit as an AI-based pre-screening tool for MSI detection from colorectal cancer histology slides. Nat Commun. 2023;14(1):6695. 37932267 10.1038/s41467-023-42453-6 PMC10628260 111. Zamanitajeddin N Jahanifar M Bilal M Eastwood M Rajpoot N Social network analysis of cell networks improves deep learning for prediction of molecular pathways and key mutations in colorectal cancer Med Image Anal 2024 93 103071 10.1016/j.media.2023.103071 38199068 Zamanitajeddin N, Jahanifar M, Bilal M, Eastwood M, Rajpoot N. Social network analysis of cell networks improves deep learning for prediction of molecular pathways and key mutations in colorectal cancer. Med Image Anal. 2024;93:103071. 38199068 10.1016/j.media.2023.103071 112. Chang X Wang J Zhang G Yang M Xi Y Xi C Predicting colorectal cancer microsatellite instability with a self-attention-enabled convolutional neural network Cell Rep Med 2023 10.1016/j.xcrm.2022.100914 36720223 PMC9975100 Chang X, Wang J, Zhang G, Yang M, Xi Y, Xi C, et al. Predicting colorectal cancer microsatellite instability with a self-attention-enabled convolutional neural network. Cell Rep Med. 2023. 10.1016/j.xcrm.2022.100914. 36720223 10.1016/j.xcrm.2022.100914 PMC9975100 113. Echle A Laleh NG Quirke P Grabsch H Muti H Saldanha O Artificial intelligence for detection of microsatellite instability in colorectal cancer&#8211;a multicentric analysis of a pre-screening tool for clinical application ESMO open 2022 7 2 100400 10.1016/j.esmoop.2022.100400 35247870 PMC9058894 Echle A, Laleh NG, Quirke P, Grabsch H, Muti H, Saldanha O, et al. Artificial intelligence for detection of microsatellite instability in colorectal cancer&#8211;a multicentric analysis of a pre-screening tool for clinical application. ESMO open. 2022;7(2):100400. 35247870 10.1016/j.esmoop.2022.100400 PMC9058894 114. Saldanha OL Quirke P West NP James JA Loughrey MB Grabsch HI Swarm learning for decentralized artificial intelligence in cancer histopathology Nat Med 2022 28 6 1232 9 10.1038/s41591-022-01768-5 35469069 PMC9205774 Saldanha OL, Quirke P, West NP, James JA, Loughrey MB, Grabsch HI, et al. Swarm learning for decentralized artificial intelligence in cancer histopathology. Nat Med. 2022;28(6):1232&#8211;9. 35469069 10.1038/s41591-022-01768-5 PMC9205774 115. Lou J Xu J Zhang Y Sun Y Fang A Liu J Ppsnet: an improved deep learning model for microsatellite instability high prediction in colorectal cancer from whole slide images Comput Methods Programs Biomed 2022 225 107095 10.1016/j.cmpb.2022.107095 36057226 Lou J, Xu J, Zhang Y, Sun Y, Fang A, Liu J, et al. Ppsnet: an improved deep learning model for microsatellite instability high prediction in colorectal cancer from whole slide images. Comput Methods Programs Biomed. 2022;225:107095. 36057226 10.1016/j.cmpb.2022.107095 116. Blake N Gaifulina R Griffin LD Bell IM Rodriguez-Justo M Thomas GM Deep learning applied to Raman Spectroscopy for the detection of microsatellite instability/MMR deficient colorectal cancer Cancers (Basel) 2023 15 6 1720 10.3390/cancers15061720 36980606 PMC10046611 Blake N, Gaifulina R, Griffin LD, Bell IM, Rodriguez-Justo M, Thomas GM. Deep learning applied to Raman Spectroscopy for the detection of microsatellite instability/MMR deficient colorectal cancer. Cancers (Basel). 2023;15(6):1720. 36980606 10.3390/cancers15061720 PMC10046611 117. Schirris Y Gavves E Nederlof I Horlings HM Teuwen J DeepSMILE: Contrastive self-supervised pre-training benefits MSI and HRD classification directly from H &amp;E whole-slide images in colorectal and breast cancer Med Image Anal 2022 79 102464 10.1016/j.media.2022.102464 35596966 Schirris Y, Gavves E, Nederlof I, Horlings HM, Teuwen J. DeepSMILE: Contrastive self-supervised pre-training benefits MSI and HRD classification directly from H &amp;E whole-slide images in colorectal and breast cancer. Med Image Anal. 2022;79:102464. 35596966 10.1016/j.media.2022.102464 118. Tsai PC Lee TH Kuo KC Su FY Lee TLM Marostica E Histopathology images predict multi-omics aberrations and prognoses in colorectal cancer patients Nat Commun 2023 14 1 1 13 10.1038/s41467-023-37179-4 37055393 PMC10102208 Tsai PC, Lee TH, Kuo KC, Su FY, Lee TLM, Marostica E, et al. Histopathology images predict multi-omics aberrations and prognoses in colorectal cancer patients. Nat Commun. 2023;14(1):1&#8211;13. 37055393 10.1038/s41467-023-37179-4 PMC10102208 119. Fujii S Kotani D Hattori M Nishihara M Shikanai T Hashimoto J Rapid screening using pathomorphologic interpretation to detect BRAF V600E mutation and microsatellite instability in colorectal cancer Clin Cancer Res 2022 28 12 2623 32 10.1158/1078-0432.CCR-21-4391 35363302 Fujii S, Kotani D, Hattori M, Nishihara M, Shikanai T, Hashimoto J, et al. Rapid screening using pathomorphologic interpretation to detect BRAF V600E mutation and microsatellite instability in colorectal cancer. Clin Cancer Res. 2022;28(12):2623&#8211;32. 35363302 10.1158/1078-0432.CCR-21-4391 120. Wang CW Muzakky H Firdi NP Liu TC Lai PJ Wang YC Deep learning to assess microsatellite instability directly from histopathological whole slide images in endometrial cancer NPJ Digit Med 2024 7 1 143 10.1038/s41746-024-01131-7 38811811 PMC11137095 Wang CW, Muzakky H, Firdi NP, Liu TC, Lai PJ, Wang YC, et al. Deep learning to assess microsatellite instability directly from histopathological whole slide images in endometrial cancer. NPJ Digit Med. 2024;7(1):143. 38811811 10.1038/s41746-024-01131-7 PMC11137095 121. Hu Q Rizvi AA Schau G Ingale K Muller Y Baits R Development and validation of a deep learning-based microsatellite instability predictor from prostate cancer whole-slide images NPJ Precis Oncol 2024 8 1 88 10.1038/s41698-024-00560-7 38594360 PMC11004110 Hu Q, Rizvi AA, Schau G, Ingale K, Muller Y, Baits R, et al. Development and validation of a deep learning-based microsatellite instability predictor from prostate cancer whole-slide images. NPJ Precis Oncol. 2024;8(1):88. 38594360 10.1038/s41698-024-00560-7 PMC11004110 122. Wang CW Lee YC Lin YJ Firdi NP Muzakky H Liu TC Deep learning can predict bevacizumab therapeutic effect and microsatellite instability directly from histology in epithelial ovarian cancer Lab Invest 2023 103 11 100247 10.1016/j.labinv.2023.100247 37741509 Wang CW, Lee YC, Lin YJ, Firdi NP, Muzakky H, Liu TC, et al. Deep learning can predict bevacizumab therapeutic effect and microsatellite instability directly from histology in epithelial ovarian cancer. Lab Invest. 2023;103(11):100247. 37741509 10.1016/j.labinv.2023.100247 123. Su F Li J Zhao X Wang B Hu Y Sun Y Interpretable tumor differentiation grade and microsatellite instability recognition in gastric cancer using deep learning Lab Invest 2022 102 6 641 9 10.1038/s41374-022-00742-6 35177797 Su F, Li J, Zhao X, Wang B, Hu Y, Sun Y, et al. Interpretable tumor differentiation grade and microsatellite instability recognition in gastric cancer using deep learning. Lab Invest. 2022;102(6):641&#8211;9. 35177797 10.1038/s41374-022-00742-6 124. Lee SH Lee Y Jang HJ Deep learning captures selective features for discrimination of microsatellite instability from pathologic tissue slides of gastric cancer Int J Cancer 2023 152 2 298 307 10.1002/ijc.34251 36054320 Lee SH, Lee Y, Jang HJ. Deep learning captures selective features for discrimination of microsatellite instability from pathologic tissue slides of gastric cancer. Int J Cancer. 2023;152(2):298&#8211;307. 36054320 10.1002/ijc.34251 125. Nowak M Jabbar F Rodewald AK Gneo L Tomasevic T Harkin A Single-cell AI-based detection and prognostic and predictive value of DNA mismatch repair deficiency in colorectal cancer Cell Rep Med 2024 10.1016/j.xcrm.2024.101727 39293403 PMC11525017 Nowak M, Jabbar F, Rodewald AK, Gneo L, Tomasevic T, Harkin A, et al. Single-cell AI-based detection and prognostic and predictive value of DNA mismatch repair deficiency in colorectal cancer. Cell Rep Med. 2024. 10.1016/j.xcrm.2024.101727. 39293403 10.1016/j.xcrm.2024.101727 PMC11525017 126. Jiang W Mei WJ Xu SY Ling YH Li WR Kuang JB Clinical actionability of triaging DNA mismatch repair deficient colorectal cancer from biopsy samples using deep learning EBioMedicine 2022 10.1016/j.ebiom.2022.104120 35753152 PMC9240789 Jiang W, Mei WJ, Xu SY, Ling YH, Li WR, Kuang JB, et al. Clinical actionability of triaging DNA mismatch repair deficient colorectal cancer from biopsy samples using deep learning. EBioMedicine. 2022. 10.1016/j.ebiom.2022.104120. 35753152 10.1016/j.ebiom.2022.104120 PMC9240789 127. Whangbo J Lee YS Kim YJ Kim J Kim KG Predicting mismatch repair deficiency status in endometrial cancer through multi-resolution ensemble learning in digital pathology Journal of Imaging Informatics in Medicine 2024 37 4 1674 82 10.1007/s10278-024-00997-z 38378964 PMC11300772 Whangbo J, Lee YS, Kim YJ, Kim J, Kim KG. Predicting mismatch repair deficiency status in endometrial cancer through multi-resolution ensemble learning in digital pathology. Journal of Imaging Informatics in Medicine. 2024;37(4):1674&#8211;82. 38378964 10.1007/s10278-024-00997-z PMC11300772 128. Umemoto M Mariya T Nambu Y Nagata M Horimai T Sugita S Prediction of mismatch repair status in endometrial cancer from histological slide images using various deep learning-based algorithms Cancers (Basel) 2024 16 10 1810 10.3390/cancers16101810 38791889 PMC11119770 Umemoto M, Mariya T, Nambu Y, Nagata M, Horimai T, Sugita S, et al. Prediction of mismatch repair status in endometrial cancer from histological slide images using various deep learning-based algorithms. Cancers (Basel). 2024;16(10):1810. 38791889 10.3390/cancers16101810 PMC11119770 129. Swaerts K Dedeurwaerdere F De Smet D De Jaeger P Martens GA DeltaMSI: artificial intelligence-based modeling of microsatellite instability scoring on next-generation sequencing data BMC Bioinformatics 2023 24 1 73 10.1186/s12859-023-05186-3 36859168 PMC9976396 Swaerts K, Dedeurwaerdere F, De Smet D, De Jaeger P, Martens GA. DeltaMSI: artificial intelligence-based modeling of microsatellite instability scoring on next-generation sequencing data. BMC Bioinformatics. 2023;24(1):73. 36859168 10.1186/s12859-023-05186-3 PMC9976396 130. Chen J Wang M Zhao D Li F Wu H Liu Q MSINGB: a novel computational method based on NGBoost for identifying microsatellite instability status from tumor mutation annotation data Interdiscip Sci Comput Life Sci 2023 15 1 100 110 10.1007/s12539-022-00544-w 36350503 Chen J, Wang M, Zhao D, Li F, Wu H, Liu Q, et al. MSINGB: a novel computational method based on NGBoost for identifying microsatellite instability status from tumor mutation annotation data. Interdiscip Sci Comput Life Sci. 2023;15(1):100&#8211;10. 10.1007/s12539-022-00544-w 36350503 131. Cao Y Wang D Wu J Yao Z Shen S Niu C MSI-XGNN: an explainable GNN computational framework integrating transcription-and methylation-level biomarkers for microsatellite instability detection Brief Bioinform 2023 24 6 bbad362 10.1093/bib/bbad362 37833839 Cao Y, Wang D, Wu J, Yao Z, Shen S, Niu C, et al. MSI-XGNN: an explainable GNN computational framework integrating transcription-and methylation-level biomarkers for microsatellite instability detection. Brief Bioinform. 2023;24(6):bbad362. 37833839 10.1093/bib/bbad362 132. Shi B Wang W Fang S Wu S Zhu L Chen Y Raman spectroscopy analysis combined with computed tomography imaging to identify microsatellite instability in gastric cancers Spectrochim Acta A Mol Biomol Spectrosc 2025 325 125062 10.1016/j.saa.2024.125062 39226670 Shi B, Wang W, Fang S, Wu S, Zhu L, Chen Y, et al. Raman spectroscopy analysis combined with computed tomography imaging to identify microsatellite instability in gastric cancers. Spectrochim Acta A Mol Biomol Spectrosc. 2025;325:125062. 39226670 10.1016/j.saa.2024.125062 133. Qiu W Yang J Wang B Yang M Tian G Wang P Evaluating the microsatellite instability of colorectal cancer based on multimodal deep learning integrating histopathological and molecular data Front Oncol 2022 12 925079 10.3389/fonc.2022.925079 35865460 PMC9295995 Qiu W, Yang J, Wang B, Yang M, Tian G, Wang P. Evaluating the microsatellite instability of colorectal cancer based on multimodal deep learning integrating histopathological and molecular data. Front Oncol. 2022;12:925079. 35865460 10.3389/fonc.2022.925079 PMC9295995 134. Ma KL Mitchell TC Dougher M Sharon CE Tortorello GN Elder DE Tumor-infiltrating lymphocytes in necrotic tumors after melanoma neoadjuvant anti-PD-1 therapy correlate with pathologic response and recurrence-free survival Clin Cancer Res 2024 30 21 4987 94 10.1158/1078-0432.CCR-23-3775 39248505 PMC11539852 Ma KL, Mitchell TC, Dougher M, Sharon CE, Tortorello GN, Elder DE, et al. Tumor-infiltrating lymphocytes in necrotic tumors after melanoma neoadjuvant anti-PD-1 therapy correlate with pathologic response and recurrence-free survival. Clin Cancer Res. 2024;30(21):4987&#8211;94. 39248505 10.1158/1078-0432.CCR-23-3775 PMC11539852 135. Wood SJ Gao Y Lee JH Chen J Wang Q Meisel JL High tumor infiltrating lymphocytes are significantly associated with pathological complete response in triple negative breast cancer treated with neoadjuvant KEYNOTE-522 chemoimmunotherapy Breast Cancer Res Treat 2024 205 1 193 9 10.1007/s10549-023-07233-2 38286889 Wood SJ, Gao Y, Lee JH, Chen J, Wang Q, Meisel JL, et al. High tumor infiltrating lymphocytes are significantly associated with pathological complete response in triple negative breast cancer treated with neoadjuvant KEYNOTE-522 chemoimmunotherapy. Breast Cancer Res Treat. 2024;205(1):193&#8211;9. 38286889 10.1007/s10549-023-07233-2 136. Wolf GT Liu S Bellile E Sartor M Rozek L Thomas D Tumor infiltrating lymphocytes after neoadjuvant IRX-2 immunotherapy in oral squamous cell carcinoma: interim findings from the INSPIRE trial Oral Oncol 2020 111 104928 10.1016/j.oraloncology.2020.104928 32738599 Wolf GT, Liu S, Bellile E, Sartor M, Rozek L, Thomas D, et al. Tumor infiltrating lymphocytes after neoadjuvant IRX-2 immunotherapy in oral squamous cell carcinoma: interim findings from the INSPIRE trial. Oral Oncol. 2020;111:104928. 32738599 10.1016/j.oraloncology.2020.104928 137. Liu R Yang F Yin JY Liu YZ Zhang W Zhou HH Influence of tumor immune infiltration on immune checkpoint inhibitor therapeutic efficacy: a computational retrospective study Front Immunol 2021 12 685370 10.3389/fimmu.2021.685370 34220837 PMC8248490 Liu R, Yang F, Yin JY, Liu YZ, Zhang W, Zhou HH. Influence of tumor immune infiltration on immune checkpoint inhibitor therapeutic efficacy: a computational retrospective study. Front Immunol. 2021;12:685370. 34220837 10.3389/fimmu.2021.685370 PMC8248490 138. Zheng DD Li YY Yuan XY Lu JL Zhang MF Fu J Immune cell patterns before and after neoadjuvant immune checkpoint blockade combined with chemoradiotherapy in locally advanced esophageal squamous cell carcinoma BMC Cancer 2024 24 1 649 10.1186/s12885-024-12406-3 38802821 PMC11129487 Zheng DD, Li YY, Yuan XY, Lu JL, Zhang MF, Fu J, et al. Immune cell patterns before and after neoadjuvant immune checkpoint blockade combined with chemoradiotherapy in locally advanced esophageal squamous cell carcinoma. BMC Cancer. 2024;24(1):649. 38802821 10.1186/s12885-024-12406-3 PMC11129487 139. Yam C Yen EY Chang JT Bassett RL Alatrash G Garber H Immune phenotype and response to neoadjuvant therapy in triple-negative breast cancer Clin Cancer Res 2021 27 19 5365 75 10.1158/1078-0432.CCR-21-0144 34253579 PMC8752638 Yam C, Yen EY, Chang JT, Bassett RL Jr, Alatrash G, Garber H, et al. Immune phenotype and response to neoadjuvant therapy in triple-negative breast cancer. Clin Cancer Res. 2021;27(19):5365&#8211;75. 34253579 10.1158/1078-0432.CCR-21-0144 PMC8752638 140. Yamaguchi H Hsu JM Sun L Wang SC Hung MC Advances and prospects of biomarkers for immune checkpoint inhibitors Cell Rep Med 2024 10.1016/j.xcrm.2024.101621 38906149 PMC11293349 Yamaguchi H, Hsu JM, Sun L, Wang SC, Hung MC. Advances and prospects of biomarkers for immune checkpoint inhibitors. Cell Rep Med. 2024. 10.1016/j.xcrm.2024.101621. 38906149 10.1016/j.xcrm.2024.101621 PMC11293349 141. Cheng N Wang B Xu J Xue L Ying J Tumor stroma ratio, tumor stroma maturity, tumor-infiltrating immune cells in relation to prognosis, and neoadjuvant therapy response in esophagogastric junction adenocarcinoma Virchows Arch 2024 10.1007/s00428-024-03755-2 38383941 Cheng N, Wang B, Xu J, Xue L, Ying J. Tumor stroma ratio, tumor stroma maturity, tumor-infiltrating immune cells in relation to prognosis, and neoadjuvant therapy response in esophagogastric junction adenocarcinoma. Virchows Arch. 2024. 10.1007/s00428-024-03755-2. 38383941 10.1007/s00428-024-03755-2 142. Wang Q Zhong W Shen X Hao Z Wan M Yang X Tertiary lymphoid structures predict survival and response to neoadjuvant therapy in locally advanced rectal cancer NPJ Precis Oncol 2024 8 1 61 10.1038/s41698-024-00533-w 38431733 PMC10908779 Wang Q, Zhong W, Shen X, Hao Z, Wan M, Yang X, et al. Tertiary lymphoid structures predict survival and response to neoadjuvant therapy in locally advanced rectal cancer. NPJ Precis Oncol. 2024;8(1):61. 38431733 10.1038/s41698-024-00533-w PMC10908779 143. Krishnamoorthy M Lenehan JG Maleki Vareki S Neoadjuvant immunotherapy for high-risk, resectable malignancies: scientific rationale and clinical challenges JNCI J Natl Cancer Inst 2021 113 7 823 32 10.1093/jnci/djaa216 33432320 PMC8246900 Krishnamoorthy M, Lenehan JG, Maleki Vareki S. Neoadjuvant immunotherapy for high-risk, resectable malignancies: scientific rationale and clinical challenges. JNCI J Natl Cancer Inst. 2021;113(7):823&#8211;32. 33432320 10.1093/jnci/djaa216 PMC8246900 144. Kang J Zhang C Zhong WZ Neoadjuvant immunotherapy for non-small cell lung cancer: state of the art Cancer Commun 2021 41 4 287 302 10.1002/cac2.12153 PMC8045926 33689225 Kang J, Zhang C, Zhong WZ. Neoadjuvant immunotherapy for non-small cell lung cancer: state of the art. Cancer Commun. 2021;41(4):287&#8211;302. 10.1002/cac2.12153 PMC8045926 33689225 145. Wu R Jia Y Li N Lu X Yao Z Ma Y Evaluation of breast cancer tumor-infiltrating lymphocytes on ultrasound images based on a novel multi-cascade residual U-shaped network Ultrasound Med Biol 2023 49 11 2398 406 10.1016/j.ultrasmedbio.2023.08.003 37634979 Wu R, Jia Y, Li N, Lu X, Yao Z, Ma Y, et al. Evaluation of breast cancer tumor-infiltrating lymphocytes on ultrasound images based on a novel multi-cascade residual U-shaped network. Ultrasound Med Biol. 2023;49(11):2398&#8211;406. 37634979 10.1016/j.ultrasmedbio.2023.08.003 146. Jia Y Wu R Lu X Duan Y Zhu Y Ma Y Deep learning with transformer or convolutional neural network in the assessment of tumor-infiltrating lymphocytes (TILs) in breast cancer based on US images: a dual-center retrospective study Cancers (Basel) 2023 15 3 838 10.3390/cancers15030838 36765796 PMC9913836 Jia Y, Wu R, Lu X, Duan Y, Zhu Y, Ma Y, et al. Deep learning with transformer or convolutional neural network in the assessment of tumor-infiltrating lymphocytes (TILs) in breast cancer based on US images: a dual-center retrospective study. Cancers (Basel). 2023;15(3):838. 36765796 10.3390/cancers15030838 PMC9913836 147. Zhang M Li X Zhou P Zhang P Wang G Lin X Prediction value study of breast cancer tumor infiltrating lymphocyte levels based on ultrasound imaging radiomics Front Oncol 2024 14 1411261 10.3389/fonc.2024.1411261 38903726 PMC11187250 Zhang M, Li X, Zhou P, Zhang P, Wang G, Lin X. Prediction value study of breast cancer tumor infiltrating lymphocyte levels based on ultrasound imaging radiomics. Front Oncol. 2024;14:1411261. 38903726 10.3389/fonc.2024.1411261 PMC11187250 148. Hu L Jin P Xu W Wang C Huang P Clinical and radiomics integrated nomogram for preoperative prediction of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer Front Oncol 2024 14 1370466 10.3389/fonc.2024.1370466 38567151 PMC10985173 Hu L, Jin P, Xu W, Wang C, Huang P. Clinical and radiomics integrated nomogram for preoperative prediction of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer. Front Oncol. 2024;14:1370466. 38567151 10.3389/fonc.2024.1370466 PMC10985173 149. Lu X, Jia Y, Zhang H, Wu R, Zhao W, Yao Z, et&#160;al. Deep learning&#8211;based and BI-RADS guided radiomics model for tumour-infiltrating lymphocytes evaluation in breast cancer. Br J Radiol. 2024;p. tqae129. 10.1093/bjr/tqae129 38995740 150. Su GH Xiao Y Jiang L Zheng RC Wang H Chen Y Radiomics features for assessing tumor-infiltrating lymphocytes correlate with molecular traits of triple-negative breast cancer J Transl Med 2022 20 1 471 10.1186/s12967-022-03688-x 36243806 PMC9571493 Su GH, Xiao Y, Jiang L, Zheng RC, Wang H, Chen Y, et al. Radiomics features for assessing tumor-infiltrating lymphocytes correlate with molecular traits of triple-negative breast cancer. J Transl Med. 2022;20(1):471. 36243806 10.1186/s12967-022-03688-x PMC9571493 151. Jeon SH Kim SW Na K Seo M Sohn YM Lim YJ Radiomic models based on magnetic resonance imaging predict the spatial distribution of CD8+ tumor-infiltrating lymphocytes in breast cancer Front Immunol 2022 13 1080048 10.3389/fimmu.2022.1080048 36601118 PMC9806253 Jeon SH, Kim SW, Na K, Seo M, Sohn YM, Lim YJ. Radiomic models based on magnetic resonance imaging predict the spatial distribution of CD8+ tumor-infiltrating lymphocytes in breast cancer. Front Immunol. 2022;13:1080048. 36601118 10.3389/fimmu.2022.1080048 PMC9806253 152. Qian H Ren X Xu M Fang Z Zhang R Bu Y Magnetic resonance imaging-based radiomics was used to evaluate the level of prognosis-related immune cell infiltration in breast cancer tumor microenvironment BMC Med Imaging 2024 24 1 31 10.1186/s12880-024-01212-9 38308230 PMC10835863 Qian H, Ren X, Xu M, Fang Z, Zhang R, Bu Y, et al. Magnetic resonance imaging-based radiomics was used to evaluate the level of prognosis-related immune cell infiltration in breast cancer tumor microenvironment. BMC Med Imaging. 2024;24(1):31. 38308230 10.1186/s12880-024-01212-9 PMC10835863 153. Ren J Yang G Song Y Zhang C Yuan Y Machine learning-based MRI radiomics for assessing the level of tumor infiltrating lymphocytes in oral tongue squamous cell carcinoma: a pilot study BMC Med Imaging 2024 24 1 33 10.1186/s12880-024-01210-x 38317076 PMC10845803 Ren J, Yang G, Song Y, Zhang C, Yuan Y. Machine learning-based MRI radiomics for assessing the level of tumor infiltrating lymphocytes in oral tongue squamous cell carcinoma: a pilot study. BMC Med Imaging. 2024;24(1):33. 38317076 10.1186/s12880-024-01210-x PMC10845803 154. Huang H Li Z Wang D Yang Y Jin H Lu Z Machine learning models based on quantitative dynamic contrast-enhanced MRI parameters assess the expression levels of CD3+, CD4+, and CD8+ tumor-infiltrating lymphocytes in advanced gastric carcinoma Front Oncol 2024 14 1365550 10.3389/fonc.2024.1365550 38549936 PMC10973004 Huang H, Li Z, Wang D, Yang Y, Jin H, Lu Z. Machine learning models based on quantitative dynamic contrast-enhanced MRI parameters assess the expression levels of CD3+, CD4+, and CD8+ tumor-infiltrating lymphocytes in advanced gastric carcinoma. Front Oncol. 2024;14:1365550. 38549936 10.3389/fonc.2024.1365550 PMC10973004 155. Li G Li L Li Y Qian Z Wu F He Y An MRI radiomics approach to predict survival and tumour-infiltrating macrophages in gliomas Brain 2022 145 3 1151 61 10.1093/brain/awab340 35136934 PMC9050568 Li G, Li L, Li Y, Qian Z, Wu F, He Y, et al. An MRI radiomics approach to predict survival and tumour-infiltrating macrophages in gliomas. Brain. 2022;145(3):1151&#8211;61. 35136934 10.1093/brain/awab340 PMC9050568 156. He H Jin Z Dai J Wang H Sun J Xu D Computed tomography-based radiomics prediction of CTLA4 expression and prognosis in clear cell renal cell carcinoma Cancer Med 2023 12 6 7627 38 10.1002/cam4.5449 36397666 PMC10067074 He H, Jin Z, Dai J, Wang H, Sun J, Xu D. Computed tomography-based radiomics prediction of CTLA4 expression and prognosis in clear cell renal cell carcinoma. Cancer Med. 2023;12(6):7627&#8211;38. 36397666 10.1002/cam4.5449 PMC10067074 157. Li R Bing X Su X Zhang C Sun H Dai Z The potential value of dual-energy CT radiomics in evaluating CD8+, CD163+ and EquationSource IDSMA+ cells in the tumor microenvironment of clear cell renal cell carcinoma Clin Transl Oncol 2025 27 2 716 726 10.1007/s12094-024-03637-8 39083142 Li R, Bing X, Su X, Zhang C, Sun H, Dai Z, et al. The potential value of dual-energy CT radiomics in evaluating CD8+, CD163+ and SMA+ cells in the tumor microenvironment of clear cell renal cell carcinoma. Clin Transl Oncol. 2025;27(2):716&#8211;26. 39083142 10.1007/s12094-024-03637-8 158. Chen L Chen L Ni H Shen L Wei J Xia Y Prediction of CD3 T cells and CD8 T cells expression levels in non-small cell lung cancer based on radiomic features of CT images Front Oncol 2023 13 1104316 10.3389/fonc.2023.1104316 36860311 PMC9968855 Chen L, Chen L, Ni H, Shen L, Wei J, Xia Y, et al. Prediction of CD3 T cells and CD8 T cells expression levels in non-small cell lung cancer based on radiomic features of CT images. Front Oncol. 2023;13:1104316. 36860311 10.3389/fonc.2023.1104316 PMC9968855 159. Wu L Li J Ruan X Ren J Ping X Chen B Prediction of VEGF and EGFR expression in peripheral lung cancer based on the radiomics model of spectral CT enhanced images Int J Gen Med 2022 15 6725 10.2147/IJGM.S374002 36039307 PMC9419990 Wu L, Li J, Ruan X, Ren J, Ping X, Chen B. Prediction of VEGF and EGFR expression in peripheral lung cancer based on the radiomics model of spectral CT enhanced images. Int J Gen Med. 2022;15:6725. 36039307 10.2147/IJGM.S374002 PMC9419990 160. Meng Y Zhang H Li Q Liu F Fang X Li J Magnetic resonance radiomics and machine-learning models: an approach for evaluating tumor-stroma ratio in patients with pancreatic ductal adenocarcinoma Acad Radiol 2022 29 4 523 35 10.1016/j.acra.2021.08.013 34563443 Meng Y, Zhang H, Li Q, Liu F, Fang X, Li J, et al. Magnetic resonance radiomics and machine-learning models: an approach for evaluating tumor-stroma ratio in patients with pancreatic ductal adenocarcinoma. Acad Radiol. 2022;29(4):523&#8211;35. 34563443 10.1016/j.acra.2021.08.013 161. Liao H, Yuan J, Liu C, Zhang J, Yang Y, Liang H, et al. One novel transfer learning-based CLIP model combined with self-attention mechanism for differentiating the tumor-stroma ratio in pancreatic ductal adenocarcinoma. Radiol Med. 2024;(11):16. 10.1007/s11547-024-01902-y. 10.1007/s11547-024-01902-y 39412688 162. Long S Li M Chen J Zhong L Dai G Pan D Transfer learning radiomic model predicts intratumoral tertiary lymphoid structures in hepatocellular carcinoma: a multicenter study J Immunother Cancer 2025 13 3 e011126 10.1136/jitc-2024-011126 40037925 PMC11881188 Long S, Li M, Chen J, Zhong L, Dai G, Pan D, et al. Transfer learning radiomic model predicts intratumoral tertiary lymphoid structures in hepatocellular carcinoma: a multicenter study. J Immunother Cancer. 2025;13(3):e011126. 40037925 10.1136/jitc-2024-011126 PMC11881188 163. Liu S Amgad M More D Rathore MA Salgado R Cooper LA A panoptic segmentation dataset and deep-learning approach for explainable scoring of tumor-infiltrating lymphocytes NPJ Breast Cancer 2024 10 1 52 10.1038/s41523-024-00663-1 38942745 PMC11213912 Liu S, Amgad M, More D, Rathore MA, Salgado R, Cooper LA. A panoptic segmentation dataset and deep-learning approach for explainable scoring of tumor-infiltrating lymphocytes. NPJ Breast Cancer. 2024;10(1):52. 38942745 10.1038/s41523-024-00663-1 PMC11213912 164. Meirelles AL Kurc T Kong J Ferreira R Saltz JH Teodoro G Building efficient cnn architectures for histopathology images analysis: a case-study in tumor-infiltrating lymphocytes classification Front Med 2022 9 894430 10.3389/fmed.2022.894430 PMC9197439 35712087 Meirelles AL, Kurc T, Kong J, Ferreira R, Saltz JH, Teodoro G. Building efficient cnn architectures for histopathology images analysis: a case-study in tumor-infiltrating lymphocytes classification. Front Med. 2022;9:894430. 10.3389/fmed.2022.894430 PMC9197439 35712087 165. Yosofvand M Khan SY Dhakal R Nejat A Moustaid-Moussa N Rahman RL Automated detection and scoring of tumor-infiltrating lymphocytes in breast cancer histopathology slides Cancers (Basel) 2023 15 14 3635 10.3390/cancers15143635 37509295 PMC10377197 Yosofvand M, Khan SY, Dhakal R, Nejat A, Moustaid-Moussa N, Rahman RL, et al. Automated detection and scoring of tumor-infiltrating lymphocytes in breast cancer histopathology slides. Cancers (Basel). 2023;15(14):3635. 37509295 10.3390/cancers15143635 PMC10377197 166. Verdicchio M Brancato V Cavaliere C Isgr&#242; F Salvatore M Aiello M A pathomic approach for tumor-infiltrating lymphocytes classification on breast cancer digital pathology images Heliyon 2023 10.1016/j.heliyon.2023.e14371 36950640 PMC10025040 Verdicchio M, Brancato V, Cavaliere C, Isgr&#242; F, Salvatore M, Aiello M. A pathomic approach for tumor-infiltrating lymphocytes classification on breast cancer digital pathology images. Heliyon. 2023. 10.1016/j.heliyon.2023.e14371. 36950640 10.1016/j.heliyon.2023.e14371 PMC10025040 167. Shvetsov N Gr&#248;nnesby M Pedersen E M&#248;llersen K Busund LTR Schwienbacher R A pragmatic machine learning approach to quantify tumor-infiltrating lymphocytes in whole slide images Cancers (Basel) 2022 14 12 2974 10.3390/cancers14122974 35740648 PMC9221016 Shvetsov N, Gr&#248;nnesby M, Pedersen E, M&#248;llersen K, Busund LTR, Schwienbacher R, et al. A pragmatic machine learning approach to quantify tumor-infiltrating lymphocytes in whole slide images. Cancers (Basel). 2022;14(12):2974. 35740648 10.3390/cancers14122974 PMC9221016 168. Abousamra S Gupta R Hou L Batiste R Zhao T Shankar A Deep learning-based mapping of tumor infiltrating lymphocytes in whole slide images of 23 types of cancer Front Oncol 2022 11 806603 10 3389 10.3389/fonc.2021.806603 PMC8889499 35251953 Abousamra S, Gupta R, Hou L, Batiste R, Zhao T, Shankar A, et al. Deep learning-based mapping of tumor infiltrating lymphocytes in whole slide images of 23 types of cancer. Front Oncol. 2022;11(806603):10&#8211;3389. 10.3389/fonc.2021.806603 PMC8889499 35251953 169. Machuca-Aguado J Conde-Mart&#237;n AF Alvarez-Mu&#241;oz A Rodr&#237;guez-Zarco E Polo-Velasco A Rueda-Ramos A Machine learning quantification of intraepithelial tumor-infiltrating lymphocytes as a significant prognostic factor in high-grade serous ovarian carcinomas Int J Mol Sci 2023 24 22 16060 10.3390/ijms242216060 38003250 PMC10671555 Machuca-Aguado J, Conde-Mart&#237;n AF, Alvarez-Mu&#241;oz A, Rodr&#237;guez-Zarco E, Polo-Velasco A, Rueda-Ramos A, et al. Machine learning quantification of intraepithelial tumor-infiltrating lymphocytes as a significant prognostic factor in high-grade serous ovarian carcinomas. Int J Mol Sci. 2023;24(22):16060. 38003250 10.3390/ijms242216060 PMC10671555 170. Xu H Cha YJ Clemenceau JR Choi J Lee SH Kang J Spatial analysis of tumor-infiltrating lymphocytes in histological sections using deep learning techniques predicts survival in colorectal carcinoma The Journal of Pathology: Clinical Research 2022 8 4 327 39 35484698 10.1002/cjp2.273 PMC9161341 Xu H, Cha YJ, Clemenceau JR, Choi J, Lee SH, Kang J, et al. Spatial analysis of tumor-infiltrating lymphocytes in histological sections using deep learning techniques predicts survival in colorectal carcinoma. The Journal of Pathology: Clinical Research. 2022;8(4):327&#8211;39. 35484698 10.1002/cjp2.273 PMC9161341 171. Zheng Q Yang R Ni X Yang S Jiao P Wu J Quantitative assessment of tumor-infiltrating lymphocytes using machine learning predicts survival in muscle-invasive bladder cancer J Clin Med 2022 11 23 7081 10.3390/jcm11237081 36498655 PMC9739988 Zheng Q, Yang R, Ni X, Yang S, Jiao P, Wu J, et al. Quantitative assessment of tumor-infiltrating lymphocytes using machine learning predicts survival in muscle-invasive bladder cancer. J Clin Med. 2022;11(23):7081. 36498655 10.3390/jcm11237081 PMC9739988 172. Fassler DJ Torre-Healy LA Gupta R Hamilton AM Kobayashi S Van Alsten SC Spatial characterization of tumor-infiltrating lymphocytes and breast cancer progression Cancers (Basel) 2022 14 9 2148 10.3390/cancers14092148 35565277 PMC9105398 Fassler DJ, Torre-Healy LA, Gupta R, Hamilton AM, Kobayashi S, Van Alsten SC, et al. Spatial characterization of tumor-infiltrating lymphocytes and breast cancer progression. Cancers (Basel). 2022;14(9):2148. 35565277 10.3390/cancers14092148 PMC9105398 173. Pan X Lin H Han C Feng Z Wang Y Lin J Computerized tumor-infiltrating lymphocytes density score predicts survival of patients with resectable lung adenocarcinoma iScience 2022 10.1016/j.isci.2022.105605 36505920 PMC9730047 Pan X, Lin H, Han C, Feng Z, Wang Y, Lin J, et al. Computerized tumor-infiltrating lymphocytes density score predicts survival of patients with resectable lung adenocarcinoma. iScience. 2022. 10.1016/j.isci.2022.105605. 36505920 10.1016/j.isci.2022.105605 PMC9730047 174. Yang X Li X Xu H Du S Wang C He H Predicting CTLA4 expression and prognosis in clear cell renal cell carcinoma using a pathomics signature of histopathological images and machine learning Heliyon 2024 10.1016/j.heliyon.2024.e34877 39145002 PMC11320204 Yang X, Li X, Xu H, Du S, Wang C, He H. Predicting CTLA4 expression and prognosis in clear cell renal cell carcinoma using a pathomics signature of histopathological images and machine learning. Heliyon. 2024. 10.1016/j.heliyon.2024.e34877. 39145002 10.1016/j.heliyon.2024.e34877 PMC11320204 175. Firmbach D Benz M Kuritcyn P Bruns V Lang-Schwarz C Stuebs FA Tumor-stroma ratio in colorectal cancer&#8211;comparison between human estimation and automated assessment Cancers (Basel) 2023 15 10 2675 10.3390/cancers15102675 37345012 PMC10216342 Firmbach D, Benz M, Kuritcyn P, Bruns V, Lang-Schwarz C, Stuebs FA, et al. Tumor-stroma ratio in colorectal cancer&#8211;comparison between human estimation and automated assessment. Cancers (Basel). 2023;15(10):2675. 37345012 10.3390/cancers15102675 PMC10216342 176. Xinsen L Yang K Bingzhi C Xiuhong C Xinling L Xinyao X Vague-Segment Technique: Automatic Computation of Tumor Stroma Ratio for Breast Cancer on Whole Slides IEEE J Biomed Health Inform 2023 28 2 905 916 10.1109/JBHI.2023.3341101 38079367 Xinsen L, Yang K, Bingzhi C, Xiuhong C, Xinling L, Xinyao X, et al. Vague-Segment Technique: Automatic Computation of Tumor Stroma Ratio for Breast Cancer on Whole Slides. IEEE J Biomed Health Inform. 2023;28(2):905&#8211;16. 10.1109/JBHI.2023.3341101 38079367 177. van Rijthoven M Obahor S Pagliarulo F van den Broek M Schraml P Moch H Multi-resolution deep learning characterizes tertiary lymphoid structures and their prognostic relevance in solid tumors Commun Med 2024 4 1 5 10.1038/s43856-023-00421-7 38182879 PMC10770129 van Rijthoven M, Obahor S, Pagliarulo F, van den Broek M, Schraml P, Moch H, et al. Multi-resolution deep learning characterizes tertiary lymphoid structures and their prognostic relevance in solid tumors. Commun Med. 2024;4(1):5. 38182879 10.1038/s43856-023-00421-7 PMC10770129 178. Chen Z Wang X Jin Z Li B Jiang D Wang Y Deep learning on tertiary lymphoid structures in hematoxylin-eosin predicts cancer prognosis and immunotherapy response NPJ Precis Oncol 2024 8 1 73 10.1038/s41698-024-00579-w 38519580 PMC10959936 Chen Z, Wang X, Jin Z, Li B, Jiang D, Wang Y, et al. Deep learning on tertiary lymphoid structures in hematoxylin-eosin predicts cancer prognosis and immunotherapy response. NPJ Precis Oncol. 2024;8(1):73. 38519580 10.1038/s41698-024-00579-w PMC10959936 179. Failmezger H Zwing N Tresch A Korski K Schmich F Computational tumor infiltration phenotypes enable the spatial and genomic analysis of immune infiltration in colorectal cancer Front Oncol 2021 11 552331 10.3389/fonc.2021.552331 33791196 PMC8006941 Failmezger H, Zwing N, Tresch A, Korski K, Schmich F. Computational tumor infiltration phenotypes enable the spatial and genomic analysis of immune infiltration in colorectal cancer. Front Oncol. 2021;11:552331. 33791196 10.3389/fonc.2021.552331 PMC8006941 180. Liu Z Liu L Weng S Guo C Dang Q Xu H Machine learning-based integration develops an immune-derived lncRNA signature for improving outcomes in colorectal cancer Nat Commun 2022 13 1 816 10.1038/s41467-022-28421-6 35145098 PMC8831564 Liu Z, Liu L, Weng S, Guo C, Dang Q, Xu H, et al. Machine learning-based integration develops an immune-derived lncRNA signature for improving outcomes in colorectal cancer. Nat Commun. 2022;13(1):816. 35145098 10.1038/s41467-022-28421-6 PMC8831564 181. Zhang N Zhang H Wu W Zhou R Li S Wang Z Machine learning-based identification of tumor-infiltrating immune cell-associated lncRNAs for improving outcomes and immunotherapy responses in patients with low-grade glioma Theranostics 2022 12 13 5931 10.7150/thno.74281 35966587 PMC9373811 Zhang N, Zhang H, Wu W, Zhou R, Li S, Wang Z, et al. Machine learning-based identification of tumor-infiltrating immune cell-associated lncRNAs for improving outcomes and immunotherapy responses in patients with low-grade glioma. Theranostics. 2022;12(13):5931. 35966587 10.7150/thno.74281 PMC9373811 182. Pan Y Jin X Xu H Hong J Li F Luo T Developing a prognostic model using machine learning for disulfidptosis related lncRNA in lung adenocarcinoma Sci Rep 2024 14 1 13113 10.1038/s41598-024-63949-1 38849442 PMC11161591 Pan Y, Jin X, Xu H, Hong J, Li F, Luo T, et al. Developing a prognostic model using machine learning for disulfidptosis related lncRNA in lung adenocarcinoma. Sci Rep. 2024;14(1):13113. 38849442 10.1038/s41598-024-63949-1 PMC11161591 183. Peng Q Tao J Xu Y Shen Y Wang Y Jiao Y Lipid metabolism-associated genes serve as potential predictive biomarkers in neoadjuvant chemoradiotherapy combined with immunotherapy in rectal cancer Transl Oncol 2024 39 101828 10.1016/j.tranon.2023.101828 38000147 PMC10709626 Peng Q, Tao J, Xu Y, Shen Y, Wang Y, Jiao Y, et al. Lipid metabolism-associated genes serve as potential predictive biomarkers in neoadjuvant chemoradiotherapy combined with immunotherapy in rectal cancer. Transl Oncol. 2024;39:101828. 38000147 10.1016/j.tranon.2023.101828 PMC10709626 184. Wei F Azuma K Nakahara Y Saito H Matsuo N Tagami T Machine learning for prediction of immunotherapeutic outcome in non-small-cell lung cancer based on circulating cytokine signatures J Immunother Cancer 2023 11 7 e006788 10.1136/jitc-2023-006788 37433717 PMC10347453 Wei F, Azuma K, Nakahara Y, Saito H, Matsuo N, Tagami T, et al. Machine learning for prediction of immunotherapeutic outcome in non-small-cell lung cancer based on circulating cytokine signatures. J Immunother Cancer. 2023;11(7):e006788. 37433717 10.1136/jitc-2023-006788 PMC10347453 185. Li N Zhan X Machine learning identifies Pan-cancer landscape of Nrf2 oxidative stress response pathway-related genes Oxid Med Cell Longev 2022 2022 1 8450087 10.1155/2022/8450087 35242279 PMC8886747 Li N, Zhan X. Machine learning identifies Pan-cancer landscape of Nrf2 oxidative stress response pathway-related genes. Oxid Med Cell Longev. 2022;2022(1):8450087. 35242279 10.1155/2022/8450087 PMC8886747 186. Ye G Wu G Zhang C Wang M Liu H Song E CT-based quantification of intratumoral heterogeneity for predicting pathologic complete response to neoadjuvant immunochemotherapy in non-small cell lung cancer Front Immunol 2024 15 1414954 10.3389/fimmu.2024.1414954 38933281 PMC11199789 Ye G, Wu G, Zhang C, Wang M, Liu H, Song E, et al. CT-based quantification of intratumoral heterogeneity for predicting pathologic complete response to neoadjuvant immunochemotherapy in non-small cell lung cancer. Front Immunol. 2024;15:1414954. 38933281 10.3389/fimmu.2024.1414954 PMC11199789 187. Qu W Chen C Cai C Gong M Luo Q Song Y Non-invasive prediction for pathologic complete response to neoadjuvant chemoimmunotherapy in lung cancer using CT-based deep learning: a multicenter study Front Immunol 2024 15 1327779 10.3389/fimmu.2024.1327779 38596674 PMC11003263 Qu W, Chen C, Cai C, Gong M, Luo Q, Song Y, et al. Non-invasive prediction for pathologic complete response to neoadjuvant chemoimmunotherapy in lung cancer using CT-based deep learning: a multicenter study. Front Immunol. 2024;15:1327779. 38596674 10.3389/fimmu.2024.1327779 PMC11003263 188. Huang D Lin C Jiang Y Xin E Xu F Gan Y Radiomics model based on intratumoral and peritumoral features for predicting major pathological response in non-small cell lung cancer receiving neoadjuvant immunochemotherapy Front Oncol 2024 14 1348678 10.3389/fonc.2024.1348678 38585004 PMC10996281 Huang D, Lin C, Jiang Y, Xin E, Xu F, Gan Y, et al. Radiomics model based on intratumoral and peritumoral features for predicting major pathological response in non-small cell lung cancer receiving neoadjuvant immunochemotherapy. Front Oncol. 2024;14:1348678. 38585004 10.3389/fonc.2024.1348678 PMC10996281 189. Liu J Sui C Bian H Li Y Wang Z Fu J Radiomics based on 18F-FDG PET/CT for prediction of pathological complete response to neoadjuvant therapy in non-small cell lung cancer Front Oncol 2024 14 1425837 10.3389/fonc.2024.1425837 39132503 PMC11310012 Liu J, Sui C, Bian H, Li Y, Wang Z, Fu J, et al. Radiomics based on 18F-FDG PET/CT for prediction of pathological complete response to neoadjuvant therapy in non-small cell lung cancer. Front Oncol. 2024;14:1425837. 39132503 10.3389/fonc.2024.1425837 PMC11310012 190. Ye G Wu G Qi Y Li K Wang M Zhang C Non-invasive multimodal CT deep learning biomarker to predict pathological complete response of non-small cell lung cancer following neoadjuvant immunochemotherapy: a multicenter study J Immunother Cancer 2024 12 9 e009348 10.1136/jitc-2024-009348 39231545 PMC11409329 Ye G, Wu G, Qi Y, Li K, Wang M, Zhang C, et al. Non-invasive multimodal CT deep learning biomarker to predict pathological complete response of non-small cell lung cancer following neoadjuvant immunochemotherapy: a multicenter study. J Immunother Cancer. 2024;12(9):e009348. 39231545 10.1136/jitc-2024-009348 PMC11409329 191. Han X Wang M Zheng Y Wang N Wu Y Ding C Delta-radiomics features for predicting the major pathological response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer Eur Radiol 2024 34 4 2716 2726 10.1007/s00330-023-10241-x 37736804 Han X, Wang M, Zheng Y, Wang N, Wu Y, Ding C, et al. Delta-radiomics features for predicting the major pathological response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer. Eur Radiol. 2024;34(4):2716&#8211;26. 37736804 10.1007/s00330-023-10241-x 192. Cui Y Lin Y Zhao Z Long H Zheng L Lin X Comprehensive 18F-FDG PET-based radiomics in elevating the pathological response to neoadjuvant immunochemotherapy for resectable stage III non-small-cell lung cancer: a pilot study Front Immunol 2022 13 994917 10.3389/fimmu.2022.994917 36466929 PMC9713843 Cui Y, Lin Y, Zhao Z, Long H, Zheng L, Lin X. Comprehensive 18F-FDG PET-based radiomics in elevating the pathological response to neoadjuvant immunochemotherapy for resectable stage III non-small-cell lung cancer: a pilot study. Front Immunol. 2022;13:994917. 36466929 10.3389/fimmu.2022.994917 PMC9713843 193. Yang N Yue HL Zhang BH Chen J Chu Q Wang JX Predicting pathological response to neoadjuvant or conversion chemoimmunotherapy in stage IB-III non-small cell lung cancer patients using radiomic features Thorac Cancer 2023 14 28 2869 76 10.1111/1759-7714.15052 37596822 PMC10542462 Yang N, Yue HL, Zhang BH, Chen J, Chu Q, Wang JX, et al. Predicting pathological response to neoadjuvant or conversion chemoimmunotherapy in stage IB-III non-small cell lung cancer patients using radiomic features. Thorac Cancer. 2023;14(28):2869&#8211;76. 37596822 10.1111/1759-7714.15052 PMC10542462 194. She Y He B Wang F Zhong Y Wang T Liu Z Deep learning for predicting major pathological response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer: a multicentre study EBioMedicine 2022 10.1016/j.ebiom.2022.104364 36395737 PMC9672965 She Y, He B, Wang F, Zhong Y, Wang T, Liu Z, et al. Deep learning for predicting major pathological response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer: a multicentre study. EBioMedicine. 2022. 10.1016/j.ebiom.2022.104364. 36395737 10.1016/j.ebiom.2022.104364 PMC9672965 195. Liu C Zhao W Xie J Lin H Hu X Li C Development and validation of a radiomics-based nomogram for predicting a major pathological response to neoadjuvant immunochemotherapy for patients with potentially resectable non-small cell lung cancer Front Immunol 2023 14 1115291 10.3389/fimmu.2023.1115291 36875128 PMC9978193 Liu C, Zhao W, Xie J, Lin H, Hu X, Li C, et al. Development and validation of a radiomics-based nomogram for predicting a major pathological response to neoadjuvant immunochemotherapy for patients with potentially resectable non-small cell lung cancer. Front Immunol. 2023;14:1115291. 36875128 10.3389/fimmu.2023.1115291 PMC9978193 196. Wang F Yang H Chen W Ruan L Jiang T Cheng L A combined model using pre-treatment CT radiomics and clinicopathological features of non-small cell lung cancer to predict major pathological responses after neoadjuvant chemoimmunotherapy Curr Probl Cancer 2024 50 101098 10.1016/j.currproblcancer.2024.101098 38704949 Wang F, Yang H, Chen W, Ruan L, Jiang T, Cheng L, et al. A combined model using pre-treatment CT radiomics and clinicopathological features of non-small cell lung cancer to predict major pathological responses after neoadjuvant chemoimmunotherapy. Curr Probl Cancer. 2024;50:101098. 38704949 10.1016/j.currproblcancer.2024.101098 197. Li C Zhou Z Hou L Hu K Wu Z Xie Y A novel machine learning model for efficacy prediction of immunotherapy-chemotherapy in NSCLC based on CT radiomics Comput Biol Med 2024 178 108638 10.1016/j.compbiomed.2024.108638 38897152 Li C, Zhou Z, Hou L, Hu K, Wu Z, Xie Y, et al. A novel machine learning model for efficacy prediction of immunotherapy-chemotherapy in NSCLC based on CT radiomics. Comput Biol Med. 2024;178:108638. 38897152 10.1016/j.compbiomed.2024.108638 198. She Y He B Wang F Zhong Y Wang T Liu Z Deep learning for predicting major pathological response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer: a multicentre study EBioMedicine 2022 10.1016/j.ebiom.2022.104364 36395737 PMC9672965 She Y, He B, Wang F, Zhong Y, Wang T, Liu Z, et al. Deep learning for predicting major pathological response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer: a multicentre study. EBioMedicine. 2022. 10.1016/j.ebiom.2022.104364. 36395737 10.1016/j.ebiom.2022.104364 PMC9672965 199. Zhao J He Y Yang X Tian P Zeng L Huang K Assessing treatment outcomes of chemoimmunotherapy in extensive-stage small cell lung cancer: an integrated clinical and radiomics approach J Immunother Cancer 2023 11 9 e007492 10.1136/jitc-2023-007492 37730276 PMC10514620 Zhao J, He Y, Yang X, Tian P, Zeng L, Huang K, et al. Assessing treatment outcomes of chemoimmunotherapy in extensive-stage small cell lung cancer: an integrated clinical and radiomics approach. J Immunother Cancer. 2023;11(9):e007492. 37730276 10.1136/jitc-2023-007492 PMC10514620 200. Wang JL Tang LS Zhong X Wang Y Feng YJ Zhang Y A machine learning radiomics based on enhanced computed tomography to predict neoadjuvant immunotherapy for resectable esophageal squamous cell carcinoma Front Immunol 2024 15 1405146 10.3389/fimmu.2024.1405146 38947338 PMC11211602 Wang JL, Tang LS, Zhong X, Wang Y, Feng YJ, Zhang Y, et al. A machine learning radiomics based on enhanced computed tomography to predict neoadjuvant immunotherapy for resectable esophageal squamous cell carcinoma. Front Immunol. 2024;15:1405146. 38947338 10.3389/fimmu.2024.1405146 PMC11211602 201. Shi L Li C Bai Y Cao Y Zhao S Chen X CT radiomics to predict pathologic complete response after neoadjuvant immunotherapy plus chemoradiotherapy in locally advanced esophageal squamous cell carcinoma Eur Radiol 2025 35 3 1594 1604 10.1007/s00330-024-11141-4 39470794 Shi L, Li C, Bai Y, Cao Y, Zhao S, Chen X, et al. CT radiomics to predict pathologic complete response after neoadjuvant immunotherapy plus chemoradiotherapy in locally advanced esophageal squamous cell carcinoma. Eur Radiol. 2025;35(3):1594&#8211;604. 39470794 10.1007/s00330-024-11141-4 202. Kong W Xu J Huang Y Zhu K Yao L Wu K CT-based habitat radiomics for predicting treatment response to neoadjuvant chemoimmunotherapy in esophageal cancer patients Front Oncol 2024 14 1418252 10.3389/fonc.2024.1418252 39691599 PMC11649542 Kong W, Xu J, Huang Y, Zhu K, Yao L, Wu K, et al. CT-based habitat radiomics for predicting treatment response to neoadjuvant chemoimmunotherapy in esophageal cancer patients. Front Oncol. 2024;14:1418252. 39691599 10.3389/fonc.2024.1418252 PMC11649542 203. Zhang Z Luo T Yan M Shen H Tao K Zeng J Voxel-level radiomics and deep learning for predicting pathologic complete response in esophageal squamous cell carcinoma after neoadjuvant immunotherapy and chemotherapy J Immunother Cancer 2025 13 3 e011149 10.1136/jitc-2024-011149 40090670 PMC11911808 Zhang Z, Luo T, Yan M, Shen H, Tao K, Zeng J, et al. Voxel-level radiomics and deep learning for predicting pathologic complete response in esophageal squamous cell carcinoma after neoadjuvant immunotherapy and chemotherapy. J Immunother Cancer. 2025;13(3):e011149. 40090670 10.1136/jitc-2024-011149 PMC11911808 204. Ramtohul T Lepagney V Bonneau C Jin M Menet E Sauge J Use of pretreatment perfusion MRI-based intratumoral heterogeneity to predict pathologic response of triple-negative breast cancer to neoadjuvant chemoimmunotherapy Radiology 2024 312 3 e240575 10.1148/radiol.240575 39225608 Ramtohul T, Lepagney V, Bonneau C, Jin M, Menet E, Sauge J, et al. Use of pretreatment perfusion MRI-based intratumoral heterogeneity to predict pathologic response of triple-negative breast cancer to neoadjuvant chemoimmunotherapy. Radiology. 2024;312(3):e240575. 39225608 10.1148/radiol.240575 205. Seban RD Arnaud E Loirat D Cabel L Cottu P Djerroudi L 18F]FDG PET/CT for predicting triple-negative breast cancer outcomes after neoadjuvant chemotherapy with or without pembrolizumab Eur J Nucl Med Mol Imaging 2023 50 13 4024 35 10.1007/s00259-023-06394-y 37606858 Seban RD, Arnaud E, Loirat D, Cabel L, Cottu P, Djerroudi L. 18F]FDG PET/CT for predicting triple-negative breast cancer outcomes after neoadjuvant chemotherapy with or without pembrolizumab. Eur J Nucl Med Mol Imaging. 2023;50(13):4024&#8211;35. 37606858 10.1007/s00259-023-06394-y 206. Lin P Xie W Li Y Zhang C Wu H Wan H Intratumoral and peritumoral radiomics of MRIs predicts pathologic complete response to neoadjuvant chemoimmunotherapy in patients with head and neck squamous cell carcinoma J Immunother Cancer 2024 12 11 e009616 10.1136/jitc-2024-009616 39500529 PMC11552555 Lin P, Xie W, Li Y, Zhang C, Wu H, Wan H, et al. Intratumoral and peritumoral radiomics of MRIs predicts pathologic complete response to neoadjuvant chemoimmunotherapy in patients with head and neck squamous cell carcinoma. J Immunother Cancer. 2024;12(11):e009616. 39500529 10.1136/jitc-2024-009616 PMC11552555 207. Wang Y Zhang W Chen L Xie J Zheng X Jin Y Development of an interpretable deep learning model for pathological tumor response assessment after neoadjuvant therapy Biol Proced Online 2024 26 1 10 10.1186/s12575-024-00234-5 38632527 PMC11022344 Wang Y, Zhang W, Chen L, Xie J, Zheng X, Jin Y, et al. Development of an interpretable deep learning model for pathological tumor response assessment after neoadjuvant therapy. Biol Proced Online. 2024;26(1):10. 38632527 10.1186/s12575-024-00234-5 PMC11022344 208. Han D Li H Zheng X Fu S Wei R Zhao Q Whole slide image-based weakly supervised deep learning for predicting major pathological response in non-small cell lung cancer following neoadjuvant chemoimmunotherapy: a multicenter, retrospective, cohort study Front Immunol 2024 15 1453232 10.3389/fimmu.2024.1453232 39372403 PMC11449764 Han D, Li H, Zheng X, Fu S, Wei R, Zhao Q, et al. Whole slide image-based weakly supervised deep learning for predicting major pathological response in non-small cell lung cancer following neoadjuvant chemoimmunotherapy: a multicenter, retrospective, cohort study. Front Immunol. 2024;15:1453232. 39372403 10.3389/fimmu.2024.1453232 PMC11449764 209. Yehan Z Sheng Q Hong Y Jiayu L Jun H Juan J To develop a prognostic model for neoadjuvant immunochemotherapy efficacy in esophageal squamous cell carcinoma by analyzing the immune microenvironment Front Immunol 2024 15 1312380 10.3389/fimmu.2024.1312380 38726002 PMC11079241 Yehan Z, Sheng Q, Hong Y, Jiayu L, Jun H, Juan J, et al. To develop a prognostic model for neoadjuvant immunochemotherapy efficacy in esophageal squamous cell carcinoma by analyzing the immune microenvironment. Front Immunol. 2024;15:1312380. 38726002 10.3389/fimmu.2024.1312380 PMC11079241 210. Terada K Yoshizawa A Liu X Ito H Hamaji M Menju T Deep learning for predicting effect of neoadjuvant therapies in non-small cell lung carcinomas with histologic images Mod Pathol 2023 36 11 100302 10.1016/j.modpat.2023.100302 37580019 Terada K, Yoshizawa A, Liu X, Ito H, Hamaji M, Menju T, et al. Deep learning for predicting effect of neoadjuvant therapies in non-small cell lung carcinomas with histologic images. Mod Pathol. 2023;36(11):100302. 37580019 10.1016/j.modpat.2023.100302 211. Han Z Zhang Z Yang X Li Z Sang S Islam MT Development and interpretation of a pathomics-driven ensemble model for predicting the response to immunotherapy in gastric cancer J Immunother Cancer 2024 12 5 e008927 10.1136/jitc-2024-008927 38749538 PMC11097892 Han Z, Zhang Z, Yang X, Li Z, Sang S, Islam MT, et al. Development and interpretation of a pathomics-driven ensemble model for predicting the response to immunotherapy in gastric cancer. J Immunother Cancer. 2024;12(5):e008927. 38749538 10.1136/jitc-2024-008927 PMC11097892 212. Casarrubios M Provencio M Nadal E Insa A Del Rosario G-CM L&#225;zaro-Quintela M Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy J Immunother Cancer 2022 10 9 e005320 10.1136/jitc-2022-005320 36171009 PMC9528578 Casarrubios M, Provencio M, Nadal E, Insa A, Del Rosario G-CM, L&#225;zaro-Quintela M, et al. Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy. J Immunother Cancer. 2022;10(9):e005320. 36171009 10.1136/jitc-2022-005320 PMC9528578 213. Lu X Gou Z Chen H Li L Chen F Bao C Gene panel predicts neoadjuvant chemoimmunotherapy response and benefit from immunotherapy in HER2-negative breast cancer J Immunother Cancer 2024 12 8 e009587 10.1136/jitc-2024-009587 39134345 PMC11337705 Lu X, Gou Z, Chen H, Li L, Chen F, Bao C, et al. Gene panel predicts neoadjuvant chemoimmunotherapy response and benefit from immunotherapy in HER2-negative breast cancer. J Immunother Cancer. 2024;12(8):e009587. 39134345 10.1136/jitc-2024-009587 PMC11337705 214. Ji Z Wang X Xin J Ma L Zuo D Li H Multiomics reveals tumor microenvironment remodeling in locally advanced gastric and gastroesophageal junction cancer following neoadjuvant immunotherapy and chemotherapy J Immunother Cancer 2024 12 12 e010041 10.1136/jitc-2024-010041 39653554 PMC11629098 Ji Z, Wang X, Xin J, Ma L, Zuo D, Li H, et al. Multiomics reveals tumor microenvironment remodeling in locally advanced gastric and gastroesophageal junction cancer following neoadjuvant immunotherapy and chemotherapy. J Immunother Cancer. 2024;12(12):e010041. 39653554 10.1136/jitc-2024-010041 PMC11629098 215. Tang H Yang Q Tang Q Li X Ding W Chen W Integrated transcriptomics unravels implications of glycosylation-regulating signature in diagnosis, prognosis and therapeutic benefits of hepatocellular carcinoma Comput Biol Med 2022 148 105886 10.1016/j.compbiomed.2022.105886 35973372 Tang H, Yang Q, Tang Q, Li X, Ding W, Chen W. Integrated transcriptomics unravels implications of glycosylation-regulating signature in diagnosis, prognosis and therapeutic benefits of hepatocellular carcinoma. Comput Biol Med. 2022;148:105886. 35973372 10.1016/j.compbiomed.2022.105886 216. Liu L Liang L Luo Y Han J Lu D Cai R Unveiling the power of gut microbiome in predicting neoadjuvant immunochemotherapy responses in esophageal squamous cell carcinoma Research 2024 7 0529 10.34133/research.0529 39545038 PMC11562848 Liu L, Liang L, Luo Y, Han J, Lu D, Cai R, et al. Unveiling the power of gut microbiome in predicting neoadjuvant immunochemotherapy responses in esophageal squamous cell carcinoma. Research. 2024;7:0529. 39545038 10.34133/research.0529 PMC11562848 217. Wu C Zhang G Wang L Hu J Ju Z Tao H Spatial proteomic profiling elucidates immune determinants of neoadjuvant chemo-immunotherapy in esophageal squamous cell carcinoma Oncogene 2024 43 37 2751 67 10.1038/s41388-024-03123-z 39122893 Wu C, Zhang G, Wang L, Hu J, Ju Z, Tao H, et al. Spatial proteomic profiling elucidates immune determinants of neoadjuvant chemo-immunotherapy in esophageal squamous cell carcinoma. Oncogene. 2024;43(37):2751&#8211;67. 39122893 10.1038/s41388-024-03123-z 218. Zhang M Zhu L Liang S Mao Z Li X Yang L Pulmonary function test-related prognostic models in non-small cell lung cancer patients receiving neoadjuvant chemoimmunotherapy Front Oncol 2024 14 1411436 10.3389/fonc.2024.1411436 38983930 PMC11231186 Zhang M, Zhu L, Liang S, Mao Z, Li X, Yang L, et al. Pulmonary function test-related prognostic models in non-small cell lung cancer patients receiving neoadjuvant chemoimmunotherapy. Front Oncol. 2024;14:1411436. 38983930 10.3389/fonc.2024.1411436 PMC11231186 219. Huang Q Liu Z Yu Y Rong Z Wang P Wang S Prediction of response to neoadjuvant chemo-immunotherapy in patients with esophageal squamous cell carcinoma by a rapid breath test Br J Cancer 2024 130 4 694 700 10.1038/s41416-023-02547-w 38177659 PMC10876947 Huang Q, Liu Z, Yu Y, Rong Z, Wang P, Wang S, et al. Prediction of response to neoadjuvant chemo-immunotherapy in patients with esophageal squamous cell carcinoma by a rapid breath test. Br J Cancer. 2024;130(4):694&#8211;700. 38177659 10.1038/s41416-023-02547-w PMC10876947 220. Wang Y Song Y Wang R Wu Y Li M Xu K Clinical factors and major pathological response after neoadjuvant chemoimmunotherapy in potentially resectable lung squamous cell carcinoma Front Oncol 2024 14 1265228 10.3389/fonc.2024.1265228 38680859 PMC11045983 Wang Y, Song Y, Wang R, Wu Y, Li M, Xu K, et al. Clinical factors and major pathological response after neoadjuvant chemoimmunotherapy in potentially resectable lung squamous cell carcinoma. Front Oncol. 2024;14:1265228. 38680859 10.3389/fonc.2024.1265228 PMC11045983 221. Hu M Li X Lin H Lu B Wang Q Tong L Easily applicable predictive score for MPR based on parameters before neoadjuvant chemoimmunotherapy in operable NSCLC: a single-center, ambispective, observational study Int J Surg 2024 110 4 2275 87 10.1097/JS9.0000000000001050 38265431 PMC11020048 Hu M, Li X, Lin H, Lu B, Wang Q, Tong L, et al. Easily applicable predictive score for MPR based on parameters before neoadjuvant chemoimmunotherapy in operable NSCLC: a single-center, ambispective, observational study. Int J Surg. 2024;110(4):2275&#8211;87. 38265431 10.1097/JS9.0000000000001050 PMC11020048 222. Feng J Wang L Yang X Chen Q Cheng X Pathologic complete response prediction to neoadjuvant immunotherapy combined with chemotherapy in resectable locally advanced esophageal squamous cell carcinoma: real-world evidence from integrative inflammatory and nutritional scores J Inflamm Res 2022 10.2147/JIR.S367964 35832830 PMC9271687 Feng J, Wang L, Yang X, Chen Q, Cheng X. Pathologic complete response prediction to neoadjuvant immunotherapy combined with chemotherapy in resectable locally advanced esophageal squamous cell carcinoma: real-world evidence from integrative inflammatory and nutritional scores. J Inflamm Res. 2022. 10.2147/JIR.S367964. 35832830 10.2147/JIR.S367964 PMC9271687 223. Han W Weng K Zhang P Hong Z Predictive value of systemic immune-inflammation index for pathological complete response in patients receiving neoadjuvant immunochemotherapy for locally advanced esophageal cancer Front Surg 2023 9 1091601 10.3389/fsurg.2022.1091601 36684142 PMC9845901 Han W, Weng K, Zhang P, Hong Z. Predictive value of systemic immune-inflammation index for pathological complete response in patients receiving neoadjuvant immunochemotherapy for locally advanced esophageal cancer. Front Surg. 2023;9:1091601. 36684142 10.3389/fsurg.2022.1091601 PMC9845901 224. Zhai W Zhang C Duan F Xie J Dai S Lin Y Dynamics of peripheral blood inflammatory index predict tumor pathological response and survival among patients with locally advanced non-small cell lung cancer who underwent neoadjuvant immunochemotherapy: a multi-cohort retrospective study Front Immunol 2024 15 1422717 10.3389/fimmu.2024.1422717 39108262 PMC11300317 Zhai W, Zhang C, Duan F, Xie J, Dai S, Lin Y, et al. Dynamics of peripheral blood inflammatory index predict tumor pathological response and survival among patients with locally advanced non-small cell lung cancer who underwent neoadjuvant immunochemotherapy: a multi-cohort retrospective study. Front Immunol. 2024;15:1422717. 39108262 10.3389/fimmu.2024.1422717 PMC11300317 225. Zhai WY Duan FF Lin YB Lin YB Zhao ZR Wang JY Pan-immune-inflammatory value in patients with non-small-cell lung cancer undergoing neoadjuvant immunochemotherapy J Inflamm Res 2023 10.2147/JIR.S418276 37576157 PMC10422963 Zhai WY, Duan FF, Lin YB, Lin YB, Zhao ZR, Wang JY, et al. Pan-immune-inflammatory value in patients with non-small-cell lung cancer undergoing neoadjuvant immunochemotherapy. J Inflamm Res. 2023. 10.2147/JIR.S418276. 37576157 10.2147/JIR.S418276 PMC10422963 226. Peng J Zou D Han L Yin Z Hu X A support vector machine based on liquid immune profiling predicts major pathological response to chemotherapy plus anti-PD-1/PD-L1 as a neoadjuvant treatment for patients with resectable non-small cell lung cancer Front Immunol 2021 12 778276 10.3389/fimmu.2021.778276 35095850 PMC8797141 Peng J, Zou D, Han L, Yin Z, Hu X. A support vector machine based on liquid immune profiling predicts major pathological response to chemotherapy plus anti-PD-1/PD-L1 as a neoadjuvant treatment for patients with resectable non-small cell lung cancer. Front Immunol. 2021;12:778276. 35095850 10.3389/fimmu.2021.778276 PMC8797141 227. Yang Y Yi Y Wang Z Li S Zhang B Sang Z A combined nomogram based on radiomics and hematology to predict the pathological complete response of neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma BMC Cancer 2024 24 1 460 10.1186/s12885-024-12239-0 38609892 PMC11015586 Yang Y, Yi Y, Wang Z, Li S, Zhang B, Sang Z, et al. A combined nomogram based on radiomics and hematology to predict the pathological complete response of neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma. BMC Cancer. 2024;24(1):460. 38609892 10.1186/s12885-024-12239-0 PMC11015586 228. Xu L Si H Zhuang F Li C Zhang L Zhao Y Predicting therapeutic response to neoadjuvant immunotherapy based on an integration model in resectable stage IIIA (N2) non-small cell lung cancer J Thorac Cardiovasc Surg 2025 169 1 242 253 10.1016/j.jtcvs.2024.05.006 38763304 Xu L, Si H, Zhuang F, Li C, Zhang L, Zhao Y, et al. Predicting therapeutic response to neoadjuvant immunotherapy based on an integration model in resectable stage IIIA (N2) non-small cell lung cancer. J Thorac Cardiovasc Surg. 2025;169(1):242&#8211;53. 38763304 10.1016/j.jtcvs.2024.05.006 229. Qi Y Hu Y Lin C Song G Shi L Zhu H A preoperative predictive model based on multi-modal features to predict pathological complete response after neoadjuvant chemoimmunotherapy in esophageal cancer patients Front Immunol 2025 16 1530279 10.3389/fimmu.2025.1530279 39958355 PMC11827421 Qi Y, Hu Y, Lin C, Song G, Shi L, Zhu H. A preoperative predictive model based on multi-modal features to predict pathological complete response after neoadjuvant chemoimmunotherapy in esophageal cancer patients. Front Immunol. 2025;16:1530279. 39958355 10.3389/fimmu.2025.1530279 PMC11827421 230. Nie F Pei X Du J Shi W Wang J Feng L Multiomics-based deep learning prediction of prognosis and therapeutic response in patients with extensive-stage small cell lung cancer receiving chemoimmunotherapy: a retrospective cohort study Int J Gen Med 2025 10.2147/IJGM.S506485 40026810 PMC11869764 Nie F, Pei X, Du J, Shi W, Wang J, Feng L, et al. Multiomics-based deep learning prediction of prognosis and therapeutic response in patients with extensive-stage small cell lung cancer receiving chemoimmunotherapy: a retrospective cohort study. Int J Gen Med. 2025. 10.2147/IJGM.S506485. 40026810 10.2147/IJGM.S506485 PMC11869764 231. Gao Y Ventura-Diaz S Wang X He M Xu Z Weir A An explainable longitudinal multi-modal fusion model for predicting neoadjuvant therapy response in women with breast cancer Nat Commun 2024 15 1 9613 10.1038/s41467-024-53450-8 39511143 PMC11544255 Gao Y, Ventura-Diaz S, Wang X, He M, Xu Z, Weir A, et al. An explainable longitudinal multi-modal fusion model for predicting neoadjuvant therapy response in women with breast cancer. Nat Commun. 2024;15(1):9613. 39511143 10.1038/s41467-024-53450-8 PMC11544255 232. Khanna NN, Maindarkar MA, Viswanathan V, Fernandes JFE, Paul S, Bhagawati M, et&#160;al. Economics of artificial intelligence in healthcare: diagnosis vs. treatment. In: Healthcare. vol.&#160;10. MDPI; 2022. p. 2493. 10.3390/healthcare10122493 PMC9777836 36554017 233. Askr H Elgeldawi E Aboul Ella H Elshaier YA Gomaa MM Hassanien AE Deep learning in drug discovery: an integrative review and future challenges Artif Intell Rev 2023 56 7 5975 6037 10.1007/s10462-022-10306-1 36415536 PMC9669545 Askr H, Elgeldawi E, Aboul Ella H, Elshaier YA, Gomaa MM, Hassanien AE. Deep learning in drug discovery: an integrative review and future challenges. Artif Intell Rev. 2023;56(7):5975&#8211;6037. 36415536 10.1007/s10462-022-10306-1 PMC9669545 234. Nam Y Kim J Jung SH Woerner J Suh EH Lee Dg Harnessing artificial intelligence in multimodal omics data integration: paving the path for the next frontier in precision medicine Annu Rev Biomed Data Sci 2024 10.1146/annurev-biodatasci-102523-103801 38768397 PMC11972123 Nam Y, Kim J, Jung SH, Woerner J, Suh EH, Lee Dg, et al. Harnessing artificial intelligence in multimodal omics data integration: paving the path for the next frontier in precision medicine. Annu Rev Biomed Data Sci. 2024. 10.1146/annurev-biodatasci-102523-103801. 38768397 10.1146/annurev-biodatasci-102523-103801 PMC11972123 235. Cai Z Poulos RC Liu J Zhong Q Machine learning for multi-omics data integration in cancer iScience 2022 10.1016/j.isci.2022.103798 35169688 PMC8829812 Cai Z, Poulos RC, Liu J, Zhong Q. Machine learning for multi-omics data integration in cancer. iScience. 2022. 10.1016/j.isci.2022.103798. 35169688 10.1016/j.isci.2022.103798 PMC8829812 236. Acharya D Mukhopadhyay A A comprehensive review of machine learning techniques for multi-omics data integration: challenges and applications in precision oncology Brief Funct Genomics 2024 23 5 549 60 10.1093/bfgp/elae013 38600757 Acharya D, Mukhopadhyay A. A comprehensive review of machine learning techniques for multi-omics data integration: challenges and applications in precision oncology. Brief Funct Genomics. 2024;23(5):549&#8211;60. 38600757 10.1093/bfgp/elae013 237. Tuminello S Sikavi D Veluswamy R Gamarra C Lieberman-Cribbin W Flores R PD-L1 as a prognostic biomarker in surgically resectable non-small cell lung cancer: a meta-analysis Transl Lung Cancer Res 2020 9 4 1343 10.21037/tlcr-19-638 32953509 PMC7481631 Tuminello S, Sikavi D, Veluswamy R, Gamarra C, Lieberman-Cribbin W, Flores R, et al. PD-L1 as a prognostic biomarker in surgically resectable non-small cell lung cancer: a meta-analysis. Transl Lung Cancer Res. 2020;9(4):1343. 32953509 10.21037/tlcr-19-638 PMC7481631 238. Strickler JH Hanks BA Khasraw M Tumor mutational burden as a predictor of immunotherapy response: is more always better? Clin Cancer Res 2021 27 5 1236 41 10.1158/1078-0432.CCR-20-3054 33199494 PMC9912042 Strickler JH, Hanks BA, Khasraw M. Tumor mutational burden as a predictor of immunotherapy response: is more always better? Clin Cancer Res. 2021;27(5):1236&#8211;41. 33199494 10.1158/1078-0432.CCR-20-3054 PMC9912042 239. Tao W Sun Q Xu B Wang R Towards the prediction of responses to cancer immunotherapy: a multi-omics review Life 2025 15 2 283 10.3390/life15020283 40003691 PMC11856636 Tao W, Sun Q, Xu B, Wang R. Towards the prediction of responses to cancer immunotherapy: a multi-omics review. Life. 2025;15(2):283. 40003691 10.3390/life15020283 PMC11856636 240. Venetis K Frascarelli C Bielo LB Cursano G Adorisio R Ivanova M Mismatch repair (MMR) and microsatellite instability (MSI) phenotypes across solid tumors: a comprehensive cBioPortal study on prevalence and prognostic impact Eur J Cancer 2025 217 115233 10.1016/j.ejca.2025.115233 39827722 Venetis K, Frascarelli C, Bielo LB, Cursano G, Adorisio R, Ivanova M, et al. Mismatch repair (MMR) and microsatellite instability (MSI) phenotypes across solid tumors: a comprehensive cBioPortal study on prevalence and prognostic impact. Eur J Cancer. 2025;217:115233. 39827722 10.1016/j.ejca.2025.115233 241. Zhu Y Zhao F Li Z Yu J Current landscape and future directions of biomarkers for predicting responses to immune checkpoint inhibitors Cancer Manag Res 2018 10.2147/CMAR.S167400 30122997 PMC6086110 Zhu Y, Zhao F, Li Z, Yu J. Current landscape and future directions of biomarkers for predicting responses to immune checkpoint inhibitors. Cancer Manag Res. 2018. 10.2147/CMAR.S167400. 30122997 10.2147/CMAR.S167400 PMC6086110 242. Li X Wang M Wang M Yu X Guo J Sun T Predictive and prognostic roles of pathological indicators for patients with breast cancer on neoadjuvant chemotherapy J Breast Cancer 2019 22 4 497 521 10.4048/jbc.2019.22.e49 31897326 PMC6933033 Li X, Wang M, Wang M, Yu X, Guo J, Sun T, et al. Predictive and prognostic roles of pathological indicators for patients with breast cancer on neoadjuvant chemotherapy. J Breast Cancer. 2019;22(4):497&#8211;521. 31897326 10.4048/jbc.2019.22.e49 PMC6933033 243. Domenghino A, Walbert C, Birrer DL, Puhan MA, Clavien PA, consensus&#160;group Jury Heuskel Dieter 4 Man Nancy Kwan 5 Monteiro Jo&#227;o 6 Perellon Juan F 7 P&#233;rez Mart&#237;nez Sara 8 9 10 Seedat Soraya 11 Urbaniok Frank 12 13 Woodbridge&#160;Jayson O, et&#160;al. Consensus recommendations on how to assess the quality of surgical interventions. Nat Med. 2023;29(4):811&#8211;822. 10.1038/s41591-023-02237-3 37069361 244. Cortazar P Zhang L Untch M Mehta K Costantino JP Wolmark N Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis Lancet 2014 384 9938 164 72 10.1016/S0140-6736(13)62422-8 24529560 Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164&#8211;72. 24529560 10.1016/S0140-6736(13)62422-8 245. Hellmann MD Chaft JE William WN Rusch V Pisters KM Kalhor N Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint Lancet Oncol 2014 15 1 e42 e50 10.1016/S1470-2045(13)70334-6 24384493 PMC4734624 Hellmann MD, Chaft JE, William WN, Rusch V, Pisters KM, Kalhor N, et al. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol. 2014;15(1):e42&#8211;50. 24384493 10.1016/S1470-2045(13)70334-6 PMC4734624 246. Dong F Yan J Zhang X Zhang Y Liu D Pan X Artificial intelligence-based predictive model for guidance on treatment strategy selection in oral and maxillofacial surgery Heliyon 2024 10.1016/j.heliyon.2024.e35742 39170321 PMC11336844 Dong F, Yan J, Zhang X, Zhang Y, Liu D, Pan X, et al. Artificial intelligence-based predictive model for guidance on treatment strategy selection in oral and maxillofacial surgery. Heliyon. 2024. 10.1016/j.heliyon.2024.e35742. 39170321 10.1016/j.heliyon.2024.e35742 PMC11336844 247. Waqas A Naveed J Shahnawaz W Asghar S Bui MM Rasool G Digital pathology and multimodal learning on oncology data BJR|Artificial Intelligence 2024 1 1 ubae014 10.1093/bjrai/ubae014 Waqas A, Naveed J, Shahnawaz W, Asghar S, Bui MM, Rasool G. Digital pathology and multimodal learning on oncology data. BJR|Artificial Intelligence. 2024;1(1):ubae014. 248. Rudin C Stop explaining black box machine learning models for high stakes decisions and use interpretable models instead Nat Mach Intell 2019 1 5 206 215 10.1038/s42256-019-0048-x 35603010 PMC9122117 Rudin C. Stop explaining black box machine learning models for high stakes decisions and use interpretable models instead. Nat Mach Intell. 2019;1(5):206&#8211;15. 35603010 10.1038/s42256-019-0048-x PMC9122117 249. Ghassemi M Oakden-Rayner L Beam AL The false hope of current approaches to explainable artificial intelligence in health care Lancet Digit Health 2021 3 11 e745 e750 10.1016/S2589-7500(21)00208-9 34711379 Ghassemi M, Oakden-Rayner L, Beam AL. The false hope of current approaches to explainable artificial intelligence in health care. Lancet Digit Health. 2021;3(11):e745&#8211;50. 34711379 10.1016/S2589-7500(21)00208-9 250. Lu SC Swisher CL Chung C Jaffray D Sidey-Gibbons C On the importance of interpretable machine learning predictions to inform clinical decision making in oncology Front Oncol 2023 13 1129380 10.3389/fonc.2023.1129380 36925929 PMC10013157 Lu SC, Swisher CL, Chung C, Jaffray D, Sidey-Gibbons C. On the importance of interpretable machine learning predictions to inform clinical decision making in oncology. Front Oncol. 2023;13:1129380. 36925929 10.3389/fonc.2023.1129380 PMC10013157 251. Alzubaidi L Zhang J Humaidi AJ Al-Dujaili A Duan Y Al-Shamma O Review of deep learning: concepts, CNN architectures, challenges, applications, future directions J Big Data 2021 8 1 74 10.1186/s40537-021-00444-8 33816053 PMC8010506 Alzubaidi L, Zhang J, Humaidi AJ, Al-Dujaili A, Duan Y, Al-Shamma O, et al. Review of deep learning: concepts, CNN architectures, challenges, applications, future directions. J Big Data. 2021;8:1&#8211;74. 33816053 10.1186/s40537-021-00444-8 PMC8010506 252. Marey A Arjmand P Alerab ADS Eslami MJ Saad AM Sanchez N Explainability, transparency and black box challenges of AI in radiology: impact on patient care in cardiovascular radiology Egypt J Radiol Nucl Med 2024 55 1 183 10.1186/s43055-024-01356-2 Marey A, Arjmand P, Alerab ADS, Eslami MJ, Saad AM, Sanchez N, et al. Explainability, transparency and black box challenges of AI in radiology: impact on patient care in cardiovascular radiology. Egypt J Radiol Nucl Med. 2024;55(1):183. 253. Vimbi V Shaffi N Mahmud M Interpreting artificial intelligence models: a systematic review on the application of LIME and SHAP in Alzheimer&#8217;s disease detection Brain Inform 2024 11 1 10 10.1186/s40708-024-00222-1 38578524 PMC10997568 Vimbi V, Shaffi N, Mahmud M. Interpreting artificial intelligence models: a systematic review on the application of LIME and SHAP in Alzheimer&#8217;s disease detection. Brain Inform. 2024;11(1):10. 38578524 10.1186/s40708-024-00222-1 PMC10997568 254. Saranya A Subhashini R A systematic review of explainable artificial intelligence models and applications: recent developments and future trends Decis Anal J 2023 7 100230 10.1016/j.dajour.2023.100230 Saranya A, Subhashini R. A systematic review of explainable artificial intelligence models and applications: recent developments and future trends. Decis Anal J. 2023;7:100230. 255. Nahiduzzaman M Abdulrazak LF Kibria HB Khandakar A Ayari MA Ahamed MF A hybrid explainable model based on advanced machine learning and deep learning models for classifying brain tumors using MRI images Sci Rep 2025 15 1 1649 10.1038/s41598-025-85874-7 39794374 PMC11724088 Nahiduzzaman M, Abdulrazak LF, Kibria HB, Khandakar A, Ayari MA, Ahamed MF, et al. A hybrid explainable model based on advanced machine learning and deep learning models for classifying brain tumors using MRI images. Sci Rep. 2025;15(1):1649. 39794374 10.1038/s41598-025-85874-7 PMC11724088 256. Luca AR Ursuleanu TF Gheorghe L Grigorovici R Iancu S Hlusneac M Impact of quality, type and volume of data used by deep learning models in the analysis of medical images Inf Med Unlocked 2022 29 100911 10.1016/j.imu.2022.100911 Luca AR, Ursuleanu TF, Gheorghe L, Grigorovici R, Iancu S, Hlusneac M, et al. Impact of quality, type and volume of data used by deep learning models in the analysis of medical images. Inf Med Unlocked. 2022;29:100911. 257. Sarker IH Deep learning: a comprehensive overview on techniques, taxonomy, applications and research directions SN Comput Sci 2021 2 6 1 20 10.1007/s42979-021-00815-1 PMC8372231 34426802 Sarker IH. Deep learning: a comprehensive overview on techniques, taxonomy, applications and research directions. SN Comput Sci. 2021;2(6):1&#8211;20. 10.1007/s42979-021-00815-1 PMC8372231 34426802 258. Zhao Z Alzubaidi L Zhang J Duan Y Gu Y A comparison review of transfer learning and self-supervised learning: definitions, applications, advantages and limitations Expert Syst Appl 2024 242 122807 10.1016/j.eswa.2023.122807 Zhao Z, Alzubaidi L, Zhang J, Duan Y, Gu Y. A comparison review of transfer learning and self-supervised learning: definitions, applications, advantages and limitations. Expert Syst Appl. 2024;242:122807. 259. Yan R Qu L Wei Q Huang SC Shen L Rubin DL Label-efficient self-supervised federated learning for tackling data heterogeneity in medical imaging IEEE Trans Med Imaging 2023 42 7 1932 43 10.1109/TMI.2022.3233574 37018314 PMC10880587 Yan R, Qu L, Wei Q, Huang SC, Shen L, Rubin DL, et al. Label-efficient self-supervised federated learning for tackling data heterogeneity in medical imaging. IEEE Trans Med Imaging. 2023;42(7):1932&#8211;43. 37018314 10.1109/TMI.2022.3233574 PMC10880587 260. Kim MJ Kim SH Kim SM Nam JH Hwang YB Lim YJ The advent of domain adaptation into artificial intelligence for gastrointestinal endoscopy and medical imaging Diagnostics 2023 13 19 3023 10.3390/diagnostics13193023 37835766 PMC10572560 Kim MJ, Kim SH, Kim SM, Nam JH, Hwang YB, Lim YJ. The advent of domain adaptation into artificial intelligence for gastrointestinal endoscopy and medical imaging. Diagnostics. 2023;13(19):3023. 37835766 10.3390/diagnostics13193023 PMC10572560 261. Sinha S Lee YM Challenges with developing and deploying AI models and applications in industrial systems Discov Artif Intell 2024 4 1 55 10.1007/s44163-024-00151-2 Sinha S, Lee YM. Challenges with developing and deploying AI models and applications in industrial systems. Discov Artif Intell. 2024;4(1):55. 262. Suwannaphong T Jovan F Craddock I McConville R Optimising TinyML with quantization and distillation of transformer and mamba models for indoor localisation on edge devices Sci Rep 2025 15 1 10081 10.1038/s41598-025-94205-9 40128553 PMC11933347 Suwannaphong T, Jovan F, Craddock I, McConville R. Optimising TinyML with quantization and distillation of transformer and mamba models for indoor localisation on edge devices. Sci Rep. 2025;15(1):10081. 40128553 10.1038/s41598-025-94205-9 PMC11933347 263. Molla G Bitew M Revolutionizing personalized medicine: synergy with multi-omics data generation, main hurdles, and future perspectives Biomedicines 2024 12 12 2750 10.3390/biomedicines12122750 39767657 PMC11673561 Molla G, Bitew M. Revolutionizing personalized medicine: synergy with multi-omics data generation, main hurdles, and future perspectives. Biomedicines. 2024;12(12):2750. 39767657 10.3390/biomedicines12122750 PMC11673561 264. Vanguri RS Luo J Aukerman AT Egger JV Fong CJ Horvat N Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L) 1 blockade in patients with non-small cell lung cancer Nat Cancer 2022 3 10 1151 64 10.1038/s43018-022-00416-8 36038778 PMC9586871 Vanguri RS, Luo J, Aukerman AT, Egger JV, Fong CJ, Horvat N, et al. Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L) 1 blockade in patients with non-small cell lung cancer. Nat Cancer. 2022;3(10):1151&#8211;64. 36038778 10.1038/s43018-022-00416-8 PMC9586871 265. Putrama IM Martinek P Heterogeneous data integration: challenges and opportunities Data Brief 2024 10.1016/j.dib.2024.110853 39286416 PMC11402636 Putrama IM, Martinek P. Heterogeneous data integration: challenges and opportunities. Data Brief. 2024. 10.1016/j.dib.2024.110853. 39286416 10.1016/j.dib.2024.110853 PMC11402636 266. Hyun JW Li Y Huang C Styner M Lin W Zhu H STGP: spatio-temporal Gaussian process models for longitudinal neuroimaging data Neuroimage 2016 134 550 62 10.1016/j.neuroimage.2016.04.023 27103140 PMC4912881 Hyun JW, Li Y, Huang C, Styner M, Lin W, Zhu H. STGP: spatio-temporal Gaussian process models for longitudinal neuroimaging data. Neuroimage. 2016;134:550&#8211;62. 27103140 10.1016/j.neuroimage.2016.04.023 PMC4912881 267. Zhang Y Liu C Liu M Liu T Lin H Huang CB Attention is all you need: utilizing attention in AI-enabled drug discovery Brief Bioinform 2024 25 1 bbad467 10.1093/bib/bbad467 PMC10772984 38189543 Zhang Y, Liu C, Liu M, Liu T, Lin H, Huang CB, et al. Attention is all you need: utilizing attention in AI-enabled drug discovery. Brief Bioinform. 2024;25(1):bbad467. 10.1093/bib/bbad467 PMC10772984 38189543 268. Liu Z Hu Y Qiu Z Niu Y Zhou D Li X Cross-modal attention network for retinal disease classification based on multi-modal images Biomed Opt Express 2024 15 6 3699 714 10.1364/BOE.516764 38867787 PMC11166426 Liu Z, Hu Y, Qiu Z, Niu Y, Zhou D, Li X, et al. Cross-modal attention network for retinal disease classification based on multi-modal images. Biomed Opt Express. 2024;15(6):3699&#8211;714. 38867787 10.1364/BOE.516764 PMC11166426 269. Norori N Hu Q Aellen FM Faraci FD Tzovara A Addressing bias in big data and AI for health care: a call for open science Patterns 2021 10.1016/j.patter.2021.100347 34693373 PMC8515002 Norori N, Hu Q, Aellen FM, Faraci FD, Tzovara A. Addressing bias in big data and AI for health care: a call for open science. Patterns. 2021. 10.1016/j.patter.2021.100347. 34693373 10.1016/j.patter.2021.100347 PMC8515002 270. Arora A Alderman JE Palmer J Ganapathi S Laws E Mccradden MD The value of standards for health datasets in artificial intelligence-based applications Nat Med 2023 29 11 2929 38 10.1038/s41591-023-02608-w 37884627 PMC10667100 Arora A, Alderman JE, Palmer J, Ganapathi S, Laws E, Mccradden MD, et al. The value of standards for health datasets in artificial intelligence-based applications. Nat Med. 2023;29(11):2929&#8211;38. 37884627 10.1038/s41591-023-02608-w PMC10667100 271. Ueda D Kakinuma T Fujita S Kamagata K Fushimi Y Ito R Fairness of artificial intelligence in healthcare: review and recommendations Jpn J Radiol 2024 42 1 3 15 10.1007/s11604-023-01474-3 37540463 PMC10764412 Ueda D, Kakinuma T, Fujita S, Kamagata K, Fushimi Y, Ito R, et al. Fairness of artificial intelligence in healthcare: review and recommendations. Jpn J Radiol. 2024;42(1):3&#8211;15. 37540463 10.1007/s11604-023-01474-3 PMC10764412 272. Cross JL Choma MA Onofrey JA Bias in medical AI: implications for clinical decision-making PLoS Digit Health 2024 3 11 e0000651 10.1371/journal.pdig.0000651 39509461 PMC11542778 Cross JL, Choma MA, Onofrey JA. Bias in medical AI: implications for clinical decision-making. PLoS Digit Health. 2024;3(11):e0000651. 39509461 10.1371/journal.pdig.0000651 PMC11542778 273. Hasanzadeh F Josephson CB Waters G Adedinsewo D Azizi Z White JA Bias recognition and mitigation strategies in artificial intelligence healthcare applications NPJ Digit Med 2025 8 1 154 10.1038/s41746-025-01503-7 40069303 PMC11897215 Hasanzadeh F, Josephson CB, Waters G, Adedinsewo D, Azizi Z, White JA. Bias recognition and mitigation strategies in artificial intelligence healthcare applications. NPJ Digit Med. 2025;8(1):154. 40069303 10.1038/s41746-025-01503-7 PMC11897215 274. Agarwal R Bjarnadottir M Rhue L Dugas M Crowley K Clark J Addressing algorithmic bias and the perpetuation of health inequities: an AI bias aware framework Health Policy Technol 2023 12 1 100702 10.1016/j.hlpt.2022.100702 Agarwal R, Bjarnadottir M, Rhue L, Dugas M, Crowley K, Clark J, et al. Addressing algorithmic bias and the perpetuation of health inequities: an AI bias aware framework. Health Policy Technol. 2023;12(1):100702. 275. Murdoch B Privacy and artificial intelligence: challenges for protecting health information in a new era BMC Med Ethics 2021 22 1 5 10.1186/s12910-021-00687-3 34525993 PMC8442400 Murdoch B. Privacy and artificial intelligence: challenges for protecting health information in a new era. BMC Med Ethics. 2021;22:1&#8211;5. 34525993 10.1186/s12910-021-00687-3 PMC8442400 276. Narayan SM Kohli N Martin MM Addressing contemporary threats in anonymised healthcare data using privacy engineering NPJ Digit Med 2025 8 1 145 10.1038/s41746-025-01520-6 40050672 PMC11885643 Narayan SM, Kohli N, Martin MM. Addressing contemporary threats in anonymised healthcare data using privacy engineering. NPJ Digit Med. 2025;8(1):145. 40050672 10.1038/s41746-025-01520-6 PMC11885643 277. Han D Babaei R Zhao S Cheng S Exploring the efficacy of learning techniques in model extraction attacks on image classifiers: a comparative study Appl Sci 2024 14 9 3785 10.3390/app14093785 Han D, Babaei R, Zhao S, Cheng S. Exploring the efficacy of learning techniques in model extraction attacks on image classifiers: a comparative study. Appl Sci. 2024;14(9):3785. 278. Khalid N Qayyum A Bilal M Al-Fuqaha A Qadir J Privacy-preserving artificial intelligence in healthcare: techniques and applications Comput Biol Med 2023 158 106848 10.1016/j.compbiomed.2023.106848 37044052 Khalid N, Qayyum A, Bilal M, Al-Fuqaha A, Qadir J. Privacy-preserving artificial intelligence in healthcare: techniques and applications. Comput Biol Med. 2023;158:106848. 37044052 10.1016/j.compbiomed.2023.106848 279. Gu X Sabrina F Fan Z Sohail S A review of privacy enhancement methods for federated learning in healthcare systems Int J Environ Res Public Health 2023 20 15 6539 10.3390/ijerph20156539 37569079 PMC10418741 Gu X, Sabrina F, Fan Z, Sohail S. A review of privacy enhancement methods for federated learning in healthcare systems. Int J Environ Res Public Health. 2023;20(15):6539. 37569079 10.3390/ijerph20156539 PMC10418741 280. Aziz R Banerjee S Bouzefrane S Le Vinh T Exploring homomorphic encryption and differential privacy techniques towards secure federated learning paradigm Future Internet 2023 15 9 310 10.3390/fi15090310 Aziz R, Banerjee S, Bouzefrane S, Le Vinh T. Exploring homomorphic encryption and differential privacy techniques towards secure federated learning paradigm. Future Internet. 2023;15(9):310. 281. Schmidt A Regulatory challenges in healthcare IT: Ensuring compliance with HIPAA and GDPR Acad J Sci Technol 2020 3 1 1 7 Schmidt A. Regulatory challenges in healthcare IT: Ensuring compliance with HIPAA and GDPR. Acad J Sci Technol. 2020;3(1):1&#8211;7. 282. Zhang B Zhong H Han B Neoadjuvant immunotherapy for patients with non-small cell lung cancer&#8211;is a new era coming? JAMA Oncol 2023 9 3 301 2 10.1001/jamaoncol.2022.6898 36701143 Zhang B, Zhong H, Han B. Neoadjuvant immunotherapy for patients with non-small cell lung cancer&#8211;is a new era coming? JAMA Oncol. 2023;9(3):301&#8211;2. 36701143 10.1001/jamaoncol.2022.6898 283. Rouanne M Bajorin DF Hannan R Galsky MD Williams SB Necchi A Rationale and outcomes for neoadjuvant immunotherapy in urothelial carcinoma of the bladder Eur Urol Oncol 2020 3 6 728 38 10.1016/j.euo.2020.06.009 33177001 Rouanne M, Bajorin DF, Hannan R, Galsky MD, Williams SB, Necchi A, et al. Rationale and outcomes for neoadjuvant immunotherapy in urothelial carcinoma of the bladder. Eur Urol Oncol. 2020;3(6):728&#8211;38. 33177001 10.1016/j.euo.2020.06.009 284. Nanda R Liu MC Yau C Shatsky R Pusztai L Wallace A Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial JAMA Oncol 2020 6 5 676 84 10.1001/jamaoncol.2019.6650 32053137 PMC7058271 Nanda R, Liu MC, Yau C, Shatsky R, Pusztai L, Wallace A, et al. Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial. JAMA Oncol. 2020;6(5):676&#8211;84. 32053137 10.1001/jamaoncol.2019.6650 PMC7058271 285. Li Y Wu X Fang D Luo Y Informing immunotherapy with multi-omics driven machine learning NPJ Digit Med 2024 7 1 67 10.1038/s41746-024-01043-6 38486092 PMC10940614 Li Y, Wu X, Fang D, Luo Y. Informing immunotherapy with multi-omics driven machine learning. NPJ Digit Med. 2024;7(1):67. 38486092 10.1038/s41746-024-01043-6 PMC10940614 286. Xie T Huang A Yan H Ju X Xiang L Yuan J Artificial intelligence: illuminating the depths of the tumor microenvironment J Transl Med 2024 22 1 799 10.1186/s12967-024-05609-6 39210368 PMC11360846 Xie T, Huang A, Yan H, Ju X, Xiang L, Yuan J. Artificial intelligence: illuminating the depths of the tumor microenvironment. J Transl Med. 2024;22(1):799. 39210368 10.1186/s12967-024-05609-6 PMC11360846 287. Ligero M, El&#160;Nahhas OS, Aldea M, Kather JN. Artificial intelligence-based biomarkers for treatment decisions in oncology. Trends in Cancer. 2025. 10.1016/j.trecan.2024.12.001 39814650 288. Niso G Botvinik-Nezer R Appelhoff S De La Vega A Esteban O Etzel JA Open and reproducible neuroimaging: from study inception to publication Neuroimage 2022 263 119623 10.1016/j.neuroimage.2022.119623 36100172 PMC10008521 Niso G, Botvinik-Nezer R, Appelhoff S, De La Vega A, Esteban O, Etzel JA, et al. Open and reproducible neuroimaging: from study inception to publication. Neuroimage. 2022;263:119623. 36100172 10.1016/j.neuroimage.2022.119623 PMC10008521 289. Beam AL Manrai AK Ghassemi M Challenges to the reproducibility of machine learning models in health care JAMA 2020 323 4 305 6 10.1001/jama.2019.20866 31904799 PMC7335677 Beam AL, Manrai AK, Ghassemi M. Challenges to the reproducibility of machine learning models in health care. JAMA. 2020;323(4):305&#8211;6. 31904799 10.1001/jama.2019.20866 PMC7335677 290. Shiferaw KB Roloff M Balaur I Welter D Waltemath D Zeleke AA Guidelines and standard frameworks for artificial intelligence in medicine: a systematic review JAMIA Open 2025 8 1 ooae155 10.1093/jamiaopen/ooae155 39759773 PMC11700560 Shiferaw KB, Roloff M, Balaur I, Welter D, Waltemath D, Zeleke AA. Guidelines and standard frameworks for artificial intelligence in medicine: a systematic review. JAMIA Open. 2025;8(1):ooae155. 39759773 10.1093/jamiaopen/ooae155 PMC11700560 291. Heil BJ Hoffman MM Markowetz F Lee SI Greene CS Hicks SC Reproducibility standards for machine learning in the life sciences Nat Methods 2021 18 10 1132 5 10.1038/s41592-021-01256-7 34462593 PMC9131851 Heil BJ, Hoffman MM, Markowetz F, Lee SI, Greene CS, Hicks SC. Reproducibility standards for machine learning in the life sciences. Nat Methods. 2021;18(10):1132&#8211;5. 34462593 10.1038/s41592-021-01256-7 PMC9131851 292. Tsay J Braz A Hirzel M Shinnar A Mummert T Extracting enhanced artificial intelligence model metadata from software repositories Empir Software Eng 2022 27 7 176 10.1007/s10664-022-10206-6 Tsay J, Braz A, Hirzel M, Shinnar A, Mummert T. Extracting enhanced artificial intelligence model metadata from software repositories. Empir Software Eng. 2022;27(7):176."
}